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Abstract 
 
Neuronal function is a highly complex process, and model organisms are required to 
elucidate novel pathway components that may play a role in neurological disease. High-
throughput targeted RNAi screens were performed on worm strains sensitive to neuronal 
RNAi, in order to assess the functional consequences of changing gene expression on 
synaptic function, as assessed by the relative changes in sensitivity to the 
acetylcholinesterase inhibitor aldicarb. A one-step binary aldicarb-sensitivity protein 
interaction network was constructed, using all genes with a known aldicarb sensitivity 
phenotype as core nodes. Connectivity and betweenness to genes known to cause a 
change in aldicarb sensitivity was measured. 19 genes highly connected and 17 high 
betweenness genes displayed a change in aldicarb sensitivity, with 8 having both high 
betweenness and connectivity.  
 
Previous microarray studies on the effects of sodium valproate were carried out on wild 
type worms (Munasinghe, 2015), and suggested that valproate could conditionally 
influence synaptic function at neuromuscular junctions. To investigate this relationship 
further genes that exhibited dose dependent changes in gene expression were identified 
and clustered within the one-step aldicarb betweenness network using a module 
prediction algorithm. Proteins within functional modules that were not previously 
known to exhibit aldicarb sensitivity were systematically screened, and 16 genes were 
shown to cause a significant change in the rate of aldicarb-induced paralysis, including 
sel-12 and dhhc-2, a palmitoyl-acyl transferase. 
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Data from valproate dose response microarrays were re-analyzed and DAVID, Ingenuity 
and WebGestalt analyses were performed on the subset of genes showing valproate-
induced changes in gene expression. Several known disease associations were identified, 
including Alzheimer’s disease, epilepsy and Huntington’s disease. Microarray data from 
other available valproate sensitivity studies were also analyzed, and the overlap in genes 
with the worm micro array dataset was assessed. This analysis suggests that changes in 
neuronal development and differentiation, Wnt signaling and cholinergic transmission 
may all be functionally affected by exposure to valproate. 
 
Dhhc-2 is a member of the palmitoyl-acyl transferase family, and the rest of the family 
was systematically tested using aldicarb-sensitivity assays. The dhhc-13 mutant was 
shown to cause hypersensitivity and the dhhc-14 showed resistance to aldicarb, 
suggesting mechanisms of reciprocal conditional regulation. Hypersensitivity to aldicarb 
was also observed when dhhc-1 and dhhc-5 were knocked down, while dhhc-3, -11, and 
spe-10 genetic knockdown led to resistance. The dhhc-2 mutant and RNAi knockdown 
both caused enhanced paralysis when treated with 15mM valproate, suggesting a 
functional effect of the drug at neuromuscular junctions. A selection of human PATs were 
analyzed in the Y2H library screens using cytoplasmic domains of DHHC5, 5, 13 and 17. 
DHHC5CT, 17N and 13N revealed 11, 13 and 11 interaction partners, respectively. 
Membrane based Y2H library screening was also carried out, and 17 novel interaction 
partners of full length DHHC9 were identified, including reticulin and selenoprotein K. 
These screens revealed interesting novel interaction partners, which could provide new 
insights into the mechanisms by which PAT family members may differentially affect 
neuromuscular function. 
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1.1 Summary 
 
Neuronal function is dependent on the appropriate conditional release and action of 
neurotransmitters at synaptic and motor neuron junctions. This process is highly 
complex, as demonstrated by the diverse array and variable prognosis and 
pathophysiology of early- and late-onset neuropathies. Although the fundamental 
processes involved in synaptic signaling are well understood, the spectrum of functional 
regulators, conditional dominance or the combinatorial consequence of somatic 
mutations affecting biological pathways, such as transcriptional regulation, post-
translational modifications and the intracellular environment remain unclear. To 
enhance understanding of these processes, it would be difficult to begin in humans due 
to the comparative low percentage coverage of the functional and physical human 
interactome. By first elucidating candidate effectors in C. elegans, then extrapolating this 
information to predict the functional relevance of human orthologues, these candidates 
can then be prioritized for functionally relevant interactome studies, with the aim of 
providing higher network coverage of evolutionary conserved effectors of synaptic 
function. 
 
This chapter will give an overview of: 
 Neurotransmission 
 The use of Caenorhabditis elegans in neurobiology 
 Protein Interaction Networks 
 Sodium valproate (also known as VPA or valproic acid) 
 Protein palmitoylation and palmitoyl acyl transferases (PATs) 
 Methods of elucidating interaction partners 
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1.2 History of neurotransmission research 
 
Our general understanding of the fundamental principles of neurotransmission 
originated from pioneering studies by Emil du Bois Reymond, who discovered action 
potentials and chemical synapses (Sudhof, 2013). In the 19th Century Santiago Ramon y 
Cajal described the ‘neuron doctrine’, which describes the concept that the nervous 
system is composed of discrete individual cells (López-Muñoz & Alamo, 2009).  Another 
key figure in defining the physiological concept of synapses was Sherrington, who in 
1925 developed a theory of the action of synapses, even though the detailed structure of 
the synapse remained unknown until early electron microscopy studies were performed 
in the 1950s (Robertson, 1953) .  
 
In 1969 Bernard Katz published a paper describing the fundamentals of neuronal 
transmission through detailed electrophysiological analysis (Katz, 1970). In this seminal 
work Katz proposed two hypotheses, the first of which was the quantal hypothesis, which 
described the exocytosis of neurotransmitter-filled vesicles at distinct points on the pre-
synaptic membrane. Heuser and Reese elaborated on this hypothesis in 1973, showing 
evidence that fusion of vesicles with the active zone of the presynaptic membrane is 
followed by recycling of vesicles into endosomal organelles (Heuser & Reese, 1973). This 
hypothesis was further substantiated by electron microscopy showing synaptic vesicle 
fusion at the presynaptic membrane (Heuser et al., 1979) 
 
The second hypothesis proposed by Katz was the ‘calcium hypothesis’, which stated that 
the effect of a nerve impulse was to elicit calcium ion entry into the presynaptic terminal, 
leading to vesicle fusion.  Katz proposed that a calcium sensor was responsible for the 
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triggering of fusion pore opening. Following this proposal, synaptotagmin proteins Syt1, 
Syt 2 and Syt 9 were all shown to bind calcium, and function as calcium sensors (J. Xu, 
Mashimo, & Sudhof, 2007). 
 
In order for neurotransmitter to be released across the synaptic cleft, a fusion event must 
occur between the synaptic vesicle and the presynaptic membrane. This is generally 
thought to occur by the fusion of three soluble N-ethylmaleimide sensitive fusion (NSF) 
Attachment Receptor Proteins (SNARE) and SM (Sec1/Munc18-like) proteins. SNAREs 
consist of the V-SNARE Synaptobrevin (also known as VAMP-2), which is found on the 
synaptic vesicle membrane, and the t-SNAREs Synaptosomal-Associated-Protein 25kDa 
(SNAP-25) and syntaxin-1, located on the presynaptic membrane (Sudhof & Rizo, 2011). 
When fusion occurs, N to C terminal zippering of the 4 alpha helices from the three SNARE 
proteins occurs, two alpha helices being derived from SNAP-25 and one alpha helix being 
provided by synaptobrevin and syntaxin-1 respectively.  This zippering causes the 
synaptic vesicle and pre-synaptic membranes to be brought into close proximity, leading 
to membrane destabilization and fusion pore formation. NSF then disassembles the 
assembled SNARE complex. 
 
The formation of SNARE complexes is tightly regulated, and munc18-1 and munc13 are 
both known to be required for membrane fusion. Interestingly, Munc18-1 has both 
stimulatory and inhibitory effects on vesicle fusion, as it binds to syntaxin-1, keeping it 
in a closed conformation, thus preventing membrane fusion. However it is also capable 
of binding to the assembled SNARE complex, where it may promote vesicle fusion 
(Dawidowski & Cafiso, 2016). 
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Two chaperone systems are also involved in synaptic vesicle fusion. The first of these is 
the complex of cysteine string protein alpha (CSPα), Hsc70 and SGT. This complex binds 
to SNAP-25 on the presynaptic membrane, maintaining it in a monomeric form that is 
capable of forming SNARE complexes.  The second chaperone system is centered around 
synucleins, which act to increase the rate of complex formation (Sudhof & Rizo, 2011). 
Mutations in synuclein have been shown to cause Parkinson’s disease. 
 
1.3 Use of C. elegans to study neurobiology  
 
Sydney Brenner could be described as the godfather of C. elegans neurobiology as he 
began to study the genetics of worms as model organisms in 1963. In 1967 he carried 
out the first chemical mutagenesis studies on wild type worms.  Using the chemical ethyl 
methane sulfonate (EMS) he phenotypically characterized around 100 mutants that had 
easily visible phenotypes (Brenner, 1974). Of particular interest were those that had 
uncoordinated movement, which he described as the “Unc” phenotype. These mutated 
genes included may genes now known to be involved in the process of 
neurotransmission, including unc-30, which controls differentiation of some GABA 
neurons, as well as those in neuronal path-finding, such as unc-6, which plays a role in 
axonal outgrowth. 
 
Although Brenner’s early studies were performed in C. briggsae, he then switched to C. 
elegans, due to its relative ease of growth and maintenance.  C. elegans are earth dwelling 
microscopic self-fertilizing hermaphrodites (XX). When hatched, the worms are around 
0.25mm long but grow to 1mm in length once they reach adulthood, which takes around 
3 days. They are transparent, meaning that fluorescent constructs can be easily used to 
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investigate protein localization or dynamics. In addition, protein-protein interactions can 
also be studied in vivo (Feinberg et al., 2008). To observe worm phenotypes, such as egg 
laying and feeding, dissection microscopes can be used to observe phenotypic changes in 
worms grown in petri dishes. For higher resolution images, compound or confocal 
microscopes are used to achieve single-cell resolution (Corsi, Wightman, & Chalfie, 2015). 
Although the majority of worms are hermaphrodites, less than one percent of the 
population is male (XO). This allows scientists to perform genetic crosses to generate 
worms with genotypes of interest. The fact that 99% of the population is self-fertilizing 
is greatly advantageous as it means that a whole worm population can be generated from 
a single worm. 
 
During development C. elegans go through four larval stages, known as L1, L2, L3 and L4. 
At the end of each stage, a new cuticle is formed and the old cuticle molts from the worm. 
Around 12 hours after the L4 stage of development adult worms begin to produce 
progeny. Egg laying continues for 2-3 days until the worms have run out of sperm. After 
this, progeny can only develop if they are mated with a male worm. Following the 
reproduction phase, wild type worms live for another 2-3 weeks under normal conditions 
(Corsi et al., 2015).  
 
In 1975, dauer larva were discovered (Cassada & Russell, 1975), where C. elegans go into 
an arrested developmental stage in response to environmental stress. This is sometimes 
known as L2d –an alternative L3 stage. In this phase a cuticle forms around the whole of 
the organism, plugging the mouth so that the worm cannot feed or develop. This increases 
the worm’s resistance to chemicals, and in this state the worm can survive for many 
months with no food source. Three main parameters for dauer arrest are population 
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density, supply of food and temperature.  This phase is useful in a lab setting. For example 
when strains are ordered, they are often in transit for several days and hence they run 
out of food. However, rather than starving and dying, worms (in L1 phase) signal to 
become dauer. Therefore, when the worms arrive in the lab, they can be transferred to 
petri dishes containing bacteria. This causes the worms to molt (and lose their mouth 
plugs), enabling feed to resume, and development to L4 and adult worms to continue 
(Cassada & Russell, 1975). 
 
C. elegans provide a simple model organism, which can be used to genetically investigate 
the physiological regulators of neuronal function. The C. elegans genome encodes around 
19000 genes, and a single pair of X chromosomes. An adult hermaphrodite has 302 
neurons, and forms about 2000 synapses at neuromuscular junctions (NMJ) (White, 
Southgate, Thomson, & Brenner, 1986), not including an additional 5000 non 
neuromuscular synapses (e.g. interneurons). The synaptic and gap junctions formed in 
worms are stereotypical from worm to worm, showing about 75% reproducibility. In 
1986 electron microscopy studies generated a near complete map of the worm neuronal 
network, known as the connectome (White et al., 1986). However, this map was lacking 
in certain areas of the network, especially in ventral cord neurons. In 2011 Dmitri 
Chklovskii and his group published a complete map of the connectome, and this 
represents the first and only complete connectome in any organism (Varshney, Chen, 
Paniagua, Hall, & Chklovskii, 2011). This allowed them to test relationships of signal 
propagation to behavioural phenotypes (Varshney et al., 2011), demonstrating why C. 
elegans is an ideal model organism in which to study neurobiology. 
 
1.4 Neurotransmitters from C. elegans to Humans 
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1.4.1 Acetylcholine 
 
The first neurotransmitter to be discovered was acetylcholine (Ach) in 1921, and it was 
later shown to also act as an excitatory neurotransmitter in nematodes (del Castillo, De 
Mello, & Morales, 1963), although at this stage, not in C. elegans specifically. Excitatory 
cholinergic signaling facilitates many functions in C. elegans, from egg laying to 
pharyngeal pumping and defecation cycles. However, most significantly for this study is 
its effect on locomotion.  
 
Acetylcholine is the primary excitatory neurotransmitter in C. elegans (Rand, 2007). The 
enzyme choline acetyltransferase (ChAT) catalyzes the synthesis of acetylcholine from 
choline, which is then loaded into synaptic vesicles by the Vesicular Acetylcholine 
Transporter (VAchT, Unc-17). One classical way to determine whether a neuron is 
cholinergic or not is to test for the expression of these two proteins. The lumen of the 
synaptic vesicle is acidic, due to the action of an ATP-dependent proton-pump, which 
allows VAChT to exchange protons for the acetylcholine, resulting in acetylcholine uptake 
into synaptic vesicles. At this point, docking, priming and release of the acetylcholine 
containing vesicles is very similar to that of other neurotransmitters (Rand, 2007). 
Following vesicle/membrane fusion, acetylcholine is released into the synaptic cleft 
where it binds to two main types of acetylcholine receptor – ionotropic heterotrimeric 
receptors that are responsive to the drug levamisole, and homomeric receptors that are 
insensitive to levamisole but sensitive to nicotine. Activation of these receptors leads to 
an influx of sodium and calcium cations, leading to depolarization of the muscle cell, and 
muscle contraction (Rand, 2007). 
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To re-set the cholinergic signal, acetylcholinesterases (AChEs) degrades acetylcholine in 
the synaptic cleft back into acetate and choline molecules. Four AChEs (ace-1, ace-2, ace-
3, and ace-4) have been discovered in C. elegans. Ace-1 is expressed in a few neurons, 
however, its predominant site of expression is in muscle cells. In contrast, motor neurons 
express Ace-2. Ace-3 has been shown to have AChE activity but this only represents a 
small proportion of the AChE activity in C. elegans. To date, Ace-4 has not been shown to 
have enzymatic activity. ((Combes, Fedon, Toutant, & Arpagaus, 2003), (Lewis, Gehman, 
Baer, & Jackson, 2013)), Choline then needs to be returned to the presynaptic terminal 
by transporters such as Choline-Transporter 1 (CHO-1), which mediates high-affinity 
choline uptake, and whose loss leads to a decreased acetylcholine production (Matthies, 
Fleming, Wilkes, & Blakely, 2006). SNF-6 has also been reported as a choline transporter, 
but little research has been carried out into its role in comparison to CHO-1 at the NMJ. 
 
In humans, acetylcholine is thought to act more as a neuromodulator than a 
neurotransmitter in the brain (Picciotto, Higley, & Mineur, 2012), whereas in the 
peripheral nervous system (at NMJs) it has an excitatory role. A neuromodulator is a 
chemical that causes a change of state of a neuron (or group of neurons), but is not 
directly excitatory. Cholinergic signaling has roles in the excitability of neurons, as well 
as influencing synaptic transmission itself and inducing synaptic plasticity. However the 
machinery behind the cholinergic signaling is highly conserved. For example, the human 
ortholog of VAChT (also termed VAChT) was elucidated via sequence similarity to the C. 
elegans protein. This provides an excellent example of how the identification of novel 
effectors in C. elegans can provide new insight into evolutionary conserved effectors of 
human synaptic function. 
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1.4.2 GABA (gamma-amino-butyric acid) 
 
In vertebrates, the most common inhibitory neurotransmitter is GABA. Significantly, 
GABA is also a vital neurotransmitter in C. elegans, primarily at NMJs (Jorgensen, 2005).  
In C. elegans GABA is found in 26 neurons, including D-type neurons (dorsal and ventral 
muscles), RME motor neurons (head muscle) as well as in the AVL and DVB motor 
neurons. GABA is only excitatory in the AVL/DVB motor neurons, where it controls the 
contraction of the enteric body muscles, enabling defecation. In other neurons, GABA acts 
as an inhibitory neurotransmitter.  
 
For locomotion to occur in C. elegans, the dorsal and ventral longitudinal muscles must 
alternatively contract and relax (Jorgensen, 2005). When the dorsal muscles contract, the 
ventral muscles relax and vice versa. Acetylcholine release from ventral or dorsal 
cholinergic motor neurons causes body wall muscle contraction. Acetylcholine also 
stimulates GABA to be released, by either the dorsal or ventral GABA motor neurons (the 
opposite to where the acetylcholine was released). GABA crosses the synapse and binds 
to a heterodimer of Unc-49A and Unc-49B subunits (Jorgensen, 2005). This heterodimer 
forms a ligand activated chloride channel, and is the ortholog of vertebrate GABA-A 
receptors. Upon binding GABA, chloride ions are able to diffuse into the cell, leading to 
hyperpolarization and decreased excitability of the membrane. If the chloride ion 
concentration is high in the muscle, muscle contraction inhibition still occurs because the 
membrane voltage is clamped at that of the chloride equilibrium potential, preventing 
further depolarization (Jorgensen, 2005). From this it can be seen that a balance of 
excitatory: inhibitory Ach: GABA signaling is essential for normal locomotion. This is the 
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reason why worms lacking GABA “shrink” as contraction of both dorsal and ventral 
muscles occurs. 
 
In vertebrates, GABA inhibition is caused by either activation of chloride channels 
(mediated by the GABA-A receptor), or by the combined opening of potassium and 
inhibiting calcium channels (mediated by the GABA-B receptor).  GABAergic 
neurotransmission is essential for neuron synchronization in the brain, and therefore is 
key to neuronal communication and memory processing (Nava-Mesa, Jiménez-Díaz, 
Yajeya, & Navarro-Lopez, 2014). 
 
1.4.3 Glutamate 
 
The main excitatory neurotransmitter in humans is glutamate, which is a biological 
precursor of GABA (Danbolt, 2001). Glutamate is transported by Vesicular Glutamate 
Transporters (VGLUTs) into synaptic vesicles.  At the postsynaptic zone, Postsynaptic 
Density (PSD)-95 anchors the glutamate receptors N-methyl-D-asparatate receptor 
(NMDAR) and alpha-amino-3-hydroxy-5-methyl-4-isoxalonepropionic acid receptor 
(AMPAR) to the surface.  As described previously the balance of excitatory: inhibitory 
neurotransmission in C. elegans is required for their locomotion. Likewise, this balance is 
also required in humans, as imbalances have been proposed to lead to diseases such as 
autism spectrum disorders and schizophrenia as well as neurodegenerative disorders 
like Alzheimer’s disease (Nava-Mesa et al., 2014). 
Ionotropic glutamate receptors have also been identified in C. elegans neurons, for 
example subunits have been detected in both RIA and command interneurons (Brockie & 
Maricq, 2006). By mutating receptor subunits, functions of glutamatergic 
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neurotransmission can be elucidated. The first example of this was in glr-1 mutants, 
where mutants were found to have defective long-term memory, avoidance to stimuli 
(such as nose-touch or octanol), and foraging behaviour (Wang GJ et al., 2010). This 
excitatory neurotransmission is hence also vital in worm neurons. 
 
As well as acetylcholine, GABA and glutamate, C. elegans also use other chemicals as 
neurotransmitters, including biogenic amines, and neuropeptides. Four biogenic amines 
are found in C. elegans. These are octopamine, tyramine, dopamine and serotonin. In 
vertebrates other signaling amines are also produced, such as histamine and epinephrine, 
however, this is not the case in C. elegans.  
 
1.4.4 Other Neurotransmitters in C. elegans 
 
Serotonin is a conserved regulator of energy balance from invertebrates to vertebrates. 
Serotonin has been found to act with another biogenic amine, octopamine to control body 
fat loss in C. elegans (Noble, Stieglitz, & Srinivasan, 2013). Serotonin has also been linked 
to locomotion behavior, and is synthesized in neurosecretory motor neurons. Thus 
defects in serotonin signaling can affect the locomotive behavior of worms. In humans 
defects in serotoninergic neurotransmission have been linked to multiple psychological 
disorders, from schizophrenia to depression and anorexia nervosa (Lin, Lee, & Yang, 
2014). 
 
Octopamine is synthesized from tyramine, and has been described as the invertebrate 
equivalent of norepinephrine. In the octopamine biosynthesis pathway, tyrosine is firstly 
converted to another amine neurotransmitter, tyramine, which is then converted to 
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octopamine. However, tyramine and octopamine have been found to have distinct 
receptors, leading to the conclusion that both can act as neurotransmitters (Alkema, 
Hunter-Ensor, Ringstad, & Horvitz, 2005; Wragg et al., 2007). 
 
Dopamine signaling is vital in C. elegans for responding to changes in environmental 
conditions. An important example is the response to food availability (Chase & Koelle, 
2007). Dopamine signaling is induced in the presence of food, which is thought to lower 
their locomotion rate upon entering a food source. Interestingly the dopaminergic and 
octopaminergic pathways link in SIA cholinergic neurons. Upon presence of food, 
dopamine signaling inhibits the release of octopamine, which leads to decreased c-AMP 
response element-binding protein (CREB) induction. Inhibition of dopaminergic 
receptors causes a Resistance to Inhibitors of Cholinesterase (RIC) phenotype, making 
the interpretation of the aldicarb-sensitivity assays more complex (Suo & Ishiura, 2013). 
 
There are over 100 genes in C. elegans (C. Li & Kim, 2008) encoding over 250 
neuropeptides. These include insulin-related peptides (INPs), FMRFamide-related 
peptides (FLPs), and neuropeptide-like proteins (NLPs). These directly or indirectly 
affect synaptic function, with some being reported to act as neurotransmitters 
themselves. Some neuropeptides have been reported to regulate locomotion in C. elegans, 
and several neuropeptide mutants (e.g. nlp-12) have been shown to confer resistance to 
aldicarb, indicating a change in cholinergic or GABA signaling (Sieburth et al., 2005). 
Certain neuropeptides, such as flp-1 and flp-8, have also been shown to play a role in 
homeostasis of the excitatory: inhibitory balance at the NMJ (Stawicki, Takayanagi-Kiya, 
Zhou, & Jin, 2013). Thus, neuropeptide signaling is crucial for C. elegans locomotion and 
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other phenotypes such as egg laying, metabolism and their response to different 
environmental conditions. 
 
1.5 Increasing Complexity of Neurotransmission 
 
The complexity of neurotransmission increases when the effects of conditional post-
translational modifications and cross talk between pathways are considered.  
 
1.5.1 Phosphorylation 
 
 In the 1990s studies showed the effect of Protein Kinase A (PKA)-dependent 
phosphorylation at the presynaptic and postsynaptic terminals (Nguyen & Woo, 2003). 
Phosphorylation has since been shown to be critical in some forms of long-term memory 
and synaptic plasticity. PKA plays a role in the recruitment of synaptic vesicles to the 
readily releasable pool (from the reserved pool), and certain phosphoproteins are 
localized on synaptic vesicles. Key examples of these are synapsins (Menegon et al., 
2006). Synapsin 1 and 2 normally act to tether synaptic vesicles to the actin cytoskeleton.  
They are phosphorylated by PKA following calcium stimulation in hippocampal neurons. 
This stimulation leads to an increased rate of synaptic vesicle exocytosis, as the vesicles 
dissociate from the actin cytoskeleton. As well as having one site for PKA 
phosphorylation, synapsin-1 also has two sites for calmodulin-dependent kinase II 
(CAMKII) phosphorylation, and all isoforms have consensus sequences to allow other 
kinase activity (e.g. Mitogen-activated Protein Kinase (MAPK)). In combination these 
facts suggest that neurotransmission and hence locomotion defects could be seen if 
phosphorylation pathways were altered. 
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1.5.2 Glycosylation 
 
Other posttranslational modifications that increase the complexity of synaptic 
transmission include glycosylation. O-GlcNac–modification is the addition of one N-
acetylglucosamine to serines and threonines (O-linkage) of proteins, and is also thought 
to be a reversible dynamic process. O-GlcNAc Transferase (OGT) and O-GlcNACases 
catalyze the addition and removal of O-GlcNAC, respectively (Tallent et al., 2009). O-
GlcNAC, OGT and O-GlcNACases are all highly abundant in the brain, especially in the 
hippocampus. Furthermore, pharmacological modulation of O-GlcNAc levels has been 
shown to alter synaptic plasticity (Tallent et al., 2009). It has been shown that there are 
extensive O-GlcNAc-modifications of proteins expressed in the pre- and post-synaptic 
terminals. Synapsin-1 for example, has 9 sites of potential O-GlcNAC-modification. It has 
also been shown that in many proteins, O-GlcNAC and phosphate compete for sites on 
their target proteins, thus providing links to signaling pathways and conditional variation 
or modulation of responses. In rats, synapsin-1 has three O-GlcNAc sites, two of which 
are also CAMKII sites (Skorobogatko et al., 2014). Glycosylation of these sites has been 
reported to increase phosphorylation of synapsin-1 at serine-9 in mice, which is a site 
known to be phosphorylated by PKA. However phosphorylation of two other sites (MAPK 
and CAMKII) was also reported, increasing the complexity of regulatory crosstalk (Tallent 
et al., 2009).  
 
1.5.3 Ubiquitination 
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There is a significant amount of evidence to demonstrate the important role of the 
ubiquitin proteasome system (UPS) in both pre- and post-synaptic compartments 
(Rinetti & Schweizer, 2010). There is a large amount of combinatorial diversity in the 
UPS. There are only one or two genes encoding E1 ubiquitin activating enzymes, tens of 
E2 ubiquitin-conjugating enzymes, but up to 1000 genes encoding E3 ubiquitin ligases, 
with many showing neuron specific expression (Nakayama & Nakayama, 2006). The UPS 
system has been shown to play a role in the formation of the presynaptic terminal, 
regulating both axonal growth and growth cone guidance (Rinetti & Schweizer, 2010). 
This role is conserved throughout evolution, as in Apylsia, inhibition of the proteasome 
leads to increased strength of neurotransmission, with an increase in the number of 
presynaptic boutons (Zhao, Hegde, & Martin, 2003). This has also been shown in 
Drosophila melanoganster NMJs, with the increased strength being due to an increased 
level of Dunc-13 (Unc-13) – the fly ortholog of human Munc13 (Speese, Trotta, Rodesch, 
Aravamudan, & Broadie, 2003). This change was dependent on PKA, again showing the 
complex effects of crosstalk between post-translational pathways. In humans, studies 
have been carried out in hippocampal neurons, where proteasomal inhibition for 2 hours 
led to an increase in the size of the recycling pool of vesicles (Willeumier, Pulst, & 
Schweizer, 2006). This increased pool size was dependent on neuronal activity, 
suggesting a regulatory role for the UPS at synapses.  
 
In C. elegans the multi-subunit ubiquitin ligase Anaphase Promoting Complex (APC) has 
been reported to regulate the excitatory: inhibitory balance at the NMJ, as APC mutants 
(and knockdowns) caused hypersensitivity to aldicarb, which was rescued by APC-
expression, specifically in GABA neurons, indicative of a role in GABA signaling (Kowalski 
et al., 2014). 
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1.6 Lipid Modifications – Palmitoylation 
 
1.6.1 Palmitoylation  
 
Lipid modification is required for the membrane localization, trafficking and function of 
many proteins. There are three main kinds of lipid modification; prenylation, 
myristoylation and palmitoylation. Prenylation is a non-reversible reaction where either 
15- or 20-carbon isoprenoids are added to proteins near to the C-terminus (F. L. Zhang & 
Casey, 1996).  Myristoylation is also non-reversible, but involves the addition of 14-
carbon myristate to N-terminal glycines of target proteins (Wright, Heal, Mann, & Tate, 
2010). In contrast, palmitoylation is the most common kind of lipid-modification of 
proteins in the brain, and classically involves the addition of the 16-carbon fatty acid 
palmitate to a cysteine residue on substrate proteins. 
 
There are two types of palmitoylation reactions possible for target proteins. The less 
common is N-palmitoylation, where a non-reversible amide bond forms between the 
palmitoyl group and the target protein. The more common type is S-palmitoylation, 
which will be the focus of this section. S-palmitoylation (also known as S-acylation) is a 
reversible reaction where a thioesterase bond is formed between the cysteine residue of 
the target protein and palmitate. 
 
As palmitoylation is the most prevalent post-translational lipid modification in neurons, 
numerous studies have uncovered several examples of palmitoylated neuronal proteins.  
Examples include signaling proteins (such as HRAS and RHOB), synaptic scaffolding 
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proteins, such as Postsynaptic Density Protein (PSD)-95, neuronal cell adhesion 
molecules and synaptic vesicle proteins (Fukata & Fukata, 2010). Unlike other forms of 
lipid modification, palmitoylation substrates tend to have multiple palmitoylated amino 
acids. The cysteine-string domain of CSPα, for example, is palmitoylated several times, 
which is essential for its function. Mutations in CSPα lead to adult neuronal ceroid 
lipofuscinosis (ANCL), and mutations may affect the palmitoylation of it’s cysteine-string 
domain (Greaves et al., 2012). 
 
Both integral membrane and cytoplasmic proteins can be palmitoylated, and there are 
over 200 known proteins in the palmitoylation database (known as the palmitoylome) 
(Sanders et al., 2015). Palmitoylation of cytoplasmic proteins can allow the protein to be 
anchored to membranes. This is the case for SNAP-25. Anchoring to the membrane allows 
SNAP-25 (with syntaxin-1) to form SNARE complexes with VAMP2 on vesicles to enable 
neuronal exocytosis (Greaves, Prescott, Gorleku, & Chamberlain, 2010). Interestingly 
both VAMP2 and syntaxin-1 have also been reported to be palmitoylated (Drisdel & 
Green, 2004; Veit, Becher, & Ahnert-Hilger, 2000). As both are transmembrane proteins, 
the role of palmitoylation cannot only be to facilitate membrane anchorage.   
 
The reversible nature of S-palmitoylation makes it a vital modification to allow the 
intracellular shuttling of proteins. H- and N-Ras go through rapid palmitoylation/de-
palmitoylation cycles, which causes shuttling between the Golgi apparatus and the 
plasma membrane (Fukata & Fukata, 2010). Their rate of shuttling determines Ras 
signaling, which is in turn linked to MAPK signaling, thus directly linking palmitoylation 
and phosphorylation pathways. Another example of shuttling is the enzyme glutamate 
decarboxylase (GAD65), which is responsible for the synthesis of GABA.  However, there 
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is still much to understand about the role and conditional nature of palmitoylation in the 
crosstalk of the different pathways of synaptic transmission.  
 
Palmitoylation can also change the interaction profiles of soluble proteins. Postsynaptic 
Density (PSD)-95 is localized at excitatory synapses, and has two N-terminal 
palmitoylation sites (El-Husseini et al., 2002). Palmitoylation of PSD-95 is essential for its 
localization at the PSD, which leads to AMPAR clustering. Therefore palmitoylation is 
essential for excitatory glutamatergic signaling in mammals, and has been suggested to 
play a role in synaptic plasticity (El-Husseini et al., 2002). PSD-95 palmitoylation is also 
required for the binding to cyclin-dependent kinase-like 5 (CDKL5). Inhibiting this 
interaction (through down regulation of CDKL5 or PSD-95 mutation) leads to an 
inhibition of dendritic spine formation and growth (Zhu et al., 2013).  
 
Palmitoylation of integral membrane proteins also serves multiple purposes.  For 
example, palmitoylation of integral membrane proteins can lead to their localization at 
specific subdomains of the plasma membrane, for example in lipid rafts. Non-receptor 
tyrosine kinases  (NRTKs) and linker for activation of T cells (LATs) are both 
palmitoylated, and this palmitoylation allows clustering into lipid rafts. If this does not 
occur, T cell activation is attenuated (Guan & Fierke, 2011; Kabouridis, Magee, & Ley, 
1997). The hydrophobic palmitate has also been proposed to cause a membrane tilt of 
the substrate integral membrane protein, which can alter the protein’s interaction profile 
(Blaskovic, Blanc, & Van Der Goot, 2013; Joseph & Nagaraj, 1995). 
 
1.6.2 Palmitoylation enzymes 
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Palmitoylation is an enzyme-mediated reaction, and the enzymes required to add 
palmitate to substrates are known as palmitoyl-acyl transferases (PATs). Protein-
palmitoyl thioesterases (PPTs) and acyl protein thioesterases (APTs) remove the 
palmitate from substrates. The first PAT to be discovered was Effector of Ras Function 2p 
(Erf2p) in Saccharomyces cerevisiae (Lobo, Greentree, Linder, & Deschenes, 2002). In 
combination with the auxiliary protein Effector of Ras Function 4 (Erf4p), it was found to 
palmitoylate Ras2p at the endoplasmic reticulum (ER). The rate of Erf2p palmitoylation 
has been shown to be dependent on Erf4p, but no mechanism has yet been elucidated to 
describe this. 
 
From this another PAT was discovered known as Akr1p, which functions independently 
to palmitoylate Yck2p (Roth, Feng, Chen, & Davis, 2002).  By comparing Erf2p and Akr1p’s 
sequences, a common motif was found, which contained the Asp-His-His-Cys (DHHC) 
domain in a 51 cysteine-rich amino acid span. Identification of this motif enabled 
systematic screening of yeast and other organisms for potential PATs. From this, seven 
family members were elucidated in S. cerevisiae, fifteen in C. elegans, twenty-two in 
Drosophila melanogaster, twenty-four in mice, and twenty-three in humans.  It is not 
however known if all of these proteins function as active PATs (Huang et al., 2009). 
 
Far less is understood about PPT enzymes, due to the lack of a common motif, unlike the 
PATs, all of which encode a DHHC domain. Palmitoyl-protein thioesterase 1 (PPT1) has 
been shown to de-palmitoylate substrates such as H-Ras and G-alpha subunits, and is 
localized in lysosomes and synaptic vesicles (Lehtovirta et al., 2001; Liu, Dudler, & Gelb, 
1996). Another branch of palmitoyl thioesterases are known as acyl-protein thioesterase 
(APT) 1 and 2, which are localized in the cytosol. APT1 is known to de-palmitoylate 
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substrates such as SNAP-23, H-Ras and G protein alpha subunits. APT2 has a different 
substrate profile, and so far is known only to de-palmitoylate Growth Associated Protein 
43 (GAP-43) (Tomatis, Trenchi, Gomez, & Daniotti, 2010). α/β-Hydrolase domain-
containing protein 17 members have also been discovered, which specifically 
depalmitoylate PSD-95 (Yokoi et al., 2016). 
 
1.6.3 Mechanism of PAT action 
 
There is some debate regarding the mechanism of action of the PAT family. By studying 
the yeast PAT Akr1p, it was found that upon incubation with palmitate, auto-
palmitoylation occurs, where a bond forms between the PAT and the palmitate group. 
This palmitate can be removed using the chemical hydroxylamine, suggesting a thioester 
bond, and mutation of the DHHC motif inhibited auto-palmitoylation as well as the trans-
palmitoylation of substrate (Guan & Fierke, 2011; Mitchell, Mitchell, Ling, Budde, & 
Deschenes, 2010). Some of the human PAT family members have also been shown to be 
palmitoylated, namely DHHC9, DHHC15 and DHHC17 (Kang et al., 2008; Swarthout et al., 
2005b). These studies lead to the proposal of a two-step mechanism of palmitoylation, in 
which a labile thioester bond is formed between the cysteine of the PAT (in the DHHC 
sequence) and the palmitate molecule (Figure 1.1). This palmitate is then either 
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hydrolyzed or transferred to the substrate at a specific cysteine residue (Guan & Fierke, 
2011).  
 
 
1.6.4 C. elegans PATs 
 
In C. elegans there are fifteen PATs, predicted on the basis of containing a DHHC domain 
(Edmonds & Morgan, 2014).  However, only five of the PATs have knock out mutants 
available, and few phenotypes have been seen with these mutants. For example, 
locomotion assays revealed that the dhhc-12 mutant has a decreased rate of locomotion, 
and the dhhc-14 mutant has a significant increased locomotive rate (Edmonds & Morgan, 
2014). Lifespan was also analyzed in the same study, showing that dhhc-1, -9 and -14 
mutants each have a reduced mean lifespan, whereas dhhc-12 and dhhc-13 mutants have 
an increased median lifespan, and spe-10 causing a significant increase in the maximum 
Figure 1.1 – Proposed two-step mechanism of PAT enzymatic activity. All PATs are 
transmembrane proteins. In the first step of the reaction a labile thioester bond is formed 
between the cysteine in the DHHC domain of the PAT and palmitoyl-CoA. This is known as 
autopalmitoylation. The palmitoyl group is then transferred to the substrate. 
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lifespan (Edmonds & Morgan, 2014). However, no synaptic function assays were carried 
out on these mutants, and RNAi experiments revealed no other phenotypes. 
 
1.6.5 Human PAT family 
 
All PATs are transmembrane proteins, having between four and six transmembrane 
domains. Every human PAT contains the DHHC motif, located within a 51-amino acid 
cysteine-rich domain between two transmembrane domains. However, some other PAT 
family members in other organisms have differences in this motif. For example, in S. 
cerevisiae, Akr-1, Akr-2 and Pfa-5 have DHYC instead of a DHHC motif (where Y is 
tryptophan) (Mitchell, Vasudevan, Linder, & Deschenes, 2006). The localization of these 
family members varies, with some known to localize to the ER, Golgi and plasma 
membrane (PM).  
 
The consensus sequence for PAT family member substrates is still not fully understood. 
Different PATs are known to have different substrate specificities – for example DHHC17 
is known to have many substrates (Mitchell et al., 2006), whereas DHHC9 is thought to 
only palmitoylate H- and N-Ras (Swarthout et al., 2005b). All of the human PATs except 
DHHC13, DHHC23 and DHHC24 have been shown to be functional, though not all of these 
have been demonstrated in human systems. 
 
The closest ortholog to the yeast Erf2 PAT is zDHHC9, which has been shown to 
palmitoylate N- and H-Ras. This palmitoylation only occurs when DHHC9 is bound to the 
auxiliary protein GCP16 (Swarthout et al., 2005b). There are 3 Ras family members, N-, 
H-, and K-Ras. All Ras isoforms are farnesylated in their C-termini, which allows low 
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affinity interactions with membranes (Eisenberg et al., 2013). H- and N-Ras are 
pamitolyated either once or twice on cysteine residues in the C-terminal hypervariable 
region. This palmitoylation enhances the membrane association of H- and N-Ras. 
However in this region K-Ras instead has 6 lysine residues that mediate hydrophobic 
interactions with membranes (Eisenberg et al., 2013). 
 
As mentioned previously, the target proteins of many of the PATs is unknown, as for the 
majority of PATs there is not yet an identified consensus binding sequence, which would 
help the prediction of substrates. It has been shown in co-expression studies that regions 
outside of the DHHC cysteine rich (DHHC-CR) domain may confer specificity. For 
example, when the DHHC-CR domain of DHHC15 is replaced by that of DHHC3 no 
palmitoylation of a known DHHC3 palmitoylation substrate, SNAP23 is observed 
(Greaves, Gorleku, Salaun, & Chamberlain, 2010).  
 
This theory is enhanced by two of the PATs; DHHC17, also known as Huntingtin 
Interacting Protein 14 (HIP14) and DHHC13 (HIP14L), both of which have N-terminal N-
Ankyrin repeat domains. DHHC17 is known to interact with the neuronal protein 
Huntington (HTT), and when the N-terminus of DHHC17 was added to DHHC3, which 
does not normally show activity/interact with HTT, DHHC3 and HTT interacted (Huang 
et al., 2009). As well as HTT, DHHC17 has also been shown to palmitoylate other neuronal 
proteins, such as JNK3a2, SNAP25b and CSPα. Although zDHHC13 does not seem to 
palmitoylate JNK3a2, SNAP25b or CSPα, it binds all of the above proteins. Recently a 
sequence motif was found for DHHC13/17 substrate proteins – in symbolic form this is 
ΨβXXQP, where Ψ is any aliphatic amino acid, i.e. valine, isoleucine, alanine, or proline. β 
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indicates C-beta branched valine, isoleucine, or threonine. X indicates any amino acid 
(Lemonidis, Sanchez-Perez, & Chamberlain, 2015).   
 
The algorithm known as CSS-PALM was created as a method to determine palmitoylation 
substrates (Zhou, Xue, Yao, & Xu, 2006). This predicts palmitoylation sites based on a 
clustering algorithm, where they collected experimentally verified palmitoylation sites 
(in version 4.0 this was 583 palmitoylation sites from 277 proteins), and grouped them 
into subsets based on their sequence similarity (Zhou et al., 2006). This algorithm has 
been shown to predict palmitoylation sites for around 1000 proteins in a short time frame 
(within 2 minutes). This is a useful tool in determining substrates of palmitoylation. 
 
Many of the PATs have known cellular localization. Most of the PATs are localized at the 
Golgi or ER. Interestingly some PATs have specific localization profiles. For example 
human DHHC2 has been shown to localize to dendritic vesicles, on Rab11 positive 
endosomes, and DHHC8 is localized near synapses (Greaves, Carmichael, & Chamberlain, 
2011; Thomas, Hayashi, Huganir, & Linden, 2013). Some DHHC family members have also 
been found to change their localization dependent on neuronal activity, a key example 
being DHHC5 (Brigidi, Santyr, Shimell, Jovellar, & Bamji, 2015). Normally DHHC5 is 
localized in dendritic spines, and is sequestered there by forming a complex with Fyn 
kinase (which phosphorylates DHHC5) and PSD-95. Upon neuronal activity, this complex 
is disrupted, and DHHC5 is internalized and transported to dendritic shafts, where it 
palmitoylates delta-catenin (Brigidi et al., 2015). Palmitoylated delta-catenin stabilizes 
N-cadherin at synapses, and mediates changes in dendritic spine remodeling, synapse 
efficacy, and thus learning and memory (Brigidi et al., 2014).  
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 The TMD organelle predictor can also be used to predict the localization of 
transmembrane proteins. This prediction software uses the first two transmembrane 
domains to predict localization, and has an overall success rate of 82% (Sharpe, Stevens, 
& Munro, 2010).  
 
1.7 Neuronal Function of PATs 
 
There are multiple key examples of PATs playing a role in neuronal function (Fukata & 
Fukata, 2010). As mentioned previously, palmitoylation of PSD-95 is key for 
glutamatergic signaling, as well as dendritic spine formation and development. DHHC3 is 
localized on the Golgi membrane and has been shown to be the major PAT responsible 
for palmitoylating PSD-95, as well as GABA receptors at inhibitory synapses (Keller et al., 
2004). However, palmitoylation of PSD-95 by DHHC2 has also been reported. DHHC2 has 
a very different localization to DHHC3, being predominantly restricted to dendritic 
spines. This palmitoylation allows dynamic changes in the palmitoylation state of PSD-95 
at the synapse (Noritake et al., 2009). This suggests that multiple PATs may have similar 
substrate specificities, but play different roles depending on their localization. 
 
Palmitoylation has also been implicated in various neurological diseases, and mutations 
in certain PATs have been proposed to be a factor in disease onset/progression.  
 
1.8 Disease Related PATs 
 
1.8.1 DHHC8 
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The most widely studied DHHC enzyme in terms of neurological disease is DHHC8. The 
gene encoding DHHC8 (zDHHC8) is located on chromosome 22 at 22q11.2. Either a 3Mb 
or 1.5Mb deletions have been shown to be associated with the development of 
schizophrenia (Mukai et al., 2004), as well as other emotional deficits and autism.  Genetic 
deletion at this locus also leads to DiGeorge syndrome, which is associated with a 20- to 
30-fold increase in the risk of the patient developing schizophrenia. Around 30% of 
patients with this micro-deletion develop schizophrenia. As well as this, genetic variants 
of zDHHC8 have also been associated with schizophrenia (Mukai et al., 2008). 
 
DHHC8 knockout mice have been shown to exhibit a reduction in pre-pulse inhibition, a 
phenotype that has also been shown in some schizophrenic patients.  In a mouse model, 
where a 1.3Mb chromosomal deficiency was created on the syntenic chromosome to 
22q11.2, primary hippocampal neurons had a lower density of dendritic spines, an 
impairment of the growth of dendrites, and a reduced number of glutamatergic synapses 
(Mukai et al., 2008). All of these phenotypes were rescued by the reintroduction of 
DHHC8, highlighting its vital role at the synapse. However, few interaction partners and 
specific substrates of DHHC8 have yet been elucidated. 
 
Protein Interacting with C Kinase (PICK1) has been shown to be a substrate of DHHC8, 
which is involved in cerebellar long-term synaptic depression. The palmitoylation of 
PICK1 is required for the induction of long-term depression. Few other 
substrates/interaction partners have been found for DHHC8 however, therefore, it could 
be playing other roles at the synapse (Thomas et al., 2013). As DHHC8 is localized at or 
near to all synapses, DHHC8 is a very interesting PAT to study. 
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Furthermore, in a recent study, a modified acyl-biotinyl exchange (ABE) technique was 
carried on post-mortem brains from patients suffering from schizophrenia. Samples were 
collected from the frontal cortex and homogenized. They found that palmitolylation was 
reduced by 20% in the brains of patients suffering from schizophrenia, specifically in the 
dorsolateral prefrontal cortex (Pinner, Tucholski, Haroutunian, McCullumsmith, & 
Meador-Woodruff, 2015). This effect was not seen in rats treated with anti-psychotic 
medication, suggesting defects in palmitoylation could be the cause or effect of 
schizophrenia. 
 
1.8.2 DHHC5 
 
DHHC5 is localized in postsynaptic compartments, and has been demonstrated to 
palmitoylate delta-catenin and grip-1b (Brigidi et al., 2014). In mice that are homozygous 
for a hypomorphic allele of zDHHC5, impaired synaptic plasticity as well as impaired 
performance on learning and memory tasks was observed (Y. Li et al., 2010). Genome-
wide association studies have shown an association between DHHC5 and bipolar 
disorder and schizophrenia (Brigidi et al., 2015). As well as this, one paper lists a non-
sense mutation of zDHHC5 being found in a patient diagnosed with schizophrenia 
(Fromer et al., 2014). 
 
1.8.3 DHHC17 and DHHC13 
 
Another PAT of high interest is DHHC17, which to date has been shown to palmitoylate 
thirteen substrates in mammals. These substrates include neuronal proteins such as 
synaptotagmin-1, SNAP-25, and HTT. In Huntington’s disease, expansion in the 
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trinucleotide CAG repeat region of the HTT gene is the causative factor, which encodes a 
polyglutamine stretch. If a patient has more than 36 repeats of this CAG, the patient will 
develop Huntington’s disease provided their life span is long enough. The polyglutamine 
stretch causes HTT to aggregate, leading to toxicity and neurodegeneration (Bates, 2003). 
Studies have found that in some sufferers with Huntington’s disease, this polyglutamine 
expansion prevents its interaction with DHHC17, meaning that palmitoylation is 
decreased (Fukata & Fukata, 2010). This decreased palmitoylation is postulated to cause 
an accumulation of HTT. HTT and DHHC17 appear to have a lot of inter-regulation. For 
example, mutation of HTT has been shown to decrease the palmitoylation of another 
substrate of HIP14, SNAP-25 (Huang et al., 2011). This was corroborated in a study of a 
Huntington’s disease mouse model (YAC128), where a reduced SNAP-25 palmitoylation 
was observed (Singaraja et al., 2011). 
 
Recently, a yeast 2-hybrid (Y2H) screen was carried out to find novel interaction partners 
of DHHC17 (Butland et al., 2014). In this paper a Y2H library screen was carried out using 
a pool of three fragments of HIP14 against the human ORFeome. This screen identified 
214 non-redundant proteins, 36 of which were shared with one of DHHC17’s known 
substrates, HTT. Seventeen of these genes were known to play a role in Huntington’s 
disease. Synaptic-related proteins were identified, and interestingly this also included K-
Ras. This screen, however, was not carried out on full length DHHC17.  
 
DHHC13 is the only other human PAT family member to have an N-ankyrin repeat 
domain at the N-terminus. It is ubiquitously expressed, but studies have shown it to play 
an important role in the central nervous system (CNS). DHHC13 has been reported to 
palmitoylate SNAP-25, and mutant mice develop features of Huntington’s disease. Both 
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DHHC17 and DHHC13 interact with HTT, and when either of these PAT proteins were 
mutated in mice, this interaction was interrupted (Sutton et al., 2013). Both mutants 
displayed motor defects in climbing and learning, although some differences were seen, 
for example in the time of onset of the neuropathy. DHHC17 knockouts showed 
neuropathy from embryonic stages, whereas DHHC13 knockouts showed deficits later, 
when the mice were adults (Sutton et al., 2013). This shows both proteins are interesting 
candidates for further study. 
 
1.8.4 DHHC9  
 
DHHC9 is localized in the Golgi and has four transmembrane domains, with the catalytic 
DHHC domain located between the second and third transmembrane region. The N-, C-, 
and DHHC domain are all cytoplasmic (Fukata & Fukata, 2010). Mutations in zDHHC9 
have been linked to X-linked intellectual disability (XLID), associated with marfonoid 
habitus. XLID is one of the most common causes of mental disorders, with 79 other genes 
being associated with XLID (Mitchell et al., 2014). Four different mutations of zDHHC9 
have been found, which lead to XLID.  Two are nonsense mutations, caused by a 
truncation or a frameshift. The other two are missense variants (Mitchell et al., 2014). As 
the nonsense mutations delete the catalytic domain, these mutations render DHHC9 non-
functional. However the two missense mutations have been suggested to alter auto-
palmitoylation of DHHC9 in different ways. Both reduce the steady state level of the 
DHHC9 that has been palmitoylated. The P150S mutation decreases the initial burst of 
palmitoylation, but the R148 increases the rate of hydrolysis of the palmitoyl-steady state 
substrate (Mitchell et al., 2014). Either mutation is proposed to decrease the rate of N- 
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and H-Ras palmitoylation. It is important to note that no mechanisms have been proven 
for exactly how zDHHC9 mutations functionally leads to the symptoms seen in XLID. 
 
1.9 Problems of palmitoylation research 
 
The progress of palmitoylation research has been slow since the discovery of Erf2. This 
is due to the difficulty in studying palmitoylation. Firstly there is a significant level of 
redundancy in the PATs – cells/tissues often express several different PATs. For example 
HeLa cells express 20 of the 23 PAT family members. Carrying out multiple gene 
knockouts is not usually realistic/feasible, hence elucidating which PAT palmitoylates 
which substrate in human cells is very challenging. Furthermore, carrying out in vitro 
assays is also problematic due to the low levels of PAT activity in its soluble state, and the 
fact that it is difficult to purify substrates without their palmitate group. Nevertheless in 
recent years, new techniques such as ABE and click chemistry have allowed 
palmitoylation to be detected more sensitively.  
 
1.10 C. elegans genetic manipulation techniques 
 
To assess if a gene has an effect on synaptic function in C. elegans, the gene can be 
disrupted via different methods – namely mutation (to generate loss of function or gain-
of-function mutants), RNAi (to knock down the expression of selective gene transcripts), 
or the generation of transgenic constructs (to express variants of the gene of interest).  
 
1.10.1 Microinjection 
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When generating transgenic constructs, microinjection is commonly used and constructs 
can be targeted to specific regions of the worm, dependent on the construct design. For 
example, the neurosensitive Tu3311 strain was generated by injecting a construct of the 
sid-1 gene fused to the pUNC-119 promoter into the worm (Calixto, Chelur, Topalidou, 
Chen, & Chalfie, 2010). This means that the sid-1 gene is over-expressed in all neurons. 
There are many advantages of this system as fluorescent constructs can be injected in to 
allow visualization of the gene under a fluorescent microscope. Temperature sensitive 
alleles can also be used, which allows the temporal assessment of the gene’s activity, 
which is useful when mutating the gene would cause lethality at the developmental stage. 
RNAi can also be performed by microinjection. However, microinjection of worms is 
considered difficult in comparison to other methods of genetic manipulation, and is not a 
viable technique to combine with high-throughput screens. 
 
1.10.2 Mutation 
 
 For mutation screens, either forward genetic screens or reverse genetic screens can be 
carried out (Kutscher & Shaham, 2014). In forward genetic screens, the whole genome is 
mutagenized, and unknown genes are sought that have caused a change in a biological 
process (e.g. egg laying). A common mutagenesis agent used is EMS. This induces random 
genetic mutations in the C. elegans embryo. The worms are then genotyped to elucidate 
where a mutation has taken place. Stocks of these worms can then be made and stored.  
Other forms of forward genetics are radiation-induced and transposon-induced 
mutagenesis.  
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In reverse genetic screens, target-selected and gene-targeted mutagenesis can be 
performed. In target-selected mutagenesis, the whole genome is mutagenized but only a 
single gene is then selected for commonly by the polymerase chain reaction (PCR). In 
gene-targeted mutagenesis, a single gene is mutated (i.e. the rest of the worm is not 
mutagenized). An example of this form of mutagenesis is clustered regularly interspaced 
short palindromic repeats (CRISPR), which has become a widely used method of gene 
editing. CRISPR utilizes the Cas9 protein, which binds a single guide RNA, and cleaves 
DNA complementary to a 20bp region of this RNA strand, generating double strand 
breaks (Frøkjær-Jensen, 2013). CRISPR has been used in C. elegans to mutate endogenous 
genes to study gene function, as well as to insert fluorescent protein coding sequences 
into genomes to analyze the expression and localization of endogenous proteins (Katic & 
Grosshans, 2013; Rose et al., 2007).  
 
The main advantage of generating mutant strains is that mutations are heritable and 
100% efficient. Although RNAi can give variable results, depending on how efficiently the 
RNAi has been up-taken, genomic mutations tend to give more reliable results. However 
when a gene is essential, mutating it can lead to lethality or sterility, making it impossible 
to make knockout worms for these genes.  Another disadvantage is that as the worm 
background is not neuronally sensitive, the mutation occurs throughout the entire worm. 
For genes that are expressed throughout the worm this can lead to phenotypes that are 
not due to the change of gene expression in neurons. Another point to note is that 
mutations may delete a locus of genes, not just the specific gene of interest. Generating 
mutants can also be time-consuming and laborious. 
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Human protein constructs can also be injected into worms, in order to analyze the effect 
of overexpression of toxic proteins in worms. One example of this is the transgenic worms 
overexpressing amyloid beta (Aβ)(McColl et al., 2012). Aβ is formed from proteolytic 
cleavage of amyloid precursor protein (APP), and Aβ peptide buildup is a characteristic 
of plaques found in several neurodegenerative diseases, the most well known being in 
Alzheimer’s disease. Although C. elegans express an ortholog of APP – APL-1, an ortholog 
of Aβ has not been observed (due to a lack of cleavage sites for γ-secretase). The group 
transgenically expressed Aβ1-42 (a fragment consisting of 42 amino acids) and 
phenotypically characterized the worms. By overexpressing human proteins in C. elegans, 
drug screens can also be used to screen for possible therapeutics in humans.  This is far 
simpler and more rapid than using the drugs in more complex organisms.  In addition, 
neuroprotective compounds have also been tested in C. elegans screens (Chen, Barclay, 
Burgoyne, & Morgan, 2015). This shows the possible power of using C. elegans to better 
understand the mechanism of action of drugs with multiple effects and plausible targets. 
 
1.10.3 RNAi 
 
RNAi has successfully been used in C. elegans for many years for reverse genetic screens. 
It is systemic, meaning that when worms are either soaked in dsRNA or fed bacteria 
expressing dsRNA, the dsRNA can spread throughout the worm to take effect (Calixto et 
al., 2010). RNAi is also hereditary – it has been shown to last for up to 4 generations 
(Grishok, 2005). There are two methods of ingestion of RNAi – the first of these is soaking 
the worms in a solution concentrated in dsRNA. However, the more simplistic technique 
is the ingestion of bacteria expressing dsRNA, which is the technique focused on here. 
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There are two main libraries of dsRNA clones, from the Ahringer (Fraser et al., 2000; 
Kamath et al., 2003) and Vidal (Rual et al., 2004a) labs. The Ahringer library has 16,757 
clones, and the inserts contain introns and exons between 500bp and 2.5kb. The Vidal 
library is smaller, with 11,511 clones, and is known as the ORFeome-RNAi v1.1 (Kamath 
et al., 2003; Rual et al., 2004b), as full-length open-reading frames (ORFs) are inserted 
into a double T7 vector. The bacterial strain HT115 is used in both libraries, which has an 
isopropyl beta-d-1-thiogalactopyranoside (IPTG) inducible T7 polymerase as well as 
having disruption of the dsRNAse RNAse III. The dsRNA construct is fused to a promoter 
dependent on T7 polymerase. Therefore, only when T7 polymerase is expressed will the 
bacteria express dsRNA, hence IPTG induces the bacterial expression of dsRNA. Feeding 
plates containing Nematode Growth Medium (NGM) and IPTG are poured and seeded 
with bacteria containing the dsRNA construct of interest. T7 polymerase is induced, 
leading to dsRNA production. Worms feed on the bacteria, and the dsRNA is taken up into 
cells. Although RNAi is systemic, some specialized machinery is required. SID-1 and SID-
2 channels are independently required for the uptake of dsRNA. SID-2 channels are only 
expressed in the intestine apical membrane, and SID-1 is expressed at very low levels in 
neurons (Calixto et al., 2010). 
 
Feeding RNAi is efficient in all cell types apart from neurons. However if dsRNA is directly 
injected into the neurons, the gene of interest is knocked down, indicating the process is 
inefficient due to the low levels of SID-1. In 2010,  a strain of transgenic worms was 
produced that pan-neuronally expressed SID-1, under the control of the Punc-119 
promoter (Calixto et al., 2010). Significantly these worms exhibited an increased 
efficiency of knockdown in the neurons, and also a decreased knockdown in non-
neuronal tissues. Furthermore, as non-neuronal RNAi is blocked in these SID-1 strains, 
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neuronal phenotypes for genes that were lethal when knocked down in non-neuronal 
tissues, can be tested. Two of the strains they generated were Tu3311 (Punc119-Sid-1) 
and Tu3335 (Punc119-Sid1-Lin15b), where Tu3335 showed the highest efficiency of 
RNAi. Lin15b has been previously shown to enhance RNAi in other strains (Lehner et al., 
2006), but is known to affect mechanosensation, so is not always a suitable strain to use 
for behavioural assays.  
 
1.11 The aldicarb-sensitivity assay to find effectors of synaptic function 
 
To test for effectors of synaptic function, aldicarb-sensitivity assays have been carried out 
for many years (T R Mahoney, Luo, & Nonet, 2006). Normally at the cholinergic synapse, 
post calcium stimulation, acetylcholine–filled vesicles merge with the presynaptic 
membrane and acetylcholine diffuses across the synaptic cleft to the postsynaptic 
receptors. In C. elegans there are thought to be two types of acetylcholine-receptive 
postsynaptic receptors – nicotinic-sensitive and levamisole-sensitive receptors. To 
recycle the acetylcholine, in the synaptic cleft, acetylcholinesterase hydrolyses the 
acetylcholine into choline and acetate, which then are transported back into the 
presynaptic terminal.  
 
Aldicarb is an acetylcholinesterase inhibitor. This means that when worms are picked 
onto plates containing aldicarb, it is absorbed into the worm, and acetylcholinesterase is 
inhibited (T R Mahoney et al., 2006). Acetylcholine builds up at cholinergic NMJ in 
synaptic clefts. This hyperstimulates the acetylcholine receptors on the postsynaptic 
membrane, leading to constant muscle contraction or paralysis. In this study, paralysis is 
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defined as no detectable movement when worms are touched on the head or tail with a 
platinum wire (Figure 1.2).  
 
There are two previously described methods for carrying out aldicarb assays. The first of 
these involves “chronic” exposure to aldicarb (del Castillo et al., 1963), where L3 worms 
are picked onto plates containing low concentrations of aldicarb, and the number of 
progeny is measured. The second uses “acute” exposure, where worms are placed onto 
plates containing the aldicarb and the rate of paralysis is assessed.  This is the more 
commonly used method, and was the method employed in this study. 
 
To assess whether genetic knockdown has an effect on synaptic function, the time for 
aldicarb-induced paralysis to occur is measured. Figure 1.2 shows the principles of the 
aldicarb assay, and Figure 1.3 displays a typical graph showing results from a full time 
course assay. If the average paralysis is longer than that of the wild type (or control) 
worm, the phenotype is described as a Resistance to Inhibitors of Cholinesterase (RIC). 
More than 50 genes have been shown to cause this type of RIC phenotype. This could 
happen for many reasons. For example knocking down a gene involved in acetylcholine 
secretion would cause a decreased rate of acetylcholine secretion, leading to a delay in 
paralysis. Paralysis also could be due to a change in acetylcholine metabolism or 
catabolism. As C. elegans locomotion is dictated by contraction (cholinergic) and 
relaxation (GABAergic) of opposite muscles, a fault in GABA signaling could also cause a 
change in the rate of paralysis. This means that a decreased rate of paralysis could be due 
to an increase in GABAergic signaling. For example, by knocking down a gene prevented 
inhibition of GABA secretion.  
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If the opposite phenotype is seen, i.e. when worms paralyze quicker than the wild type 
worm, this is known as a Hypersensitivity to Inhibitors of Cholinesterases (HIC) 
phenotype. This is a less common phenotype than a RIC and could be due to increase 
cholinergic or decreased GABAergic signaling. For example a HIC phenotype results if 
Figure 1.2 – The principle of the aldicarb sensitivity assay at the cholinergic NMJ. 
A. Under normal conditions acetylcholine is released from the pre-synaptic terminal 
upon calcium stimulation, travels across the synaptic cleft and binds to acetylcholine 
receptors on the postsynaptic membrane, inducing muscle contraction. After a certain 
amount of time, acetylcholinesterase degrades the acetylcholine and the choline and 
acetate are recycled. B. When aldicarb is absorbed into the worm, acetylcholinesterases 
are inhibited, meaning acetylcholine builds up in the synaptic cleft, leading to 
hypercontraction, paralysis and then death. C. If a gene is knocked down/mutated that 
decreases the secretion of acetylcholine, it will take longer for paralysis to occur, which 
is known as a RIC phenotype. D. If a gene is knocked down/mutated that increases the 
secretion of acetylcholine, paralysis will be quicker, which is known as a HIC phenotype. 
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there is an increased secretion of acetylcholine or a decreased number of cholinergic 
receptors. A HIC phenotype can also result if GABA neurotransmission is inhibited. 
 
Aldicarb assays can be used to better elucidate complex pathways. For example the G-
protein coupled signaling pathway is involved in acetylcholine release from ventral cord 
neurons – when mutated some genes in the pathway cause a strong RIC phenotype (e.g. 
RIC-8 and egl-3), while others cause a HIC phenotype (inhibitory factors such as DGK-1) 
(Rand, 2007).  Aldicarb assays can be used to identify novel effectors of synaptic function. 
Certain mutations (e.g. cha-1) cause a decreased secretion of only acetylcholine, however 
others (such as synaptobrevin and synaptotagmin) cause a decreased secretion of all 
neurotransmitters (Rand, 2007). This means that following a phenotype, investigating 
the molecular basis to the phenotype can be complex but important. Hence by elucidating 
genes that cause a RIC or a HIC phenotype, complex pathways and the effects of 
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Figure 1.3 – Graph showing typical result of aldicarb-sensitivity assay. The numbers of 
paralysed worms are counted at each time point through the use of a platinum wire being 
pressed against the head and tail of the worms. The percentage of worms paralysed at each time 
point is calculated and plotted against time. If a RIC phenotype is observed, the rate of paralysis 
is slower than the control worm, and a shift to the right on the graph is seen (shown by the green 
line). If a HIC phenotype is observed, the rate of paralysis is faster than the control worm, and a 
shift to the left on the graph is observed (shown by the red line). 
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conditional crosstalk that underpin cholinergic/GABA/general neurotransmission might 
be better understood. 
 
1.12 Advantages and Disadvantages of C. elegans 
 
1.12.1 Advantages of C. elegans 
 
There are many advantages to using C. elegans as a model organism. As mentioned 
previously they are easy to maintain in the lab. At room temperature, a worm grows from 
egg to adult in 3 days. L1 worms can also be frozen at -800C by using glycerol (Stiernagle, 
2006). They can grow either on solid NGM with calcium chloride, magnesium sulphate 
and potassium phosphate supplementation, seeded with OP50 bacteria. If high 
throughput screening is required, C. elegans can also be grown in liquid. Both options are 
cost-effective, making C. elegans a cheap organism to maintain. 
 
 There is also a plethora of mutants/strains available via the Caenorhabditis Genome 
Centre (CGC), priced at just over £4 per strain. They are genetically tractable, and there 
are multiple methods of genetic manipulation including mutations, RNAi knockdowns 
and overexpressing constructs via microinjection.  The aldicarb-assay is also a simple 
method to identify genes involved in synaptic function. 
 
Importantly for systems biology, C. elegans have high percentage coverage of their 
physical and functional interactome, and they are the only organisms to have a complete 
connectome (Varshney et al., 2011; White et al., 1986). Furthermore, there are few ethics 
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regarding their use, and very high numbers of worms can be generated in a short space 
of time (allowing high-throughput screening). 
 
1.12.2 Advantages of the aldicarb-sensitivity assay 
 
The aldicarb sensitivity assay has been used for many years in the study of C. elegans 
synaptic function, and so the assay is well characterized. The endpoint of paralysis is 
quick to measure, and easy to see. It can also be manipulated to enable carrying out of 
semi high-throughput screens. Furthermore as it shows general synaptic transmission 
defects, it can be used as a general screen for effectors of synaptic function (Rose et al., 
2007). 
 
1.12.3 Disadvantages of C. elegans 
 
Although C. elegans have many advantages, disadvantages must be considered prior to 
their usage. Firstly, as C. elegans are a model organism it can sometimes be difficult to 
determine the relevance in a human system. For this reason, other organism and/or 
techniques are used, if this is appropriate. It is important for this reason, to check the 
similarity and identity of the worm and human orthologs of interest.  
There can be variability between worm plates if for example; one worm strain is faster 
growing than another due to the particular mutation or knockdown that occurred. If not 
dealt with this can also lead to starving of the quicker growing plate, or the use of 
immature worms for the slower growing plate.  For these reasons all assays should be 
carried out on gravid adult hermaphrodites that are not starved or overcrowded. 
Furthermore, RNAi can have variable efficiency. 
Chapter 1: Introduction 
 57 
1.12.4 Disadvantages of the aldicarb-sensitivity assay 
 
Although used frequently in the past, there are limitations to the aldicarb-sensitivity 
assay. One is the subjective nature of the experiment – it is necessary to do all of the 
experiments blind. This means that the person carrying out the experiment is not aware 
of which plate is which strain/knockdown. If a mutant is known to cause a specific 
phenotype that would make them obvious to the experimenter, where possible a control 
worm that shows the same phenotype should also be used in the assay. 
 
 Furthermore if the aldicarb assay is used following RNAi knockdown, high variancy can 
occur due to the variable efficiency of the RNAi, and the fact that RNAi is rarely 100% 
efficient. Knocking down a gene itself can cause phenotypes in the worm, such as an 
altered motility or locomotion. This must be kept in mind when performing the assay.  
 
The main disadvantage of the aldicarb-sensitivity assay however, is the fact that it does 
not delineate why a RIC or HIC phenotype has occurred. As mentioned previously, if the 
mutation affects GABA, or another neurotransmitter pathway, a phenotype may also be 
seen. A phenotype may also result if a regulatory process has become abnormal, or the 
synthesis/degradation of the neurotransmitter itself has occurred. One main control used 
in RNAi experiments to check that RNAi has worked is to use a positive control in the 
aldicarb-sensitivity assay. This commonly is egl-30, which is actually an octopamine 
receptor, highlighting the complexity of mutants that can cause an aldicarb phenotype.   
For these reasons, other assays should be carried out to determine to reason behind a RIC 
or HIC phenotype. For example checking whether the phenotype is caused due to pre- or 
post-synaptic changes. 
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Levamisole is a cholinergic agonist, which acts by inactivating levamisole-sensitive 
postsynaptic acetylcholine receptors (Locke et al., 2008). If a genetic mutation has caused 
a RIC phenotype in response to aldicarb treatment, this phenotype could be caused by a 
change at the pre- or post-synaptic membranes at a cholinergic NMJ. If the gene has 
caused a change in the number of levamisole-sensitive receptors, this will cause a 
phenotype with both aldicarb and levamisole. If the gene affects acetylcholine at the 
presynaptic level, no difference in phenotype will be seen compared to N2 worms, when 
worms are treated with levamisole. 
 
1.13 Sodium Valproate 
 
Sodium valproate, also known as valproic acid (VPA) was first synthesized in 1882 as an 
analogue of valeric acid (Terbach et al., 2011). In 1962 it was found to have 
anticonvulsant and mood-stabilizing properties, leading it to be a prime drug for the 
treatment of epilepsy. Currently VPA is also used to treat some cases of bipolar disorder 
and neuropathic pain, as well as migraines.  It has also been shown to have anti-cancer 
properties – for example it has been shown to enhance growth arrest and apoptosis of 
chronic myeloid leukemia cells (Morotti et al., 2006). Its mechanism of action is debated 
and many different roles have been discussed.  
 
Due to its value in the medical field, a lot of research has been undertaken to work out the 
mechanism behind the drug’s action. It is thought to act via the GABAergic pathway, 
increasing the concentration of GABA in the brain by multiple mechanisms – for example 
by increasing the activity of glutamate decarboxylase and inhibiting GABA 
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aminotransferase (Lloyd, 2013). VPA has also been proposed to inhibit voltage-gated 
sodium channels and T-type calcium channels (Lloyd, 2013). However many of these 
early studies are disputed, as they might not be valid at the levels of therapeutic doses 
used in humans. VPA has also been reported to decrease aspartate levels in nerve 
terminals in the hippocampus (Morland, Nordengen, & Gundersen, 2012). Aspartate is an 
excitatory transmitter, and thus decreasing the levels decreases excitatory 
neurotransmission. 
 
VPA has been reported to have neuroprotective effects, due to its anti-oxidant properties 
(Christian et al., 2012). The term “neuroprotective” means that the drug has properties 
that protect nerves against damage due to reduced supply of oxygen and/or glucose. VPA 
has been shown to reduce brain damage in a model of cerebral ischemia in rats, via 
modulation of caspases (Christian et al., 2012; Ren, Leng, Jeong, Leeds, & Chuang, 2004). 
Treatment has also been reported to affect both neuronal plasticity and neurite 
outgrowth (Yuan et al., 2001). VPA has been shown to activate the ERK signaling pathway, 
leading to activation of MEK, c-Fos and Gap-43 (Yuan et al., 2001). Gap-43 is known to be 
important for neuronal plasticity, and c-Fos is used as an indirect marker for neuronal 
activity (Bullitt, 1990). By generating in vitro and in vivo models, VPA has been shown to 
promote the outgrowth of neurites, which is dependent on MEK (10, 58). VPA has also 
been used in combination with antipsychotic medications to treat schizophrenia (Tseng 
et al., 2016).   Interestingly, certain proteins implicated in schizophrenia, such as 
Disrupted-In-Schizophrenia-1 (DISC1) and Dysbindin-1, when mutated also affect 
neurite outgrowth (Ma, Fei, Fu, Ren, & Wang, 2011; Miyoshi et al., 2003), suggesting 
neurite outgrowth is an important factor for how VPA ameliorates the symptoms of 
schizophrenia. 
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VPA has also been shown to be a histone deacetylase (HDAC) inhibitor (Göttlicher et al., 
2002). This role is thought to be independent of the role VPA plays in preventing seizures, 
though few experiments delineating this have been carried out. Specifically VPA is a class 
1 HDAC inhibitor, which causes the proteosomal degradation of HDAC2 (Kramer et al., 
2003). HDAC inhibition leads to a shift towards acetylation, leading to hyper-acetylated 
histone cores. This regulates the expression of genes such as the transcription factor AP-
1. HDAC inhibition by VPA is thought to at least partially explain the ability of VPA to 
induce the differentiation of certain carcinoma cells, and reduce tumour growth and 
metastases in animal models (Kramer et al., 2003).  
 
Despite the benefits of VPA, it has also been shown to be teratogenic, meaning that it can 
be harmful to foetuses in pregnant mothers. VPA has also been shown to cause 
neurodevelopmental defects, such as reduced cognitive function and learning difficulties, 
as well as major congenital malformations such as heart abnormalities and neural tube 
defects (8, 58). This implies that VPA has a detrimental developmental role. Mechanisms 
proposed to explain this teratogenicity include VPA accumulation in the foetus, as well as 
VPA acting to increase the level of reactive oxygen species (ROS). In the first three months 
of pregnancy the foetus is able to metabolize VPA to produce ROS, but has a poor anti-
oxidant defense system (Lloyd, 2013). This means ROS can damage proteins, lipids and 
DNA in the foetus, causing abnormalities. However other pathways have also been 
proposed to cause teratogenicity, such as VPA causing decreased levels of folate (Lloyd, 
2013). Folate is essential for foetal development and maturation. HDAC inhibition has 
also been proposed to cause teratogenicity. This shows the complexity of VPA 
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mechanisms, and how a simpler organism needs to be used to better understand this 
drug’s effect. 
 
Due to the huge number of possible mechanism of how VPA treatment leads to an anti-
convulsant effect, C. elegans have been used due to the ease of studying their 
neurobiology.  
 
1.14 VPA in C. elegans 
 
VPA has been studied in C. elegans and has been found to cause interesting phenotypes. 
Firstly, it has been proposed to extend C. elegans lifespan. 6mM VPA treatment resulted 
in an increase in the mean adult lifespan from 16.2 to 21.9 days (Evason, Collins, Huang, 
Hughes, & Kornfeld, 2008), and also reduced the age-related decline of body movement. 
In this paper they also used the drug valpromide (VPD), which is an aliphatic amide 
analogue that shares the anticonvulsant activity of VPA. However it cannot inhibit HDACs, 
meaning that VPD can be used to determine whether an effect is due to inhibition of 
HDACs. Both VPA and VPD caused the lifespan increase as well as an increase in dauer 
formation.   
 
VPA has also been proposed to ameliorate dopaminergic neurodegeneration in C. elegans. 
In a worm model of Parkinson’s disease, where alpha-synuclein is overexpressed, VPA 
attenuated degeneration of the six anterior dopaminergic neurons of the worm, 
increasing from 11.2% to 72% of worms exhibiting non-degenerated neurons at day 7 
(Kautu, Carrasquilla, Hicks, Caldwell, & Caldwell, 2013). As in humans, they propose that 
VPA activates ERK-MAPK signaling, increasing the number of neurites. Knocking down 
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the worm ortholog of ERK, mpk-1, and its upstream regulator, mek-2, prevented this 
protective effect (Kautu et al., 2013). This suggests that certain roles of VPA; such as in 
the ERK-MAPK pathway may be conserved between species. Hence through the study of 
the role of VPA in C. elegans, more could be understood about the conserved role VPA 
plays at the synapse. 
 
1.15 Protein Interaction Networks  
 
In 1941 the theory of one gene encoding one enzyme to have one function was proposed 
(Beadle & Tatum, 1941). Since then this has been disproven, and it has been shown that 
proteins rarely act in isolation. Instead they often act as parts of complex molecular 
machines or pathways, and enzymes can have multiple binding partners to affect 
different functions in a cell.  
 
Graph theory has been used to explain properties of protein-protein interaction (PPI) 
networks (Vidal, Cusick, & Barabási, 2011). Firstly PPI networks are scale-free, meaning 
that there are a few highly connected nodes connected to many nodes with few 
interaction partners. Nodes with a high number of interaction partners are known as 
hubs. This feature of connections between nodes is known as connectivity. PPI networks 
are also described, as “small-world” as the average distance between any two proteins is 
small. For this reason, random perturbations of genes (which are not hubs) does not 
greatly affect the integrity of the network, whereas mutation of hubs can disrupt the 
network to such a degree that the network is fragmented into smaller sub-networks 
(Vidal et al., 2011).   
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Another feature of networks is that they are modular, meaning that clusters of proteins 
form where there are large numbers of interactions between themselves, but they have 
fewer connections between the clusters. These modules can be used to uncover proteins 
with novel functions, by the principle of “guilt-by-association” (Oliver, 2000) – i.e. if a 
protein is found in a module containing proteins involved in e.g. transcription, it is likely 
that this protein also plays a role in this process. 
 
As well as connectivity, another topological measure used in networks is betweenness 
centrality (Joy, Brock, Ingber, & Huang, 2005). Betweenness centrality is a measure of 
how many times a protein is found in the shortest path between two other proteins. 
Proteins can have high betweenness but a low connectivity, i.e. hubs do not necessarily 
have high betweenness values. Betweenness is a good measure of the level of control a 
node may have within a network. If perturbed, large effects on the integrity of networks 
are seen.  Figure 1.4 shows a simple schematic to illustrate betweenness – protein A is in 
the shortest path between protein C and proteins G, F, E, D and B. However in the top 
panel, A has high connectivity but in the bottom panel node A forms fewer connections 
and thus does not have a high connectivity. 
 
It is important to note that in the original PPI maps, neither alternatively spliced isoforms, 
nor post-translational modifications were considered. For a complete interaction map, 
these must be taken into account. An example of this is an autism spliceform network that 
was created, which used all clonable isoforms of autism candidate genes to find novel 
interaction partners. A third of the interactions found in their screens were from the non-
reference isoforms of the genes (Corominas et al., 2014). Furthermore with over 200 
different types of post-translational modification (Jensen, 2006), post-translational 
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modifications and protein-protein interactions can often be functionally linked. For 
example phosphorylation of one protein can modulate its binding to several other 
proteins. Both of these examples highlight how traditional interaction networks can be 
increased using extra data like isoforms. 
 
1.16 PPI Methods 
 
To study the interactions of proteins, multiple techniques have been developed, some of 
which show direct or binary interactions, others indirect or co-complex interactions. 
Direct assays include yeast-two-hybrid (Y2H) assays, and protein complementation 
assays.  Indirect assays are those such as affinity-purification mass spectrometry and co-
immunoprecipitation experiments. These are described as indirect as it is not known in 
these assays whether a binding partner is attached directly or via another protein to the 
bait of interest.  
 
1.16.1 Y2H techniques 
Figure 1.4 Simple networks to show the 
concepts of connectivity and betweenness. 
A. Protein A is in the shortest path between 
proteins C and proteins G, F, E, D and B. It has 
high connectivity (as it is connected to all six 
other nodes) and high betweenness. B. 
Although protein A is still in the shortest path 
between proteins C and proteins G, F, E, D and 
B, it is only directly connected to B and C. Thus 
it has a high betweenness but lower 
connectivity.  
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In 1989, the Y2H system was initially published as a novel system to investigate binary 
PPI (Fields & Song, 1989). In the classical yeast-two-hybrid system, the bait of interest is 
attached via its N-terminus to the DNA binding domain (DB), and the prey via its N-
terminus to the activation domain (AD) of the transcription factor Gal4 (Fields & Song, 
1989). When the bait and prey interact, Gal4 becomes functionally active and reporter 
genes are transcribed. Examples of reporter genes are biosynthetic genes such as ADE2 
and HIS3, which enable yeast to grow on plates lacking adenine and histidine, 
respectively, and enzymatic genes such as lacZ, which enzymatically degrades X-Gal to 
produce a blue pigment visible on plates. Other reporter genes such as AUR1-C, which 
causes the yeast to be resistant to the antibiotic aureobasidin A, have also been used and 
shown to cause lower background activity. Figure 1.5 shows the principle of the classical 
Y2H assay. 
There are two general types of yeast-two-hybrid assay – targeted array based matings 
and library screenings. In a targeted Y2H mating assay both bait and prey genes are 
known and are simply screened against each other. Alternatively, library screening can 
be carried out in yeast to find novel interaction partners of the bait of interest. In general 
high complexity whole cDNA libraries are used, which contain cDNA extracted from a 
certain tissue/organism, e.g. foetal brain.  
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Advantages of a targeted matrix mating approach are that the position and identity of 
both bait and prey is known, therefore no sequencing is needed to interpret positive 
interactions. This process can also be automated relatively easily. However, library 
screening is advantageous when novel PPI are sought, and the protocol requires little 
hands-on time and technical skill. Other advantages of Y2H are that is it relatively simple 
and easy to scale up into a high-throughput assay. It is non-biased, and is a method of 
detecting binary interactions.  It is also far cheaper than other techniques for elucidating 
interaction partners, such as mass spectrometry.  
 
One limitation of library screening however is that, as the prey binding the bait of interest 
is not pre-defined, colony PCR analysis must be performed, as well as sequencing in order 
UAS	 Reporter	Gene(s)	
BD	
	
Bait	
Prey	 AD	 No	interac on	
No	transcrip on	
of	reporter	
gene(s)	
UAS	 Reporter	Gene(s)	
BD	
	
Bait	 AD	
Interac on	
Transcrip on	of	
reporter	gene(s)	
Prey	
RNA	
Polymerase	
II	
Figure 1.5 – The molecular basis of the classic yeast two hybrid methodology. The bait of interest 
is fused to the DNA binding domain (BD) and the prey to the activation domain (AD) of the Gal4 
transcription factor. A. Bait and prey do not interact, meaning there is no transcription of reporter 
genes. This means, for example, that the yeast will not grow on media lacking adenine or histidine (the 
genes ADE2 and HIS3 are common reporter genes). B. The bait and prey proteins interact. The BD and 
AD are in close enough proximity to function as the whole transcription factor, recruiting RNA 
polymerase II, and transcribing reporter genes. This means that for example if ADE2 and HIS3 are two 
of the reporter genes transcribed, the yeast will be able to grow on plates lacking adenine and histidine, 
indicating an interaction has occurred. 
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to determine the identity of the potential interaction partner. This makes library 
screening both time-consuming and expensive. Other limitations of the classic Y2H 
system are that as the genes are being expressed in yeast, post-translational 
modifications and the folding of the protein may not be the same in yeast as in humans, 
leading to different protein interaction profiles. Also, tagging of the proteins with bait or 
prey domains may lead to incorrect folding. Another limitation is that the data is 
qualitative, i.e. the strength of an interaction cannot be measured. Furthermore the 
classical system only works for soluble proteins – they must be able to reach the nucleus 
for an interaction to occur.  Transmembrane proteins have issues as they may not be 
targeted to the nucleus, and so cannot activate the reporter genes, or the hydrophobic 
transmembrane domains may misfold preventing binding to appropriate interaction 
partners. This last limitation can be overcome by using a second-generation Y2H 
technique, known as membrane-based yeast-two hybrid (MYTH). 
 
1.16.2 MYTH 
 
In 2002 Igor Stagljar published a paper describing the MYTH system, which allowed the 
examination of full-length membrane proteins in a Y2H system (Stagljar & Fields, 2002). 
This system utilizes ubiquitin, which can be split into two fragments – N-terminal NubI, 
and C-terminal Cub domains. These two fragments can spontaneously re-associate to 
form pseudoubiquitin. To prevent this, NubI is mutated at isoleucine 13 to a glycine 
residue, making a fragment known as NubG. The Cub domain is attached via the N- or C-
terminus to the membrane protein of interest – this is the bait protein in the system. The 
Cub domain is also fused to the reporter molecule, consisting of E. coli DB, LexA and 
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Herpes simplex AD, VP16. The prey can be cytosolic or membrane bound, and is fused to 
the NubG domain of ubiquitin.  
 
Upon bait and prey interaction, the two ubiquitin fragments are brought into close 
enough proximity to re-associate and form pseudoubiquitin. Ubiquitin-specific proteases 
can then hydrolyze the amide bond between ubiquitin and the protein, leading to release 
of the LexA-VP16 transcription factor tag, which is then free to translocate to the nucleus, 
where it activates transcription of reporter genes. Like in the traditional yeast-two-
hybrid, these are typically ADE2, HIS3 and lacZ. Figure 1.6 shows the principle of the 
MYTH system. 
 
Advantages of the MYTH system are that it allows the screening of full-length membrane 
proteins. MYTH can also be used in library screens, where cDNA libraries are generated 
with N- or C-terminal NubG fusions.  This means the MYTH is relatively easy to scale up 
and can be used as a discovery tool to elucidate novel interaction partners for proteins 
that have previously been tricky to study.  
Limitations of MYTH are that the N- and/or C-terminal domain of the bait protein must 
be localized in the cytosol for the system to work. It is also limited to looking at binary 
interactions, as in most cases, an indirect interaction of bait and prey would not allow 
pseudoubiquitin formation, as they would not be in close enough proximity.  
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The main aim of this work was to identify novel effectors of synaptic function, whose 
human orthologs may play a role in neurological/neurodegenerative diseases. As 
mentioned in 1.2.3, wild type nor worms classically hypersensitive to RNAi have neuronal 
sensitivity to RNAi, due to a lack of sid-1 neuronal expression (Winston, Molodowitch, & 
Hunter, 2002).  This means that in RNAi screens previously performed (Sieburth et al., 
2005), false negatives may have occurred when genes were inefficiently knocked down 
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Figure 1.6 – Membrane Based Yeast Two Hybrid concept. The transmembrane bait 
protein of interest is fused to the C-terminal Cub domain of ubiquitin, which is tagged with 
the E. coli DNA binding domain (DB), LexA and the Herpes simplex activation domain (AD) 
known as PLV. The prey protein can be cytosolic or transmembrane and is tagged with the 
N-terminal Nub domain (with I13G mutation). When bait and prey interact, 
psedoubiquitin is formed. Ubiquitin specific proteases release the PLV, which then 
translocates to the nucleus to activate the transcription of reporter genes such as ADE2, 
HIS3 and lacZ. 
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in neurons. Also, expression throughout the worm could have lead to lethality, whereas 
specificity to neurons may prevent this phenotype. For this reason we decided to carry 
out high throughput aldicarb screening in the sid-1 expressing Tu3311 strain, which 
displayed higher efficiency and specificity of neuronal RNAi. Gene lists to test can be 
generated by generating aldicarb one-step networks, and prioritizing based on 
connectivity and betweenness.  
 
Previously a microarray was carried out on wild type worms following VPA treatment 
(Munasinghe, 2015). A bespoke clustering algorithm was used to identify genes that 
exhibited similar dose dependent changes in gene expression. To complement this data a 
one-step known RIC/HIC protein interaction network (as described in chapter 3) was 
generated, and sub-networks generated containing novel genes to test in the high 
throughput aldicarb screens. Furthermore, by looking at the human orthologs of hits from 
these screens, candidates can then be identified to use in yeast two-hybrid library 
screening, in order to identify novel interaction partners, which may themselves play a 
role in neurological/neurodegenerative diseases. 
 
1.17 Aims of the study  
 
The overall aim of the PhD work carried out were: 
 To elucidate novel effectors of synaptic function in C. elegans 
 To investigate the effect of sodium VPA on C. elegans synaptic function 
 To investigate protein-protein interaction networks of human orthologs of a 
selection of novel synaptic effectors. 
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2.1 Reagents 
 
All chemicals were obtained from Sigma-Aldrich (Poole, UK), unless otherwise stated. 
 
2.2 Worm strains 
 
All C. elegans strains used in this study were obtained from the CGC (University of 
Minnesota). These include: N2, Tu3311 (unc119p::YFP + unc119p::Sid-1),  rrf-3(NL2039), 
Tu3335 (lin15b X [unc-119p::YFP + unc-119p::sid-1 + mec-6p::mec-6],  LT186 (sma-
6(WK7) II), CB904 (unc-38(e264) I), MT6490 (unc-25(n2569)III), VC1433 (unc-
25(ok1901)III), RB1044 (Y47H9C.2(ok990) I), VC2067 (C43H6.7(gk985) X), VC2039 
(F59C6.2(gk1013) I), VC108(H32C10(gk36) IV) and VC918(dhhc-14(ok10232) X).  OP50 
was also obtained from the CGC.   
 
All worms were maintained at 200C as previously described (Brenner, 1974). For C. 
elegans maintenance, worms were grown in 55mm petri dishes containing 10ml NGM  
(0.3% NaCl (w/v), 0.25% peptone (Formedium) and 2% agar (Bioagar, Biogene)). After 
autoclaving and immediately prior to pouring the plates, 1mM CaCl2, 1mM MgS04, 5μg/ml 
cholesterol and 25mM KH2PO4 were added to the media. Detail relating to the 
preparation of the stock solutions is shown in Table 2.1. After pouring, plates were dried 
in a sterile hood, and 55μl of OP50 E. coli was added to each plate. These were then 
incubated at 37°C overnight prior to use. 
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 Grams/100
ml dH2O 
Sterilization 
Procedure 
Storage Stock 
Concentration 
CaCl2 11.09 Sterile Filter Room 
Temperature 
1M (in dH2O) 
MgSO4 12.04 Autoclave Room 
Temperature 
1M (in dH2O) 
KH2PO4 13.61 Autoclave Room 
Temperature 
1M (in dH2O) 
Cholesterol 0.5 (in 100% 
ethanol) 
Sterile Filter 4°C 5mg/ml  
Table 2.1 – Chemicals required to make NGM media.  
 
For long term storage at -80°C, a plate containing worms that had been starved for at 
least one day was washed with 3ml of autoclaved M9 buffer (0.3% KH2PO4, 0.6% 
Na2HPO4, 0.5% NaCl, 1mM MgSO4 in dH2O). 3ml of freezing buffer (0.585% NaCl, 0.68% 
KH2PO4, 30% glycerol, 3mM MgSO4, in dH2O, autoclaved) was then added and 1ml 
aliquots of resuspended worms were then pipetted into 1.8ml cryovials and stored at -
80°C . 
 
2.3 RNAi feeding 
 
Although Tu3311 and Tu3335 strains have enhanced neuronal RNAi, optimization of 
previously published protocols was required to carry out optimal RNAi knockdowns 
(Kamath & Ahringer, 2003; Sieburth et al., 2005; Vashlishan et al., 2008).  
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All E. coli expressing the dsRNA were obtained from the C. elegans Vidal library (Rual, 
2004) or were created and gifted by Matt Edmonds and Alan Morgan (University of 
Liverpool) as indicated. E. coli were streaked out onto Luria Broth (LB, 10% NaCl, 10% 
tryptone, 5% yeast extract, 10% agar) plates supplemented with 100μg/ml ampicillin. 
After overnight incubation at 37°C, multiple colonies were picked into 3ml Luria Broth 
supplemented with 100μg/ml ampicillin. Subcultures were incubated at 37°C with 
shaking overnight.  Glycerols were made of all constructs by adding 80μl of 80% glycerol 
(w/v) to 200μl subculture. These were vortexed briefly before storing at -80°C .  
 
1M IPTG stock solutions were made up in dH2O and stored in the dark at -20°C. 6 well 
(Cytooone CC7672-7506) dishes were used firstly to make 4mM IPTG (Melford) feeding 
NGM plates, as described above in section 2.2, with the additional supplementation of 
100μg/ml ampicillin and 4mM IPTG. Once dry these plates were seeded with 40μl of 
bacterial stock. Dishes were then left in the dark for 48 hours, before picking 2 gravid 
worms to each plate. After 4 days these were treated with bleach and transferred onto 
48-hr seeded 55cm plates (Greiner) in triplicate (Stiernagle, 2006) to synchronize/age-
match the worms.  
 
2.4 Pharmacological Assays 
 
1mM aldicarb (dissolved in 70% ethanol) was used for all aldicarb-sensitivity assays, and 
each experiment was carried out blind in triplicate. The assay was run in a similar manner 
to previously published protocols (Timothy R Mahoney, Luo, & Nonet, 2006). In brief, 
between 20-30 young gravid worms were picked from plates containing F2 non-starved 
worms. For full-time course assays, paralysis of worms on aldicarb plates was assessed 
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every 20-40 minutes, until all worms were paralyzed, as judged by prodding the head or 
tail with a metal wire. Prior to high throughput assays, the rate of paralysis of the control 
(Tu3311 fed with L440 dsRNA-expressing bacteria) was assessed. From this an 
appropriate time point for the high throughput assays was chosen. For some assays, 
paralysis was assessed at two time points, but this made the assay slower throughput and 
paralysis was often found to be very similar at both time points. Therefore, unless 
otherwise indicated, only one time point between 100-160 minutes was used in all high 
throughput assays. Any worms that crawled off the plate or underwent vulval prolapse 
were discarded from the assay. 
 
Other pharmacological assays performed in this study are summarized in Table 2.2. In 
levamisole, valproate, and drug combination assays, only paralysis were measured as 
described above for aldicarb assays.  
  
Drug Solvent Stock 
Concentration 
Final 
Concentration 
Aldicarb 70% Ethanol 1M 1mM 
Sodium 
Valproate 
dH2O 50mg/ml 15mM 
Levamisole M9 buffer 100mM 0.1mM 
Table 2.2 – Concentrations and solvents used for the pharmacological agents used in C. elegans 
studies. 
 
2.5 Statistical Analysis 
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For the high throughput aldicarb-sensitivity assays, the mean number of paralyzed 
worms for the test sample was compared against the mean number of paralyzed worms 
for the negative control (measured for each repeat) using an unpaired t-test. A change in 
the rate of paralysis was deemed to be significant if the p value was less than 0.05. To plot 
the increase/decrease in paralysis, the differences of the test samples against the 
negative control were normalized to the mean of the control and plotted as a 
positive/negative percentage. 
 
2.5 Data visualization and network generation 
 
Cytoscape is a program commonly used to visualize protein interaction networks. The 
free online tool also enables the integration of gene-expression data. In this study the 
version of Cytoscape used was either 2.8.3 or 3.2.1, as specified in the legends of the 
respective tables. Interaction networks are presented in the form of nodes (proteins), and 
edges (interactions). For the C. elegans networks, databases used to access primary data 
were Wormnet version 3 (Cho et al., 2014), the CCSB Worm Interactome 8 yeast-2-hybrid 
data sets (Simonis et al., 2009) and the worm version of BioGrid. Wormnet integrates data 
from C. elegans as well as known interlogs in humans, mouse, S. cerevisiae and D. 
melanoganster. Cytoscape was also used to calculate the connectivity and betweenness 
scores of nodes in selected worm sub-networks.  
 
For the PAT interaction networks, data was integrated from BioGrid, as well as an in-
house human interactome (created by Russell Hyde and Jonathan Woodsmith), which 
curates data from several other databases – Human Protein Reference Database (HPRD) 
(Keshava Prasad et al., 2009), IntAct (Kerrien et al., 2007), Molecular Interaction 
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Database (MINT) (Licata et al., 2012), as well as an older version of Biogrid. For fly 
interactions, the Drosophila Interactions Database (DroID) was used. Wormnet (Cho et 
al., 2014) was mined for C. elegans interactions. For the human PAT family, as well as 
BioGrid, the human CCSB (Rolland et al., 2014), Human Integrated Protein-Protein 
Interaction rEference (HIPPIE) (Schaefer et al., 2012) and Bioplex (Huttlin et al., 2015) 
were incorporated. All genetic interactions were removed, and all ID’s were converted 
into human orthologs. 
 
2.6 Microarray Analysis 
 
Although the single-channel Agilent microarray was carried out in 2012 (Munasinghe, 
2015), we re-analyzed the data from the array to identify sets of genes that were 
significantly up- or down-regulated in response to valproic acid treatment. Full detail of 
this analysis can be found in Chapter 4. The programming language known as R was used 
for the microarray analysis. R is a language widely used in data science for data analysis 
and visualization. The open-source language was used in the program RStudio, which is 
a graphical user interface that provides a simple way to develop R scripts and visualize 
results, such as heatmaps. 
 
DAVID (Database for Annotation, Visualisation and Integrated Discovery) and Ingenuity 
Pathway Analysis were used to analyse enrichment of genes. C. elegans genes were also 
converted to their human orthologs, before inputting into the databases, as Ingenuity is 
not 100% compatible with worms. 
 
2.7 Cloning of constructs 
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 Standard gateway cloning procedures were used to clone human DHHC enzymes 
according to the manufacturer’s instructions (Invitrogen). PCR primers were designed to 
amplify the gene of interest, with flanking attB sequences. Primers were synthesized by 
Life Technologies (ThermoFisher). The attB sequences used in the primer design are as 
follows: 
Forward:  gaattcacaagtttgtacaaaaaagcaggctggATG  
Reverse (without a stop codon): gtcgaccactttgtacaagaaagctggGTG 
 
This allows recombination into the pDONR223 entry vector to create a gateway-entry 
clone with attL sites. The desired gene targets were amplified from either 210ng HeLa 
cDNA, or from the gene of interest (in a different vector). High Fidelity Hot Start KOD 
polymerase (Invitrogen) was used to amplify all genes of interest. 
To clone the human PAT family members, primers were designed with the attB N-
terminal portion and a gene-specific 15bp region. Primers used in this study are shown 
in Table 2.3. 
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Mouse 
PAT 
family 
members were transferred from an entry vector (PEF-BOS-HA) into the pDONR223 
vector through KOD PCR, BP reactions, transformation and minipreps, as detailed in the 
following sections.   
 
2.7.1 Proof-reading PCR using high-fidelity KOD enzyme 
 
Constituents used to amplify the PAT family members and add AttB sites are shown in 
Table 2.4. 
 
Reagent Final Concentration μl/reaction 
Forward Primer 
(10μM) 
0.5μM 0.5 
Reverse Primer (10μM) 0.5μM 0.5 
Gene	Symbol Size	(bp) Primer Primer	sequence
ZDHHC9 1094 Forward ATGtctgtgatggtggtgaga
Reverse	(-	stop) cttctcagcttcagctgc
zDHHC3 899 Forward ATGcttatcccca	cccac
Reverse	(-	stop) gaccacatactggtacgg
zDHHC4 1034 Forward ATGgactttctggtcctcttc
Reverse	(-	stop) ttcttgtttcttcctctc
zDHHC5 2147 Forward ATGcccgcagagtctggaaag
Reverse	(-	stop) caccgaaatctcatagg
zDHHC7 1037 Forward ATGcagccatcaggacacagg
Reverse	(-	stop) cactgagaactccgggcc
zDHHC16 1131 Forward ATGcgaggccagcggagcctg
Reverse	(-	stop) cactgccatcacagaggc
Table 2.3 – Gene specific primer sequences for the human PAT family 
members successfully cloned. 
Chapter 2: Materials and Methods 
 80 
10 x KOD buffer 1x 2.5 
MgSO4 (25mM) 15mM 1.5 
dNTPs (2mM) 0.2mM 2.5 
DNA / cDNA DNA: 10ng 
cDNA: 200-250ng 
DNA: 1 
cDNA: 
HSKOD - 0.5 
dH2O - Up to 25 
Total 25ul 25 
Table 2.4 -  Mastermix constituents for Hotstart KOD polymerase reactions. 
In the PCR machine the cycle used was: 
1. 94°C for 2 minutes 
2. 94°C for 30 seconds 
3. 55°C/60°C/65°C/68°C for 1 minute (dependent on the melting temperature of the 
primers) 
4. 70°C for 30 seconds per kilobase of amplified construct 
5. Go to 2. 29 – 39 times. When cloning from cDNA 39 repeats were used. Otherwise 
29 repeats occurred. 
6. 4°C hold. 
 
2.7.2 Gateway BP reactions 
 
After PCR amplification to add on the attB sites, BP reactions were carried out using BP 
clonase II (Invitrogen), following the reaction scheme shown in Table 2.5 
Reagent Volume  
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PCR amplified product 2μl 
pDONR223 100ng 
BP Clonase/Buffer Mix 1μl 
Water Up to 5μl 
Proteinase K 0.5μl 
Table 2.5 – Reaction scheme for BP reaction. 
PCR amplified product, pDONR223 and BP Clonase/Buffer mix were mixed in a 1.5ml 
eppendorf tube before incubating at 25°C for 16 hours. Following this, 0.5μl of proteinase 
K was added and the mixture was heated at 37°C to terminate the reaction. 
 
To check the band size of PCR products, 1% agarose gels were used, where the agarose 
(Bioline) was melted in 0.5% TBE. After cooling slightly, Sybr-safe (Thermofisher) was 
added (1:20,000 dilution) to allow DNA visualization and Gels were run at 120V for 40 
minutes unless otherwise specified. 
2.7.3 Transformation into RecA- bacteria 
 
Following the BP reaction, transformations were carried out into either chemically 
competent sliver efficiency alpha-select (Bioline), or stellar competent (Clontech) cells. 
2μl of BP reaction was transformed into 25μl alpha select or stellar cells. These were 
incubated on ice for 30 minutes before being heat shocked at 42°C for 45 seconds. 
Samples were then returned to ice for 30 seconds and 250μl of SOC media was added, 
and samples were incubated at 37°C, 200rpm for 1hour. 200μl of samples were then 
spread onto LB (10% tryptone, 10% NaCl, 5% yeast extract, 10% bioagar) with the 
antibiotic required for construct selection. Antibiotic resistance of the vectors used in this 
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study are shown in Table 2.6. Plates were incubated overnight at 37°C in a static 
incubator. 
 
Vector Antibiotic 
pDONR223 Spectinomycin (100ug/ml) 
pGBKT7 Kanamycin (50ug/ml) 
pAMBV Kanamycin (50ug/ml) 
Table 2.6 – Antibiotic resistances of vectors used. 
 
2.7.4 Bacterial colony PCR 
 
Following transformation, diagnostic PCRs were carried out on a selection of (5-6) 
colonies to ascertain that the transformation was successful and the construct was 
present in the bacteria. Table 2.7 shows the mastermix for diagnostic bacterial colony 
PCRs. 
 
Reagent Final Concentration μl/reaction 
Forward Primer 
(10μM) 
0.7μM 0.7 
Reverse Primer (10μM) 0.7uM 0.7 
dNTPs (25mM) 0.625mM 0.25 
NH4 buffer (10x) 1x 1 
MgCl2 (50mM) 2.25mM 0.4 
BioTaq - 0.05 
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dH2O - 6.9 
Table 2.7 – Mastermix for diagnostic bacterial colony PCR. 
 
Samples were kept on ice during preparation. After dispensing 10μl per sample, half of 
each colony was picked into each tube. 
 
The PCR cycle used when performing diagnostic PCRs is as follows: 
1. 95°C for 5 minutes 
2. 95°C for 1 minute 
3. 55°C/60°C for 1 minute (temperature is dependent on the melting temperature of 
the primers used) 
4. 72°C for 1 minute per kilobase of DNA to amplify 
5. Go to 2. 34 times. 
6. 72°C for 5 minutes 
7. 15°C hold 
Following PCR samples were run on 1% agarose gels. Colonies that gave rise to bands of 
the correct size were picked from the remaining spot on the LB plate into 9ml LB 
containing appropriate selection antibiotic. These were then incubated overnight at 37°C, 
shaking at 200rpm. The next day glycerols were made to preserve the constructs. 200μl 
of subculture and 80μl 80% glycerol (weight/volume) were mixed in a 1.5ml eppendorf, 
kept on ice for a few minutes, and then transferred to the -80°C freezer. 
 
Minipreps (Wizard) were carried out to extract the DNA from bacteria, as described in 
the kit manual. Constructs were then sent to GATC Biotech for sequencing. 
Chapter 2: Materials and Methods 
 84 
 
2.7.5 Matchmaker Gold Construct Generation using Seamless Ligation Cloning Extract 
 
pGBKT7 is a bait vector used in the Matchmaker Gold yeast two hybrid system. To clone 
into this vector, primers were designed that had flanking pGBKT7 regions, as indicated 
below.  
 
F: CATGGAGGCCGAATTCatg…cDNA of interest 
R (with stop): GCAGGTCGACGGATCC…reverse complement of gene of interest + stop codon 
The pGBKT7 vector was enzymatically cut using BamH1-HF (NEB) and EcoR1-HF (NEB), 
using the reaction scheme shown in Table 2.7. 
Reagent Amount 
Uncut pGBKT7 5μg 
BamH1-HF 5 units 
EcoR1-HF 5 units 
CutSmart Buffer 5μl 
Water Up to 50μl 
Table 2.8 – Reaction scheme for enzymatic double digest of the pGBKT7 vector  
Digests were incubated for 2 hours at 37°C. The enzymes were then denatured at 65°C 
for 20 minutes. Cut Vectors were run on a 0.8% agarose gel, then gel-extracted and 
purified (Qiagen). 
 
2.7.6 SLICE extract generation 
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In order to clone genes into vectors that are not gateway compatible, another method was 
required. For this, we used a method recently developed in the Motohashi lab (Kyoto, 
Japan), where they were able to generate bacterial lysates that were capable of carrying 
out seamless ligation of an insert into an appropriately cut vector (Motohashi, 2015). This 
is an incredibly cheap and simple methodology, and when compared to the commercial 
In-fusion seamless-ligation kit, efficiencies were found to be very similar.  
 
The SLICE extract can be created from any strain of bacteria that is RecA(-). Alpha-select 
cells were used in this case.  On the first day 5ml of 2xLB (20% tryptone, 20% NaCl, 10% 
yeast extract) was inoculated with 5μl of cells, and incubated overnight at 200rpm, 37°C. 
The culture was then diluted with the addition of 45ml 2xLB, and poured into a 1 litre 
flask. This was then incubated for around 3 hours, until a 1:10 dilution of the culture gave 
an optical density reading of 0.3 at 600nm. Cells were harvested by centrifugation at 
4300rpm for 20 minutes at 4°C. The supernatant was removed, and the pellet was re-
suspended in 50ml ice-cold sterilized water. Cells were then spun down at 4300rpm, 4°C 
for 10 minutes. the supernatant was again discarded, and the pellet was re-suspended in 
1.2ml 3% Triton X-100 (w/v), diluted in 50mM TrisHCl (pH 8.0): For 10ml: 0.5ml 1M 
TrisHCl, 0.3ml Triton X-100, 9.2ml dH2O, adjusted to pH 8.0 using 5M HCl or NaOH. 
This was then transferred to a 1.5ml eppendorf. The cells were incubated for 10 minutes 
at room temperature, then spun down at 13,000rpm, 4°C, for 5 minutes. The supernatant 
was transferred to a fresh eppendorf on ice. One volume of ice cold 80% glycerol was 
added. The lysate was aliquoted into PCR tubes (50μl per tube), before being snap frozen, 
and stored at -80°C 
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SLICE buffer was prepared as shown in Table 2.9 before being sterile filtered. The mixture 
was aliquoted and stored at -20°C. 
 
Reagent Stock 
Concentration 
Final 
Concentration 
Volume (ml) 
Tris-HCL, pH 7.5 1M 500mM 5 
MgCl2 1M 100mM 1 
ATP 100mM 10mM 1 
DTT 100mM 10mM 1 
Water - - 2 
Table 2.9 – SLICE buffer constituents. 
 
2.7.7 SLICE reactions 
 
To ligate the gene of interest to the cut pGBKT7 vector, SLICE reactions was carried out 
according to the reaction scheme shown in Table 2.10. 
 
Reagent Amount 
Cut Vector 10ng 
PCR amplified gene of interest 30ng 
SLICE extract 1μl 
SLICE buffer 1μl 
Water  Up to 10μl 
Table 2.10 – Reaction scheme for SLICE reaction 
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Reactions were placed in a 37°C heat block for 15 minutes before being transferred to ice. 
Transformations, diagnostic PCRs and minipreps were then carried out as previously 
described. 
 
2.8 Y2H Library screening 
 
2.8.1 Constituents/media required for screening 
 
The media required for yeast growth and maintenance is shown in Tables 2.11 to 2.14. 
 
 
 
 
YPAD  (500ml)  
D-Glucose (Formedium) 10g 
Bioagar (for solid, Biogene) 10g 
Peptone (Formedium) 10g 
Yeast Extract (Formedium) 5g 
Adenine Hemisulphate  0.1g 
Table 2.11 – Constituents of YPAD media 
SD-X  (where X represents the amino 
acids lacking from the medium, 
500ml) 
 
D-Glucose 10g 
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Yeast Nitrogen Base without Amino 
Acids (Formedium) 
3.35g 
Bioagar (if making solid media) 10g 
Appropriate amount of amino acid 
mixture 
See Table 2.11 and 2.12 
Table 2.12 – Constituents of yeast selective dropout media. 
 
 
 
 
 
 
 
A/H/L/W/U DropOut (DO)  
Amino Acid Grams/100L  
Arginine 2 
Isoleucine 3 
Lysine 3 
Methionine 2 
Phenylalanine 5 
Threonine 20 
Tyrosine 3 
Valine 15 
Total (g/L) 0.53 
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Table 2.13 – Recipe for dropout salts mixture for SD media 
SD – X powder mix (for 100L) 
 -L* -W -WL -WLAH 
Adenine 
Hemisulphate 
(A) 
0.6 0.6 0.6 - 
Leucine (L) - 1.0 - - 
Histidine (H) 0.2 0.2 0.2 0.2 
Uracil (U) 0.2 0.2 0.2 0.2 
A/H/L/W/U 
DO 
5.3 5.3 5.3 5.3 
Total g/L 0.63 0.73 0.63 0.57 
Table 2.14 – Recipe for selective media amino acid additions.  
* Tryptophan (W) is added to the media after autoclaving.  
Powders of the amino acids were added to falcon tubes, shielded from the light, and kept 
at 4°C until needed. When preparing the media, the appropriate mass of powder was 
added to the other constituents (Table 2.14). Bottles were then filled with 500ml water, 
and autoclaved. 
To clone fragments of constructs, the same flanking pGBKT7 primers were used, but the 
gene-specific primers were designed so as to only clone the fragment needed.  
 
2.8.2 Preparation of competent yeast cells 
 
Constructs were transformed into the Y2HGold strain (Clontech), as per the Matchmaker 
gold manual, with a few adjustments. 10ml of YPAD was added to a 50ml falcon tube, and 
Chapter 2: Materials and Methods 
 90 
inoculated with one colony of Y2HGold. The culture was then incubated overnight at 
300C, shaking at 200-220rpm.  5ml of the overnight culture was then added to a further 
45ml YPAD, split into two 50ml tubes, and incubated for 90 minutes at 300C, shaking at 
200-220rpm. Cultures were centrifuged at 2300rpm for 5 minutes at room temperature. 
The supernatant was discarded and pellets were re-suspended in 30ml dH2O. Tubes were 
then centrifuged again at 2300rpm for 5 minutes, and the supernatant was discarded and 
pellets were re-suspended in 1.5ml 1.1xTE/LiOAc (for 10ml, 1.1ml 10x TE buffer, 1.1ml 
100mM LiOAc, 7.8ml dH2O), and transferred to 2ml eppendorfs. Eppendorfs were 
centrifuged at 13000rpm for 15 seconds, and then the pellets were re-suspended in 600ul 
1.1xTe/LiOAc. At this point the yeast were ready to be transformed with constructs. 
 
2.8.3 Yeast Transformation 
 
For each set of transformations, a negative control, empty pGBKT7 vector was also 
carried out to check bait toxicity. To a pre-chilled 1.5ml eppendorf 100ng plasmid DNA 
(sequenced gene of interest in the pGBKT7 vector, or the negative control) was added, 
with 5μl of 10mg/ml salmon testes DNA that had been denatured at 95°C for 5 minutes 
just prior to use. To each tube 50μl of the competent Y2HGold were added and mixed 
gently. 500μl of PEG/LiOAc (for 5ml, 1ml 50% (w/v) PEG, 1ml LiOAc, 3ml dH2O) were 
then added. Samples were then incubated at 30°C for 30 minutes, before the addition of 
20μl DMSO. Yeast were then heat shocked by placing them in a water bath set at 42°C for 
1 hour to allow the entry of the DNA into the yeast cells. After this incubation, tubes were 
centrifuged at 13000rpm for 15 seconds, and pellets were re-suspended in 1ml YPAD 
plus (Clontech), and incubated in a 30°C incubator, shaking at 200-220rpm for 1 hour, to 
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allow recovery of the yeast cells. Samples were then centrifuged at 13000rpm for 15 
seconds, and pellets re-suspended in 1ml 0.9% (w/v) NaCl solution. 
 
100μl of 1/10 and 1/100 dilutions of the empty pGBKT7 transformation were spread 
onto 90mm –W plates. 100μl of 1/10 and 1/100 dilutions of the gene-pGBKT7 constructs 
were also spread onto the –W plates, as well as –W plates supplemented with X-Alpha Gal 
(-W/X) and plates supplemented with both X-Alpha-Gal and Aureobasidin A (-W/X/A). 
Table 2.15 summarizes the preparation of these two chemicals. 
 
To proceed to the next stage, growth of yeast should occur on the –W plates, blue colonies 
should appear on the –W/X plates and no yeast should grow when aureobasidin A is 
added to the media. This is the autoactivation test. If colonies on the gene-pGBKT7 plate 
appear much smaller than those on the negative control plate, this indicates construct 
toxicity, negating its use for future experiments. 
 
Constituent Stock 
Solution 
Solvent Storage Working 
Concentration 
Aureobasidin A 500μg/ml 100% Ethanol 4C 200ng/ml 
X-alpha-Gal 20mg/ml Dimethylformamide -20C 40μg/ml 
Table 2.15 – Constituents required for matchmaker library screening – Aureobasidin A and X-
alpha Gal. Both are added after the media has been autoclaved. 
 
2.8.4 Matchmaker Gold Yeast Library Screening 
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The library was performed as described in the Matchmaker manual, with the following 
differences. Initially bait was grown in 5ml –W, and left shaking at 200rpm for 8 hours. 
At this point, a further 45ml –W was added, and transferred to a 1L flask.  This was then 
incubated overnight at 30°C, 200rpm. 
 
Clontech’s Matchmaker normalized human brain library (Cat Number: 630479) was used 
to perform library screens. This was amplified in the lab by diluting 500μl of the human 
brain library stock to a total volume of 7.5ml. This was then pipetted equally onto 50 
140mm –L plates, and incubated at 30°C for 3 days. To each plate, 4ml of liquid –L was 
added and the yeast scraped into a sterile conical flask. A further 1ml of the liquid –L was 
added to the same plate, and the rest of the yeast was scraped off. The optical density was 
tested (at 600nm), and glycerol was added to a final percentage of 80%. 1ml aliquots of 
the library were made, and then stored at -80°C. 
 
To carry out a library screen, after the overnight amplification of bait, the culture was 
poured into 50ml non-skirted centrifuge tubes and centrifuged at 2300rpm for 5 minutes. 
The pellets were re-suspended in a combined volume of 1ml 2xYPAD (combine the 
pellets). An aliquot of the library was defrosted on ice, and 1ml was added to the bait re-
suspension. This was then poured onto a 140mm YPAD plate, and incubated at 30°C for 
5 hours. 
 
After 5 hours, 4ml of 0.5x YPAD (supplemented with 80μg/ml kanamycin) was pipetted 
onto the plate, and the yeast scraped off into a sterile 15ml centrifuge tube. 1ml of YPAD 
was used to scrape the remainder of the yeast into the same tube. 100μl of the 5ml was 
used to make 1 in 10, 1 in 100, and 1 in 1000 dilutions.  The remaining yeast was pipetted 
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equally between sixteen 140mm –WL plates with aureobasidin A. Plates were incubated 
for 3-5 days at 30°C. After this, the mating efficiency was calculated as follows: 
 
Mating efficiency = 100 * (colonies on -90mm –WL plate  x dilution factor*10)/(colonies 
on either –L or –W plate, whichever had fewer) 
 
Colonies were picked from the –WL/Aureobasidin A plates, into 100ul 0.9% NaCl, and 
2.5μl was spotted onto higher stringency –WLAH/X-alpha-Gal/Aureobasidin A plates. If 
possible 96 or 2x96 colonies were picked. These plates were then further incubated for 
3-5 days at 30°C. 
2.8.5 Diagnostic yeast colony PCR 
 
Diagnostic yeast colony PCRs were carried out on all colonies that showed robust growth 
on the –WLAH/X/A plates, which also turn blue. 
For the yeast colony PCR, the primers pGADT7.F and pGADT7.R were used: 
pGADT7.F: cgactcactatagggcgagc 
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pGADT7.R: gatggtgcacgatgcacag 
 
 
These primers amplify the prey, leaving flanking regions to allow recombination back 
into the pGADT7 vector in the Y187 yeast (see library gap repair section). 3μl of 20mM 
NaOH was pippetted into each well. Picking colonies into the solution and incubating at 
Figure 2.1 – pGADT7 map. A. Circular map of pGADT7, generated in Snapgene. B. 
Region amplified by pGADT7.f and pGADT7.r primers.  
A 
B 
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room temperature for 20 minutes leads to yeast lysis. For a 96 well plate, a 120-reaction 
mastermix was made as shown in Table 2.16 (for one reaction). 
 
Reagent Start 
Concentration 
End 
Concentration 
Volume (μl) 
pGADT7.F  10μM 0.5μM 0.75 
pGADT7.R  10μM 0.5μM 0.75 
dNTPs  25mM 0.42mM 0.45 
MgCl2  50mM 1.5mM 1.5 
10 x NH4 buffer  10x 1x 0.75 
DMSO   0.3 
BioTaq   0.15 
dH2O   7.35 
Table 2.16 – Reaction scheme for diagnostic yeast colony PCR 
12μl of mastermix was added to each 3μl of lysed yeast, sealed and run in the PCR 
machine on the following cycle: 
1. 95°C for 5 minutes 
2. 95°C for 1 minute 
3. 60°C for 1 minute 
4. 72°C for 3:30 minutes 
5. Go to 2. 39 times 
6. 72°C for 5 minutes 
7. 15°C hold 
1% agarose gels were then used to determine band presence.  
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2.8.6 Library gap repair 
 
After amplification of interacting prey inserts, PCR products were gap repaired back into 
the yeast Y187 strain (Clontech). In this process the cut pGADT7 vector and the PCR 
fragment is transformed into the yeast. A table showing the reaction scheme for digesting 
pGADT7 is shown in Table 2.17. 
 
Constituent  
Uncut pGADT7 5μg 
Nco1 5 units 
NEBuffer 3.1 5μl 
dH2O Up to 50μl 
Table 2.17 – Reaction scheme for Nco1 digest of pGADT7 
Samples were heated at 37°C for 2 hours, then denatured at 80°C for 20 minutes. As with 
the pGBKT7 vector digestion, digested pGADT7 was run on a 0.6% agarose gel, then 
extracted and purified. 
 
The library gap repair process is very different to the protocol recommended by Clontech, 
who instead carry out 96 well minipreps on colonies that grow on the –WLAH/X/A plates. 
The adaptation used in this study is a far cheaper and a well-established method 
previously used in other Y2H studies in the Sanderson lab (Markson et al., 2009). 
10ml of YPAD is inoculated with Y187 yeast (that had been freshly streaked out onto 
YPAD plates), and incubated overnight at 30°C, shaking at 200rpm. The following day, 
5ml was discarded, and 45ml YPAD added and split into two 50ml falcons. The subculture 
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was incubated at 30°C , 200rpm for 90 minutes. The Y187 was then centrifuged at 
2300rpm for 5 minutes to spin down the yeast. The pellets were combined and re-
suspended in 30ml dH2O. Cultures were then centrifuged at 2300rpm for 5 minutes, and 
the pellet was re-suspended in 1.5ml 1.1xTe/LiOAc (Transformation solution 1, Table 
2.23). The culture was then transferred to a 2ml eppendorf and centrifuged at 13000rpm 
for 15 seconds. The pellet was then re-suspended in the mastermix shown in Table 2.18.  
 
Constituent  
50% PEG 3350 1110μl 
1M LiOAc 167μl 
10ng/ml Salmon testes DNA 
(denatured at 95c for 5 minutes) 
40μl 
pGADT7 cut with Nco1 60ng 
dH2O 170μl 
Table 2.18 – Mastermix for library gap repair 
The pellet was re-suspended in the mastermix then 8μl of cell re-suspension was pipetted 
per well in a 96 well plate. 4μl of the YCPCR products (section 2.8.4) were then added to 
these wells and mixed by pipetting. The plates were sealed and the following program 
was used on the PCR machine: 
1. 30°C for 30 minutes 
2. 42°C for 25 minutes 
3. 30°C for 1 minute 
The transformed yeast was then pipetted onto a 140mm –L agar plate to select for the 
prey (i.e. the interacting protein to the protein of interest). 4μl was pipetted at a time to 
Chapter 2: Materials and Methods 
 98 
prevent spots from merging. Plates were then incubated for 3-5 days at 30°C, before 
photographing each plate and recording the number of colonies per spot. 
 
2.8.7 Reconfirmation of prey against the original bait 
 
After the prey has been selected for and is in the Y187 yeast, a standard yeast mating was 
performed to test whether the prey will bind to the bait of interest. As well as testing the 
prey against the bait of interest, the prey is also mated against empty-PGBKT7 (in the 
Y2HGold yeast strain) as a negative control. Several colonies from each spot of the library 
gap repair plate were picked into 25μl of dH2O. 4ul of each re-suspension was then 
pipetted onto two 140mm plates containing YPAD, then left to dry. Bait (either the gene 
of interest or the empty vector) were then re-suspended in 500μl dH2O, and 4μl of the re-
suspension were pipetted onto each spot, so that one plate contains the mating of the 
gene of interest and the prey, and the other is the empty vector against the prey. Plates 
were then incubated for 24 hours at 30°C. 
 
Yeast was then replicated from the YPAD plates to –WL plates using standard velvet 
replication procedure (Fields & Song, 1989) and -WL plates were incubated for 48 hours, 
and then the replication process was repeated onto –WLAH/X/A and –WLAH plates. 
These plates were then incubated for 1 – 2 weeks at 30°C , and pictures were taken every 
few days.  
 
The expected results after this time are shown in Table 2.19. If colonies appear on the –
WLAH/X/A plate where the bait is the empty vector, these are false positives and should 
not be sent for sequencing.  
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Genuine Positive Hit 
 Agar plate 2mm colonies? Colour 
Bait + 
candidate prey 
-WL/X Yes Blue 
Bait + 
candidate prey 
-WLAH/X/AbA Yes Blue 
Empty pGBKT7 
+ candidate 
prey 
-WL/X Yes White 
Empty pGBKT7 
+ candidate 
prey 
-WLAH/X/AbA No N/A 
 
 
False Positive 
 Agar plate 2mm colonies? Colour 
Bait + 
candidate prey 
-WL/X Yes Blue 
Bait + 
candidate prey 
-WLAH/X/AbA Yes Blue 
Empty pGBKT7 
+ candidate 
prey 
-WL/X Yes Blue 
Empty pGBKT7 
+ candidate 
prey 
-WLAH/X/AbA Yes Blue 
Table 2.19 – Summary of results expected for a positive and false positive result 
Prey hits were then sent for sequencing using the pGADT7.F sequencing primer (Section 
2.8.4). 
 
2.8.8 MYTH construct generation 
 
To use constructs in the membrane-based yeast-two-hybrid library system, the pAMBV 
vector was used. This is a C-terminally tagged vector.  
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Figure 2.2 – AMBV4 vector map generated using Snapgene. 
 
Primers were designed to have the following flanking regions: 
Forward: tgcacaatatttcaagctataccaagcatacaatcaactccaagcaacacaATG…cDNA of interest  
Reverse: tcgacggtatcgataagcttgatatcgaattcctgcagat…Reverse complement of Gene of 
interest without stop codon 
 
Following the flanking regions, primers were designed to have 15bp gene specific regions 
of mouse PAT family members. The primers used are shown in Table 2.20. 
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Following successful KOD polymerase chain reaction to add these flanking ends to cDNAs 
of interest, gap repairs were carried out to recombine the insert into the pAMBV vector 
using the yeast native recombination enzymes. For this, the pAMBV vector was digested 
by Nco1. Table 2.18 shows the reaction scheme. Samples were heated at 3°7c for 2 hours, 
and then Nco1 was denatured by heating the sample at 80°C for 20 minutes. 
 
Constituent  
Uncut pAMBV 5μg 
Nco1 5 units 
Cutsmart Buffer 5μl 
dH2O Up to 50μl 
Table 2.21 – Reaction scheme for pAMBV digest 
 
2.8.9 Gap repair of gene of interest and pAMBV into Nmy51 
 
The yeast strain Nmy51 was used for all transformations in the MYTH system. One colony 
of freshly streaked out Nmy51 was inoculated in 5ml YPAD broth, and incubated 
overnight shaking at 200rpm, 30°C. The 5ml culture was then diluted by a further 45ml 
Table 2.20 - Gene specific primer sequences for mouse DHHC family members of 
interest. 
 
Gene	Symbol Size	(bp) Primer Primer	sequence
zDHHC8 2288 Forward ATGccccgcagccccgggacg
Reverse	(-	stop) caccgagatttcatacgt
zDHHC13 1868 Forward ATGgagggcccgggcctgggc
Reverse	(-	stop) tacagagcgaaggactttc
zDHHC17 1898 Forward ATGaccaagatggcggacggc
Reverse	(-	stop) cacaagctggtacccaga
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YPAD, and transferred to two 50ml falcons. These were grown at 30°C , 200rpm, for a 
further 3 to 4 hours, until the OD was between 0.6 and 0.8.  
 
Cultures were centrifuged at 1100g for 5 minutes, and the supernatant was discarded. 
Each pellet was re-suspended in 25ml dH2O, and then centrifugation was repeated as 
above. Pellets were re-suspended in 1ml dH2O. 
 
For transformations and gap repairs, a solution containing PEG and LiOAc was required, 
and this transformation solution is shown in Table 2.22. 
Constituent Volume  
50% PEG 3350 2.4ml 
1M LiOAc 300μl 
10ng/ml Salmon testes DNA 
(denatured at 95°C for 5 minutes) 
50μl 
Table 2.22 – Transformation solution for gap repair and transformation of baits into Nmy51 
 
For each gap repair reaction, 100μl of the yeast cells, 300μl of the transformation solution 
(Table 2.22), 50fmol of PCR product and 200fmol of pAMBV vector were combined in a 
1.5ml eppendorf.  
 
Reactions were mixed and incubated at 30°C for 30 minutes, followed by heat shock at 
42°C for one hour. The solutions were then centrifuged at 1100g for 5 minutes, and the 
pellets re-suspended in 200μl dH2O. These were then plated onto selective –L plates, and 
incubated at 30°C for 2-4 days until colonies appear. 
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DNA was isolated from the transformants by inoculating single colonies into 4ml –L broth 
and incubating overnight at 200rpm, 30°C. DNA was then extracted from the subcultures 
using a commercial miniprep kit, following the manufacturer’s instructions with one 
extra step, where after initial re-suspension a small volume of lime soda beads were 
added to the re-suspension to break yeast cell walls and enhance extraction of DNA. As 
these minipreps give a low yield of DNA, they were transformed back into alpha-select 
cells as described previously.  Diagnostic PCRs, minipreps and sequencing were then 
carried out following successful transformation. 
 
As these minipreps give a low yield of DNA, they were transformed back into alpha-select 
cells as described previously.  Diagnostic PCRs, minipreps and sequencing were then 
carried out following successful transformation. 
 
Once sequenced, constructs were transformed back into the Nmy51 strain. The method 
is the same as for gap repair, except 200fmol of the insert and vector were transformed 
into the yeast. Following successful transformation, several colonies were picked into 
800ul –L media. These were incubated overnight at 200rpm, 30°C. 200ul 80% glycerol 
was then added, and the mixtures vortexed and frozen at -80°C. 
 
2.8.10 Bait Autoactivation – NubGI Test 
 
As with the matchmaker system, baits need to be checked for autoactivation prior to their 
use in a library screen. However, the autoactivation test used in MYTH is very different to 
that in the Matchmaker.  In this system, two proteins Ost1 and Fur4 are fused to NubG 
and NubI fragments. NubI is the native N-terminal fragment of ubiquitin, and will 
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spontaneously bind Cub fragments, even if the bait and prey themselves do not interact. 
For a bait to pass this test (dependent on it’s subcellular localization), it must interact 
with only the NubI constructs. 
 
To carry out the NubGI test, the bait was freshly streaked out onto –L plates. Colonies 
were then picked into 5ml of –L broth, and incubated overnight at 30°C, 200rpm. 45ml of 
–L was added, and the culture grown until the OD was between 0.6 and 0.8. At this stage, 
transformation was carried out as previously. Cultures were centrifuged at 1100g for 5 
minutes, and supernatant was discarded. Each pellet was re-suspended in 25ml dH2O. 
Centrifugation was repeated as above, and pellets are re-suspended in 1ml dH2O. 
100μl of yeast, 300μl of transformation solution (Table 2.22), and 150ng of each of the 
NubGI constructs (Ost1-NubI, Ost1-NubG, Fur4-NubI, Fur4-NubG) were combined in an 
eppendorf. These were incubated at 30°C for 30 minutes, followed by 42°C for 1 hour. 
Samples were centrifuged at 1100g for 5 minutes, then re-suspended in 200μl dH2O, and 
plated onto double selection (-WL) plates. Plates were incubated for 3-5 days, until 1-
2mm colonies had grown. On –WL plates, colonies should appear when both NubG and 
NubI constructs have been transformed, as the plate selects for the presence (not 
binding) of bait and prey.  Single colonies of each transformed bait and NubGI control 
were re-suspended in 0.9% NaCl, and ten-fold dilutions are made (0, 1:10, 1:100 and 
1:1000). These were spotted onto –WL plates, as well as –WLH and –WLAH plates, which 
had varying concentrations of 3-aminotrizol (3AT) in the media (from 0 to 10mM 3AT). 
3AT limits bait expression, and if auto-activation can be prevented by using higher 
concentrations of 3AT. Plates were grown for 2-4 days and assessed for growth. 
 
2.8.11 MYTH library screening 
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The MYTH library system is different to that of the Matchmaker because a DNA library is 
transformed into the bait-transformed yeast, whereas in Matchmaker, a mating-based 
screen is used. 
 
To begin, 2-3 colonies of the bait construct (in Nmy51) were inoculated into 10ml –L 
broth, and incubated for 8 hours, shaking at 200rpm, 30°C.  The 10ml starter culture was 
then added to 100ml –L in a 1 litre flask, and grown overnight at 30°C, 200rpm. The next 
day, the optical density of the culture was measured, and the amount of culture required 
for 30 units calculated. This volume of culture was centrifuged at 1100g for 5 minutes. 
The pellet was re-suspended in 10ml pre-warmed 2 x YPAD and transferred to a 1 litre 
flask. The falcon tube was rinsed with a further 40ml 2xYPAD, and then another 150ml 
2xYPAD was added to the flask. 
 
Yeast were grown at 200rpm, 30°C until the OD reaches 0.6 (between 3 and 5 hours). 
The two solutions are required for transformation, shown in Tables 2.23. 
 
Once grown the yeast cultures were divided into four 50ml falcons, and centrifuged at 
700g for 5 minutes. Pellets were re-suspended in 30ml dH2O, and the centrifugation step 
repeated. 1ml of Transformation Solution I (Table 2.23) was then added to each tube, and 
the pellets re-suspended and transferred to a 1.5ml eppendorf. Yeast were then 
centrifuged at 1100g for 5 minutes, and re-suspended in 600μl Transformation solution 
I (Table 2.23). 
 
 
Chapter 2: Materials and Methods 
 106 
Constituent Volume  
Transformation Solution I 
10xTE buffer 1.1ml 
1M LiOAc 1.1ml 
dH2O 7.8ml 
Transformation Solution II 
1M LiOAc 1.5ml 
10 x TE buffer 1.5ml 
50% PEG 12ml 
Table 2.23 Transformation solutions required for MYTH library screening 
 
To each of four 50ml falcons, 600μl yeast cells, 2.5ml of Transformation solution II, 20μl 
10mg/ml salmon testes DNA (denatured at 95c for 5 minutes), and 8μg of the foetal brain 
Nub-library were added. Each falcon was vortexed for 1 minute, then incubated at 30°C 
for 45 minutes, vortexing every 15 minutes. 160μl DMSO was then added to each tube, 
and incubated at 42°C for 20 minutes. Following this, samples were centrifuged at 1100g 
for 5 minutes, and each pellet was re-suspended in 3ml 2xYPAD. Samples were then 
pooled. Cultures were centrifuged at 1100g for 5 minutes, and the pellet was re-
suspended in 4.9ml 0.9% NaCl. 100ul of the re-suspension was used to make 1:10, 1:100 
and 1:1000 dilutions, and these dilutions were plated onto 90mm –WL plates, and grown 
at 30°C for 3-4 days. 
 
200ul aliquots of the remaining 4.8ml cell suspension were pipetted onto –WLAH plates 
(with 3AT as needed), and grown for 3-5 days. If colonies grow, they were picked into 
100ul 0.9% NaCl, and 2.5ul volumes were spotted onto –WLAH (with 3AT if needed) + X-
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gal plates (Table 2.24). Colonies that show robust growth and turn blue can be used for 
further analysis.  
 
Constituent  
-WLAH media 450ml 
X-Gal (100mg/ml) 400ul  
Sodium Phosphate solution (7g 
sodium phosphate dibasic and 3g 
sodium phosphate monobasic in 
100ml dH2O) 
50ml 
Table 2.24 – Recipe for X-gal selection plates in MYTH library screening. X-gal and sodium 
phosphate are added after the –WLAH media has been autoclaved and cooled to around 50c. 
 
2.8.12 Diagnostic yeast colony PCR of MYTH interaction partners 
 
For the yeast colony PCRs of prey that underwent robust growth and turned blue on the 
–WLAH/X-Gal plates, the NubGX seq F and pPR3N seq R primers were used: 
NubGX seq F: GTCGAAAATTCAAGACAAGG 
pPR3N seq R: AAGCGTGACATAACTAATTAC 
 
Yeast were lysed in a 96 well format by pipetting 3μl of 20mM NaOH into each well of a 
96 well plate. Yeast colonies were then picked into the solution and incubated at room 
temperature for 20 minutes. For a 96 well plate, a 120-reaction mastermix was made. The 
reaction scheme is as shown in Table 2.25 (for one reaction). 
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Reagent Start 
Concentration 
End 
Concentration 
Volume (μl) 
NubGX Seq F  10μM 0.5μM 0.75 
NubGX Seq R  10μM 0.5μM 0.75 
dNTPs  25mM 0.42mM 0.45 
MgCl2  50mM 1.5mM 1.5 
10 x NH4 buffer  10x 1x 0.75 
DMSO   0.3 
BioTaq   0.15 
dH2O   7.35 
Table 2.25 – Reaction scheme for diagnostic yeast colony PCR in the MYTH library screening 
 
12μl of mastermix was added to each 3μl of lysed yeast, sealed and run in the PCR 
machine on the following cycle: 
1. 95°C for 5 minutes 
2. 95°C for 1 minute 
3. 60°C for 1 minute 
4. 72°C for 3:30 minutes 
5. Go to 2. 39 times 
6. 72°C for 5 minutes 
7. 15°C hold 
1% agarose gels were then used to determine band presence.  
 
2.8.13 Gap repair of MYTH prey yeast colony PCR fragments into the pPR3N vector 
Chapter 2: Materials and Methods 
 109 
 
The yeast colony PCR fragments obtained as described in section 2.8.13 were then gap 
repaired back into the prey pPR3N vector, which had been digested with Sfi1 (Table 
2.26).  
Constituent  
Uncut pPR3N 5ug 
Sfi1 5 units 
Cutsmart Buffer (10x) 5ul 
dH2O Up to 50ul 
Table 2.26 – Digestion Reaction Scheme of the MYTH pPR3N vector 
Samples were incubated for 2 hours at 50°C , then run on a 0.6% agarose gel and 
extracted as per the manufacturer’s protocol. 
 
5ml of YPAD is inoculated with a single colony of Nmy51 yeast (that had been freshly 
streaked out onto YPAD plates), and incubated overnight at 30°C, shaking at 200rpm. The 
following day, 5ml was discarded, 45ml YPAD added and the optical density was checked 
and diluted to 0.15. The culture was then incubated at 30°C, 200rpm for four to five hours, 
until the optical density reached 0.6. Once this optical density was reached, the culture 
was centrifuged at 700g for 5 minutes to spin down the yeast, and the pellet the re-
suspended in 25ml dH2O. The culture was then centrifuged at 2300rpm for 5 minutes, 
and the supernatant removed. In a 2ml tube the mastermix shown in Table 2.27 was 
made, which is enough for 96 reactions. The mixture was vortexed, and then used to re-
suspend the pellet. 
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Constituent  
50% PEG 3350 1110μl 
1M LiOAc 167μl 
10ng/ml Salmon testes DNA 
(denatured at 95c for 5 minutes) 
40μl 
dH2O 170μl 
Table 2.27 – Mastermix for library gap repair of MYTH prey fragments. 
The mixture was vortexed, and then used to re-suspend the pellet.  
 
To a 1.5ml eppendorf, 8μl of yeast per reaction was added (for 96 reactions this would be 
768μl), 5ng of the original bait/reaction (for 96 reactions this would be 480ng) and 5ng 
of the pPR3N (digested with Sfi1). 8μl of this suspension was pipetted per well in a 96 
well plate (or PCR tube). 2-4μl of the YCPCR products (section 2.8.13) were then added 
to these wells and mixed by pipetting. The plates were sealed and the following program 
was used on the PCR machine: 
 
1. 30°C for 30 minutes 
2. 42°C for 25 minutes 
3. 30°C for 1 minute 
The transformed yeast was then spotted onto a 140mm plate filled with solid –WL agar, 
3-4μl at a time (allowing the spots to dry before spotting on top). Plates were then 
incubated for 3 days at 30°C, before being photographed and the number of colonies per 
spot recorded. 
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3-4 colonies of each spot were then re-suspended in 20μl dH2O, and spotted onto –WLAH 
(with the 3AT concentration used in the library screen), and –WLAH/X-Gal (with the 3AT 
concentration used in the library screen). The plates were then incubated for 2-3 days at 
30°C and pictures were taken after this time. 
 
2.8.14 Yeast colony PCR for MYTH prey sequencing 
 
Yeast that underwent robust growth on the –WLAH and –WLAH/X-Gal plates (section 
2.8.14), and had strong yeast colony PCR bands (section 2.8.13) were picked, and re-
grown for 3-4 days. 
 
Each freshly grown colony was picked into 10ul 20mM NaOH, and incubated at 99°C for 
10 minutes. The reaction scheme for the MiFi Polymerase PCR cycle is shown in Table 
2.28. 
 
Reagent Start 
Concentration 
End 
Concentration 
Volume (μl) 
NubGX Seq F  10μM 0.4μM 1.2 
NubGX Seq R  10μM 0.4μM 1.2 
5x Buffer 5x 1x 6 
MiFi polymerase   1.2 
Yeast    2 
dH2O   18.4 
Table 2.28 – MiFi Polymerase PCR mastermix (for one reaction) 
Samples were then run in the PCR machine on the following cycle: 
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1. 95°C for 2 minutes 
2. 95°C for 15 seconds 
3. 55°C for 15 seconds 
4. 72°C for 1 minute 45 seconds 
5. Back to step 2. 30 times. 
6. 4°C  hold. 
 
5μl of the reaction was then run on 1% agarose gel to check for prey presence. The rest 
of the reaction mixture (25μl) was sent for sequencing with the NubGX seq F primer. 
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Chapter 3 – Elucidating novel effectors of 
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3.1 Abstract 
 
Understanding the complex machinery underpinning synaptic function is necessary to 
better elucidate the pathophysiology of a wide range of neurological disorders, from 
autism to schizophrenia and Alzheimer’s disease. C. elegans are an ideal model organism 
to use to elucidate these factors due to the high coverage of their physical and functional 
interactome, the relative ease of RNAi mediated knockdown of target genes and the 
ability to assess subtle changes in  synaptic function via the aldicarb-sensitivity assay. 
Initially, we used two network-based criteria to identify potential novel regulators of 
synaptic function or plasticity, based on connectivity and betweenness scores in 
phenotypically defined aldicarb one-step protein interaction networks. 
 
Many proteins in the one-step aldicarb network were found to have a high number of 
interaction partners that were known to cause an aldicarb phenotype, as well as having 
a high betweenness centrality in the aldicarb and synaptic transmission one-step 
network. In total 37 novel candidate proteins were common between the two methods of 
network analysis, with 33 and 30 nodes being identified in the connectivity and 
betweenness screens, respectively. Following aldicarb-sensitivity assays, a total of 28 
genes were found to cause a significant change in the rate of paralysis. 8 of these were 
shared between the datasets, with 11 and 8 genes were elucidated to cause a significant 
shift in the rate of paralysis in the connectivity and betweenness screens, respectively. 
Nodes with human orthologs were identified and chosen for further analysis. 
Significantly, only the human orthologs of 7 genes found in both datasets, 1 gene found 
specifically in the betweenness dataset, and 4 genes found in the connectivity dataset 
were in the current synaptomeDB, and the majority of these proteins are predicted to 
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have a postsynaptic distribution. From this data a subset of potential novel regulators of 
synaptic efficacy were selected.   
 
3.2 Introduction 
 
3.2.1 Network based methods to elucidate effectors of synaptic function 
 
As previously discussed (see Introduction), many studies into the genes affecting 
neuronal function have already been carried out in C. elegans, Large-scale RNAi screens 
were carried out in worms hypersensitive to RNAi, which elucidated 185 genes that 
decreased acetylcholine secretion, and 90 genes that regulated GABA neurotransmission 
(Sieburth et al., 2005; Vashlishan et al., 2008). However the worm strains used were not 
neuronally sensitive to RNAi due to the lack of Sid-1 expression, and thus genes expressed 
neuron-specifically may not have been knocked down efficiently.  In addition, even if 
neuronal knockdown did occur, it is possible that knockdown in the muscles of the worm 
may counteract any phenotype, and deletion of genes with essential developmental roles 
may result in lethality before neuronal effects could be analyzed. For this reason we chose 
to perform screens in a strain of C. elegans with a higher neuronal sensitivity to RNAi.  
 
To identify novel effectors without performing unbiased global RNAi screens we adopted 
network based approaches that offer the potential to logically prioritize candidates to be 
tested. Previous studies show that connectivity, betweenness and the principle of “guilt 
by association” are important properties in biological networks (Oliver, 2000). Therefore, 
the construction and analysis of functional/phenotypic networks may logically provide a 
mechanism of capturing as yet untested components of common phenotypic processes.   
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Applying the principle of guilt by association, proteins that are highly connected to 
proteins known to cause a RIC or HIC phenotype are more likely to also cause the same 
phenotype. This property is known as connectivity. Connectivity values for all nodes in 
the network were simply defined by how many proteins with a known aldicarb-
sensitivity phenotype a currently untested protein interacts with.   Another algorithm 
that can be used to prioritize functionally relevant proteins within a network is  
“betweenness centrality”, which reflects how many times a given protein is in the shortest 
path between two other proteins. By ranking the betweenness of the one-step interacting 
proteins, those of higher betweenness again have the potential to have a greater 
functional impact, which in this study would be to cause an aldicarb phenotype when 
expression was suppressed.  
 
In order to test these principles, a higher-throughout aldicarb methodology was required. 
Traditionally full time course aldicarb experiments are carried out. However, this 
approach significantly restricts the number of candidate genes/proteins that can be 
tested, due to the need to check the worm’s paralysis every 30 minutes, and inherent day-
to-day variability, meaning that comparative experiments should ideally be carried out 
on the same day. Therefore, to make the assay higher throughput, we experimentally 
defined one or two time points when any changes in aldicarb-sensitivity should be 
detected.  
 
3.2.2 Aims 
 
The aims of this chapter were to: 
- Optimize the aldicarb-sensitivity assay on the neurosensitive Tu3311 strain. 
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- Generate a C. elegans one-step network using genes already known to cause an 
aldicarb-sensitivity assay as the core nodes. 
- Generate lists of novel proteins with highest connectivity and betweenness 
relative to known aldicarb-sensitivity proteins 
- Carry out high-throughput aldicarb-sensitivity screens following knockdown of 
identified highest connectivity and betweenness genes. 
 
3.3 Results 
 
3.3.1 Optimization of higher-throughput aldicarb-sensitivity assays 
 
As aldicarb-sensitivity assays are inherently subjective to significant day-to-day 
variability, the assay was optimized so that it could be used in a reproducible high-
throughput manner, in combination with RNAi feeding. 
 
Initially wild-type (N2) worms were tested for aldicarb-sensitivity to 1mM aldicarb, as 
this was the most commonly used drug concentration used in previous publications. 
However, in these papers large discrepancies are seen in the average times that N2 
worms take to paralyze. For this reason standard assay conditions were required to limit 
these differences. A detailed protocol is described in the Methods section, however, in 
brief, drying aldicarb plates in a sterile hood for 20 minutes gave the most consistent 
results, and were very different from plates dried for different time periods. Furthermore, 
unlike some protocols, bacteria were not seeded onto plates. This meant that if worms 
crawled off the plate, they were discounted from the experiment. This is also the case if 
worms underwent vulval prolapse. The effect of storing the plates at 4°C  or room 
Chapter 3: Connectivity and Betweenness 
 118 
temperature overnight was also tested, as well as the age of the worms used in the 
experiments (data not shown). It is vital to note that all assays for one experiment were 
carried out on the same day – Figure 3.1 shows two aldicarb assays where N2 worms had 
been treated with 1mM aldicarb on separate occasions. The results reveal a large 
difference between the two experiments, possibly due to the age or health of the worms, 
or variability in the batch of the aldicarb used. 
 
3.3.2 RNAi optimization 
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Figure 3.1 - Experiment to show day-to-day variability in aldicarb assays. In each replicate 
experiment 20 worms were picked onto 1mM aldicarb plates, the numbers of paralysed 
worms were counted every 30 minutes, and the percentage of paralysis calculated and plotted. 
Although efforts were made to directly replicate assay conditions significant day-to-day 
variability can be seen. For this reason all comparative aldicarb assays were carried out on the 
same day. In each case assays were performed in triplicate (N=3) and error bars represent the 
standard deviation.  
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After optimizing the aldicarb assay with wild-type worms, the Sid-1 mutant worm strains 
(Tu3311 and Tu3335) were tested using the aldicarb assay, as these strains would be used 
for RNAi experiments. These strains express the double-stranded RNA channel Sid-1 
under the control of the Unc-119 promoter. This ensures that Sid-1 is pan-neuronally 
expressed, which should enhance the uptake of dsRNA into neurons. Significantly, 
compared to N2 worms, both Tu3311 and Tu3335 showed a RIC phenotype (Figures 3.2 
and 3.3). Tu3335 is known to have an additional mutation in mec-6, which is known to 
cause effects on mechanosensation. For this reason there is a possibility that the mec-6 
mutation could interfere with changes in aldicarb-sensitivity following gene knockdown.  
Tu3311 therefore was the strain selected for use in these higher throughput RNAi 
screens.  
 
Figure 3.2 - The Tu3311 worm strain exhibits an inherent RIC phenotype compared to N2 
worms. In each case, three sets of 20 worms were picked onto 1mM aldicarb plates and 
paralysis of worms on each plate was measured every 20 minutes. The percentage of 
paralyzed worms at each time point were then calculated and plotted. N=3. Error bars 
represent standard deviation. 
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As the Tu3311 strain exhibited an inherent RIC phenotype it was important to first test 
whether additional RIC changes could be detected in Tu3311 worms. To address this 
issue, the observed rate of paralysis in the Tu3311 (Sid-1 mutant) strain was compared 
to that of the rrf-3 mutant strain (NL2099), which has enhanced sensitivity of RNAi 
throughout the worm. There was no significant difference in rate of paralysis observed 
between Tu3311 and rrf-3. However, Tu3335 was found to have a slightly HIC phenotype 
compared to these strains (Figure 3.4). Significantly, this data suggests that there is little 
difference between the synaptic functions of each of the strains before RNAi knockdown. 
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Figure 3.3 - The Tu3335 worm strain shows a mild RIC phenotype when compared to 
wild type N2 worms. Three sets of 20 worms for each strain were picked onto 1mM aldicarb 
plates and paralysis of worms on each plate was measured every 30 minutes. The percentage 
of paralyzed worms at each time point were then calculated and plotted. N=3. Error bars 
represent standard deviation. 
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As rab-3 is known to cause a characteristic RIC shift when knocked down or mutated in 
C. elegans, this genetic knockdown was used as a positive control for RNAi efficacy and to 
test whether additional RIC changes could be detected in Tu3311 worms.  The rab-3 
knockdown in Tu3311 was tested, and the predicted RIC phenotype was observed (Figure 
3.5), after optimizing assay conditions by increasing the IPTG concentration in feeding 
plates to 4mM, and performing paralysis assays on second-generation (F2) worms. Egl-
30 is another gene that is known to cause a RIC phenotype. An example of Tu3311 
knockdown with egl-30 can be seen in Figure 3.6, and rab-3 knockdown in rrf-3 in Figure 
3.7. Although RIC phenotypes were seen in both Tu3311 and rrf-3 strains, the Tu3311 
gave a more consistent phenotype in our hands. This in combination with the neuronal 
restriction of RNAi sensitivity in the Tu3311 strain led to the selection of Tu3311 worms 
Figure 3.4 - Tu3311 and rrf-3 show comparable rates of aldicarb-induced paralysis 
although the Tu3335 strain appears to be marginally more sensitive. All assays were 
carried out in triplicate (N=3) as described in Figures 3.2 and 3.3.  Error bars represent 
standard deviation. 
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as the preferred strain for subsequent large-scale assays. Tu3335 was also tested as a 
potential host strain for systematic aldicarb sensitivity assays.  Interestingly, the Tu3335 
strain showed an even greater RIC shift following rab-3 knockdown (Figure 3.8). 
However, due to the issues of altered motility in this strain a decision was made to 
perform planned high throughput screens in the Tu3311 strain and reserve the Tu3335 
strain, to retest borderline positive candidates observed in the Tu3311 strain.  
 
 
 
 
Figure 3.5 - Rab-3 induced RIC phenotypes can still be detected in Tu3311 neuro-
sensitive worms. To assess whether additional RIC phenotypes could be detected in the 
Tu3311strain of worms, which have an inherent mild RIC phenotype.  TU3311 worms were 
picked onto 4mM IPTG feeding plates seeded with bacteria containing either a rab-3 dsRNA 
vector (know RIC positive) or an empty L440 dsRNA vector control. Following gene 
knockdown as described in materials and methods, F2 generation worms were picked onto 
1mM aldicarb plates and the relative rate of paralysis was periodically measured over a 270-
minute period. In each case, assays were performed in triplicate (n=3) and error bars 
represent standard deviation   
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Figure 3.7 - Effect of rab-3 knockdown in the globally RNAi sensitive rrf-3 worm strain. 
As for experiments performed in the Tu3311 worm strain positive (rab-3) and negative (L440 
vector) assays were performed in triplicate (N=3), with numbers of paralyzed worms being 
counted periodically over a 300 minute period.  Error bars represent standard deviation. 
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Figure 3.6 - Egl-30 induced RIC phenotypes can still be detected in Tu3311 neuro-sensitive 
worms. To assess whether additional RIC phenotypes could be detected in the Tu3311strain of 
worms, which have an inherent mild RIC phenotype. Egl-30 and control RNAi knockdown assays 
were performed prior to aldicarb sensitivity assays as described for Figure 3.5  The relative rate 
of paralysis was periodically measured over 200 minutes. In each case, assays were performed 
in triplicate (n=3) and error bars represent standard deviation.  
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To carry out the higher throughput assays, it was necessary to pick a time point that could 
be used to reliably capture alterations in aldicarb-induced paralysis. Due to aldicarb 
batch variability, prior to performing all high-throughput screens, the worm strain of 
interest was knocked down with the negative (L440) and positive (rab-3 or egl-30) 
controls, and picked onto aldicarb plates. The representative rate of paralysis was then 
measured, and a standard time point chosen for each batch, where a significant change in 
the percentage paralysis was observed. This was found to be within the range of 100-160 
minutes, as indicated in figure legends. 
 
3.3.3 C. elegans network generation 
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Figure 3.8 - Knockdown of rab-3 induces a strong RIC effect in Tu3335 neurosensitive 
worms. To assess the effects of inhibiting rab-3 expression in the alternate neurosensitive RNAi 
strain Tu3335. Assays were carried out in triplicate (n=3) with test (rab-3) or control (L440) 
RNAi knockdown and aldicarb sensitivity assays were performed as described in Figure 3.5. 
Error bars represent standard deviation. 
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Wormnet version 3 (Cho et al., 2014) and the Worm Interactome Version 8 (Simonis et 
al., 2009) were used to chelate information about C. elegans PPIs known at the time of 
network generation.  From Wormnet, genetic interactions were removed, as were co-
expression, gene neighbourhoods, phylogenetic profiles, co-citation and protein tertiary 
structures. The remaining protein interactions were either high-throughput, 
small/medium scale for C. elegans as well as the interologs: D. melanoganster (fly), H. 
sapiens, D. rerio (zebrafish) and S. Cerevisiae (budding yeast).  The worm interactome 
consists of eight Y2H PPI screens for C. elegans proteins, as well as curated PPIs and 
interologs. The modified Wormnet and worm interactome networks were merged, 
generating a network of 9668 nodes and 125674 edges (Supplementary Figure 3.1).  
 
Wormbase was used to annotate genes according to their aldicarb-sensitivity phenotype, 
based on existing annotation of genes for ‘Resistance to Aldicarb’ and ‘Hypersensitivity 
to Aldicarb’. In addition, data mining was carried out using PubMed, in order to find other 
genes, which caused an aldicarb-sensitivity phenotype when their expression was 
altered. A list of the genes found to cause resistance or hypersensitivity to aldicarb are 
provided in Supplementary Figure 3.1. Although 252 genes were annotated as causing a 
RIC (240) or HIC (12) phenotype, only 195 of these had any known interaction partners, 
hence only these proteins could be used to generate aldicarb-related protein interaction 
networks (Supplementary Figure 3.2 shows the aldicarb nodes not represented in the 
network). 
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One-step aldicarb related networks were created using known RIC/HIC proteins as the 
core/seed nodes. Proteins interacting with these core proteins in a one-step network are 
known as nearest neighbours. The network of proteins known to have an aldicarb 
phenotype together with all nearest neighbours contains 3162 nodes and 6195 edges 
(Figure 3.9), including 184 proteins (red nodes) that when knocked down/mutated or 
overexpressed confer a RIC phenotype and 11 proteins (blue node) with a known HIC 
phenotype. The 2967 grey nodes in this network represent non-phenotypically 
characterized proteins that are candidates for the connectivity analysis. 
 
 
Figure 3.9 - A one-step C. elegans aldicarb sensitivity network. The core nodes (red and blue) 
are proteins known to cause a RIC or a HIC phenotype respectively, while grey nodes are one 
step connected proteins with no known aldicarb phenotype.  Cytoscape v2.8 was used to 
generate this network. 
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3.3.4 Connectivity 
 
A simple method to prioritize nodes for phenotypic screening is to rank uncharacterized 
nodes according to their connectivity with proteins that are already known to have some 
form of aldicarb phenotype.  
 
For this analysis, interactions between nearest neighbours that do not involve a protein 
known to have an aldicarb-sensitivity phenotype were removed from the one-step 
network. The connecting nodes were then degree-sorted with respect to connectivity to 
RIC- or HIC- proteins. Table 3.1 contains a ranked list of the top 100 highly connected 
candidate proteins for phenotypic testing and the availability of appropriate dsRNA 
constructs in the Vidal RNAi library.   
 
3.3.5 Aldicarb-screening of novel  candidate proteins identified by network connectivity 
analysis 
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As seventy of the hundred most highly connected candidate proteins had corresponding 
dsRNA clones in the Vidal C. elegans RNAi library, knockdown of these genes were tested 
in the Tu3311 strain to allow identification of additional proteins that contribute to or 
regulate synaptic function.  In addition, the relative utility of the different network 
biology algorithms for capturing novel synaptic regulators could be compared. 
Table 3.1 - A list of the Top 100 proteins ranked according to the relative degree of 
connectivity to known RIC/HIC proteins within a RIC /HIC one step network. Following 
network generation, interactions between the one-step nodes were removed. The one-step 
nodes were then degree-sorted and ranked. The availability of RNAi clones for the top 100 
proteins is also indicated. 
 
ID Gene	Symbol Degree Connectivity	Ranknai ID Gene	SymbolDegree Connectivity	Ranknai
AC7.2 soc-2 26 1 Yes F25H5.4 eef-2 8 51 Yes
B0001.4 B0001.4 19 2 No F33H1.2 gpd-4 8 52 Yes
B0024.9 trx-2 18 3 No F45F2.12 his-8 8 53 Yes
B0025.1 vps-34 18 4 No F52D10.3 ftt-2 8 54 No
B0034.3 casy-1 17 5 No F55G1.11 his-60 8 55 Yes
B0035.10 his-45 16 6 Yes F56C9.1 gsp-2 8 56 Yes
B0035.11 leo-1 15 7 Yes F56E10.2 daam-1 8 57 Yes
B0035.13 B0035.13 13 8 Yes F56F3.5 rps-1 8 58 Yes
B0035.4 pfd-4 13 9 No JC8.3 rpl-12 8 59 No
B0035.7 his-47 13 10 No K01H12.2 ant-1.3 8 60 No
B0035.8 his-48 13 11 No K03A1.6 his-38 8 61 Yes
B0035.9 his-46 13 12 Yes K04G2.1 iftb-1 8 62 No
B0041.4 rpl-4 13 13 Yes K06C4.2 his-28 8 63 Yes
B0205.3 rpn-10 12 14 Yes K07D4.3 rpn-11 8 64 Yes
B0205.6 B0205.6 12 15 Yes K10B3.7 gpd-3 8 65 Yes
B0205.7 kin-3 12 16 Yes K10B3.8 gpd-2 7 66 Yes
B0218.3 pmk-1 12 17 No K12C11.2 smo-1 7 67 Yes
B0222.2 pitr-2 12 18 Yes M03F4.2 act-4 7 68 No
B0228.5 trx-1 11 19 No M28.5 M28.5 7 69 Yes
B0228.7 B0228.7 11 20 Yes R08C7.3 htz-1 7 70 No
B0250.1 rpl-2 11 21 Yes T01C3.6 rps-16 7 71 Yes
B0250.5 B0250.5 11 22 No T04C12.4 act-3 7 72 Yes
B0252.4 cyn-10 10 23 No T04C12.5 act-2 7 73 Yes
B0261.2 let-363 10 24 Yes T04C12.6 act-1 7 74 Yes
B0272.1 tbb-4 10 25 No T04C9.1 T04C9.1 7 75 Yes
B0272.3 B0272.3 10 26 Yes T08B2.10 rps-17 7 76 Yes
B0280.1 glr-2 10 27 Yes T09F3.3 gpd-1 7 77 Yes
B0280.3 rpia-1 10 28 Yes T10C6.11 his-4 7 78 Yes
B0280.9 B0280.9 10 29 No T20F5.2 pbs-4 7 79 Yes
B0281.3 B0281.3 10 30 Yes T20G5.1 chc-1 7 80 Yes
B0286.3 B0286.3 10 31 Yes T21H3.3 cmd-1 7 81 Yes
B0303.15 mrpl-11 10 32 No T22F3.4 rpl-11.1 7 82 No
B0303.3 B0303.3 9 33 No W01B11.3 nol-5 7 83 Yes
B0336.10 rpl-23 9 34 Yes W08E3.3 ola-1 7 84 Yes
B0336.2 arf-1.2 9 35 Yes W09B6.1 W09B6.1 7 85 Yes
B0348.6 ife-3 9 36 Yes Y22D7AL.5 hsp-60 7 86 Yes
B0365.1 acly-2 9 37 No Y24D9A.4 rpl-7A 7 87 Yes
B0393.1 rps-0 9 38 No Y43C5A.6 rad-51 7 88 No
B0395.3 B0395.3 9 39 Yes Y46E12BL.2 Y46E12BL.2 7 89 No
B0403.4 pdi-6 9 40 Yes Y48G8AL.8 rpl-17 7 90 Yes
B0412.4 rps-29 9 41 Yes Y48G9A.3 gcn-1 7 91 Yes
C01G10.8 C01G10.8 9 42 Yes Y50D7A.6 klp-20 7 92 Yes
C34B2.6 C34B2.6 9 43 Yes Y54F10BM.2 iffb-1 7 93 No
C47E8.5 daf-21 9 44 Yes Y55F3AR.1 Y55F3AR.1 7 94 Yes
C53H9.1 rpl-27 9 45 No Y71H2AM.19laf-1 7 95 Yes
D2045.6 cul-1 8 46 Yes Y71H2B.3 ppfr-4 7 96 Yes
F15C11.2 ubql-1 8 47 No ZC434.2 rps-7 7 97 Yes
F18G5.3 gpa-12 8 48 Yes ZK131.5 his-11 7 98 Yes
F20H11.3 mdh-2 8 49 Yes ZK131.9 his-15 7 99 Yes
F22D6.3 nars-1 8 50 No ZK370.2 sma-2 6 100 Yes
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Figure 3.10 and Table 3.2 show the percentage change in paralysis in comparison to a 
negative control, in which Tu3311 worms were treated with the empty vector (L440).  
Comparison of the mean normalized difference in the rates of paralysis compared to the 
control, rather than absolute individual rates allowed data from different days to be 
plotted on the same graph, improving data interpretation.  Unpaired t-tests were 
performed on comparative percentage paralysis data between control (L440) and 
candidate knockdown worms, in each case p values < 0.05 were considered as significant. 
Chapter 3: Connectivity and Betweenness 
 130 
 
Figure 3.10 - Comparative percentage changes in aldicarb induced paralysis for the top 
100 connected genes. In each case, replicate (N=3) test and control RNAi knockdown assays 
were performed prior to aldicarb sensitivity assays as described for Figure 3.5. The percentage 
change in paralysis relative to the L440 negative control was measured after 140 minutes. Egl-
30 was included as a positive control. Asterixes represent statistically significant changes where 
p values are <0.05 (Section 2.5). Error bars represent standard deviation. 
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Aldicarb screens were performed twice measuring the rate of paralysis between 140 and 
160 minutes. This resulted in the identification of 19 reproducibly significant hits. Figure 
3.11 and table 3.3 show the second aldicarb-sensitivity assay carried out.  
 
 
 
 
 
  
 
 
Figure 3.11 - Independent secondary validation of aldicarb sensitivity phenotype.  A 
replicate series of targeted RNAi aldicarb sensitivity assays (n=3) was performed as shown in 
Figure 3.10, however in this case paralysis was measured after 160 minutes exposure to 
aldicarb. As before (*) represent significant changes in aldicarb induced paralysis. Data linked 
to this plot is shown in Table 3.3. Error bars represent standard deviation. 
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Table 3.2 – Background data associated with Figure 3.10 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name %	change	compared	to	L440 Standard	Deviation P	value Significant?
AC7.2 WBGene00004929 soc-2 -52.57 11.05 0.008 Yes
B0205.6 WBGene00015021 B0205.6 -46.34 9.09 0.009 Yes
B0250.5 WBGene00007122 B0250.5 -49.40 18.57 0.039 Yes
B0272.1 WBGene00006538 tbb-4 32.41 11.43 0.006 Yes
B0280.9 WBGene00015104 B0280.9 -40.05 20.75 0.049 Yes
B0286.3 WBGene00015116 pacs-1 -68.04 10.59 0.005 Yes
B0303.15 WBGene00015133 mrpl-11 -58.64 17.49 0.012 Yes
B0336.10 WBGene00004435 rpl-23 -53.04 21.01 0.015 Yes
B0348.6 WBGene00002061 ife-3 -51.46 21.77 0.025 Yes
B0365.1 WBGene00007150 acly-2 -52.39 27.99 0.048 Yes
B0395.3 WBGene00007175 B0395.3 65.23 25.84 0.011 Yes
C34B2.6 WBGene00016391 C34B2.6 -58.87 6.11 0.003 Yes
F15C11.2 WBGene00008852 ubql-1 -43.10 20.04 0.037 Yes
F25H5.4 WBGene00001167 eef-2 -20.35 11.66 0.049 Yes
F45F2.12 WBGene00001882 his-8 -53.77 22.53 0.027 Yes
F52D10.3 WBGene00001502 ftt-2 -55.16 15.87 0.006 Yes
F56C9.1 WBGene00001748 gsp-2 -29.04 10.27 0.020 Yes
F56F3.5 WBGene00004470 rps-1 -27.00 12.35 0.028 Yes
K04G2.1 WBGene00010560 iftb-1 -44.79 14.01 0.017 Yes
M03F4.2 WBGene00000066 act-4 -38.15 9.79 0.012 Yes
M28.5 WBGene00010896 M28.5 -72.63 22.69 0.011 Yes
T04C9.1 WBGene00020209 T04C9.1 -40.27 19.68 0.046 Yes
T10C6.11 WBGene00001878 his-4 -61.15 26.12 0.038 Yes
T22F3.4 WBGene00004422 rpl-11.1 -52.46 26.86 0.032 Yes
W08E3.3 WBGene00012344 ola-1 -53.97 16.24 0.016 Yes
W09B6.1 WBGene00004076 pod-2 -54.69 15.97 0.010 Yes
Y22D7AL.5 WBGene00002025 hsp-60 -15.37 9.15 0.049 Yes
Y71H2B.3 WBGene00022193 ppfr-4 -36.37 12.42 0.027 Yes
Gene	Symbol Wormbase	Gene	ID Gene	Name %	change	compared	to	L440 Standard	Deviation P	value Significant?
B0001.4 WBGene00007089 B0001.4 -49.53 28.46 0.073 No
B0024.9 WBGene00007099 trx-2 -11.34 15.64 0.322 No
B0025.1 WBGene00006932 vps-34 -6.79 17.11 0.552 No
B0034.3 WBGene00000403 casy-1 -18.76 15.97 0.159 No
B0035.11 WBGene00007110 leo-1 -15.67 34.64 0.504 No
B0035.4 WBGene00007107 pfd-4 -57.42 35.33 0.064 No
B0035.8 WBGene00001922 his-48 -29.69 38.11 0.271 No
B0041.4 WBGene00004415 rpl-4 -21.35 13.91 0.079 No
B0205.7 WBGene00002191 kin-3 -36.86 24.70 0.069 No
B0218.3 WBGene00004055 pmk-1 13.06 28.02 0.414 No
B0222.2 WBGene00015054 pitr-2 -8.53 33.62 0.695 No
B0228.7 WBGene00015064 B0228.7 -31.78 29.10 0.172 No
B0252.4 WBGene00000886 cyn-10 -26.12 40.93 0.363 No
B0272.3 WBGene00007129 B0272.3 -32.73 37.08 0.217 No
B0280.1 WBGene00015099 ggtb-1 -9.36 29.44 0.621 No
B0280.3 WBGene00015101 rpia-1 23.82 37.98 0.285 No
B0303.3 WBGene00015125 B0303.3 -2.61 43.16 0.922 No
B0336.2 WBGene00000182 arf-1.2 -22.95 26.38 0.228 No
B0403.4 WBGene00015168 pdi-6 16.20 28.84 0.384 No
B0412.4 WBGene00004498 rps-29 -26.46 29.95 0.224 No
C47E8.5 WBGene00000915 daf-21 19.52 64.10 0.599 No
C53H9.1 WBGene00004441 rpl-27 13.92 41.52 0.585 No
D2045.6 WBGene00000836 cul-1 -41.55 43.58 0.189 No
F18G5.3 WBGene00001674 gpa-12 26.15 62.65 0.461 No
F20H11.3 WBGene00003162 mdh-2 -4.52 38.38 0.849 No
F22D6.3 WBGene00003815 nars-1 -32.03 23.92 0.138 No
JC8.3 WBGene00004424 rpl-12 0.67 43.65 0.922 No
K01H12.2 WBGene00010485 ant-1.3 -9.71 23.47 0.515 No
K07D4.3 WBGene00004467 rpn-11 -17.84 28.04 0.340 No
K10B3.7 WBGene00001685 gpd-3 -28.54 70.68 0.527 No
K10B3.8 WBGene00001684 gpd-2 -20.92 42.24 0.448 No
K12C11.2 WBGene00004888 smo-1 -47.16 25.93 0.051 No
R08C7.3 WBGene00019947 htz-1 57.42 13.98 0.126 No
T01C3.6 WBGene00004485 rps-16 -37.89 24.49 0.057 No
T04C12.4 WBGene00000065 act-3 -25.02 55.63 0.486 No
T04C12.6 WBGene00000063 act-1 -20.09 38.38 0.427 No
T08B2.10 WBGene00004486 rps-17 -7.13 23.09 0.630 No
T10C6.14 WBGene00001875 his-1 -13.62 55.32 0.696 No
W01B11.3 WBGene00020915 nol-5 10.71 24.18 0.462 No
Y48G8AL.8 WBGene00004429 rpl-17 -29.24 17.98 0.072 No
ZC434.2 WBGene00004476 rps-7 -28.95 23.33 0.120 No
ZK370.2 WBGene00004856 sma-2 0.70 33.83 0.973 No
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3.3.6 Data analysis of novel effectors of aldicarb sensitivity identified from network 
connectivity screens 
 
Wormbase and Wormmine were used to investigate the potential function of the subset 
of newly identified proteins that conferred modified aldicarb phenotypes when knocked 
down (Table 3.4). This analysis revealed similarities that enabled some of the identified 
proteins to be grouped together. For example, rpl-11.1 and rpl-23 are both components 
of the large ribosomal subunit. Two histone genes (his-4 and his-8) were also identified 
and other proteins are known to be involved in either transcription or translation. For 
example eef-2 is a translation elongation factor, and ife-3 is an mRNA-cap binding protein. 
Analysis of the data using the DAVID process enrichment tool revealed the most enriched 
processes to be associated with embryonic and larval development (Table 3.5).
Table 3.3 – Background data associated with Figure 3.11. 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name %	Change	Compared	To	L440 Standard	Deviation P	value Significant?
Y71H2B.3 WBGene00022193 ppfr-4 -56.17 17.06 0.006 Yes
W09B6.1 WBGene00004076 pod-2 -60.08 21.16 0.008 Yes
W08E3.3 WBGene00012344 ola-1 -75.30 35.65 0.024 Yes
T22F3.4 WBGene00004422 rpl-11.1 -59.54 11.97 0.014 Yes
T10C6.11 WBGene00001878 his-4 -72.88 24.59 0.007 Yes
M03F4.2 WBGene00000066 act-4 -65.95 11.72 0.001 Yes
K04G2.1 WBGene00010560 iftb-1 -61.97 7.99 0.002 Yes
F56F3.5 WBGene00004470 rps-1 -54.84 32.53 0.044 Yes
F56C9.1 WBGene00001748 gsp-2 -75.42 21.75 0.007 Yes
F52D10.3 WBGene00001502 ftt-2 -62.16 14.14 0.018 Yes
F45F2.12 WBGene00001882 his-8 -46.88 20.83 0.039 Yes
F15C11.2 WBGene00008852 ubql-1 -91.08 1.41 0.000 Yes
C34B2.6 WBGene00016391 C34B2.6 -58.87 3.53 0.000 Yes
B0348.6 WBGene00002061 ife-3 -73.44 7.59 <0.0001 Yes
B0336.10 WBGene00004435 rpl-23 -48.43 18.18 0.018 Yes
B0303.15 WBGene00015133 mrpl-11 -88.41 6.88 0.001 Yes
B0250.5 WBGene00007122 B0250.5 -29.42 18.04 0.049 Yes
B0205.6 WBGene00015021 B0205.6 -67.52 18.38 0.007 Yes
F25H5.4 WBGene00001167 eef-2 -44.78 11.11 0.002 Yes
Y22D7AL.5 WBGene00002025 hsp-60 -3.33 9.62 0.752 No
M28.5 WBGene00010896 M28.5 -49.14 36.90 0.100 No
B0395.3 WBGene00007175 B0395.3 -30.13 13.21 0.106 No
B0365.1 WBGene00007150 acly-2 -54.80 30.74 0.158 No
B0286.3 WBGene00015116 pacs-1 -36.54 36.84 0.168 No
B0272.1 WBGene00006538 tbb-4 -32.26 43.87 0.290 No
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Gene	Symbol Wormbase	Gene	ID Gene	Name Description
B0303.15 WBGene00015133 mrpl-11 Encodes	an	ortholog	of	human	MRPL11	(mitochondrial	ribosomal	protein	11).
Involved	in	embryonic	and	larval	development,	receptor-mediated	endocytocytosis	and	reproduction.
F15C11.2 WBGene00008852 ubql-1 Encodes	an	ortholog	of	the	human	UBQLN	(Ubiquilin)	family.	Involved	in	the	determination	of	lifespan.	Predicted	to	be	able	to	bind	damamged	DNA.
M03F4.2 WBGene00000066 act-4 Encodes	an	actin	isoform	most	similar	to	act-2;	an	act-4	reporter	gene	is	expressed	in	body	wall	and	vulval	muscles	and	the	spermatheca.
F56C9.1 WBGene00001748 gsp-2 Encodes	an	ortholog	of	human	PPP1CA	(protein	phosphatase	1,	catalytic	subunit,	alpha	isozyme)	and	PPP1CC	(protein	phosphatase	1,	catalytic	subunit,	gamma	isozyme).
	Involved	in	embroyonic	development,	locomotion,	peptidyl-serine	dephosphorylation,	cytokinesis,	meiotic	chromosome	segregation,	mitotic	nuclear	division	and	the	molting	cycle.
F45F2.12 WBGene00001882 his-8 Encodes	an	H2B	histone.	His-8	is	contained	within	the	histone	gene	cluster	HIS2.
W08E3.3 WBGene00012344 ola-1 Encodes	an	ortholog	of	OLA1	(ObG-like	ATPase	1).	Involved	in	embryonic	development.	Predicted	to	have	GTP	binding	activity.
B0250.5 WBGene00007122 B0250.5 Encodes	an	ortholog	of	human	HIBADH	(3-hydroxyisobutyrate	dehydrogenase).	Predicted	to	have	the	ability	to	bind	NAD,	
	and	dehydrogenate	3-hydroxyisobutyrate	and	phosphogluconate,	based	on	protein	domain	information.
F56F3.5 WBGene00004470 rps-1 Encodes	a	small	ribosomal	subunit	S3A	protein.
K04G2.1 WBGene00010560 iftb-1 Encodes	the	C.	elegans	ortholog	of	translation	initiation	factor	2	beta	(eIF2beta);	by	homology,	IFTB-1	is	predicted	to	function	in	translation	initiation	and	start	codon	recognition.
Loss	of	iftb-1		indicates	it's	activity	is	required	for	processes	including	growth,	development,	and	body	morphogenesis.	Loss	in	adult	animals	extends	lifespan.
F52D10.3 WBGene00001502 ftt-2 Encodes	a	14-3-3	protein.	Required	the	regulation	of	the	localization	of	YAP-1	product,	a	Yes-associated	protein	(Yap)	homolog,	between	the	cytoplasm	and	the	nucleus.
W09B6.1 WBGene00004076 pod-2 Encodes	an	acetyl-CoA	carboxylase.	By	sequence	similarity,	POD-2	is	predicted	to	catalyze	the	first	step	in	de	novo	fatty	acid	biosynthesis.	POD-2	is	required	for	proper	embryonic		
polarity	and	for	osmotic	protection	of	the	eggshell;	pod-2	activity	is	also	required	for	molting.
B0205.6 WBGene00015021 B0205.6 Encodes	an	ortholog	of	NFS1	(NFS1	cysteine	desulfurase).	Involved	in	embryonic	and	larval	development	and	reproduction.	Predicted	to	have	cysteine	desulfurase	and	
pyridoxal	phosphate	binding	activity,	based	on	protein	domain	information.
T22F3.4 WBGene00004422 rpl-11.1 Encodes	a	large	ribosomal	subunit	L11	protein.
B0336.10 WBGene00004435 rpl-23 Encodes	a	large	ribosomal	subunit	L23	protein.
T10C6.11 WBGene00001878 his-4 Encodes	an	H2B	histone.
Y71H2B.3 WBGene00022193 ppfr-4 Encodes	the	C.	elegans	ortholog	of	TAP42,	a	protein	phosphatase	2A	(PP2A)	regulatory	subunit.	PPFR-4(RNAi)	in	wild-type	animals	results	in	fertility	defects	in	F1	hermaphrodites,	
who	exhibit	a	90-95%	decrease	in	the	total	number	of	eggs	laid.
F25H5.4 WBGene00001167 eef-2 Encodes	a	homolog	of	translation	elongation	factor	2	(EF-2),	a	GTP-binding	protein	essential	for	the	elongation	phase	of	protein	synthesis.	EEF-2	is	required	for	embryogenesis	and	
vulval	morphogenesis,	and	is	expressed	during	all	stages	of	development,	including	the	dauer	larval	stage.
C34B2.6 WBGene00016391 C34B2.6 Encodes	a	homolog	of	the	Lon	mitochondrial	protease.	Loss	of	C34B2.6	activity	results	in	impaired	proteolysis	of	the	ATFS-1	bZip	transcription	factor	that	partitions	between	the	
mitochondria	and	the	nucleus	and	functions	as	part	of	the	mitochondrial	unfolded	protein	response	(UPRmt).
B0348.6 WBGene00002061 ife-3 Encodes	one	of	five	C.	elegans	homologs	of	the	mRNA	cap-binding	protein	eIF4E.
Table 3.4 - A brief description of hits from the connectivity screen. Information was derived from Wormbase. 
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Table 3.5 - Top ranked biological processes identified by DAVID Biological Process Enrichment tool. A list of gene symbols corresponding to novel 
proteins found to effect aldicarb sensitivity following network connectivity analysis were entered into the DAVID functional enrichment package 
using default settings. 
 
Biological	Process Count Genes
Embryonic	development	ending	in	birth	or	egg	hatching 15 mrpl-11,	act-4,	gsp-2,	his-8,	ola-1,	rps-1,	scbp-2,	pod-2,	rpl-23,	B0205.6,	rpl-11.1,	his-4,	ppfr-4,	eef-2,	lonp-1,	ife-3
Nematode	larval	development 11 mrpl-11,	act-4,	his-4,	his-8,	ppfr-4,	eef-2,	rps-1,	scbp-2,	F52D10.3,	pod-2,	rpl-23,	B0205.6
Larval	development 11 mrpl-11,	act-4,	his-4,	his-8,	ppfr-4,	eef-2,	rps-1,	scbp-2,	F52D10.3,	pod-2,	rpl-23,	B0205.6
Post-embryonic	development 11 mrpl-11,	act-4,	his-4,	his-8,	ppfr-4,	eef-2,	rps-1,	scbp-2,	F52D10.3,	pod-2,	rpl-23,	B0205.6
Growth 10 mrpl-11,	act-4,	his-4,	his-8,	ppfr-4,	eef-2,	rps-1,	scbp-2,	F52D10.3,	rpl-23,	B0205.6
Translation 7 mrpl-11,	eef-2,	rps-1,	scbp-2,	ife-3,	rpl-23,	rpl-11.1
Hermaphrodite	genitalia	development 6 act-4,	ppfr-4,	eef-2,	rps-1,	scbp-2,	rpl-11.1
Genitalia	development 6 act-4,	ppfr-4,	eef-2,	rps-1,	scbp-2,	rpl-11.1
Sex	differentiation 6 act-4,	ppfr-4,	eef-2,	rps-1,	scbp-2,	rpl-11.1
Reproductive	developmental	process 6 act-4,	ppfr-4,	eef-2,	rps-1,	scbp-2,	rpl-11.1
Molting	cycle,	protein-based	cuticle 4 gsp-2,	rps-1,	pod-2,	rpl-23
Molting	cycle,	collagen	and	cuticulin-based	cuticle 4 gsp-2,	rps-1,	pod-2,	rpl-23
Molting	cycle 4 gsp-2,	rps-1,	pod-2,	rpl-23
Translational	initiation 2 scbp-2,	ife-3
Fatty	acid	biosynthetic	process 2 pod-2,	lonp-1
Fatty	acid	metabolic	process 2 pod-2,	lonp-1
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Worm	Gene	Symbol Wormbase	Gene	ID Worm	Gene	Name Human	Gene	Symbol Human	Entrez	ID DIOPT	Score
B0205.6 WBGene00015021 B0205.6 NFS1 9054 8.816
B0250.5 WBGene00007122 B0250.5 HIBADH 11112 10.769
B0303.15 WBGene00015133 mrpl-11 MRPL11 65003 9.819
B0336.10 WBGene00004435 rpl-23 RPL23 9349 7.858
B0348.6 WBGene00002061 ife-3 EIF4E 1977 8.808
C34B2.6 WBGene00016391 C34B2.6 LONP1 9361 9.809
F15C11.2 WBGene00008852 ubql-1 UBQLN1 29979 7.809
F45F2.12 WBGene00001882 his-8 HIST1H2BA 255626 3.89
F52D10.3 WBGene00001502 ftt-2 YWHAZ 7534 7.898
F56C9.1 WBGene00001748 gsp-2 PPP1CA 5499 8.879
F56F3.5 WBGene00004470 rps-1 RPS3A 6189 8.859
K04G2.1 WBGene00010560 iftb-1 EIF2S2 8894 6.798
M03F4.2 WBGene00000066 act-4 ACTG1 71 5.868
T10C6.11 WBGene00001878 his-4 HIST1H2BA 255626 4.8
T22F3.4 WBGene00004422 rpl-11.1 RPL11 6135 8.859
W08E3.3 WBGene00012344 ola-1 OLA1 29789 8.816
W09B6.1 WBGene00004076 pod-2 ACACA 31 7.808
Y71H2B.3 WBGene00022193 ppfr-4 IGBP1 3476 10.769
F25H5.4 WBGene00001167 eef-2 EEF2 1938 7.858
Table 3.6 - A list of human orthologs of worm genes/proteins that were identified via network connectivity analysis and found to cause significant 
changes in aldicarb sensitivity following RNAi induced knockdown. Diopt FlyRNAI (Hu et al., 2011) was used to elucidate the closest human 
ortholog. The DIOPT score refers to how many databases predicted the ortholog match. 
 
Chapter 3: Connectivity and Betweenness 
 138 
Human orthologs of proteins found to confer changes in aldicarb induced phenotypes 
were elucidated using DIOPT Fly RNAi (Hu et al., 2011). Table 3.6 shows the human 
orthologs, as well as their DIOPT score, which indicate how many ortholog databases 
predicted the worm-human ortholog match. SynaptomeDB was then used to establish if 
human orthologs had a pre- or post-synaptic distribution (Pirooznia et al., 2012). 
Interestingly, of the nineteen novel positive hits, eleven were found in the synaptome, 
and their localization was found to be predominantly post-synaptic (Table 3.7).  
Table 3.7 - Synaptome localization of the human orthologs of the worm genes found 
in the connectivity screen to cause a significant aldicarb-sensitivity phenotype. Data 
was gathered using SynaptomeDB. Human orthologs were elucidated using Diopt 
flyRNAi. 
 
Gene	Symbol Gene	Name Human	Gene	Symbol Synaptome	Localization
C34B2.6 C34B2.6 LONP1 PostSynaptic
M03F4.2 act-4 ACTG1 PreSynaptic	Active	Zone
F52D10.3 ftt-2 YWHAZ PreSynaptic	Active	Zone,	PostSynaptic
W08E3.3 ola-1 OLA1 PostSynaptic
T22F3.4 rpl-11.1 RPL11 PostSynaptic
B0348.6 ife-3 EIF4E PostSynaptic
B0336.10 rpl-23 RPL23 PostSynaptic
F56C9.1 gsp-2 PPP1CA PostSynaptic
F56F3.5 rps-1 RPS3A PostSynaptic
W09B6.1 pod-2 ACACA PostSynaptic
F25H5.4 eef-2 EEF2 PreSynaptic,	PostSynaptic
Table 3.8 - A degree ranked list of interaction 
partners for novel connectivity hits not 
previously known to cause an aldicarb-
sensitivity phenotype. Data was derived from 
the one-step known aldicarb sensitivity 
network (Figure 3.9) and corresponds to 
Figure 3.12 
 
Gene	Name Degree Rank
rpl-23 16 6
act-4 12 14
ftt-2 11 19
B0205.6 9 35
ife-3 9 36
B0250.5 9 38
ubql-1 9 40
rps-1 8 48
eef-2 8 50
gsp-2 7 68
scbp-2 7 73
rpl-11.1 7 75
ola-1 7 78
his-8 7 81
his-4 7 85
pod-2 7 88
mrpl-11 7 99
ppfr-4 8 56
lonp-1 7 98
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Many of the previously known aldicarb hits have interactions with multiple novel 
regulators. Figure 3.12 shows a network displaying the novel hits found in this 
connectivity informed screen, and interacting with previously known aldicarb-sensitivity 
genes. Table 3.8 summarizes the connectivity scores of novel the regulators identified in 
this screen, while previously known aldicarb nodes that interact with multiple novel 
modulators identified in this screen are shown in Table 3.9.  
Figure 3.12 - Network showing the novel aldicarb-sensitivity genes found in the 
connectivity screen, and their interacting partners, which were previously known to 
cause an aldicarb-sensitivity phenotype. Grey nodes represent novel hits, red nodes 
indicate genes that cause a RIC phenotype when expression is altered, and blue nodes 
correspond to genes that cause a HIC phenotype when expression is altered. Cytoscape 
version 3 was used to generate this network, and interaction data was extracted from the one-
step known aldicarb sensitivity network (Figure 3.9). 
 
RIC-causing	protein	
(previously	known)	
HIC-causing	protein	
(previously	known)	
Novel	Protein	
F54E2.4
pph-6
ppfr-4
egl-10
usp-46
unc-63
nra-4
sbt-1
vps-26
vps-4
ubql-1
T24B8.7
hgrs-1
mrpl-11
B0250.5
dlc-1
wwp-1
rho-1
erp-1
hpk-1
tap-1
abts-1
myo-1
arr-1
apb-1
par-3
spc-1
stam-1
par-5agef-1
act-4
eel-1
ftt-2
lonp-1
arx-3
hum-1
taf-5
eef-2
unc-26
cav-1
ola-1
unc-64
rps-1
drp-1
gsp-2
cam-1
C50D2.3
nab-1
fsn-1
fkh-8 aps-1
unc-75
npp-6
rpl-11.1
iftb-1 mpk-1
sad-1
bcc-1
gsp-1
dyb-1
pdhk-2
unc-10
tag-232
egl-30
B0205.6
ehs-1
rac-2
unc-68
rpl-23
pat-6
ubc-25
unc-18
let-60 M4.1
snb-1
syd-2
apa-2
prx-2
egl-3
nasp-1
miro-1
rskn-2
T27A3.5
unc-2
unc-13
F54G2.1
F28C6.8
ric-4
ife-3
pptr-1
itsn-1
osm-9
his-4
pod-2
eat-6
rpt-3
rack-1
tag-257 his-8
T28D6.6
T22B11.5 
apm-1
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Table 3.9 – A list of genes that were previously known to cause an aldicarb-sensitivity 
phenotype and interact with multiple novel hits from the connectivity screen. Data was 
extracted from the one-step aldicarb network (Figure 3.9). Genes are listed if they interacted 
with more than one novel hit, and were known to cause a RIC or HIC phenotype when their 
expression was altered. 
 
Gene	Name Connectivity	to	hits Aldicarb	Phenotype Hits	Connected	To
eat-6 5 HIC pod-2,	his-8,	his-4,	act-4,	ftt-2
rack-1 5 RIC rpl-11.1,	his-8,	his-4,	scbp-2,	eef-2
rpt-3 5 RIC pod-2,	rpl-11.1,	ola-1,	his-4,	act-4
cam-1 5 RIC pod-2,	rpl-11.1,	ola-1,	rps-1,	scbp-2
cav-1 4 HIC pod-2,	B0250.5,	ola-1,	rpl-23
wwp-1 4 RIC B0205.6,	B0250.5,	lonp-1,	act-4
apb-1 4 RIC ola-1,	mrpl-11,	rpl-23,	ife-3
unc-26 4 RIC his-8,	lonp-1,	rpl-23,	ftt-2
sad-1 4 RIC rpl-11.1,	gsp-2,	his-4,	rps-1
erp-1 4 RIC B0205.6,	rps-1,	mrpl-11,	act-4
ehs-1 3 RIC B0205.6,	B0250.5,	mrpl-11
par-3 3 RIC rpl-23,	ftt-2,	ife-3
arx-3 3 RIC ola-1,	act-4,	ftt-2
gsp-1 3 RIC gsp-2,	rps-1,	ftt-2
rho-1 3 HIC B0250.5,	lonp-1,	act-4
taf-5 3 RIC lonp-1,	ftt-2,	eef-2
hum-1 3 RIC lonp-1,	act-4,	eef-2
par-5 3 RIC gsp-2,	lonp-1,	ftt-2
nab-1 3 RIC gsp-2,	rps-1,	act-4
stam-1 3 RIC ubql-1,	eef-2,	stam-1
eel-1 3 RIC B0250.5,	ola-1,	scbp-2
itsn-1 3 HIC B0205.6,	B0250.5,	ppfr-4
rskn-2 3 RIC his-8,	his-4,	eef-2
arr-1 3 RIC B0250.5,	mrpl-11,	rpl-23
spc-1 2 RIC B0205.6,	rpl-23
bcc-1 2 RIC rpl-11.1,	his-4
tag-257 2 RIC his-8,	lonp-1
unc-64 2 RIC act-4,	rpl-23
dyb-1 2 HIC act-4,	scbp-2
dlc-1 2 RIC mrpl-11,	ftt-2
osm-9 2 RIC his-8,	his-4
vps-4 2 RIC ubql-1,	ppfr-4
C50D2.3 2 RIC gsp-2,	scbp-2
agef-1 2 RIC mrpl-11,	scbp-2
mpk-1 2 RIC pod-2,	gsp-2
T24B8.7 2 RIC ubql-1,	ppfr-4
drp-1 2 RIC gsp-2,	scbp-2
tap-1 2 RIC B0205.6,	ftt-2
rac-2 2 HIC act-4,	ppfr-4
ric-4 2 RIC ubql-1,	ife-3
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Gene symbols from the network shown in Figure 3.12 were imported into DAVID, to 
determine if any synaptic biological processes were enriched. 10 genes were found to be 
associated with synaptic transmission, seven of these specifically in cholinergic 
transmission (Table 3.10). Although these are genes previously shown to cause RIC or 
HIC phenotypes, by looking at their novel interaction partners, it may be possible to 
provide some insight into the mechanism by which they confer the observed changes in 
aldicarb sensitivity, and by extrapolation synaptic function. One interesting interaction 
partner is ric-4, which is the worm ortholog of SNAP-25. SNAP-25 is essential at the 
presynaptic terminal membrane for SNARE vesicle fusion. RIC-4 interacts with the novel 
hits ubql-1 and ife-3, providing a link to their potential synaptic function.  
Furthermore when the novel genes are extracted from the main C. elegans networks, 
interactions can be seen between some of the novel regulators (Figure 3.13) suggesting 
they may also be in some way functionally 
related.  However, these interactions are all 
derived from interolog data, observed between 
 
Table 3.10 – Synaptic transmission is enriched when genes from the novel aldicarb-sensitivity 
genes from the connectivity screen and their interacting partners that cause an aldicarb-
phenotype were inputted into DAVID. Functional clustering was carried out and biological 
enrichment assessed.  
 
Gene	Name Biological	Process Aldicarb Novel	Protein	Interaction	Partners
dyb-1 Synaptic	Transmission,	Cholinergic HIC act-4,	iftb-1
ric-4 Synaptic	Transmission,	Cholinergic RIC ubql-1,	ife-3
unc-18 Synaptic	Transmission,	Cholinergic RIC rpl-23	
unc-64 Synaptic	Transmission,	Cholinergic RIC act-4,	rpl-23
unc-10 Synaptic	Transmission,	Cholinergic RIC B0205.6
unc-63 Synaptic	Transmission,	Cholinergic RIC ubql-1	
unc-75 Synaptic	Transmission,	Cholinergic RIC rpl-11.1	
ehs-1 Synaptic	Transmission RIC B0205.6,	B0250.5,	mrpl-11	
syd-2 Synaptic	Transmission RIC rpl-23	
unc-2 Synaptic	Transmission RIC ife-3	
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orthologous human or yeast proteins. In Figure 3.13 red edges denote interactions found 
in either high or low throughput human protein interaction studies. Blue edges represent 
interactions found in both S. cerevisiae and humans, while black edges have only been 
seen in S. cerevisiae. In Table 3.11 novel effector proteins are degree sorted, showing that 
eef-2 is highly connected to 10 other novel protein effectors of aldicarb sensitivity. As eef-
2 is a translation elongation factor it may be required for their protein synthesis or may 
have an additional as yet undefined role.  
 
 
 
 
 
Gene	Symbol Gene	Name Number	of	Interaction	Partner	Connectivity	Hits
F25H5.4 eef-2 10
M03F4.2 act-4 8
F56C9.1 gsp-2 6
F45F2.12 his-8 6
B0336.10 rpl-23 5
B0303.15 mrpl-11 5
T10C6.11 his-4 5
K04G2.1 iftb-1 5
B0205.6 b0205.6 5
T22F3.4 rpl-11.1 4
C34B2.6 c34b2.6 4
F56F3.5 rps-1 4
F52D10.3 ftt-2 4
F15C11.2 ubql-1 3
W08E3.3 ola-1 3
B0348.6 ife-3 3
W09B6.1 pod-2 2
Y71H2B.3 ppfr-4 1
B0250.5 b0250.5 0
Table 3.11 – Degree ranked list of interactions between novel connectivity genes 
that caused a significant change in aldicarb sensitivity.  
Figure 3.13 – Network showing interactions between novel genes found to cause an 
aldicarb-sensitivity phenotype in the network connectivity informed screen. Red edges 
denote interactions found using the human orthologs, black edges represent interactions found in 
S. cerevisiae, and green edges denote interactions found in both humans and S. cerevisiae. 
Cytoscape was used to generate the network, and a merge of Wormnet and the worm interactome 
were used to elucidate interactions between the hits. 
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The novel aldicarb-sensitivity genes were then added to the core list of RIC/HIC-causing 
genes, and a one-step network was re-generated, resulting in a new network containing 
3925 proteins connected by 10357 interactions (Figure 3.14).  
 
3.3.7 Shell Analysis in the aldicarb network 
 
The first shell of the aldicarb one step network represents direct physical interaction 
partners of aldicarb-sensitivity proteins. Due to the complexity of synaptic transmission 
it is possible that indirect regulators may also cause a change in aldicarb sensitivity when 
knocked down, even though they do not directly bind aldicarb-sensitivity genes. It could 
also be hypothesized that interactions between a gene and a known aldicarb-sensitivity 
gene become more indirect, they are less likely to cause a phenotype, in line with the 
“guilt-by-association” principle. To test which of these hypotheses was correct, we 
assessed whether proteins currently thought to be less connected to known aldicarb-
sensitivity proteins would be less likely to cause an aldicarb-sensitivity phenotype, than 
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those that had high connectivity and were directly connected to multiple aldicarb-
sensitivity proteins.  
 
Figure 3.14 – One-step aldicarb sensitivity network, using previously known RIC (red 
nodes), HIC (blue nodes) and novel regulator proteins (yellow nodes) as a core. Cytoscape 
version 3 was used to generate the network. Wormbase and literature mining were used to 
investigate the previously known RIC and HIC related genes. 
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To identify candidate proteins with reduced connectivity to known regulators of the 
aldicarb phenotype a one-step aldicarb network was used as a core. Unique proteins 
connected to the one-step nodes were then selected to define the second two-step  “shell”. 
Additional interactions to proteins in this second shell were then selected (by looking at 
adjacent edges) to create a third “shell”. Sequential creation of shells continued until no 
more proteins could be connected, resulting in 5 sequential shells containing 2925, 5909, 
581, 20 and 1 proteins, respectively (Figure 3.15). 39 nodes in the network had no 
connection to aldicarb-sensitivity genes. 
RIC/HIC	core	
Shell	1	
Shell	2	
Shell	3	
Shell	5	
No	Interac on	
Shell	4	
195	 2925	 5909	 581	
20	
1	
39	
Figure 3.15 – Shell analysis of the merged Wormnet v3 and Vidal CCSB Worm Interactome, 
using the previously known aldicarb-sensitivity genes as a core. Red nodes represent the 
core, which consists of the genes previously known to cause a RIC or a HIC phenotype. Green nodes 
represent the proteins that interact with the core proteins i.e. shell 1. Royal blue nodes represent 
proteins that interact with shell 1, which are not in the core (shell 2). Orange nodes represent 
proteins that interact with shell 2 and are not found in shell 1 (shell 3). Purple nodes represent 
proteins that interact with shell 3 but are not found in shell 2 (shell 4). The black node represents 
the one protein that interacts with shell 4 and is not in shell 3.) Light blue nodes are those that are 
found in no shells. Edges have been hidden. Cytoscape v2.8 was used to generate this network. 
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The single gene found in shell 5 (K08H10.2) did not have a dsRNA-expressing bacterial 
clone available. Nine genes from the fourth shell were knocked down in Tu3311. A 
significant RIC phenotype was observed when three of the nine genes are knocked down 
(Figure 3.16 and Table 3.12). These were Y37H2A.3 (WBGene00012563), W09G12.7 
(WBGene00021121) and npr-10 (WBGene00008278). Cdr-7 (WBGene00010472) was 
also very close to being significant. Previously, 27% of the candidates tested in the first 
shell (those with the highest connectivity, and direct connectivity to aldicarb genes) led 
to a significant result. Here, although the test set is far lower, 33% of candidates led to a 
result. It is however important to note that due to time limitations, secondary validation 
of these outer shells were not carried out. 
Figure 3.16 – Testing of a selection of genes from the shell 4 using the aldicarb-
sensitivity genes as a core. RNAi knockdown and aldicarb sensitivity assays were performed 
as described in Figure 3.5., and the percentage of paralyzed worms was calculated at 140 
minutes. The percentage change to L440 was then calculated and plotted. Egl-30 was the 
positive control. Hits are significant and marked with an asterix if calculated P values 
calculated (Section 2.5) are less than 0.05. N=3. Error bars represent standard deviation. 
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We also tested these outer shell candidates in the Tu3335 strain (Figure 3.17 and Table 
3.13).  It is interesting to note that W09G12.7 also shows a RIC phenotype in this strain, 
but no other overlap between the two strains was seen. Two other knockdowns led to 
significant RIC phenotypes in Tu3335 – these were C27D6.3 (WBGene00016161) and 
Table 3.12 –Background data associated with Figure 3.16. 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name %	change	compared	to	L440 Standard	Deviation P	Value Significant?
M01D7.7 WBGene00001196 egl-30 -48.94 11.93 0.0256 Yes
Y37H2A.3 WBGene00012563 Y37H2A.3 -40.92 4.31 0.0108 Yes
W09G12.7 WBGene00021121 W09G12.7 -35.03 6.04 0.0244 Yes
C27D6.3 WBGene00016161 C27D6.3 -26.61 7.6 0.1499 No
R05G9R.1 WBGene00019906 R05G9R.1 -26.36 13.82 0.2152 No
Y55F3AM.13 WBGene00021930 Y55F3AM.13 -23.97 16.99 0.3274 No
K01D12.13 WBGene00010472 cdr-7 -39.56 20.8 0.0504 No
F56C11.1 WBGene00000253 bli-3 -27.06 24.06 0.3353 No
C53C7.1 WBGene00008278 npr-10 -51.28 15.37 0.0461 Yes
ZK563.6 WBGene00022770 acp-1 -37.05 28.69 0.2764 No
Figure 3.17 – Testing of a selection of genes from the outer shells using the aldicarb-sensitivity 
genes as a core. RNAi knockdown and aldicarb sensitivity assays were performed as described in 
Figure 3.5, and the percentage of paralyzed worms was calculated at 140 minutes. The percentage 
change to L440 was then calculated and plotted. Egl-30 was the positive control. Hits are significant 
and marked with an asterix if calculated P values calculated (Section 2.5) are less than 0.05. N=3. 
Error bars represent standard deviation. 
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Y55F3AM.13 (WBGene00021930). Only eight candidates were tested meaning 32.5% of 
candidates gave a significant RIC phenotype in Tu3335.  
 
 
Some potentially interesting novel candidate proteins were identified while testing 
proteins in the outer interaction shells. One of these proteins was W09G12.7 (human 
ortholog FAM133A), which consistently showed a significant RIC phenotype. This protein 
is as yet uncharacterized as is cdr-7. The only information known about C27D6.3 is that 
it is involved in locomotion. The final protein found to have a positive phenotype in this 
small data set was npr-10, which is predicted to have neuropeptide Y receptor activity 
due to its protein domain structure. Its human ortholog is Prolactin Releasing Hormone 
Receptor (PRLHR). All of these hits require further validation and characterization to 
establish their potential roles in synaptic physiology. 
 
3.3.8 Using betweenness to identify novel effectors of aldicarb sensitivity  
 
To prioritize genes based on relative betweenness scores, the same aldicarb-sensitivity 
genes used for the connectivity algorithm were again utilized as core nodes. However, 
due to the lack of predictive power of the connectivity algorithm, an additional subset of 
core nodes was added based on their Gene Ontology (GO) terms. Supplementary table 3.3 
Table 3.13 – Background data associated with Figure 3.17. 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name %	change	compared	to	L440 Standard	Deviation P	Value Significant?
M01D7.7 WBGene00001196 egl-30 -83.75 16.16 0.005 Yes
C27D6.3 WBGene00016161 C27D6.3 -54.21 1.86 0.039 Yes
C53C7.1 WBGene00008278 npr-10 -18.51 13.7 0.309 No
K01D12.13 WBGene00010472 cdr-7 -18.74 14.46 0.305 No
R05G9R.1 WBGene00019906 R05G9R.1 -21.08 16.1 0.296 No
W09G12.7 WBGene00021121 W09G12.7 -63.59 15.39 0.027 Yes
Y55F3AM.13 WBGene00021930 Y55F3AM.13 -61.1 8.66 0.011 No
ZK563.6 WBGene00022770 acp-1 -39.76 16.24 0.100 No
Y37H2A.3 WBGene00012563 Y37H2A.3 -35.85 30.95 0.328 No
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shows the GO terms and genes that were selected. The hypothesis was that addition of 
these synaptic transmission related nodes to the network could enable the betweenness 
algorithm to better predict novel functional regulators of synaptic function, which could 
be detected by aldicarb sensitivity assays.  
 
The Network Analysis plugin on Cytoscape was used to rank the betweenness of nodes in 
the extended one-step known aldicarb/synaptic transmission network (Figure 3.18), 
which contained 3459 protein nodes and 75428 interactions. Table 3.14 lists the 100 
proteins with highest betweenness values, and the availability of RNAi clones in the 
knockdown library.  Aldicarb core nodes were not ranked in this table, but ranged from 
having high betweenness (as high or higher than the novel genes) to very low 
betweenness. There is a large degree of overlap between the highest connected nodes 
and nodes with highest betweenness values (Figure 3.19 and Table 3.15), with 37 
proteins being found in both datasets. In total, 67 genes in the list had available RNAi 
clones, of which 37 had already been tested in the previous connectivity screen, leaving 
30 additional proteins that were only found in the betweenness dataset.  
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Figure 3.19 – Venn diagram showing the overlap between candidate effectors identified in 
both connectivity and betweenness  network analysis.  
 
Figure 3.18 - Network to show betweenness rankings of genes in a one-step aldicarb and 
synaptic transmission network. A one-step network was created using the known aldicarb-
sensitivity genes and known genes involved in synaptic function (from GO terms). Betweenness 
was then calculated using the NetworkAnalyzer Plugin on Cytoscape, and the top 100 
betweenness ranked genes (not including known aldicarb-sensitive genes) were tested 
(provided they were in the RNAi library). Colours denote the level of betweenness, with green 
being the lowest and red being the highest-ranking betweenness nodes.  
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Table 3.14 – Highest ranking betweenness proteins/genes from the one-step aldicarb and 
synaptic related network (not including genes previously known to cause a RIC of HIC 
phenotype). Betweenness was measured using the Network analyzer plugin on Cytoscape. 
 
Gene	Name Betweenness	Centrality Betweenness	Ranking Rnai Gene	Name Betweenness	Centrality Betweenness	Ranking Rnai
rpn-10 0.01446289 1 No Y55F3AM.14 0.00317359 51 Yes
rpl-4 0.01327419 2 Yes cyc-1 0.00316899 52 Yes
his-46 0.01147944 3 No smo-1 0.00314698 53 Yes
rps-0 0.00953103 4 Yes B0228.7 0.00313343 54 Yes
pmk-1 0.00819131 5 Yes lonp-1 0.0031087 55 Yes
F10F2.2 0.00795573 6 No his-11 0.00308458 56 No
his-38 0.00781085 7 No tag-174 0.00306346 57 Yes
his-47 0.00753449 8 No spr-2 0.00302763 58 Yes
ftt-2 0.00747005 9 Yes vps-16 0.00298784 59 Yes
act-4 0.00727339 10 Yes rad-51 0.00296991 60 Yes
sma-2 0.00690071 11 Yes rpl-38 0.00288523 61 Yes
rpl-27 0.00685742 12 Yes ife-3 0.00287895 62 Yes
his-45 0.0066567 13 No cgh-1 0.00286619 63 Yes
C01G10.8 0.00664515 14 No pgk-1 0.00285258 64 Yes
pacs-1 0.00648567 15 Yes eef-2 0.0028429 65 Yes
trx-1 0.00623208 16 No pcn-1 0.0027868 66 No
daf-21 0.0061012 17 Yes kin-3 0.00277493 67 Yes
pitr-2 0.00588545 18 Yes cfim-2 0.00277219 68 Yes
B0035.13 0.00581559 19 No B0001.4 0.00276876 69 Yes
laf-1 0.00577273 20 No rpl-12 0.0026817 70 Yes
rpl-23 0.00568412 21 Yes gsp-2 0.00267409 71 Yes
tbb-4 0.00562789 22 Yes swsn-1 0.00266304 72 Yes
rpl-2 0.00558434 23 No B0281.3 0.00265989 73 No
htz-1 0.00528366 24 Yes spe-5 0.00262109 74 Yes
pbs-4 0.00509202 25 No fars-3 0.00260524 75 No
pod-2 0.00474082 26 Yes pfd-4 0.00255666 76 Yes
ant-1.3 0.00454172 27 Yes pkn-1 0.00253968 77 Yes
his-28 0.00450048 28 No eif-3b 0.00253316 78 Yes
cmd-1 0.00446641 29 No B0272.3 0.00251809 79 Yes
his-48 0.00445807 30 Yes C33F10.12 0.00251744 80 Yes
B0395.3 0.00437873 31 Yes glp-4 0.00251291 81 Yes
rpia-1 0.00432888 32 Yes dhc-1 0.00250561 82 No
gcn-1 0.00420023 33 No ubql-1 0.0024664 83 Yes
mdh-2 0.00404524 34 Yes scbp-2 0.00245909 84 Yes
cul-1 0.0039867 35 Yes his-15 0.00245177 85 No
rps-18 0.00396697 36 Yes goa-1 0.00244342 86 No
W02A2.9 0.00387459 37 No sqd-1 0.00243936 87 No
glr-1 0.00360248 38 Yes Y66H1A.4 0.00238334 88 Yes
rps-29 0.0035667 39 Yes unc-16 0.00237395 89 Yes
soc-2 0.00354351 40 Yes cyp-25a5 0.00237308 90 Yes
nars-1 0.00344108 41 Yes his-4 0.00236978 91 Yes
B0280.9 0.00336552 42 Yes daam-1 0.0023615 92 No
gpd-2 0.00335692 43 Yes rpl-30 0.00233505 93 Yes
Y46E12BL.2 0.00333671 44 No trx-2 0.00232712 94 Yes
emb-8 0.00333547 45 Yes B0250.5 0.00232511 95 Yes
mrpl-11 0.00331015 46 Yes tag-335 0.0022897 96 Yes
cpsf-1 0.00328232 47 Yes vdac-1 0.00226132 97 Yes
gpd-4 0.00322292 48 No rpn-11 0.00225889 98 Yes
sti-1 0.00322012 49 No casy-1 0.00225303 99 Yes
leo-1 0.00319567 50 Yes rpl-7A 0.00221131 100 No
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Aldicarb screens were carried out on the betweenness candidates as described for 
preceding connectivity screens. Data presented in Figure 3.20 and Table 3.16 show that 
10 of the 30 candidate proteins showed reproducibly pronounced changes in rate of 
aldicarb-induced paralysis. Significantly, all of these positive phenotypes were 
independently validated at a 160-minute time point (Figure 3.21 and Table 3.17), with 
the exception of rpy-1, which displayed no change in aldicarb sensitivity.  
  
Table 3.15 – Table to show the overlap between connectivity and betweenness screens. Genes 
found in both screens encode proteins that have both high connectivity to known RIC or HIC 
proteins or high betweenness scores in an extended RIC/HIC and synaptic transmission 
network. 
 
Gene	Name Screen Gene	Name Screen Gene	Name Screen
trx-2 Connectivity eef-1A.1 Betweenness arf-1.2 Connectivity	and	Betweenness
ubql-1 Connectivity rps-6 Betweenness rpl-27 Connectivity	and	Betweenness
rps-16 Connectivity ZK1098.1 Betweenness rps-29 Connectivity	and	Betweenness
ant-1.3 Connectivity cyn-7 Betweenness pacs-1 Connectivity	and	Betweenness
M28.5 Connectivity B0361.6 Betweenness B0250.5 Connectivity	and	Betweenness
htz-1 Connectivity unc-37 Betweenness rpl-17 Connectivity	and	Betweenness
rpl-12 Connectivity T22D1.3 Betweenness kin-3 Connectivity	and	Betweenness
his-8 Connectivity his-67 Betweenness smo-1 Connectivity	and	Betweenness
rpn-11 Connectivity his-68 Betweenness B0001.4 Connectivity	and	Betweenness
ola-1 Connectivity vdac-1 Betweenness sma-2 Connectivity	and	Betweenness
casy-1 Connectivity rpl-13 Betweenness pitr-2 Connectivity	and	Betweenness
vps-34 Connectivity rpl-35 Betweenness tbb-4 Connectivity	and	Betweenness
cul-1 Connectivity eef-1A.2 Betweenness his-48 Connectivity	and	Betweenness
rpl-11.1 Connectivity inf-1 Betweenness pmk-1 Connectivity	and	Betweenness
B0205.6 Connectivity rps-20 Betweenness B0272.3 Connectivity	and	Betweenness
gpa-12 Connectivity ruvb-2 Betweenness ife-3 Connectivity	and	Betweenness
B0228.7 Connectivity glp-4 Betweenness act-4 Connectivity	and	Betweenness
hsp-60 Connectivity Y54E10A.10 Betweenness act-1 Connectivity	and	Betweenness
soc-2 Connectivity mrpl-47 Betweenness gsp-2 Connectivity	and	Betweenness
ggtb-1 Connectivity his-3 Betweenness leo-1 Connectivity	and	Betweenness
gpd-3 Connectivity rpl-30 Betweenness rps-7 Connectivity	and	Betweenness
gpd-2 Connectivity cdk-12 Betweenness B0303.3 Connectivity	and	Betweenness
pfd-4 Connectivity orc-1 Betweenness act-3 Connectivity	and	Betweenness
mrpl-11 Connectivity rpl-1 Betweenness rps-1 Connectivity	and	Betweenness
nol-5 Connectivity rpl-38 Betweenness acly-2 Connectivity	and	Betweenness
nars-1 Connectivity rps-18 Betweenness B0280.9 Connectivity	and	Betweenness
eif-2beta Connectivity rpl-7 Betweenness ftt-2 Connectivity	and	Betweenness
pod-2 Connectivity air-2 Betweenness rpia-1 Connectivity	and	Betweenness
pdi-6 Connectivity rpy-1 Betweenness cyn-10 Connectivity	and	Betweenness
his-4 Connectivity eef-2 Connectivity	and	Betweenness rpl-4 Connectivity	and	Betweenness
T04C9.1 Connectivity rps-17 Connectivity	and	Betweenness rpl-23 Connectivity	and	Betweenness
ppfr-4 Connectivity B0395.3 Connectivity	and	Betweenness his-1 Connectivity	and	Betweenness
lonp-1 Connectivity daf-21 Connectivity	and	Betweenness mdh-2 Connectivity	and	Betweenness
pab-1 Betweenness T10C6.14 Connectivity	and	Betweenness
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Table 3.16 – Background data associated with Figure 3.20. 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name %	Change	Compared	To	L440 Standard	Deviation P	Value Significant?
C18H9.7 WBGene00004507 rpy-1 -60.68 12.54 0.008 Yes
W02D3.9 WBGene00006773 unc-37 -61.14 15.54 0.010 Yes
T23D8.6 WBGene00001942 his-68 -63.67 18.93 0.013 Yes
B0261.4 WBGene00015092 mrpl-47 -35.58 10.70 0.019 Yes
C32E8.2 WBGene00004425 rpl-13 -38.31 13.49 0.020 Yes
F31E3.5 WBGene00001168 eef-1A.1 -41.29 13.25 0.024 Yes
R03G5.1 WBGene00001169 eef-1A.2 -47.57 20.75 0.027 Yes
T10C6.12 WBGene00001877 his-3 -49.85 19.71 0.028 Yes
T23D8.5 WBGene00001941 his-67 -44.06 18.83 0.034 Yes
F53G12.10 WBGene00004418 rpl-7 -25.22 14.08 0.048 Yes
Y71F9AL.13 WBGene00004412 rpl-1 -47.95 27.80 0.053 No
B0285.1 WBGene00007135 cdk-12 -42.63 23.30 0.056 No
T22D1.10 WBGene00020687 ruvb-2 -51.87 36.63 0.084 No
Y54E10A.10 WBGene00021830 Y54E10A.10 -21.94 17.51 0.132 No
Y87G2A.5 WBGene00006936 glp-4 -64.44 42.80 0.136 No
ZK652.4 WBGene00004449 rpl-35 -40.81 23.63 0.139 No
Y39A1A.12 WBGene00012650 orc-1 -47.64 36.59 0.194 No
C06B8.8 WBGene00004452 rpl-38 -40.03 34.17 0.202 No
Y105E8A.16 WBGene00004489 rps-20 -31.44 33.79 0.202 No
ZK1098.1 WBGene00014218 ZK1098.1 -14.57 22.72 0.359 No
Y71A12B.1 WBGene00004475 rps-6 -9.39 14.65 0.366 No
Y106G6H.2 WBGene00003902 pab-1 -16.05 34.23 0.478 No
R05G6.7 WBGene00019900 vdac-1 -7.64 17.72 0.515 No
B0361.6 WBGene00015160 B0361.6 -37.42 35.59 0.628 No
T22D1.3 WBGene00020682 T22D1.3 -11.07 36.29 0.633 No
F57B9.6 WBGene00002083 inf-1 18.57 67.62 0.638 No
Y75B12B.2 WBGene00000883 cyn-7 -13.54 54.58 0.663 No
Y106G6H.3 WBGene00004444 rpl-30 -5.05 49.30 0.873 No
B0207.4 WBGene00000099 air-2 1.97 34.07 0.925 No
Y57G11C.16 WBGene00004487 rps-18 -0.18 50.53 0.996 No
Figure 3.20 – Aldicarb-sensitivity screening of genes with high betweenness values in 
the one-step aldicarb and synaptic-related network. RNAi knockdown and aldicarb 
sensitivity assays were performed as described in Figure 3.5, with the percentage measured 
at 140 minutes. The percentage change to L440 was then calculated and plotted. Egl-30 was 
the positive control. Hits are significant and marked with an asterix if calculated P values 
calculated (Section 2.5) are less than 0.05. N=3. Error bars represent standard deviation. 
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3.9 Data mining of betweenness hits 
 
Proteins showing a positive phenotype from the betweenness analysis were analyzed in 
Wormbase, to extract functional descriptors (Table 3.18). Again multiple histone proteins 
including, his-67 (WBGene00001941) and his-68 (WBGene00001942), ribosomal 
proteins and transcription factors were found in this screen. When the list of novel gene 
symbols were inputted into DAVID, similar trends as seen for data from connectivity 
screens were seen, including development and chromatin organization and assembly 
(Table 3.19). 
 
Table 3.20 shows the betweenness ranking of the hits (including those that were also 
found in the connectivity screen). There did not seem to be a bias, as nodes with a higher 
betweenness rating were no more likely to show a phenotype than those with a lower 
betweenness ranking. This suggests that the algorithm is not the best for prioritizing 
nodes to elucidate novel effectors of synaptic function, but may still elucidate interesting 
effectors. However, no analysis was carried out on genes with a low betweenness score 
in this network, in order to test the validity of this prioritization method. 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name %	Change	Compared	To	L440 Standard	Deviation P	Value Significant?
B0261.4 WBGene00015092 mrpl-47 -56.82 9.98 0.001 Yes
B0285.1 WBGene00007135 cdk-12 -77.36 3.81 0.001 Yes
C32E8.2 WBGene00004425 rpl-13 -78.17 3.20 0.001 Yes
T10C6.12 WBGene00001877 his-3 -78.37 11.00 0.001 Yes
W02D3.9 WBGene00006773 unc-37 -78.74 10.69 0.001 Yes
T23D8.5 WBGene00001941 his-67 -84.89 10.71 0.001 Yes
F31E3.5 WBGene00001168 eef-1A.1 -70.71 19.22 0.005 Yes
R03G5.1 WBGene00001169 eef-1A.2 -34.83 9.72 0.011 Yes
T23D8.6 WBGene00001942 his-68 -57.77 28.72 0.029 Yes
C18H9.7 WBGene00004507 rpy-1 -20.02 60.23 0.597 No
Table 3.17 – Background data associated with Figure 3.21. 
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The human orthologs of the betweenness candidates were found using DIOPT fly RNAI 
(Table 3.21). Interestingly, only one of the human orthologs, rpl-13 was found in the 
SynaptomeDB (Pirooznia et al., 2012). However, nine of the common hits shared between 
the connectivity and betweenness screens were also found in the synaptome database 
(Table 3.22). 
 
Positive hits identified in the connectivity and betweenness screens were then 
investigated to assess the extent of physically association between two sets of proteins 
that were found to share common functional phenotypes (Figure 3.22 and Table 3.23). 
Interestingly, his-67 interacts with six of the other positive hits, forming a cluster of 
interconnected proteins. In contrast, unc-37 (WBGene00006773) does not interact with 
any of the other novel effectors of aldicarb sensitivity.  
 
A network was then generated to show the interaction of positive effectors identified in 
betweenness screens with previously known aldicarb-sensitivity and synaptic-related 
nodes (Figure 3.23). There is a spread in the connectivity of the hits to aldicarb and/or 
synaptic related genes. Unc-37 only has one interaction partner, yet others like rpl-23 
have 23 (Table 3.24). Many genes that were previously known to cause an aldicarb-
phenotype, or have synaptic related GO terms also interacted with multiple novel protein 
effectors identified in this study (Table 3.25). 
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Gene	Symbol Wormbase	Gene	ID Gene	Name Screen Description
F31E3.5 WBGene00001168 eef-1A.1 Betweenness Identical	to	EEF-1A.2.	Encodes	a	translation	elongation	factor	1-alpha	homolog	essential	for	fertility,	the	viability	of	embryos	and	germline	maintenance.
R03G5.1 WBGene00001169 eef-1A.2 Betweenness Identical	to	EEF-1A.1	
W02D3.9 WBGene00006773 unc-37 Betweenness Encodes	the	ortholog	of	Groucho,	a	D.	Melanoganster	protein,	and	is	known	to	be	essential	in	the	specification	of	neuronal	cell	fate.	It	is	also	known	to
interact	genetically	with	transcriptional	mediator	components.
B0285.1 WBGene00007135 cdk-12 Betweenness Predicted	to	bind	ATP	and	have	protein	kinase	activity.	Involved	in	embryonic	and	larval	development,	locomotion	and	receptor-mediated	endocytosis.
T23D8.5 WBGene00001941 his-67 Betweenness Encodes	an	H4	histone	required	for	embryonic	viability	and	growth.
T23D8.6 WBGene00001942 his-68 Betweenness Encodes	an	H2A	histone.
C32E8.2 WBGene00004425 rpl-13 Betweenness Encodes	a	large	ribosomal	subunit	L13	protein.
B0261.4 WBGene00015092 mrpl-47 Betweenness Thought	to	be	a	structural	component	of	the	ribosome,	and	is	involved	in	the	determination	of	adult	lifespan,	embryonic	and	larval	development,	and	oogenesis.
T10C6.12 WBGene00001877 his-3 Betweenness Encodes	an	H2A	histone,	and	is	predicted	to	function	as	a	component	of	the	nucleosome.
F56C9.1 WBGene00001748 gsp-2 Betweenness	and	Connectivity Encodes	an	ortholog	of	human	PPP1CA	(protein	phosphatase	1,	catalytic	subunit,	alpha	isozyme)	and	PPP1CC	(protein	phosphatase	1,	catalytic	subunit,	gamma	isozyme).
M03F4.2 WBGene00000066 act-4 Betweenness	and	Connectivity Encodes	an	actin	isoform	most	similar	to	act-2;	an	act-4	reporter	gene	is	expressed	in	body	wall	and	vulval	muscles	and	the	spermatheca.
B0250.5 WBGene00007122 B0250.5 Betweenness	and	Connectivity Encodes	an	ortholog	of	human	HIBADH	(3-hydroxyisobutyrate	dehydrogenase).	Predicted	to	have	the	ability	to	bind	NAD,	
F56F3.5 WBGene00004470 rps-1 Betweenness	and	Connectivity Encodes	a	small	ribosomal	subunit	S3A	protein.
F52D10.3 WBGene00001502 ftt-2 Betweenness	and	Connectivity Encodes	a	14-3-3	protein.	Required	the	regulation	of	the	localization	of	YAP-1	product,	a	Yes-associated	protein	(Yap)	homolog,	between	the	cytoplasm	and	the	nucleus.
B0336.10 WBGene00004435 rpl-23 Betweenness	and	Connectivity Encodes	a	large	ribosomal	subunit	L23	protein.
F25H5.4 WBGene00001167 eef-2 Betweenness	and	Connectivity Encodes	a	homolog	of	translation	elongation	factor	2	(EF-2),	a	GTP-binding	protein	essential	for	the	elongation	phase	of	protein	synthesis.	
EEF-2	is	required	for	embryogenesis	and	vulval	morphogenesis,	and	is	expressed	during	all	stages	of	development,	including	the	dauer	larval	stage.
B0348.6 WBGene00002061 ife-3 Betweenness	and	Connectivity Encodes	one	of	five	C.	elegans	homologs	of	the	mRNA	cap-binding	protein	eIF4E.
Table 3.18 – Description of genes with high betweenness that caused a significant change in aldicarb sensitivity. Genes found to be in the top 100 
connectivity and betweenness tables, which caused a significant change in aldicarb sensitivity are shown. Data was mined from Wormbase.  
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Table 3.19 – Biological process enrichment of hits from the betweenness screens. Hits from the betweenness screen (including those found in both the 
connectivity and betweenness data sets) were inputted into DAVID, and functional clustering was carried out. The count signifies how many genes were 
enriched in particular biological processes. 
 
Biological	Process Count Gene	Name(s)
Embryonic	development	ending	in	birth	or	egg	hatching 15 act-4,	gsp-2,	eef-1a2,	rps-1,	rpl-23,	eef-1a1,	his-3,	mrpl-47,	unc-37,	eef-2,	his-67,	cdk-12,	his-68,	ife-3,	rpl-13
Nematode	larval	development 14 act-4,	eef-1a2,	rps-1,	ftt-2,	rpl-23,	eef-1a1,	his-3,	mrpl-47,	unc-37,	eef-2,	his-67,	cdk-12,	his-68,	rpl-13
Larval	development 14 act-4,	eef-1a2,	rps-1,	ftt-2,	rpl-23,	eef-1a1,	his-3,	mrpl-47,	unc-37,	eef-2,	his-67,	cdk-12,	his-68,	rpl-13
Post-embryonic	development 14 act-4,	eef-1a2,	rps-1,	ftt-2,	rpl-23,	eef-1a1,	his-3,	mrpl-47,	unc-37,	eef-2,	his-67,	cdk-12,	his-68,	rpl-13
Growth 13 act-4,	eef-1a2,	rps-1,	ftt-2,	rpl-23,	eef-1a1,	mrpl-47,	his-3,	eef-2,	his-67,	cdk-12,	his-68,	rpl-13
Translation 8 eef-1a1,	mrpl-47,	eef-1a2,	eef-2,	rps-1,	ife-3,	rpl-23,	rpl-13
Hermaphrodite	genitalia	development 8 act-4,	his-3,	unc-37,	eef-2,	rps-1,	cdk-12,	his-67,	his-68
Genitalia	development 8 act-4,	his-3,	unc-37,	eef-2,	rps-1,	cdk-12,	his-67,	his-68
Sex	differentiation 8 act-4,	his-3,	unc-37,	eef-2,	rps-1,	cdk-12,	his-67,	his-68
Reproductive	developmental	process 8 act-4,	his-3,	unc-37,	eef-2,	rps-1,	cdk-12,	his-67,	his-68
Reproductive	process	in	a	multicellular	organism 7 eef-1a1,	his-3,	gsp-2,	eef-1a2,	unc-37,	his-68,	ftt-2
Multicellular	organism	reproduction 7 eef-1a1,	his-3,	gsp-2,	eef-1a2,	unc-37,	his-68,	ftt-2
Chromatin	organization 4 his-3,	gsp-2,	his-67,	his-68
Chromosome	organization 4 his-3,	gsp-2,	his-67,	his-68
Oviposition 4 his-3,	gsp-2,	his-68,	ftt-2
Reproductive	behavior	in	a	multicellular	organism 4 his-3,	gsp-2,	his-68,	ftt-2
Reproductive	behavior 4 his-3,	gsp-2,	his-68,	ftt-2
Molting	cycle,	collagen	and	cuticulin-based	cuticle 3 gsp-2,	rps-1,	rpl-23
Molting	cycle,	protein-based	cuticle 3 gsp-2,	rps-1,	rpl-23
Molting	cycle 3 gsp-2,	rps-1,	rpl-23
Chromatin	assembly 3 his-3,	his-67,	his-68
Nucleosome	organization 3 his-3,	his-67,	his-68
Nucleosome	assembly 3 his-3,	his-67,	his-68
Protein-DNA	complex	assembly 3 his-3,	his-67,	his-68
DNA	packaging 3 his-3,	his-67,	his-68
Chromatin	assembly	or	disassembly 3 his-3,	his-67,	his-68
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Worm	Gene	Symbol Wormbase	Gene	ID Worm	Gene	Name Human	Entrez	ID Human	Gene	Symbol DIOPT	score
B0261.4 WBGene00015092 mrpl-47 57129 MRPL47 7.809
B0285.1 WBGene00007135 cdk-12 8621 CDK13 7.809
B0285.1 WBGene00007135 cdk-12 51755 CDK12|CDK13 7.809
C32E8.2 WBGene00004425 rpl-13 6137 RPL13 8.859
T10C6.12 WBGene00001877 his-3 8338 HIST2H2AC 2.901
W02D3.9 WBGene00006773 unc-37 7090 TLE3 5.848
F31E3.5 WBGene00001168 eef-1A.1 1915 EEF1A1 2.93
R03G5.1 WBGene00001169 eef-1A.2 1917 EEF1A2 7.808
T23D8.6 WBGene00001942 his-68 8338 HIST2H2AC 2.901
Table 3.21 – Human orthologs of the hits found solely in the betweenness screen. Diopt FlyRNAI 
(Hu et al., 2011) was used to elucidate the closest human ortholog. The DIOPT score refers to how 
many databases predicted the ortholog match.  
 
Table 3.20 – Betweenness ranking of hits from the betweenness screen. Betweenness was 
measured in the one-step aldicarb and synaptic transmission-related one-step network. 
Betweenness centrality was measured using the network-analyzer plugin on Cytoscape. 
 
Gene	Name Betweenness	Centrality Betweenness	Ranking
rpl-23 0.0097127 7
ftt-2 0.00933241 8
R03G5.1 0.00625393 15
gsp-2 0.00600663 16
act-4 0.00567444 18
T23D8.5 0.00559809 19
W02D3.9 0.00557579 20
ife-3 0.00483473 26
C32E8.2 0.00476624 27
B0250.5 0.0046099 28
B0285.1 0.00416142 36
B0261.4 0.00371284 44
eef-2 0.00363815 46
F31E3.5 0.0033845 54
T10C6.12 0.00321661 59
T23D8.6 0.00321597 60
F56F3.5 0.00304557 66
Chapter 3: Connectivity and Betweenness 
 159 
 
Table 3.23 – The number of other novel hits each hit from the betweenness screen interacts with. 
This data was generated from the network shown in Figure 3.22, which shows interactions 
between the novel betweenness genes that caused a significant change in aldicarb sensitivity. 
 
Gene	Name Screen Number	of	Betweenness	Hit	Interactors
his-67 Betweenness 6
eef-2 Betweenness|Connectivity 5
rpl-23 Betweenness|Connectivity 5
rps-1 Betweenness|Connectivity 5
gsp-2 Betweenness|Connectivity 4
his-3 Betweenness 4
eef-1a1 Betweenness 4
his-68 Betweenness 4
act-4 Betweenness|Connectivity 3
B0250.5 Betweenness|Connectivity 3
rpl-13 Betweenness 2
ftt-2 Betweenness|Connectivity 2
cdk-12 Betweenness 1
unc-37 Betweenness 1
ife-3 Betweenness|Connectivity 1
mrpl-47 Betweenness 1
Figure 3.22 – Interconnectivity of betweenness hits. Cytoscape version 3 was used to merge 
the Wormbase and worm interactome networks, in order to visualize interaction partners 
between the hits elucidated in the betweenness screen. Interactions between human 
orthologs are shown in red, S. cerevisiae in black, and both human and S. cerevisiae in green.  
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Proteins contained in the betweenness and aldicarb one-step network were analyzed 
using the DAVID biological enrichment tool. Again synaptic transmission and cholinergic 
neurotransmission appear as enriched processes, with 9 genes having GO terms of 
synaptic transmission, of which 3 are specific to cholinergic neurons (Table 3.26). All of 
these 9 genes were previously known to cause aldicarb phenotypes. When looking at 
their interacting proteins, it is interesting to note that unc-75 interacts with three of the 
novel effectors with high betweenness ranking and low connectivity values (his-68, his-
67 and his-3). These are all histone proteins, and unc-75 is required for neuron-specific 
splicing of unc-32.  
Figure 3.23 – Network showing the hits elucidated from the betweenness screen, and the 
interactors previously known to cause an aldicarb-sensitivity phenotype. Grey nodes 
represent the novel hits, red indicate genes previously shown to cause a RIC phenotype, and 
blue are genes previously shown to cause a HIC phenotype. Green nodes represent genes that 
are not known to cause an aldicarb-sensitivity phenotype, but do have synaptic related GO 
terms. The aldicarb and synaptic-transmission related network (Figure 3.18) was used to 
elucidate these interactions, and Cytoscape was used for visualization. 
 
RIC-causing	gene	
(previously	known)	
HIC-causing	gene	
(previously	known)	
Novel	Hit	
Gene	with	Synap c	
Transmission	GO	term	
eef-2
erp-1
nab-1
hum-1
nud-1
rac-2
dyb-1
myo-1
mpk-1
C50D2.3
drp-1
gsp-2
hipr-1
taf-5
act-4
gsp-1
par-5
arx-3
eat-6
dlc-1
hpk-1
klc-2
unc-116
syn-3ftt-2
tap-1
abts-1
egl-3
aps-1
miro-1
stam-1
nasp-1
rskn-2
eef-1A.1
rps-1
cam-1
fkh-8
dop-2
dys-1
fer-1
mef-2
mrpl-47
ehs-1itsn-1
rpl-23
atx-3
his-67
unc-64
unc-26
rho-1
wwp-1
rpt-3 tom-1
his-3
rack-1
his-68
glr-2
hgrs-1
unc-75
sad-1
cav-1
arr-1
prx-2
B0250.5
par-3
egl-30
tag-232
eel-1
dhc-1
apa-2
gab-1
nmr-2
egl-10
ubc-25
let-60
pat-6
unc-2
ric-4ife-3
snt-1
pptr-1
unc-13
F54G2.1
F28C6.8
spc-1
unc-11
dop-4
usp-46
fsn-1
sphk-1
rpl-13
unc-37
unc-4
mgl-1
cdtl-7
unc-18
gar-3
snb-1
M4.1
syd-2
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The core list of aldicarb-sensitivity genes was updated to include novel protein effectors 
identified in betweenness informed screens, generating a network (Figure 3.24) with 
4565 nodes and 14372 edges. 
 
Gene	Symbol Wormbase	Gene	ID Gene	Name Number	of	aldicarb/synaptic	related	interactors
W02D3.9 WBGene00006773 unc-37 1
C32E8.2 WBGene00004425 rpl-13 4
B0285.1 WBGene00007135 cdk-12 5
B0261.4 WBGene00015092 mrpl-47 8
F31E3.5 WBGene00001168 eef-1A.1 9
T10C6.12 WBGene00001877 his-3 9
T23D8.6 WBGene00001942 his-68 10
B0348.6 WBGene00002061 ife-3 11
F56C9.1 WBGene00001748 gsp-2 12
F25H5.4 WBGene00001167 eef-2 13
F56F3.5 WBGene00004470 rps-1 13
T23D8.5 WBGene00001941 his-67 13
B0250.5 WBGene00007122 B0250.5 15
F52D10.3 WBGene00001502 ftt-2 16
M03F4.2 WBGene00000066 act-4 18
B0336.10 WBGene00004435 rpl-23 23
Table 3.24 – Table showing the number of known aldicarb-sensitivity genes each hit from the 
betweenness screen interacts with. This corresponds with the network shown in figure 3.23. 
The aldicarb and synaptic-transmission related network (figure 3.18) was used to elucidate 
interaction partners of the genes in the betweenness screen, which caused a significant change 
in aldicarb sensitivity. 
 
Table 3.26 – Synaptic transmission is enriched when genes from the novel aldicarb-sensitivity genes 
from the betweenness screen and their interacting partners that cause an aldicarb-phenotype are 
inputted into DAVID. Functional clustering was carried out and biological process enrichment 
assessed (using standard DAVID parameters).  
 
Gene	Name Biological	Process Aldicarb Hit	Interactor(s)
dys-1 Synaptic	Transmission,	Cholinergic RIC mrpl-47
dyb-1 Synaptic	Transmission,	Cholinergic HIC act-4
ric-4 Synaptic	Transmission,	Cholinergic RIC ife-3
unc-18 Synaptic	Transmission,	Cholinergic RIC cdk-12,	rpl-23
unc-64 Synaptic	Transmission,	Cholinergic RIC act-4,	rpl-23
unc-75 Synaptic	Transmission,	Cholinergic RIC his-68,	his-67,	his-3
ehs-1 Synaptic	Transmission RIC mrpl-47,	B0250.5
syd-2 Synaptic	Transmission RIC rpl-23
unc-2 Synaptic	Transmission RIC ife-3
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Table 3.25 – Genes that were previously known to cause an aldicarb-sensitivity phenotype or had a related synaptic transmission GO term, which 
interacted with multiple novel hits from the connectivity screen. Data was extracted from the one-step aldicarb network (Figure 3.9). Genes are 
listed if they interacted with more than one novel hit, and were known to cause a RIC or HIC phenotype when their expression was altered. 
 
Gene	Symbol Aldicarb/Synaptic	Related Number	of	Interacting	Hits Interacting	Gene	Symbol(s)
tom-1 Synaptic	Related 4 his-3,	his-67,	act-4,	his-68
rack-1 RIC 4 his-3,	his-67,	eef-2,	his-68
rpt-3 RIC 4 his-3,	his-67,	act-4,	his-68
nab-1 RIC 3 rps-1,	act-4,	gsp-2
syx-5 Synaptic	Related 3 B0250.5,	mrpl-47,	gsp-2
sad-1 Synaptic	Related|RIC 3 rps-1,	his-67,	gsp-2
taf-5 RIC 3 his-67,	ftt-2,	eef-2
gsp-1 RIC 3 rps-1,	ftt-2,	gsp-2
unc-75 Synaptic	Related|RIC 3 his-3,	his-67,	his-68
unc-64 Synaptic	Related|RIC 2 act-4,	rpl-23
hipr-1 Synaptic	Related 2 ftt-2,	act-4
ehs-1 Synaptic	Related|RIC 2 B0250.5,	mrpl-47
gar-3 Synaptic	Related 2 cdk-12,	rpl-23
mgl-1 Synaptic	Related 2 cdk-12,	rpl-23
unc-18 Synaptic	Related|RIC 2 cdk-12,	rpl-23
eat-6 HIC 2 ftt-2,	act-4
spc-1 RIC 2 ife-3,	rpl-23
unc-116 Synaptic	Related 2 ftt-2,	B0250.5
hum-1 RIC 2 act-4,	eef-2
unc-26 Synaptic	Related|RIC 2 ftt-2,	rpl-23
rom-4 HIC 2 B0250.5,	mrpl-47
rskn-2 RIC 2 eef-1a1,	eef-2
rho-1 HIC 2 act-4,	B0250.5
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Figure 3.24 – One-step network using a core of the aldicarb-sensitivity genes and novel 
betweenness hits. Yellow nodes indicate betweenness hits, green indicate nodes found in both 
connectivity and betweenness screens, red are previously known to cause RIC phenotypes, and 
blue are previously known to cause a HIC phenotype. Cytoscape version 3 was used to generate 
this network. 
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3.3.10 Analysis of proteins found to have positive effects on synaptic function in 
both connectivity and betweenness screens 
 
As there is a large degree of overlap between the connectivity and betweenness 
datasets, the crossover between the hits was analyzed. As can be seen from data 
presented in Table 3.27 and Figure 3.25, 8 of the novel protein effectors had both 
high connectivity and betweenness values. However, it is interesting to note that 
two of the candidates (C18H9.7 and W02D3.9) had no known interaction with 
aldicarb-sensitivity genes/proteins. Also, although C18H9.7 (rpy-1) interacts with 
proteins that have synaptic related GO terms and W02D3.9 (unc-37) is associated 
with synaptic transmission, neither was previously known to have an aldicarb 
modifying phenotype. In the independent validation stage, C18H9.7 did not cause 
an aldicarb-phenotype. However unc-37 showed a 78.7% reduction in paralysis 
compared to the negative control (p  = 0.0007). For this reason a full time course 
experiment after knocking down the unc-37 (in Tu3311) was carried out. This 
confirmed the result (Figure 3.26), showing that network mediated expansion of 
GO terms is a useful approach to reveal potential novel effectors of synaptic 
function. 
 
The data generated from both of these screens was added to the current aldicarb 
and synaptic-related one-step network as core attributes. This expanded the 
network to contain 4590 nodes and 14753 edges (Figure 3.27). 
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Figure 3.25 – A Venn Diagram to show the overlap in genes found to cause a change in 
aldicarb sensitivity, which had both high betweenness and connectivity. Gene lists of the 
hits were inputted into a Venn diagram program (Venny), which generated the diagram, and 
shows that 8 genes are shared between the data sets. 
 
Table 3.27 – Table to show the hits 
found in the connectivity and 
betweenness screens, and which were 
found in both screens. 
 
Gene	Name Screen
ppfr-4 Connectivity
pod-2 Connectivity
ola-1 Connectivity
rpl-11.1 Connectivity
his-4 Connectivity
scbp-2 Connectivity
his-8 Connectivity
ubql-1 Connectivity
lonp-1 Connectivity
mrpl-11 Connectivity
B0205.6 Connectivity
rpl-13 Betweenness
cdk-12 Betweenness
mrpl-47 Betweenness
his-68 Betweenness
his-3 Betweenness
eef-1a1 Betweenness
his-67 Betweenness
gsp-2 Betweenness	&Connectivity
eef-2 Betweenness	&Connectivity
rps-1 Betweenness	&Connectivity
B0250.5 Betweenness	&Connectivity
ife-3 Betweenness	&Connectivity
ftt-2 Betweenness	&Connectivity
act-4 Betweenness	&Connectivity
rpl-23 Betweenness	&Connectivity
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Figure 3.26 – Full time course aldicarb-sensitivity assay when unc-37 was knocked down 
in Tu3311. 4mM IPTG feeding plates were seeded with unc-37 or empty L440 vector dsRNA 
expressing bacteria. After the plates were dry, adult worms were picked onto plates. Four days 
later, plates were bleached to another set of unc-37/L440 seeded 4mM IPTG feeding plates. 
Three days after this the worms (F2 generation) were picked onto 1mM aldicarb plates. Worms 
were prodded with a metal wire every 20 minutes, and paralysis was assessed. The percentage 
of paralysis at each time point was calculated and plotted. Unc-37 knockdown leads to a RIC 
phenotype. N=3. Error bars represent standard deviation. 
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3.4 Discussion 
 
3.4.1 Connectivity and Betweenness as Graph Theory Methods 
 
Multiple different conclusions can be gathered from the C. elegans experiments 
carried out in this chapter. These results firstly highlight some of the difficulties 
faced when analyzing networks. The betweenness and connectivity screens 
showed a large degree of overlap, and many hits were found that had both high 
Figure 3.27 – One-step network using a core of the aldicarb-sensitivity genes and novel 
betweenness and connectivity hits. Yellow nodes indicate genes that were found to cause a 
significant change in aldicarb sensitivity, which were in the top 100 betweenness screen (from 
the one-step aldicarb and synaptic transmission network). Dark blue nodes indicate the hits 
genes that were only found as to be in the top 100 connected genes (from the one-step aldicarb 
network), which caused a significant change in aldicarb sensitivity when knocked down. 
Green nodes indicate hit genes found in both connectivity and betweenness screens. Red 
nodes indicate genes that were previously known to cause RIC phenotypes, and light blue 
nodes indicate genes that were previously known to cause a HIC phenotype. Cytoscape version 
2 was used to generate this network, using a spring embedded network. 
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betweenness and connectivity values. There is the possibility that genes with 
higher connectivity may exhibit high levels of non-specific binding of proteins or 
sociological bias. However, as a proportion of genes that had a high number of 
physical associations with known aldicarb genes, also showed an aldicarb 
phenotype, this limits the theory that high connectivity may be non-specific, and 
therefore not functionally relevant. The principle of sociological bias was shown 
in other RNAi screens carried out in C. elegans, where genes affected in Aβ and 
polyQ over-expressing mutants, led to 27 common genes of which 20 had a high 
connectivity in a global network (Khabirova et al., 2014).  Genes that have been 
discovered to be disease-relevant are inevitably more studied, leading to 
disproportionate information relating to related proteins in public databases. 
Nevertheless, it is logical to conclude that high connectivity to known aldicarb 
sensitivity nodes may by the principle of “Guilt by association” (Oliver, 2000) and 
phenology prediction methods, indicate a novel functional association. For 
example, if a translation factor such as eef-2 is knocked down, it is logical that the 
level of many proteins would be affected, leading to changes in aldicarb-
sensitivity, as multiple biological processes would be affected. Therefore, 
connectivity is a simple yet relevant algorithm to use to attempt to elucidate novel 
effectors of synaptic function. 
 
As connectivity only looks at the nearest edges of a given node, it is a non-ideal 
graph theory analytic method if we want to look at features more in line with the 
global architecture of the network. However, when focused on the one-step 
network, it does reveal some interesting trends. Firstly, a large number of histone-
related proteins were found. This is possibly intuitive as decreasing the levels of 
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histone proteins would affect the transcription of many genes. There are many 
different ways that an aldicarb-sensitivity change could occur. Not only could 
there be a change in exocytosis of acetylcholine or GABA, but also knockdowns 
that change the efficiency/number of postsynaptic receptors would also cause an 
effect. The genes being knocked down could be causing an indirect effect much 
further downstream, which leads to paralysis. This could be the case where 
transcription/translation factors or histone proteins were knocked down. 
However, it is interesting to note that other histone proteins were included in the 
screens (his-48, his-1 and htz-1), but knockdown did not lead to a significant 
change in aldicarb-sensitivity. 
 
It has previously been suggested that proteins with a high betweenness but low 
connectivity may be important linking proteins between modules of a network 
(Joy et al., 2005). As mentioned in 3.3.11 unc-37 fulfilled this role. The ‘synaptic 
transmission’ GO term is associated with unc-37, but it has not been reported to 
interact with any known aldicarb-sensitivity genes and did not have a reported 
aldicarb modulating phenotype. Its only interaction partner, which shares the 
same GO term is F26C11.2 (unc-4). Unc-37 is a co-repressor of unc-4, which is an 
essential homeodomain protein required for synaptic choice (Pflugrad, Meir, 
Barnes, & Miller  3rd, 1997; Schneider et al., 2012). Specifically, it has been shown 
to prevent the expression of Ventral B motor neuron (VB) genes in ventral A motor 
neurons (VA) (via repression of Wnt signaling in VA neurons). Backwards 
locomotion requires AVA interneurons connecting to VA motor neurons. Unc-4 
mutants have the VA motor neurons connecting instead to AVB interneurons, 
leading to defective backward locomotion (Schneider et al., 2012). Although, 
Chapter 3: Connectivity and Betweenness 
 170 
knockdown of unc-4 has not been tested in the aldicarb-sensitivity assay, it’s RNAi 
clone is available in the Vidal RNAi library. It would therefore be interesting to test 
whether this gene also causes a RIC phenotype when knocked down in Tu3311. 
Both the VA and VB neurons are cholinergic, so we predict that the genetic 
knockdown may lead to a change in cholinergic signaling. This would require 
further testing. 
 
3.4.2 Hits connected to known aldicarb-sensitivity genes 
 
By looking at the interaction partners of the connectivity hits, ric-4 emerged as an 
aldicarb-sensitivity protein, which connects to the novel genes ife-3 and ubql-1. 
As mentioned previously ric-4 is the worm ortholog of SNAP-25. The human 
orthologs of ife-3 and ubql-1 are EIF4E and UBQLN1, respectively. Both of these 
interactions were found in the Wormnet interaction data (Cho et al., 2014). The 
interaction between EIF4E and SNAP-25 was found in humans, and the interaction 
between UBQLN1 and SNAP-25 was identified in human high throughput protein-
protein interaction studies. 
 
UBQLN1 plays a regulatory role in autophagy and the Endoplasmic Reticulum 
Associated Degradation (ERAD) pathway via the ubiquitin-proteasome system. 
Loss of UBQLN1 has been observed in the brains of patients with Alzheimer’s 
disease (Natunen et al., 2016), UBQLN1 is also found in neurofibrillary tangles and 
Lewy bodies (Mah, Perry, Smith, & Monteiro, 2000). Analysis of data from 
BIOGRID revealed interactions between UBQLN1 and two pre-senilins (PSEN1 
and PSEN2), which form the catalytic subunit of γ-secretase, which in turn is 
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responsible for cleaving both Notch and APP.  Novel data from this study shows 
that decreasing the expression of ubql-1 induced a RIC phenotype. Further 
analysis is required to investigate the mechanistic role of the proteasome system 
in the aldicarb-sensitivity phenotype.  
 
EIF4e is a translation initiation factor, which is known to play a key role in learning 
and memory. Single nucleotide polymorphisms in EIF4E have been found in 
families with autism (Waltes et al., 2014), but the potential effects of mutation or 
functional perturbation on synaptic function were not described before this study. 
Therefore, further investigation of ife-3 mutants is needed to better elucidate its 
role at the synapse.  
 
3.4.3 Overlapping hits from previous screens 
 
Some preliminary RNAi screens had previously been carried out in the lab 
(unpublished data). Although these studies were not directly complementary one 
potentially common hit was shared between these screens. This was ftt-2 
(WBGene00001502). Ftt-2 is required for controlling localization of Yap-1 
between the nucleus and cytoplasm. Yap-1 knockout mutants have been shown to 
have an extended lifespan (Iwasa et al., 2013). Ftt-2 has also been reported to 
control the localization of daf-16, the Forkhead Box O (FOXO) ortholog, which acts 
downstream of the insulin/IIS pathway. This pathway is also crucial in the 
determination of lifespan. Other genes found to cause lifespan extension, unc-64 
and unc-31, also cause RIC phenotypes when mutated, through defects in 
neurotransmitter secretion. This suggests that a similar effect could be occurring 
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in the ftt-2 knockdown. To assess this in the future, it would be necessary to 
measure the levels of acetylcholine being released in the knockdown, possibly 
through the use of fluorescent reporters. Whether ftt-2 knockdown itself leads to 
lifespan extension has also not been tested. 
 
3.4.4 Transcription and Translation Factors 
 
One interesting cluster of genes that came from both the connectivity and 
betweenness screens were translation elongation factors. In the betweenness 
screen, eef-1A.1 and eef-1A.2 both caused significant RIC phenotypes. Their 
human orthologs are EEF1A1/EEF1A2. In the connectivity screen, three 
elongation factors (eef-2, iftb-1 and ife-3) all induced a RIC phenotype. Elongation 
factor 1A (EEF1A) functions in a GTP-dependent manner, bringing the 
aminoacylated-tRNA to the ribosome. It has 2 isoforms, EEF1A1 and EEF1A2, 
which are 92% identical and have 98% amino acid similarity (Soares & Abbott, 
2013). Despite their similarity they have a highly differential pattern of expression 
with EEF1A1 being expressed in the majority of tissues, with the exception of adult 
neurons and muscle cells, which instead express EEF1A2. A paper published in 
2014 highlighted the role of EEf1A1 in the heat shock response (HSR), showing 
that EEF1A1 (but not EEF1A2) was required for HSP70 induction during heat 
shock (Vera et al., 2014). EEF1A1 was found to bind to heat shock factor 1 (HSF1), 
enhancing it’s binding to the HSP70 promoter of heat shock proteins. Interestingly 
motor neurons do not express EEF1A1, and instead express it’s isoform EEF1A2. 
Deregulation of the heat shock response has been reported in numerous 
neurodegenerative diseases (for example Parkinson’s disease, Amyotrophic 
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lateral sclerosis and Alzheimer’s disease). This paper suggests that this may 
explain why there is a lack of heat shock response in these neurons, as well as 
suggesting that the expression of EEF1A1 in the motor neurons may be a potential 
therapy for such diseases. The fact that a RIC phenotype has been confirmed in 
this study suggests it plays an important role in C. elegans neurons. It would 
therefore be interesting to test whether there has been an effect on the 
transcription of known C. elegans heat shock proteins following knock-down, in 
order to see if the delayed paralysis is due to a changed transcription of these 
genes. 
 
EEF2 has been shown to play a direct role in a form of Spinocerebellar Ataxia 26 
(SCA26) (Hekman et al., 2012). This disease is characterized with cerebellar 
atrophy and Purkinje cell degeneration. Patients display a progressive gait 
incoordination, and often show poor coordination of hands, speech and eye 
movement. Interestingly, this paper also showed that the P596H mutation in the 
yeast ortholog of EEF2 was linked to an increased rate of shifting to the -1 reading 
frame, leading to changes in proteostasis. In this study we found that EEF2 caused 
a RIC phenotype, and as well as having high connectivity and betweenness values 
in the one-step aldicarb network. EEF-2 was also highly interconnected between 
the hits. This suggests that it may be playing a role in multiple biological processes, 
which need further delineation. 
 
 
3.4.5 Lonp-1/LONP1 
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Lonp-1 is another interesting hit from the connectivity screen. The human 
ortholog of C34B2.6 is Lon peptidase 1 (LONP1), which is a mitochondrial matrix 
protein that belongs to the lon family of ATP-dependent proteases. It is a key 
protein in degrading oxidatively damaged proteins in the mitochondria. LONP1 
has been shown to be up-regulated during periods of transient stress, but down 
regulated as ageing progresses (Ngo, Pomatto, & Davies, 2013). Defects in 
mitochondrial protein quality control have been associated with numerous 
neurodegenerative diseases. Neuronal tissues are highly dependent on 
mitochondria as they have limited glycolysis capabilities (due to a lack of 6-
phophofructo-2-kinase/fructose-2,6 bisphosphate, isoform 3 (PFKFB3) (Herrero-
Mendez et al., 2009).  A patient with hereditary spastic paraplegia (SPG13) was 
shown to have decreased expression of LONP1, which was hypothesized to act as 
a compensatory mechanism following mutation of the HSPD1 gene, which encodes 
the mitochondrial chaperonin HSP60 mutation (Hansen et al., 2008). How 
dysregulated mitochondrial function (possibly via the unfolded protein response) 
alters cholinergic or GABA signaling would be of interest for further study. 
 
3.4.6 Data from outer shells of RIC network 
 
From these connectivity and betweenness screens, it is not obvious as to whether 
they help prioritize genes that will cause a RIC or a HIC phenotype. However, a 
handful of genes were elucidated by this method. To attempt to understand how 
appropriate the “guilt-by-association” principle was, and whether indirect 
interaction partners could cause an aldicarb-sensitivity phenotype, we found the 
least connected proteins to proteins known to cause aldicarb-sensitivity 
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phenotypes. In both Tu3311 and Tu3335, knockdown of some of the genes in the 
outer shells lead to a significant change in aldicarb sensitivity. 
 
From this data it is possible to make three pragmatic conclusions: While known 
physical association with a given protein may be a powerful indication that the 
two partners are functionally and phenotypically linked, this concept of guilt by 
association or phenology prediction (Oliver, 2000) may be most relevant to 
investigating common components of a particular molecular machine, or 
simplistic process with a well defined measurable endpoint. In this case the 
functional boundary of the network should be quickly exceeded and proteins in 
more distant shells may be expected to have less influence on the phenotype 
under investigation. In terms of a process as complex as synaptic transmission 
these rational assumptions appear to be too simplistic.  
 
The apparent abundance of synaptic effectors in shells unconnected with known 
RIC/HIC proteins may be due to two factors. First, interaction networks may be 
incomplete, so phenotypically related proteins may still appear unconnected. 
Secondly, disruption of proteins involved in superficially unrelated processes may 
have indirect but measurable effects on the efficiency of synaptic processes. For 
this reason it may not be logical to expect proximity within a protein interaction 
network to be a reliable indicator of a proteins potential to influence synaptic 
activity. Understanding the potential impact of non-intuitive regulators of 
synaptic function and the relative impact of disruption to more generic cellular 
functions may prove valuable in understanding or evaluating the phenotypic 
consequences of age related neuronal somatic mutations. In this context our data 
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would predict the existence of many more proteins whose function is not required 
for viability but is required for optimal synaptic function and plasticity.      
 
The background of the worms may also cause the difference in genes coming 
through as hits in the screen – Tu3335 has been reported to be more sensitive than 
Tu3311, so the use of Tu3335 is possible for future experiments where borderline 
results are seen in Tu3311.  
 
3.4.7 Conclusions 
 
Some interesting genes were found to cause a novel RIC phenotype in the 
neurosensitive Tu3311 strain when connectivity and betweenness values were 
ranked functionally relevant worm protein interaction networks, with some 
having reported neuropathological roles in humans. However, for the next stage 
of experimentation we decided to try a different method of prioritizing candidates 
to test for novel effectors of aldicarb sensitivity.  
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4.1 Abstract 
 
Sodium valproate is a drug that is commonly used to treat bipolar disorder and 
epilepsy. Surprisingly, the Falciani group observed that VPA induced paralysis in 
sma-6 mutant worms (Munasinghe, 2015).  To further investigate the effects of 
VPA dosage in worms the Falciani group performed a detailed analysis of global 
gene expression profiles in wild type worms treated with increasing 
concentrations of VPA (Munasinghe, 2015) .  Gene expression changes were 
ranked according to degree of correlation with VPA dose and values were assigned 
to nodes within a one-step known RIC/HIC protein interaction network (as 
described in chapter 3).   A bespoke clustering algorithm was then used to identify 
network modules that contained clusters of interconnected proteins that exhibit 
VPA induced changes in gene expression.  Nodes within modules that had not 
previously been tested for aldicarb-sensitivity were then systematically knocked 
down to assess their potential influence on synaptic transport, as measured by 
induced changes in the rate of aldicarb induced paralysis. Significantly, 
knockdown of 16 genes lead to a reproducible RIC phenotype, while depletion of 
dylt-1 induced a positive HIC phenotype. In addition to these functional studies 
the raw microarray data was re-analyzed, and both DAVID and Ingenuity packages 
were used to perform pathway/process enrichment analyses. This analysis 
highlighted enriched changes in neuron development, highlighting the 
involvement of genes involved in neurological diseases, such as epilepsy, 
Alzheimer’s and Huntington’s disease. 
 
4.2 Introduction 
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4.2.1 Sodium Valproate 
 
Sodium valproate, also known as valproic acid (VPA), is widely used in the 
treatment of epilepsy, bipolar disorder and in cases of schizophrenia.  Although in 
medical use since 1962, the precise mechanism of action of VPA remains unclear, 
VPA has been implicated in GABA neurotransmission, is a known teratogen, and 
is also known to be a histone deacetylase inhibitor. As such, it appears that VPA 
has a complex mode of action, which may in part be mediated by global effects on 
gene transcription. Previous studies have shown that VPA may have both anti-
cancer and neuromodulatory/neuroprotective properties. In C. elegans, VPA has 
also been shown to extend lifespan and play a role in both inositol and 
diacylglycerol signaling (Tokuoka, Saiardi, & Nurrish, 2008).  
 
A previous study by the Falciani group (University of Birmingham and University 
of Liverpool) led to the surprising observation that VPA induces paralysis in sma-
6 mutant worms (Munasinghe, 2015) .  To further investigate the effects of VPA 
dosage in worms, they performed a detailed microarray analysis of VPA dose (3-
24mM) on global gene expression in wild type N2 worms.   In collaboration, a gene 
set enrichment analysis (GSEA) was then performed to identify sets of genes that 
exhibited similar dose dependent changes in gene expression. To complement this 
data a one-step known RIC/HIC protein interaction network (as described in 
chapter 3) was generated from a simplified version of Wormnet version 1 and the 
CCSB worm interactome (Simonis et al., 2009), which contained only known C. 
elegans interactions.  
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These two datasets were then brought together to generate a known RIC/HIC one-
step interaction network in which RIC nodes were assigned phenotypic 
confidence scores.  A bespoke clustering algorithm was used, which correlates this 
information with dose response correlation scores for each node in order to 
generate drug response phenotypic network modules.  Predicted modules 
contained both known RIC/HIC and non-RIC/HIC nodes. Therefore, on the basis 
that connected nodes within these modules may share common functions or 
phenotypes all nodes within modules that had not previously been tested for 
aldicarb-sensitivity were systematically knocked down to assess their potential 
influence on synaptic transport, as measured by induced changes in the rate of 
aldicarb induced paralysis.  
 
4.2.2. Aims 
 
 
The aims of this chapter were to: 
 
- Perform high-throughput aldicarb-sensitivity assays after knocking down 
genes relating to previously untested proteins within predicted network 
modules 
- Carry out bioinformatics analyses to identify regulators/effectors of 
synaptic function that have known orthologs in the human synaptome and 
to define the known functions of all elucidated proteins  
- Re-analyze the C. elegans VPA microarray data to identify the full 
complement of genes that are significantly up- and down-regulated 
following exposure to VPA. 
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- Compare this data with that from other published studies on VPA induced 
changes in gene expression, in order to identify conserved effects or 
functional signatures. 
 
4.3 Results 
 
4.3.1 Data mining of genes in RIC/VPA related modules 
 
Data mining of candidates in the identified sub-networks was firstly carried out as 
shown in Figure 4.1. Genes relating to proteins contained in each of the four 
identified modules are shown in Tables 4.1 – 4.4, together with an indication of 
their known aldicarb phenotype. To gain insight into possible pathways that VPA 
could be affecting, a list of all genes found in the modules was generated, and 
DAVID was used to elucidate enriched pathways following VPA treatment in C. 
elegans, using the online Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database. Pathways enriched are shown in Table 4.5. From this it can be seen that 
endocytosis, Wnt signaling, TGF-β signaling and MAPK signaling are all enriched, 
showing the diverse responses that VPA may be conferring on the organism.  
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Figure 4.1 - Subnetworks identified following gene set enrichment analysis of 
microarray data for N2 worms treated with VPA. A and B show two separate 
interaction modules identified from the Vidal CCSB worm interactome, and C and D 
show two modules identified from the simplified Wormnet version 1. Red nodes 
indicate genes known to cause a RIC phenotype when their expression is altered, with 
the strength of the red colour indicating the confidence of the score. Square nodes 
indicate genes whose human orthologs were found in the synaptomeDB. White nodes 
represent genes not known to cause a RIC phenotype, and white nodes with bold 
outlines represent novel genes that had dsRNA available in the RNAi library. Networks 
were generated using Cytoscape, and module analysis was carried out by the Falciani 
group. 
 
A	 C	
B	
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Increasing	
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Wormbase	ID Gene	Symbol Gene	Name RIC
WBGene00000195 F53H8.2 arr-1 Y
WBGene00008317 C54G4.7 C54G4.7 Y
WBGene00013709 Y106G6E.6 csnk-1 Y
WBGene00012019 T25E12.4 dkf-2 Y
WBGene00001179 F28C1.2 egl-10 Y
WBGene00001184 F58A3.2 egl-15 Y
WBGene00001196 M01D7.7 egl-30 Y
WBGene00001177 B0348.4 egl-8 Y
WBGene00001746 Y18D10A.5 GSK-3 Y
WBGene00010373 H08M01.1 H08M01.1 Y
WBGene00003401 F43C1.2 mpk-1 Y
WBGene00006364 F59F5.6 syd-2 Y
WBGene00044077 T18H9.7 tag-232 Y
WBGene00008805 F14F3.2 git-1 N
WBGene00001678 Y95B8A.5 gpa-16 N
WBGene00001680 F52A8.2 gpb-2 N
WBGene00002363 F38H4.9 let-92 N
WBGene00016197 C28H8.6 pxl-1 N
WBGene00019834 R02F2.5 R02F2.5 N
WBGene00020841 T27A3.5 T27A3.5 N
Table 4.1 – Genes found in the CCSB Vidal subnetwork 1, showing Wormbase ID, gene 
symbols and gene names, together with previously known RIC phenotype.  All data was 
extracted from Wormbase. 
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Wormbase	ID Gene	Symbol Gene	Name RIC
WBGene00000001 Y110A7A.10 aap-1 N
WBGene00000064 T04C12.5 act-2 N
WBGene00000089 Y87G2A.4 aex-6 N
WBGene00000161 T20B5.1 apa-2 Y
WBGene00000158 Y105E8A.9 apg-1 N
WBGene00000150 F55A12.7 apm-1 Y
WBGene00000159 F29G9.3 APS-1 Y
WBGene00000201 Y79H2A.6 arx-3 Y
WBGene00015516 C06A8.6 C06A8.6 N
WBGene00000277 C23H4.1 cab-1 Y
WBGene00000289 C01G6.8 cam-1 Y
WBGene00000390 R07G3.1 cdc-42 N
WBGene00000479 C07H6.5 cgh-1 N
WBGene00012036 T26E3.1 clec-103 N
WBGene00000836 D2045.6 cul-1 N
WBGene00000911 C10C5.6 daf-15 Y
WBGene00000898 Y55D5A.5 DAF-2 N
WBGene00000915 C47E8.5 daf-21 N
WBGene00000903 B0412.2 daf-7 Y
WBGene00001005 T26A5.9 dlc-1 Y
WBGene00001102 C27A2.6 dsh-2 N
WBGene00008764 F13G3.4 dylt-1 N
WBGene00001133 Y48B6A.4 eat-2 N
WBGene00022069 Y67D8C.5 eel-1 Y
WBGene00008707 F11E6.3 F11E6.3 Y
WBGene00018991 F56F11.4 F56F11.4 N
WBGene00001494 H09G03.2 frm-8 Y
WBGene00008239 C50H2.1 fshr-1 Y
WBGene00001499 C26E6.5 fsn-1 Y
WBGene00001674 F18G5.3 gpa-12 N
WBGene00001747 F29F11.6 gsp-1 Y
WBGene00004101 C07G1.5 hgrs-1 Y
WBGene00001979 K05C4.6 hmp-2 N
WBGene00001994 F20B6.8 hpk-1 Y
WBGene00006386 F30F8.8 taf-5 Y
WBGene00018516 F46G11.3 tag-257 Y
WBGene00006523 F26G5.9 tam-1 Y
WBGene00006524 C44H4.5 tap-1 Y
WBGene00006542 T20B12.2 Tbp-1 N
WBGene00018740 F53B3.1 tra-4 N
WBGene00006750 T10A3.1 unc-10 Y
WBGene00006752 ZK524.2 unc-13 Y
WBGene00006742 T02C5.5 unc-2 Y
WBGene00006767 ZK897.1 unc-31 Y
WBGene00006772 C50C3.9 unc-36 Y
WBGene00006894 T17A3.1 ver-1 N
WBGene00006931 T20D3.7 vps-26 Y
WBGene00008402 D2013.2 wdfy-2 Y
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Table 4.2 – Genes found in the Vidal CCSB subnetwork 2. 
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Wormbase	ID Gene	Symbol Gene	Name RIC
WBGene00000836 D2045.6 cul-1 N
WBGene00001179 F28C1.2 egl-10 Y
WBGene00001196 M01D7.7 egl-30 Y
WBGene00001177 B0348.4 egl-8 Y
WBGene00009924 F52B11.1 F52B11.1 N
WBGene00001994 F20B6.8 hpk-1 Y
WBGene00002845 F57B9.2 let-711 N
WBGene00003009 K10B2.1 lin-23 N
WBGene00003818 H15N14.2 nsf-1 N
WBGene00003923 D1054.2 pas-2 N
WBGene00011216 R10E11.3 R10E11.3 Y
WBGene00010556 K04D7.1 rack-1 Y
WBGene00004364 Y22F5A.3 ric-4 Y
WBGene00004503 F23F12.6 rpt-3 Y
WBGene00004816 Y105C5B.13 skr-10 Y
WBGene00004809 F44G3.6 skr-3 Y
WBGene00004897 T10H9.4 snb-1 Y
WBGene00007918 C34C6.5 sphk-1 Y
WBGene00006386 F30F8.8 taf-5 Y
WBGene00044077 T18H9.7 tag-232 Y
WBGene00006542 T20B12.2 Tbp-1 N
WBGene00006750 T10A3.1 unc-10 Y
WBGene00006742 T02C5.5 unc-2 Y
Table 4.3 – Genes found in Wormnet V2 subnetwork 1  
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Wormbase	ID Gene	Symbol Gene	Name RIC
WBGene00003918 F54E7.3 par-3 Y
WBGene00003920 M117.2 par-5 Y
WBGene00022719 ZK370.5 pdhk-2 Y
WBGene00003975 T28D6.9 pen-2 N
WBGene00004032 F57F5.5 pkc-1 Y
WBGene00004034 F09E5.1 pkc-3 Y
WBGene00012348 W08G11.4 pptr-1 N
WBGene00004104 C14C11.8 pqn-13 Y
WBGene00004198 F32A5.6 prx-13 N
WBGene00004192 ZK809.7 prx-2 N
WBGene00004194 C34C6.6 prx-5 Y
WBGene00004210 Y110A2AL.8 ptc-3 Y
WBGene00004254 T14G10.2 pxf-1 N
WBGene00004273 T23H2.5 rab-10 N
WBGene00004308 C25D7.7 rap-2 N
WBGene00004390 K04G7.10 rnp-7 N
WBGene00004413 B0250.1 rpl-2 N
WBGene00004417 R151.3 rpl-6 N
WBGene00004497 Y41D4B.5 rps-28 N
WBGene00004498 B0412.4 rps-29 N
WBGene00004501 C52E4.4 rpt-1 N
WBGene00004505 F56H1.4 rpt-5 N
WBGene00007784 C27H6.2 ruvb-1 Y
WBGene00020687 T22D1.10 ruvb-2 N
WBGene00011392 T03D8.3 sbt-1 N
WBGene00004769 F35H12.3 sel-12 Y
WBGene00004808 F46A9.4 skr-2 N
WBGene00004813 Y47D7A.1 skr-7 Y
WBGene00004927 C05D9.1 snx-1 N
WBGene00004947 T28F12.3 sos-1 Y
WBGene00005022 F29F11.1 sqv-4 N
WBGene00006364 F59F5.6 syd-2 Y
WBGene00011449 T04H1.2 t04h1.2 Y
WBGene00020679 T22B11.5 T22B11.5 Y
WBGene00020837 T27A1.5 T27A1.5 Y
WBGene00012126 T28D6.6 T28D6.6 N
WBGene00044063 ZK430.2 tag-231 Y
WBGene00018516 F46G11.3 tag-257 Y
WBGene00006523 F26G5.9 tam-1 Y
WBGene00006524 C44H4.5 tap-1 Y
WBGene00018740 F53B3.1 tra-4 N
WBGene00006931 T20D3.7 vps-26 Y
WBGene00016497 C37C3.3 vps-32.2 Y
WBGene00021334 Y34D9A.10 vps-4 Y
WBGene00008402 D2013.2 wdfy-2 Y
WBGene00007009 Y65B4BR.4 wwp-1 Y
WBGene00021651 Y47G6A.27 Y47G6A.27 Y
WBGene00022027 Y65B4A.3 Y65B4A.3 Y
WBGene00003159 F32D1.10 mcm-7 Y
WBGene00003401 F43C1.2 mpk-1 Y
WBGene00003516 C43E11.6 nab-1 Y
WBGene00007500 C09H10.6 nasp-1 Y
WBGene00006438 C01F6.6 nrfl-1 N
WBGene00003877 K04E7.2 opt-2 Y
Wormbase	ID Gene	Symbol Gene	Name RIC
WBGene00000064 T04C12.5 act-2 N
WBGene00012386 Y6B3A.1 agef-1 Y
WBGene00000161 T20B5.1 apa-2 Y
WBGene00000163 R11A5.1 apb-3 N
WBGene00000150 F55A12.7 apm-1 Y
WBGene00000159 F29G9.3 APS-1 Y
WBGene00000157 F02E8.3 aps-2 Y
WBGene00000195 F53H8.2 arr-1 Y
WBGene00000201 Y79H2A.6 arx-3 Y
WBGene00015194 B0432.13 B0432.13 N
WBGene00000257 F23B12.8 bmk-1 N
WBGene00007912 C34B7.2 C34B7.2 Y
WBGene00016440 C35D10.2 C35D10.2 N
WBGene00012230 W03H9.4 cacn-1 N
WBGene00000405 T05G5.3 cdk-1 N
WBGene00000816 Y55F3AM.15 csn-4 N
WBGene00013709 Y106G6E.6 csnk-1 Y
WBGene00000911 C10C5.6 daf-15 Y
WBGene00012948 Y47H9C.2 dhhc-2 N
WBGene00001005 T26A5.9 dlc-1 Y
WBGene00013583 Y80D3A.3 dlx-1 N
WBGene00001102 C27A2.6 dsh-2 N
WBGene00001136 F13G3.8 eat-5 Y
WBGene00022069 Y67D8C.5 eel-1 Y
WBGene00001184 F58A3.2 egl-15 Y
WBGene00001189 F01D4.4 egl-21 Y
WBGene00017735 F23C8.6 F23C8.6 Y
WBGene00018371 F42H10.7 F42H10.7 N
WBGene00019060 F58F9.7 F58F9.7 N
WBGene00001494 H09G03.2 frm-8 Y
WBGene00008239 C50H2.1 fshr-1 Y
WBGene00001499 C26E6.5 fsn-1 Y
WBGene00008805 F14F3.2 git-1 N
WBGene00001690 R08B4.1 grd-1 N
WBGene00001708 F19C6.1 grk-1 N
WBGene00001745 R06A10.2 gsa-1 Y
WBGene00001746 Y18D10A.5 GSK-3 Y
WBGene00001747 F29F11.6 gsp-1 Y
WBGene00044072 ZK1128.5 ham-3 Y
WBGene00004101 C07G1.5 hgrs-1 N
WBGene00001974 T20B12.8 hmg-4 N
WBGene00001979 K05C4.6 hmp-2 Y
WBGene00002035 F29D10.4 hum-1 Y
WBGene00002132 T18H9.5 inx-10 Y
WBGene00002137 R12E2.9 inx-15 Y
WBGene00002138 R12E2.5 inx-16 Y
WBGene00002130 ZK792.2 inx-8 N
WBGene00010565 K04G2.6 K04G2.6 Y
WBGene00019544 K08F11.5 K08F11.5 Y
WBGene00002201 T17E9.1 kin-18 N
WBGene00002583 B0261.2 let-363 Y
WBGene00002335 ZK792.6 let-60 Y
WBGene00003134 F10C5.1 mat-3 N
WBGene00003912 C38D4.6 pal-1 Y
Table 4.4 – Genes found in the Wormnet V2 subnetwork 2. 
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Wormbase	Gene	ID Gene	Symbol Gene	Name Aldicarb	Phenotype Biological	Process	
WBGene00006750 T10A3.1 unc-10 RIC Synaptic	vesicle	priming,	exocytosis	and	transport,	Synaptic	transmission
WBGene00004364 Y22F5A.3 ric-4 RIC Synaptic	vesicle	priming	and	exocytosis,	Synaptic	transmission
WBGene00001177 B0348.4 egl-8 RIC Acetylcholine	secretion,	Dopamine	receptor	signaling	pathway,	Synaptic	transmission
WBGene00006767 ZK897.1 unc-31 RIC Neurotransmitter	secretion,	Synaptic	vesicle	transport,	Synaptic	transmission
WBGene00006752 ZK524.2 unc-13 RIC Neurotransmitter	secretion,	Synaptic	vesicle	transport,	Synaptic	transmission
WBGene00004913 Y38C1BA.2 snn-1 RIC Neurotransmitter	secretion,	Synaptic	transmission
WBGene00001189 F01D4.4 egl-21 RIC Acetylcholine	Secretion,	Synaptic	transmission
WBGene00002138 R12E2.5 inx-16 RIC Synaptic	transmission
WBGene00006364 F59F5.6 syd-2 RIC Synaptic	vesicle	transport,	Synaptic	transmission
WBGene00001745 R06A10.2 gsa-1 RIC Dopamine	receptor	signaling	pathway
WBGene00001179 F28C1.2 egl-10 RIC Dopamine	receptor	signaling	pathway
WBGene00001680 F52A8.2 gpb-2 Unknown Dopamine	receptor	signaling	pathway
Table 4.6 – Neurological pathways found to be enriched when merged lists of genes from all subnetworks were analysed in DAVID.  
 
Table 4.5 – Top ranked KEGG pathways identified by DAVID functional enrichment analysis, using standard parameters with genes from all identified 
modules  analysed. 
 
KEGG	Pathway Number	of	Genes Gene	Name(s)
Endocytosis			 15 aps-2,	arr-1,	ver-1,	cdc-42,	par-3,	hgrs-1,		vps-32.2,	did-2,	vps-20,	par-6,	vps-4,	wwp-1,	grk-1,	pkc-3,	apa-2
Wnt	signaling	pathway	 13 let-92,	skr-7,	ruvb-1,	skr-8,	gsk-3,	egl-8,	skr-3,	skr-2,	hmp-2,	pptr-1,	lin-23,	cul-1,	skr-10		
TGF-beta	signaling	pathway	 8 let-92,	skr-7,	skr-8,	skr-3	skr-2,	cul-1,	skr-10,	mpk-1		
MAPK	signaling	pathway	 10 unc-2,	gpa-12,	let-60,	arr-1,	sos-1,	cdc-42,	unc-36.	sem-5,	mpk-1,	kin-18	
ErbB	signaling	pathway		 7 aap-1,	let-60,	gsk-3,	sos-1,	let-363,	sem-5,	mpk-1		
Progesterone-mediated	oocyte	maturation	 7 aap-1,	cdk-1,	let-60,	gpa-16,	mat-3,	daf-21,	mpk-1		
Natural	killer	cell	mediated	cytotoxicity	 5 aap-1,	let-60,	sos-1,	sem-5,	mpk-1		
Dorso-ventral	axis	formation	 4 let-60,	sos-1,	sem-5,	mpk-1		
Ubiquitin	mediated	proteolysis	 10 eel-1,	skr-7,	skr-8,	skr-3,	skr-2,	lin-23,	mat-3,	cul-1,	wwp-1,	skr-10		
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When analyzing biological enrichment, some of the affected genes were found to 
be associated with neurological ‘biological processes’ (Table 4.6). Four genes were 
found in the dopamine receptor-signaling pathway, including egl-10 (F28C1.2), 
gsa-1 (R06A10.2), egl-8 (B0348.4) and gpb-2 (F52A8.2). Of these only gpb-2 was 
not previously known to cause a RIC phenotype. Nine further genes were 
generally involved in synaptic transmission. These were unc-10 (T10A3.1), ric-4 
(Y22F5A.3), egl-8 (B0348.4), unc-31 (ZK897.1), unc-13 (ZK524.2), snn-1 
(Y38C1BA.2), egl-21 (F01D4.4), inx-16 (R12E2.5) and syd-2 (F59F5.6). Some of 
these genes also had more specific neurological process association. This analysis 
provides further support to the fact that the predicted modules may well contain 
potentially novel regulators, or effectors of synaptic function, as hypothesized by 
the principle of “guilt-by-association”. 
Gene	Symbol Wormbase	ID Gene	Name RNAi
WBGene00001102 C27A2.6 dsh-2 Yes
WBGene00004498 B0412.4 rps-29 Yes
WBGene00016250 C30C11.4 hsp-110 Yes
WBGene00001708 F19C6.1 grk-1 Yes
WBGene00000001 Y110A7A.10 aap-1 Yes
WBGene00000479 C07H6.5 cgh-1 Yes
WBGene00019834 R02F2.5 Yes
WBGene00004034 F09E5.1 pkc-3 Yes
WBGene00001680 F52A8.2 gpb-2 Yes
WBGene00004927 C05D9.1 snx-1 Yes
WBGene00004505 F56H1.4 rpt-5 Yes
WBGene00004308 C25D7.7 rap-2 Yes
WBGene00004198 F32A5.6 prx-13 Yes
WBGene00004856 ZK370.2 sma-2 Yes
WBGene00019893 R05F9.10 sgt-1 Yes
WBGene00004808 F46A9.4 skr-2 Yes
WBGene00006405 Y116A8C.36 itsn-1 Yes
WBGene00003921 T26E3.3 par-6 Yes
WBGene00018991 F56F11.4 Yes
WBGene00020687 T22D1.10 ruvb-2 Yes
WBGene00000089 Y87G2A.4 aex-6 Yes
WBGene00008805 F14F3.2 git-1 Yes
WBGene00003923 D1054.2 pas-2 Yes
WBGene00013583 Y80D3A.3 ceh-51 Yes
WBGene00044072 ZK1128.5 ham-3 Yes
WBGene00004774 C14F5.5 sem-5 Yes
WBGene00005022 F29F11.1 sqv-4 Yes
WBGene00004153 T23F1.6 pqn-71 Yes
WBGene00002363 F38H4.9 let-92 Yes
WBGene00004307 C27B7.8 rap-1 Yes
WBGene00000405 T05G5.3 cdk-1 Yes
WBGene00004390 K04G7.10 rnp-7 Yes
WBGene00003916 H39E23.1 par-1 Yes
WBGene00000390 R07G3.1 cdc-42 Yes
WBGene00015516 C06A8.6 Yes
WBGene00003159 F32D1.10 mcm-7 Yes
WBGene00000836 D2045.6 cul-1 Yes
WBGene00012230 W03H9.4 cacn-1 Yes
WBGene00016197 C28H8.6 pxl-1 Yes
WBGene00019060 F58F9.7 Yes
WBGene00004194 C34C6.6 prx-5 Yes
WBGene00001674 F18G5.3 gpa-12 Yes
WBGene00008764 F13G3.4 dylt-1 Yes
WBGene00004417 R151.3 rpl-6 Yes
WBGene00004769 F35H12.3 sel-12 Yes
WBGene00018371 F42H10.7 ess-2 Yes
WBGene00000257 F23B12.8 bmk-1 Yes
WBGene00012948 Y47H9C.2 dhhc-2 Yes
WBGene00018740 F53B3.1 tra-4 Yes
WBGene00006542 T20B12.2 tbp-1 Yes
WBGene00008317 C54G4.7 Yes
WBGene00000816 Y55F3AM.15 csn-4 Yes
WBGene00007784 C27H6.2 ruvb-1 Yes
WBGene00004501 C52E4.4 rpt-1 Yes
WBGene00000163 R11A5.1 apb-3 Yes
WBGene00006894 T17A3.1 ver-1 Yes
WBGene00011449 T04H1.2 Yes
WBGene00016440 C35D10.2 gipc-1 Yes
WBGene00001974 T20B12.8 hmg-4 Yes
WBGene00000915 C47E8.5 daf-21 Yes
Gene	Symbol Wormbase	ID Gene	Name RNAi
WBGene00001102 C27A2.6 dsh-2 Yes
WBGene00004498 B0412.4 rps-29 Yes
WBGene00016250 C30C11.4 hsp-110 Yes
WBGene00001708 F19C6.1 grk-1 Yes
WBGene00000001 Y110A7A.10 aap-1 Yes
WBGene00000479 C07H6.5 cgh-1 Yes
WBGene00019834 R02F2.5 Yes
WBGene00004034 F09E5.1 pkc-3 Yes
WBGene00001680 F52A8.2 gpb-2 Yes
WBGene00004927 C05D9.1 snx-1 Yes
WBGene00004505 F56H1.4 rpt-5 Yes
WBGene00004308 C25D7.7 rap-2 Yes
WBGene00004198 F32A5.6 prx-13 Yes
WBGene00004856 ZK370.2 sma-2 Yes
WBGene00019893 R05F9.10 sgt-1 Yes
WBGene00004808 F46A9.4 skr-2 Yes
WBGene00006405 Y116A8C.36 itsn-1 Yes
WBGene00003921 T26E3.3 par-6 Yes
WBGene00018991 F56F11.4 Yes
WBGene00020687 T22D1.10 ruvb-2 Yes
WBGene00000089 Y87G2A.4 aex-6 Yes
WBGene00008805 F14F3.2 git-1 Yes
WBGene00003923 D1054.2 pas-2 Yes
WBGene00013583 Y80D3A.3 ceh-51 Yes
WBGene00044072 ZK1128.5 ham-3 Yes
WBGene00004774 C14F5.5 sem-5 Yes
WBGene00005022 F29F11.1 sqv-4 Yes
WBGene00004153 T23F1.6 pqn-71 Yes
WBGene00002363 F38H4.9 let-92 Yes
WBGene00004307 C27B7.8 rap-1 Yes
WBGene00000405 T05G5.3 cdk-1 Yes
WBGene00004390 K04G7.10 rnp-7 Yes
WBGene00003916 H39E23.1 par-1 Yes
WBGene00000390 R07G3.1 cdc-42 Yes
WBGene00015516 C06A8.6 Yes
WBGene00003159 F32D1.10 mcm-7 Yes
WBGene00000836 D2045.6 cul-1 Yes
WBGene00012230 W03H9.4 cacn-1 Yes
WBGene00016197 C28H8.6 pxl-1 Yes
WBGene00019060 F58F9.7 Yes
WBGene00004194 C34C6.6 prx-5 Yes
WBGene00001674 F18G5.3 gpa-12 Yes
WBGene00008764 F13G3.4 dylt-1 Yes
WBGene00004417 R151.3 rpl-6 Yes
WBGene00004769 F35H12.3 sel-12 Yes
WBGene00018371 F42H10.7 ess-2 Yes
WBGene00000257 F23B12.8 bmk-1 Yes
WBGene00012948 Y47H9C.2 dhhc-2 Yes
WBGene00018740 F53B3.1 tra-4 Yes
WBGene00006542 T20B12.2 tbp-1 Yes
WBGene00008317 C54G4.7 Yes
WBGene00000816 Y55F3AM.15 csn-4 Yes
WBGene00007784 C27H6.2 ruvb-1 Yes
WBGene00004501 C52E4.4 rpt-1 Yes
WBGene00000163 R11A5.1 apb-3 Yes
WBGene00006894 T17A3.1 ver-1 Yes
WBGene00011449 T04H1.2 Yes
WBGene00016440 C35D10.2 gipc-1 Yes
WBGene00001974 T20B12.8 hmg-4 Yes
WBGene00000915 C47E8.5 daf-21 Yes
Gene	Symbol Wormbase	ID Gene	Name RNAi
11 2 C27A2.6 dsh 2
4 8 B 12.4 rps-29
16250 C30C11.4 hsp 10
1708 F19C6.1 grk-1
00001 Y110A7A.10 aap-1
047 C07H6 5 cgh-1
19 4 R02F2.5
040 4 F09E5.1 pk -3
01680 F52A8.2 gpb-2
04927 C05D .1 snx-1
505 F56H1.4 rpt-5
4308 C25D7 7 rap-2
4198 32A5.6 prx-13
856 ZK370.2 sma-2
19893 R0 F9.10 gt
04808 6A9.4 skr-2
6405 Y116A8C.36 itsn-1
03 21 T26E3.3 par-6
991 6F11.4
20687 2D .10 ruvb-2
0089 Y87 2A.4 aex-6
8 05 F14 .2 git-1
3923 D1054. pas-2
13 83 Y80D3A.3 ceh-51
44072 ZK1128.5 ham-
477 C 4F5.5 sem-5
05022 F29F11.1 sqv-4
04153 T23F1.6 pqn-71
2363 F38H4.9 let-92
4307 2 B7 8 rap 1
WBGene00000405 T05G5.3 cdk-1 Yes
WBGene00004390 K04G7.10 rnp-7 Yes
WBGene00003916 H39E23.1 par-1 Yes
WBGene00000390 R07G3.1 cdc-42 Yes
WBGene00015516 C06A8.6 Yes
WBGene00003159 F32D1.10 mcm-7 Yes
WBGene00000836 D2045.6 cul-1 Yes
WBGene00012230 W03H9.4 cacn-1 Yes
WBGene00016197 C28H8.6 pxl-1 Yes
WBGene00019060 F58F9.7 Yes
WBGene00004194 C34C6.6 prx-5 Yes
WBGene00001674 F18G5.3 gpa-12 Yes
WBGene00008764 F13G3.4 dylt-1 Yes
WBGene00004417 R151.3 rpl-6 Yes
WBGene00004769 F35H12.3 sel-12 Yes
WBGene00018371 F42H10.7 ess-2 Yes
WBGene00000257 F23B12.8 bmk-1 Yes
WBGene00012948 Y47H9C.2 dhhc-2 Yes
WBGene00018740 F53B3.1 tra-4 Yes
WBGene00006542 T20B12.2 tbp-1 Yes
WBGene00008317 C54G4.7 Yes
WBGene00000816 Y55F3AM.15 csn-4 Yes
WBGene00007784 C27H6.2 ruvb-1 Yes
WBGene00004501 C52E4.4 rpt-1 Yes
WBGene00000163 R11A5.1 apb-3 Yes
WBGene00006894 T17A3.1 ver-1 Yes
WBGene00011449 T04H1.2 Yes
WBGene00016440 C35D10.2 gipc-1 Yes
WBGene00001974 T20B12.8 hmg-4 Yes
WBGene00000915 C47E8.5 daf-21 Yes
Tabl  4.7 – List of module genes to be test d in aldicarb-s sitivity screens. Gene information was 
collated from Wormbase, showing availability of corresponding RNAi clones in the Vidal dsRNA 
feeding library. 
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To functionally test the predicted set of novel synaptic effectors, the higher 
throughput aldicarb-sensitivity assay was used to test proteins in each module 
that did not have a known aldicarb-sensitivity phenotype. Table 4.7 shows a list of 
the candidate genes for which dsRNA clones were available, and thus were used 
to knock down of target genes in the Tu3311 strain. In total, 60 genes were 
identified, that did not have known RIC phenotypes, but did have available dsRNA 
clones.  
 
4.3.2 Screening of module analysis hits 
 
In order to assess aldicarb sensitivity, adult worm paralysis was assessed as 
described in Materials and Methods. Results from module informed aldicarb 
sensitivity screens are shown in Figure 4.2 and percentage changes in paralysis 
and corresponding p-values are provided in Table 4.8. Sixteen of the tested 
candidates showed a significant (p<0.05) RIC or HIC paralysis phenotype 
compared to the negative control. Gpb-2 was previously associated with the 
dopamine receptor signaling pathway and displayed a significant (p<0.01, n = 3) 
RIC phenotype when knocked down with a -59.4±16.4% (mean±SD) reduction 
paralysis compared to the negative control. 
 
 
Chapter 4: Sodium Valproate (VPA) 
 191 
 
 
 
Figure 4.2 – Results from aldicarb sensitivity screening following RNAi mediated 
knockdown of module genes in Tu3311 neurosensitive worms. Adult worm 
paralysis was assessed as described in Materials and Methods. The percentage change 
in paralysis for each gene is shown in comparison to a L440 empty vector negative 
control. * denotes  p<0.05. N=3. Error bars represent standard deviation. 
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 Gene	Symbol Gene	Name Wormbase	Gene	ID %	Change	Compared	to	L440 Standard	Deviation P	Value Significant?
C07H6.5 cgh-1 WBGene00000479 -76.82838585 21.30124181 0.0037 Yes
C27H6.2 ruvb-1 WBGene00007784 -62.09313296 7.492181256 0.0013 Yes
C28H8.6 pxl-1 WBGene00016197 96.55589509 32.11783875 0.0011 Yes
C52E4.4 rpt-1 WBGene00004501 -82.86327143 14.88159377 0.0008 Yes
F13G3.4 dylt-1 WBGene00008764 99.23844808 45.90871086 0.0152 Yes
F19C6.1 grk-1 WBGene00001708 -81.55870156 16.55655272 0.0012 Yes
F32A5.6 prx-13 WBGene00004198 -52.1762157 14.72709623 0.0322 Yes
F35H12.3 sel-12 WBGene00004769 -80.58504875 18.1313949 0.003 Yes
F38H4.9 let-92 WBGene00002363 -71.71743172 26.2659172 0.0097 Yes
F46A9.4 skr-2 WBGene00004808 -51.34840963 31.5754137 0.0495 Yes
F52A8.2 gpb-2 WBGene00001680 -59.40762321 16.43420336 0.0087 Yes
F58F9.7 f58f9.7 WBGene00019060 -34.98756563 21.4650472 0.0487 Yes
H39E23.1 par-1 WBGene00003916 -73.8984699 20.60631898 0.0038 Yes
T04H1.2 t04h1.2 WBGene00011449 -64.79288222 21.49648609 0.0271 Yes
T22D1.10 ruvb-2 WBGene00020687 -64.88204141 9.664656666 0.0145 Yes
Y47H9C.2 dhhc-2 WBGene00012948 -51.49943237 21.58105518 0.0485 Yes
B0412.4 rps-29 WBGene00004498 -27.68788725 33.62070055 0.2792 No
C05D9.1 snx-1 WBGene00004927 -51.25989431 43.61084793 0.1189 No
C06A8.6 c06a8.6 WBGene00015516 7.575116539 45.23460869 0.7853 No
C14F5.5 sem-5 WBGene00004774 17.88625268 49.64437347 0.5596 No
C25D7.7 rap-2 WBGene00004308 -15.76058606 25.22280893 0.3537 No
C27A2.6 dsh-2 WBGene00001102 3.414757129 61.73821005 0.9282 No
C27B7.8 rap-1 WBGene00004307 -35.04265965 37.60819153 0.1895 No
C30C11.4 hsp-110 WBGene00016250 -38.47456479 36.85940032 0.147 No
C34C6.6 prx-5 WBGene00004194 -21.14854258 37.71704796 0.3882 No
C35D10.2 gipc-1 WBGene00016440 -5.988182379 23.63564031 0.6909 No
C47E8.5 daf-21 WBGene00000915 -10.18810728 17.47946636 0.3715 No
D1054.2 pas-2 WBGene00003923 7.444820925 29.88498153 0.6835 No
D2045.6 cul-1 WBGene00000836 -15.38450015 46.31498902 0.5967 No
F14F3.2 git-1 WBGene00008805 -37.4745888 36.33959935 0.1962 No
F18G5.3 gpa-12 WBGene00001674 -53.30731189 30.65471603 0.0754 No
F23B12.8 bmk-1 WBGene00000257 10.81587591 51.23120394 0.7307 No
F29F11.1 sqv-4 WBGene00005022 24.99437793 32.32523605 0.2394 No
F32D1.10 mcm-7 WBGene00003159 -13.00734953 21.34065003 0.3748 No
F35H12.5 f35h12.5 WBGene00018077 32.7878975 60.57506843 0.3964 No
F42H10.7 ess-2 WBGene00018371 -33.43209511 23.90613011 0.1384 No
F52B11.1 cfp-1 WBGene00009924 -44.58160809 23.76081867 0.0781 No
F53B3.1 tra-4 WBGene00018740 4.576890886 20.79287431 0.7223 No
F56F11.4 f56f11.4 WBGene00018991 -13.008422 35.70541702 0.5856 No
F56H1.4 rpt-5 WBGene00004505 35.56149733 49.74307477 0.2672 No
K04G7.10 rnp-7 WBGene00004390 -26.79826673 28.21375797 0.2408 No
R02F2.5 r02f2.5 WBGene00019834 10.57148059 38.37121559 0.6551 No
R05F9.10 sgt-1 WBGene00019893 -55.44122754 37.5878478 0.0644 No
R07G3.1 cdc-42 WBGene00000390 23.55634169 52.72059453 0.4734 No
R11A5.1 apb-3 WBGene00000163 13.197378 19.04167007 0.2571 No
R151.3 rpl-6 WBGene00004417 -8.709337281 8.247828919 0.1516 No
T05G5.3 cdk-1 WBGene00000405 -6.99967881 21.55535016 0.615 No
T17A3.1 ver-1 WBGene00006894 8.717401454 18.05974785 0.4492 No
T20B12.2 tbp-1 WBGene00006542 -6.567992599 8.285119891 0.2451 No
T20B12.8 hmg-4 WBGene00001974 -35.16546301 40.80127926 0.2539 No
T23F1.6 pqn-71 WBGene00004153 -35.86646848 23.58717037 0.063 No
T26E3.3 par-6 WBGene00003921 -39.52816562 16.72639659 0.0665 No
W03H9.4 cacn-1 WBGene00012230 13.42890241 79.41563912 0.7836 No
Y110A7A.10 aap-1 WBGene00000001 10.71231799 25.21273348 0.4855 No
Y116A8C.36 itsn-1 WBGene00006405 -36.79987161 17.56030829 0.0807 No
Y48B6A.4 eat-2 WBGene00001133 -31.22982676 24.67303678 0.0946 No
Y55F3AM.15 csn-4 WBGene00000816 12.67345051 62.28587316 0.7424 No
Y80D3A.3 dlx-1 WBGene00013583 -32.88753799 37.30082716 0.2025 No
Y87G2A.4 aex-6 WBGene00000089 -43.19109546 16.0955386 0.0515 No
ZK1128.5 ham-3 WBGene00044072 17.9452376 34.54485796 0.3622 No
ZK370.2 sma-2 WBGene00004856 32.15586307 27.4714632 0.0825 No
Table 4.8 – Background data for phenotypic trends shown in Figure 4.2. 
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Due to the limited predictive power to elucidate novel effectors as discussed in 
chapter 3, more vigorous methods for determining whether a genetic knockdown 
may lead to a significant RIC or HIC phenotype were adopted. To do this, as well 
as independently validating the genes found to cause a significant RIC or HIC 
phenotype, borderline candidates were also analysed. This was both through the 
use of an independent screen and also through the use of the alternative Tu3335 
strain, which is reported to be more sensitive to neuronal RNAi than Tu3311 (but 
has an additional mutation in mec-6). 
 
In order to gain confidence in the assay and worm strains chosen for the analyses, 
some of the positive hits from the initial screen in Tu3311 (Chapter 3) were re-
tested.  When choosing borderline candidates to re-test, genes were picked that 
showed a greater than 20% absolute change in paralysis compared to the negative 
control.  However, variability between plates in this sub set of assays was high, 
resulting in insignificant p-values. Therefore, secondary independent testing was 
carried out on positive hits, as well as candidates that originally showed high 
variability, but had high average percentage changes compared to a negative 
control. For example, these included gpa-12 (-53±30.7%, mean±SD), rap-1 (-
35±37.6%), and itsn-1 (-37±7.6%) (Table 4.8). Finally, genes that showed less 
than 20% change in aldicarb-sensitivity but high variability between replicates 
(cacn-1 and csn-4) were also included in these secondary screens. In each case 
genes were again knocked down in the Tu3311 strain. However, in this case a two 
time-point aldicarb-sensitivity assay was used to assess the relative percentage of 
paralyzed worms. The additional time points chosen for this assay were 140 and 
160 minutes.  To compensate for worm batch variability in rates of paralysis, we 
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considered a positive phenotype to be reproducible if two out of three selected 
time points (100, 140 and 160 minutes) showed significant changes in paralysis 
relative to the batch control.  Unfortunately, skr-2 and F58F9.7 knockdown were 
unable to be re-screened due to technical issues. 
 
 Figure 4.3 and Tables 4.9 and 4.10 show the relative paralysis phenotypes 
following knockdown of each target gene, at both 140 and 160 minutes. In total, 
14 genes showed a significant change in paralysis in at least two of the three time 
points tested (Table 4.11). All displayed a significant RIC phenotype, with the 
exception of dylt-1, whose knockdown caused a significant HIC phenotype.  
 
4.3.3 Re-screening candidates in the Tu3335 strain 
 
After the second screening of module genes in Tu3311, large changes in standard 
deviation and large percentage changes in paralysis (>20%) for some genes were 
still being observed. For this reason the alternate Tu3335 strain was used to assess 
phenotypes following gene knockdown, as it is claimed to be more sensitive to 
neuronal RNAi than Tu3311. 
As an initial test, four of the genes (sel-12, ruvb-1, ruvb-2 and itsn-1) that 
previously showed a strong change in aldicarb sensitivity when knocked down in 
the Tu3311 strain were re-screened in Tu3335, as well as egl-30, which was 
included as a positive control. Knockdown of all of these genes also lead to 
significant changes in aldicarb sensitivity in the Tu3335 worm strain (Figure 4.4 
and Table 4.12).  
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Figure 4.3 - Genes showing a significant change in paralysis at 140 minutes following RNAi mediated knockdown in Tu3311 . Paralysis of 
adult worms was assessed as described in Materials and Methods. The percentage change in paralysis for each gene is shown in comparison to a 
L440 empty vector negative control. * denotes  p<0.05. N=3. Error bars represent standard deviation. 
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Table 4.9 – Data associated with phenotypic trends observed at the 140 minute time points shown in Figure 4.3. 
 
Gene	Symbol Gene	Name %	Change	in	Paralysis	at	140	Minutes Standard	Deviation	140	Minutes P	Value	140	Minutes Significant	at	140	Minutes?
C52E4.4 rpt-1 -47.84382284 19.71845279 0.0377 Yes
C07H6.5 cgh-1 -62.35246235 12.03083555 0.01 Yes
F38H4.9 let-92 -56.78155754 39.22318268 0.0103 Yes
C05D9.1 snx-1 -60.93669363 8.211252701 0.0392 Yes
C28H8.6 pxl-1 -46.88403881 9.345544622 0.088 Yes
C27H6.2 ruvb-1 -48.3047007 9.983682395 0.0017 Yes
F35H12.3 sel-12 -67.31526898 3.190623489 0.0128 Yes
Y47H9C.2 dhhc-2 -45.27472527 23.80872318 0.0661 No
T04H1.2 t04h1.2 -65.10220549 5.512786697 0.0102 Yes
F18G5.3 gpa-12 -42.89044289 9.287932933 0.0438 Yes
T22D1.10 ruvb-2 -61.99245802 7.30078279 0.0001 Yes
W03H9.4a cacn-1 -53.88266249 2.426084822 0.0002 Yes
C27B7.8 rap-1 -56.6784704 6.89420201 0.0293 Yes
Y116A8C.36 itsn-1 -71.86728792 8.689874688 0.0053 Yes
F13G3.4 dylt-1 75.29069767 25.2670397 0.0138 Yes
F52A8.2 gpb-2 -47.38920802 34.86845931 0.0824 No
H39E23.1 par-1 -11.89992361 25.37967305 0.4467 No
F19C6.1 grk-1 -15.92538804 24.18595659 0.2773 No
C30C11.4 hsp-110 -26.18492618 19.42914968 0.1359 No
Y87G2A.4 aex-6 -43.57565511 30.52554186 0.1074 No
F32A5.6 prx-13 6.424825175 31.59512781 0.7325 No
Y55F3AM.15 csn-4 -14.64038643 36.90029831 0.4447 No
0 8	
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Table 4.10 - Data associated with phenotypic trends observed at the 160 minute time points shown in Figure 4.3. 
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Gene	Symbol Gene	Name 100	Minute 140	Minute 160	Minute Overall
C52E4.4 rpt-1 Yes Yes No Yes
C07H6.5 cgh-1 Yes Yes Yes Yes
F38H4.9 let-92 Yes Yes No Yes
C05D9.1 snx-1 No Yes Yes Yes
C28H8.6 pxl-1 Yes Yes No Yes
C27H6.2 ruvb-1 Yes Yes Yes Yes
F35H12.3 sel-12 Yes Yes Yes Yes
Y47H9C.2 dhhc-2 Yes No Yes Yes
T04H1.2 t04h1.2 Yes Yes Yes Yes
F18G5.3 gpa-12 No Yes Yes Yes
T22D1.10 ruvb-2 Yes Yes Yes Yes
W03H9.4a cacn-1 No Yes Yes Yes
Y116A8C.36 itsn-1 No Yes Yes Yes
F13G3.4 dylt-1 Yes Yes Yes Yes
F52A8.2 gpb-2 Yes No No No
H39E23.1 par-1 Yes No No No
F19C6.1 grk-1 Yes No No No
C30C11.4 hsp-110 No No Yes No
Y87G2A.4 aex-6 No No No No
F32A5.6 prx-13 Yes No No No
Y55F3AM.15 csn-4 No No No No
C27B7.8 rap-1 No Yes No No
Table 4.11 – Summary of aldicarb screens carried out on candidates from the module 
analysis screen. The 100 minute time point was assessed in a primary assay, while 
the 140 and 160 minute time points were analysed in an independent secondary 
assay. Yes and NO indicate if the calculated p value was less or greater than 0.05 
respectively. If genetic knockdown of a target led to a significant result in two of the 
three time points, it is indicated a positive overall hit. 
 
100	minutes 140	minutes
Gene	Symbol Gene	Name %	change Stdev P	value %	change Stdev P	Value
L440 L440 0 1.51391012 - 0 1.7719606
egl-30 M01D7.7 -100 0 <0.0001 -97.400249 2.59990028 <0.0001
sel-12 F35H12.3 -47.174452 7.84753486 0.0039 -41.839849 5.9743545 0.0024
ruvb-1 C27H6.2 -72.586412 15.8299626 0.0102 -69.582909 16.3816698 0.0133
ruvb-2 T22D1.10 -61.992458 4.21510891 0.0001 -50.394073 9.78858914 0.007
itsn-1 Y116A8C.36 -41.016473 13.7067805 0.0404 -40.65785 7.86515104 0.007
Table 4.12 – Data relating to phenotypic trends shown in figure 4.4. 
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Figure 4.4 – Phenotypic trends in aldicarb-sensitivity following knockdown of a 
selection positive controls in Tu3335. Adult worm paralysis was assessed at 100 
and 140 minutes as described in Materials and Methods. In each case, percentage 
change in paralysis is shown compared to a L440 empty vector negative control. * 
denotes  p<0.05. N=3. Error bars represent standard deviation. 
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Having confirmed the potential utility of Tu3335, a selection of candidate genes 
were selected for retesting if they were close to showing a significant RIC or HIC 
phenotype, or if two of the three plates of worms showed greater than 20% change 
in paralysis. Figure 4.5 and Table 4.13 show the results from these screens, which 
show that knockdown of grk-1 (F19C6.1) led to a significant RIC phenotype, while 
hmg-4 (T20B12.8) knockdown caused a HIC phenotype. 
 
Brief descriptions of genes showing a positive phenotype are shown in Table 4.14, 
while Table 4.15 lists their closest human orthologs, which were identified using 
DIOPT fly RNAi (Hu et al., 2011). Overall, sixteen of the novel candidate genes 
caused a significant change in aldicarb-sensitivity when knocked down in Tu3311 
and/or Tu3335 worms.  
Gene	Symbol Gene	Name %	change Standard	Deviation P	value
egl-30 M01D7.7 -88.569533 4.133951837 0.0139
rpt-5 F56H1.4 6.45576533 42.25505538 0.8133
hmg-4 T20B12.8 59.9911583 36.34373235 0.0194
cfp-1 F52B11.1 -9.1217549 39.12498281 0.6981
eat-2 Y48B6A.4 -15.708812 46.05780195 0.6018
F58F9.7 F58F9.7 5.8994152 33.85705879 0.5288
grk-1 F19C6.1 -54.052583 9.49864401 0.0424
dlx-1 Y80D3A.3 -6.325952 18.6980827 0.7624
cacn-1 W03H9.4 -23.720108 13.08339314 0.2325
skr-2 F46A9.4 -38.37181 12.66186478 0.1016
sgt-1 R05F9.10 -0.0478141 19.47208174 0.9975
Table 4.13 – Data relating to phenotypic trends shown in Figure 4.5. Hmg-4 and 
grk-1 lead to significant HIC and RIC phenotypes, respectively. 
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Gene	Symbol Gene	Name Brief	Description	(From	Wormbase)
C05D9.1 snx-1 Encodes	the	ortholog	of	VPS5/SNX1	subunit	of	the	core	retromer	complex.	Regulates	retrograde	endosome-to-golgi	trafficking
C07H6.5 cgh-1 Encodes	a	putative	RNA	helicase,	which	is	expected	to	enable	decapping-dependent	mRNA	degradation
C27H6.2 ruvb-1 Encodes	a	AAA+	ATPase	and	functions	as	a	component	of	the	TOR	signaling	pathway,	which	enables	robust	protein	synthesis.
C28H8.6 pxl-1 Required	for	organized	myofilament	structure	in	the	pharynx	and	pharyngeal	muscle
C52E4.4 rpt-1 Encodes	a	predicted	ATPase	subunit	of	the	19s	complex	of	the	proteasome
F13G3.4 dylt-1 May	negatively	regulate	dynein,	and	encodes	a	putative	light	chain	subunit	of	dynein
F18G5.3 gpa-12 Encodes	a	member	of	the	G	Protein	alpha	subunit	family.	Functions	upstream	of	PLC-3	and	EGL-8,	as	well	as	TPA-1	in	pathways	regulating	feeding	and	growth.
F19C6.1 grk-1 Encodes	a	Serine/Threonine	Protein	kinase,	closely	resembling	G	Protein	Coupled	Receptor	(GPCR)	kinases.
F35H12.3 F35H12.3 Encodes	a	transmembrane	protein	orthologous	to	presenilins.	During	development,	may	positively	regulate	the	lin-12	and	glp-1	notch	signaling	pathways.
F38H4.9 let-92 Encodes	the	catalytic	subunit	of	protein	phosphatase	2a.	Required	for	embryogenesis,	larval	development,	axonal	guidance	in	the	DD	and	VD	neurons
T04H1.2 t04h1.2 Encodes	the	ortholog	of	human	GTPBP2.
T20B12.8 hmg-4 Predicted	to	be	a	member	of	the	FACT	(Facilitates	Chromatin	Transcription)	complex,	and	acts	as	a	transcription	elongation	factor.
T22D1.10 ruvb-2 Involved	in	RNAi,	locomotion,	development	and	receptor-mediated	endocytosis.	Predicted	to	have	ATP	binding	and	DNA	helicase	activity.
W03H9.4 cacn-1 Encodes	the	ortholog	of	Drosophila	CACTIN.	Required	for	distal	tip	migration	and	normal	growth.
Y116A8C.36 itsn-1 An	endocytic	adaptor	protein.	Required	for	synaptic	vesicle	recycling.
Y47H9C.2 dhhc-2 Palmitoyl-acyl	transferase	involved	in	the	determination	of	adult	lifespan.
Table 4.14 – Brief description of module genes that confer changes in aldicarb sensitivity following RNAi mediated knockdown in Tu3311 or 
Tu3335 worms. Data was mined from Wormbase. 
 
Worm	Gene	Symbol Worm	Gene	Name Wormbase	Gene	ID Human	Gene	Symbol Human	Gene	ID
C05D9.1 snx-1 WBGene00004927 SNX2 6643
C07H6.5 cgh-1 WBGene00000479 DDX6 1656
C27H6.2 ruvb-1 WBGene00007784 RUVBL1 8607
C28H8.6 pxl-1 WBGene00016197 PXN 5829
C52E4.4 rpt-1 WBGene00004501 PSMC2 5701
F13G3.4 dylt-1 WBGene00008764 DYNLT3 6990
F18G5.3 gpa-12 WBGene00001674 GNA12 2768
F19C6.1 grk-1 WBGene00001708 GRK5 2869
F35H12.3 sel-12 WBGene00004769 PSEN2 5664
F38H4.9 let-92 WBGene00002363 PPP2CA 5515
T04H1.2 t04h1.2 WBGene00011449 GTPBP2 54676
T20B12.8 hmg-4 WBGene00001974 SSRP1 6749
T22D1.10 ruvb-2 WBGene00020687 RUVBL2 10856
W03H9.4 cacn-1 WBGene00012230 CACTIN 58509
Y116A8C.36 itsn-1 WBGene00006405 ITSN1 6453
Y47H9C.2 dhhc-2 WBGene00012948 zdhhc9 79683
Table 4.15 – Human orthologs of genes from the module 
analysis screen that caused a significant change in 
aldicarb-sensitivity. Orthologs were elucidated using 
DIOPT FlyRNAi. 
 
Chapter 4: Sodium Valproate (VPA) 
 202 
4.3.4 Data mining of module hits 
 
SynaptomeDB was used to query whether any of the human orthologs of worm 
proteins found to be novel effectors of synaptic function were known to be 
localised pre- or post-synaptically. As shown in Table 4.16, five of the novel 
effector genes (cgh-1 (C07H6.5), let-92 (F38H4.9), snx-1 (C05D9.1), ruvb-1 
(C27B7.8) and itsn-1 (Y116A8C.36)) were localized postsynaptically, while one 
gene (gpa-12 (F18G5.3)) was localised pre-synaptically.  
 
 
 
 
 
 
 
The network used with the microarray data set was a simplified version of 
Wormnet version 2 and the CCSB interactome, created previously in the 
Sanderson group. As the network is a one-step RIC network, this led us to query 
whether any of the nodes tested were previously known to cause a HIC phenotype. 
Interestingly, itsn-1 (Y116A8C.36) has been shown to have this phenotype. 
However, in this study, a clear RIC phenotype was observed with a 71 and 65% 
decrease paralysis at 140 and 160 minutes (Table 4.9 and 4.10). This highlights 
possible strain-differences in observed phenotypes. 
 
Table 4.16 – Human orthologs of the genes from the module analysis screen 
that caused a significant change in aldicarb-sensitivity, which were found in 
the SynatomeDB.  
 
Gene	Name Human	Gene	Symbol Synapse	Localization
cgh-1 DDX6 PostSynaptic
let-92 PPP2CA PostSynaptic
snx-1 SNX2 PostSynaptic
gpa-12 GNA12 PostSynaptic
itsn-1 PostSynaptic PostSynaptic
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The list of module derived genes that caused RIC or HIC phenotypes were entered 
into DAVID for functional enrichment analysis. Three genes were found to have 
links to pathways previously found in the modules – Wnt, TGF-β and MAPK 
signaling. GPA12 is linked to MAPK signaling, let-92 is linked to both Wnt and TGF-
β, and RUVB1 is linked to Wnt signaling. Also, three of the 16 orthologs have 
known disease association. There are many sequence variants of GNA-12 that lead 
to diversity of human height. Notably, PSEN2 encodes presenilin-2, and is linked 
with type 4 Alzheimer’s disease, as well as cardiomyopathy.  ZDHHC9 encodes a 
palmitoyl-acyl transferase required for N- and H-Ras palmitoylation, and 
mutations in this gene are associated with X-linked mental retardation.  
 
4.3.5 Updating the C. elegans aldicarb network 
 
The novel effectors of aldicarb-sensitivity were annotated on the merged 
Wormnet and Vidal interactome (Chapter 3, section 3,3.4), and a one-step aldicarb 
network was created. This network contained 4536 nodes and 14200 edges 
(Figure 4.6). A one-step network was also created from the module derived 
positive hits, in order to reveal patterns of connectivity to known RIC and HIC 
proteins. Four of the interacting partners (other than itsn-1) were known to be 
HIC, and 31 have RIC phenotypes (Table 4.17). This generated a network of 1203 
nodes and 1478 edges (Figure 4.7).  Although there were no overlapping hits 
between the previous screens and this study, some of the hits were found to be 
interacting partners of the positive effectors from our module analysis, and 21 of 
the connectivity and betweenness hits were also found to interact with hits from 
the functional module screens (Table 4.18). 
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Figure 4.6 – Updated one-step aldicarb sensitivity network. Red nodes indicate RIC genes, 
Blue nodes represent HIC genes and Purple nodes are the novel hits from the module screen. 
The previously known RIC and HIC genes were collated from Wormbase. A spring-embedded 
layout was used to generate this network in Cytoscape. 
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Figure 4.7 – One-step network of module hits. Purple nodes represent module genes that 
induced a significant change in aldicarb sensitivity following RNAi knockdown. Red nodes 
represent genes that were known to cause a RIC phenotype, and Blue nodes are genes known to 
cause a HIC phenotype. Grey nodes represent interaction partners of module proteins. A merge 
of Wormnet version 3 and the worm interactome were used to identify one-step interaction 
partners for module proteins. 
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4.3.6 Analysis of Microarray Data 
 
The previous analysis, which led to the GSEA and module generation, examined 
changes in gene expression, i.e. whether genes were increased or decreased to a 
similar level in response to different concentrations of VPA. In this study, the 
microarray data was re-analysed to determine which genes were significantly up 
Gene	Symbol Gene	Name Aldicarb	Phenotype Connected	Gene	Name(s)	found	in	Module
C01G6.8 cam-1 RIC ruvb-2
C10C5.6 daf-16 RIC cgh-1
C32E8.10 unc-11 RIC itsn-1
C50H2.1 fshr-1 RIC grk-1,	gpa-12
D2013.2 wdfy-2 RIC snx-1
F20B6.8 hpk-1 RIC gpa-12
F23F12.6 rpt-3 RIC ruvb-1
F26G5.9 tam-1 RIC t04h1.2
F29D10.4 hum-1 RIC grk-1
F30F8.8 taf-5 RIC grk-1
F37A4.7 rbf-1 RIC dylt-1
F43C1.2 mpk-1 RIC pxl-1,	let-92
JC8.10 dyb-1 RIC itsn-1
K04D7.1 unc-26 RIC cgh-1
M117.2 rack-1 RIC cgh-1
M142.6 par-5 RIC cgh-1
R06A10.2 rle-1 RIC ruvb-1
T12E12.4 gsa-1 RIC cgh-1
T14G10.2 drp-1 RIC ruvb-1
T18H9.7 cav-1 RIC let-92
T20D3.7 pxf-1 RIC rpt-1,	snx-1
T28D6.9 tag-232 RIC sel-12,	let-92
W08G11.4 vps-26 RIC let-92
Y106G6E.6 pen-2 RIC let-92
Y18D10A.5 pptr-1 RIC pxl-1
Y22F5A.3 csnk-1 RIC itsn-1
Y65B4BR.4 gsk-3 RIC cgh-1
Y67D8C.5 ric-4 RIC gpa-12,	ruvb-1
Y6B3A.1 unc-25 RIC gpa-12
Y71H2B.10 rho-1 RIC gpa-12,	ruvb-1
ZK1248.3 wwp-1 RIC rpt-1
T13F2.8 eel-1 HIC ruvb-2
Y37D8A.23 agef-1 HIC let-92
F47G6.1 apb-1 HIC sel-12,	t04h1.2
Y51H4A.3 ehs-1 HIC pxl-1,	gpa-12
Table 4.17 – Table showing known RIC and HIC proteins that interact with novel 
module derived effectors of aldicarb sensitivity. This data correlates with the network 
shown in Figure 4.7.  
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or down regulated compared to the zero VPA control, using a two-fold change 
significance threshold at each concentration (the log2 fold change cut off is set at 
1.). This analysis was performed in R using the limma package, which allows users 
to analyse gene expression data from both microarrays and RNA-seq experiments. 
The microarray data used in this study was generated using the C. elegans (V2) 
Gene Expression Microarray. In brief, data is first read, corrected for background, 
and then normalised before a linear model is fitted to expression data for each 
gene, to determine significant changes in gene expression between conditions. For 
this modeling approach, two matrices are required. The first of these is the design 
matrix, wherein each row corresponds to an array in the experiment. The second 
is the contrast matrix, where the comparisons to be made are written, for example 
the 3mM VPA treatment against the control. After linear model fitting, Limma uses 
the Bayes method to determine standard errors. Here, the concentrations of VPA 
used were 0, 3, 6, 9, 12, 15, 18 and 24mM, and comparisons were made between 
each concentration and zero. 
 
4.3.7 Visualization of microarray data 
 
The pHeatmap package in R was used to generate heatmaps of genes showing 
VPA-induced changes in gene expression. Examples of genes that demonstrate 
increasing levels of expression with VPA concentration are shown in Figure 4.8 A, 
and examples demonstrating downregulation are shown in Figure 4.8 B. 
Chapter 4: Sodium Valproate (VPA) 
 208 
4.3.8 Data mining of microarray lists 
Figure 4.8 – Heatmap of example genes showing A. upregulation and B. 
downregulation for N2 worms treated with increasing concentrations of 
sodium VPA. Microarray data was visualized using the pHeatmap package in R. 
Colours indicate the level of expression of each gene (arbitrary units) at each 
concentration, increasing from blue to red.  
 
A 
B 
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Gene lists were merged using an R script that aggregates rows if the designated 
column is identical (e.g. Wormbase Gene ID). This led to a non-redundant list of 
944 genes that were up regulated, and 306 genes were down regulated following 
exposure to any concentration of VPA (Table 4.19). The probe IDs were converted 
to Wormbase IDs using Biomart. It is important to note that when  converting from 
Agilent to Wormbase IDs, multiple probes may be associated with one gene.  
 
The number of different concentrations at which each gene was found to be 
differentially expressed was then analysed. In all, 22 genes were up regulated at 
every concentration measured, while only one gene (R05H10.7) displayed down 
regulation at all concentrations (Table 4.20). Changes observed for all other genes 
are shown in Supplementary Tables 4.1-4.6. 
VPA	Concentration	(mM) Down-regulated	Genes Up-regulated	Genes
3 1 30
6 23 157
9 51 242
12 178 456
15 224 570
18 302 1057
24 338 1230
Merged 306 921
Table 4.19 – Number of genes that were up or down regulated following 
microarray analysis of N2 worms treated with varying concentrations of VPA. 
Analysis was carried out using R using the limma package. Comparisons were 
made between the gene expression levels at each concentration of VPA against the 
negative control, when zero VPA was used. As there were overlaps in the 
significantly up and down regulated genes, a merged list of genes was created 
where duplicates were removed.  
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Lists of significantly upregulated or downregulated genes were analysed in DAVID 
to establish enrichment of biological processes, molecular functions and perform 
KEGG or PANTHER pathway analysis. 
 
4.3.9 DAVID analysis of downregulated genes 
 
When analysing biological processes enriched in the downregulated gene list, GO 
mappings annotated directly by the source database were used, i.e. parent GO 
terms were not included. Analysis of downregulated genes identified five genes 
Table 4.20 – C. elegans genes found to be regulated for every VPA concentration tested. 
Following microarray analysis of N2 worms treated with varying concentrations of 
VPA, the concentrations at which a given gene was up or down regulated were 
analysed. Those that were significantly changed at each concentration of VPA, in 
comparison to the negative control (when no VPA was used), are listed.  
 
Gene	Name Change Confidence	 Concentrations	Observed
Cyp-13a7 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Ech-9 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Lbp-8 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Pgp-1 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
C40H1.8 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Clec-167 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
F58B4.5 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
K08D8.6 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Cyp-13a4 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Cyp-13a5 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
T16G1.6 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Clec-9 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
ZK896.5 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
C37C3.10 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Asp-12 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
F39E9.1 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
F49F1.7 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
K11H12.4 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Pho-14 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Y45G12C.4 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
Clec-210 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
F33H12.7 UpRegulation 7 18mM|3mM|6mM|9mM|12mM|15mM|24mM
F39E9.1 UpRegulation 7 3mM|6mM|9mM|12mM|15mM|18mM|24mM
R05H10.7 DownRegulation 7 3mM|6mM|9mM|12mM|15mM|18mM|24mM
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with roles in nervous system development (Table 4.21). These were syd-1 
(WBGENE00006363), dex-1 (WBGENE00017028), cwn-2 (WBGENE00000858), 
unc-86 (WBGENE00006818) and syg-2 (WBGENE00007750). Syd-1 was 
negatively regulated at 18mM, dex-1 at 12, 15, 18 and 24mM, syg-2 at 24mM, and 
cwn-2 and unc-86 were down regulated at 12mM VPA. This analysis suggests that 
there are selective changes in gene expression dependent on the concentration of 
VPA used. Significantly, at this range of concentrations, VPA appears to be 
imposing changes in neuronal functions. 
 
Another biological process enrichment tool available in DAVID (BP_FAT) was also 
used, which takes into account parental GO terms, as this may reveal other genes 
involved in neuronal processes. These parental GO terms associated with 
neuronal function are shown in Table 4.22.  From this it can be seen that 20 genes 
are associated (via parental GO terms) to nervous system development. Although 
many are not directly annotated with this GO term, these genes are still valid for 
further analysis. 
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GO	Term Biological	Process Count Worm	Name(s)
GO:0050830 Defense	response	to	gram-positive	bacterium 7 spp-2,	spp-1,	clec-7,	clec-172,	clec-82,	clec-52,	math-38
GO:0006629 Lipid	metabolic	process 11 C40H1.7,	Y49E10.17,	asm-3,	lipl-2,	lipl-1,	C39B5.14,	K03H6.2,	lipl-3,	fat-5,	fat-6,	T10B5.7
GO:0033564 Anterior/posterior	axon	guidance 3 cwn-2,	lad-2,	fmi-1
GO:0005975 Carbohydrate	metabolic	process 8 Y105E8B.9,	chil-23,	glct-2,	H18N23.2,	hex-1,	F11A5.5,glct-4,	T19H5.6
GO:0045087 Innate	immune	response 11 R07C12.1,	spp-1,	thn-1,	ZC262.9,	clec-170,	clec-172,	K08D10.14,	clec-86,	clec-82,	fat-6,	R07C12.3
GO:0016358 Dendrite	development 4 unc-52,	unc-86,	W03D8.8,	dma-1
GO:0007399 Nervous	system	development 5 syd-1,	dex-1,	cwn-2,	unc-86,	syg-2
GO:0007413 Axonal	fasiculation 5 ten-1,	plx-2,syd-9,	Y105E8B.9,	W03D8.8
GO:0042759 Long-chain	fatty	acid	biosynthetic	process 2 fat-5,	fat-6
GO:0009612 Response	to	mechanical	stimulus 3 jnk-1,	unc-86,	glr-1
GO:0007275 Multicellular	organism	development 11 syd-1,	cfz-2,	ceh-32,	ten-1,	ceh-22,	plx-2,	hbl-1,	cwn-2,	fat-5,	daao-1,	fat-6
GO:0016042 Lipid	catabolic	process 3 lipl-2,	lipl-1,	lipl-3
GO:0050650 Chondroitin	sulfate	proteoglycan	biosynthetic	process 2 glct-2,	glct-4
GO:0030204 Chondroitin	sulfate	metabolic	process 2 glct-2,	glct-4
GO:0006952 Defense	response 5 thn-2,	spp-1,	glf-1,	ilys-3,	fmo-2
GO:1904937 Sensory	neuron	migration 2 cfz-2,	cwn-2
GO:0043252 Sodium-independent	organic	anion	transport 2 F47E1.2,	F47E1.4
Neurological	Process Count	 Worm	Name(s)
Neuron	projection	development,	neuron	development,	neuron	differentiation,	neurogenesis 18 cfz-2,	dex-1,	egl-46,	plx-2,	cwn-2,	unc-52,	unc-86,	syd-9,	nab-1,	lron-12,	jnk-1,	ten-1,	Y105E8B.9,	lad-2,	W03D8.8,	syg-2,	fmi-1,	dma-1
Nervous	system	development 20 syd-1,	cfz-2,	egl-46,	dex-1,	plx-2,	cwn-2,	unc-52,	unc-86,syd-9,	nab-1,	lron-12,	jnk-1,	ten-1,	Y105E8B.9,	nsy-4,	lad-2,	W03D8.8,	syg-2,	fmi-1,	dma-1
Axon	development 15 cfz-2,	egl-46,	plx-2,	unc-86,	cwn-2,syd-9,	lron-12,	ten-1,	jnk-1,	Y105E8B.9,	lad-2,	W03D8.8,	syg-2,	fmi-1,	dma-1
Axonogenesis,	cell	morphogenesis	involved	in	neuron	differentiation,	neuron	projection	morphogenesis 12 cfz-2,	egl-46,	ten-1,	plx-2,	cwn-2,	unc-86,	Y105E8B.9,	lad-2,	syg-2,	lron-12,	fmi-1,	dma-1
Axon	guidance,	neuron	projection	guidance 9 cfz-2,	egl-46,	ten-1,	plx-2,	cwn-2,	Y105E8B.9,	lad-2,	fmi-1,	dma-1
 
GO	Term Molecular	Function Count Worm	Name(s)
GO:0030246 carbohydrate	binding 21 clec-36,	clec-51,	clec-60,	clec-49,	clec-7,	clec-48,	clec-172,	clec-86,	clec-28,	clec-52,	clec-61,	clec-170,	clec-82,	clec-160,	clec-43
GO:0005198 structural	molecule	activity 5 ifc-1,	ifp-1,	unc-52,	ifa-3,	ifd-1
GO:0008378 galactosyltransferase	activity 3 T09E11.10,	E03H4.11,	C47F8.6
GO:0017154 semaphorin	receptor	activity 2 plx-2,	kvs-1
GO:0016790 thiolester	hydrolase	activity	 2 W03D8.8,	T05E7.1
GO:0016717 oxidoreductase	activity 2 fat-5,	fat-6
GO:0048495 roundabout	binding 2 syd-1,	dma-1
GO:0004553 hydrolase	activity,	hydrolyzing	O-glycosyl	compounds 4 Y105E8B.9,	chil-23,	hex-1,	T19H5.6
GO:0004768 stearoyl-CoA	9-desaturase	activity 2 fat-5,	fat-6
GO:0005215 transporter	activity 5 F47E1.2,	EEED8.2,	T07H12.5,	F,	F47E1.4
GO:0051015 actin	filament	binding 3 cor-1,	nab-1,	ncam-1
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The enrichment of molecular functions for downregulated genes was then 
examined (Table 4.23).  The most highly enriched molecular function was 
carbohydrate binding, with 21 genes being directly associated with this GO term. 
Two genes were predicted to encode proteins with thiolester hydrolase activity. 
These two genes were T05E7.1 (WBGene00020258), - downregulated at 15, 18 
and 24mM VPA –and W03D8.8 (WBGene00020989) – downregulated at 24mM 
VPA treatment. The human orthologs of these genes are members of the acyl-coA 
thioesterases (ACOT) and bile acid CoA: amino acid N-acyltransferase (BAAT) 
families.  Both of these families in humans show palmitoyl-CoA hydrolase activity. 
When considering knockdown of dhhc-2, a palmitoyl acyl transferase, caused a RIC 
phenotype previously, this provides a few more links between the role of 
palmitoylation activity and VPA.  
 
Pathway enrichment was also performed using PANTHER. Although no pathways 
had multiple genes associated with them, many of the genes were found to be 
linked to potentially interesting pathways, or were themselves interesting genes 
(Table 4.24). Genes of particular neurological interest included: Jnk-1 
(WBGene00002178), which is involved in the amyloid-secretase pathway as well 
as Ras and TGF-β signaling. Cwn-2 (WBGene00000858) is involved in the 
presenilin pathway and wnt signaling, and Ace-3 (WBGene00000037) is an 
abnormal acetylcholinesterase. As well as cwn-2, cfz-2 is also associated with Wnt 
signaling, as it is the C. elegans frizzled homolog. Cfz-2 is also down regulated 
following exposure to VPA, further suggesting a role of Wnt signaling as a 
mediator of VPA induced changes.  
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Wormbase	Gene	ID Gene	Symbol Gene	Name Valproate	Concentration	(mM) Panther	Pathway
WBGene00000037 Y48B6A.8 ace-3 12|15|18|24 P00042:Muscarinic	acetylcholine	receptor	signaling
WBGene00000478 F27E11.3 cfz-2 18|24 P00012:Cadherin	signaling	pathway,	P00057:Wnt	signaling	pathway
WBGene00000708 M199.5 col-135 9|12|15|18|24 P00031:Inflammation	mediated	by	chemokine	and	cytokine	signaling	pathway
WBGene00000858 W01B6.1 cwn-2 12 P00004:Alzheimer	disease-presenilin	pathway,	P00005:Angiogenesis,P00012:Cadherin	signaling,	pathway,P00057:Wnt	signaling	pathway
WBGene00001477 K08C7.5 fmo-2 12|15|18|24 P05914:Nicotine	degradation
WBGene00001612 C06E1.4 glr-1 18 P00037:Ionotropic	glutamate	receptor	pathway,	P00039:Metabotropic	glutamate	receptor	group	III	pathway
WBGene00002178 B0478.1 jnk-1 15|18 P00003:Alzheimer	disease-amyloid	secretase	pathway,	P00005:Angiogenesis,P00006:Apoptosis	signaling	pathway,	
WBGene00002178 B0478.1 jnk-1 15|18 P00010:	B	cell	activation,	P00018:EGF	receptor	signaling	pathway,	P00020:FAS	signaling	pathway
WBGene00002178 B0478.1 jnk-1 15|18 P00029:Huntington	disease,P00049:Parkinson	Disease,	P00034:Integrin	signaling	pathway,	P00035:Interferon-gamma,P00046:Oxidative	Stress	Response
WBGene00002178 B0478.1 jnk-1 15|18 P00052:TGF-beta	signaling,	T	Cell	activation,	P00054:Toll	receptor	Signaling,	P04393:Ras	Signaling	pathway
WBGene00002975 C35C5.5 lev-8 18 P00044:Nicotinic	acetylcholine	receptor	signaling	pathway
WBGene00003514 T18D3.4 myo-2 12 P00016:Cytoskeletal	regulation	by	RHO	GTPase,	P00031:Inflammation,	P00044:Nicotinic	acetylcholine	receptor	signaling	pathway,	P00057:Wnt	Signaling
WBGene00004281 Y11D7A.4 rab-28 12|15|18|24 P00047:PDGF	signaling	pathway,	P00052:TGF-beta	signaling	pathway
WBGene00006759 ZK617.1 unc-22 15|18|24 P00016:Cytoskeletal	regulation	by	RHO	GTPase,	P00031:Inflammation
WBGene00006777 C27H6.1 unc-41 15|18|24 P00023:General	transcription	regulation,P00055:Transcription	regulation	by	bZIP	transcription	factor
WBGene00007401 C07A9.5 12 P00034:Integrin	signaling
WBGene00007969 C36A4.9 acs-19 15	and	24 P02722:Acetate	utilization,P02754:Methylcitrate	cycle
WBGene00009773 F46B6.8 lipl-2 12|15|18|24 P02727:Androgen/estrogene/progesterone	biosynthesis,
WBGene00009896 F49E11.11 scl-3 15|18|24 P00048:PI3	kinase	pathway
WBGene00010062 F54F3.3 lipl-1 15|18|24 P02727:Androgen/estrogene/progesterone	biosynthesis,
WBGene00011283 R90.1 12|18|24 P00049:Parkinson	disease,P00057:Wnt	signaling
WBGene00017677 F21F8.2 asp-11 6|9|12|15|18|24 P00004:Alzheimer	disease-	presenilin	pathway
WBGene00018304 F41G3.12 agr-1 24 P00034:Integrin	signaling	pathway
WBGene00020016 R11G11.14 lipl-3 12|15|18|24 P02727:Androgen/estrogene/progesterone	biosynthesis,
WBGene00020393 T10B5.7 24 P02727:Androgen/estrogene/progesterone	biosynthesis,
WBGene00021703 Y48G9A.10 cpt-3 6|9|12|15|18|24 P00043:Muscarinic	acetylcholine	receptor
Table 4.24 – Panther analysis of down regulated genes. Following microarray analysis of N2 worms treated with varying concentrations of VPA, the downregulated 
genes were analysed by inputting into DAVID for gene ontology and pathway annotation. Panther was used to elucidate pathways the genes were associated with. 
There was no clustering of genes in specific pathways, but individual genes had neurologically relevant pathways associated with them, listed in this table. 
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4.3.10 DAVID analysis of upregulated genes 
 
Genes that were significantly upregulated in response to VPA were entered into 
DAVID. Biological processes showing significant enrichment of genes include the 
innate immune response (104 assigned genes), oxidation-reduction (44 assigned 
genes) and transmembrane transport (30 assigned genes), A list of all of the 
enriched biological processes in the up-regulated data set, which are potentially 
affected by VPA treatment are shown in Table 4.25. 
 
Of most interest are those that could potentially affect neuropeptide signaling, 
including nlp-28 (WBGene00003766), nlp-29 (WBGene00003767), nlp-30 
(WBGene00003768), nlp-31 (WBGene00003769), nlp-33 (WBGene00003771), 
and nlp-34 (WBGene00015046). These are all neuropeptide-like proteins, 
although little other information is currently available for these proteins.  Nlp-29 
and nlp-33 play a role in innate immunity, and nlp-30 and nlp-31 are part of the 
YGGW amide neuropeptide family, which are expressed in the hypodermis.  
 
Molecular functions with the highest number of assigned genes were transferase 
activity (63 assigned genes), structural constituent of cuticle (62 assigned genes), 
and hydrolase activity (52 assigned genes). These are shown in Table 4.26. 
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GO	Term Biological	Process Count
GO:0045087 innate	immune	response 104
GO:0052696 flavonoid	glucuronidation 28
GO:0009813 flavonoid	biosynthetic	process 28
GO:0050829 defense	response	to	Gram-negative	bacterium 26
GO:0008152 metabolic	process 96
GO:0055114 oxidation-reduction	process 44
GO:1990170 stress	response	to	cadmium	ion 6
GO:0030968 endoplasmic	reticulum	unfolded	protein	response 13
GO:0010332 response	to	gamma	radiation 5
GO:0006508 proteolysis 31
GO:0040002 collagen	and	cuticulin-based	cuticle	development 13
GO:0055085 transmembrane	transport 30
GO:0031640 killing	of	cells	of	other	organism 3
GO:0051603 proteolysis	involved	in	cellular	protein	catabolic	process 8
GO:0006952 defense	response 12
GO:0006629 lipid	metabolic	process 17
GO:0050832 defense	response	to	fungus 5
GO:0043171 peptide	catabolic	process 5
GO:1990169 stress	response	to	copper	ion 3
GO:0034219 carbohydrate	transmembrane	transport 3
GO:0008652 cellular	amino	acid	biosynthetic	process 4
GO:0006665 sphingolipid	metabolic	process 5
GO:0006820 anion	transport 7
GO:0008643 carbohydrate	transport 4
GO:0035434 copper	ion	transmembrane	transport 3
GO:0016311 dephosphorylation 6
GO:0042908 xenobiotic	transport 2
GO:0007218 neuropeptide	signaling	pathway 6
Table 4.25 - Biological process enrichment of genes that were up regulated in response 
to N2 worms being treated with VPA. Following microarray analysis of N2 worms 
treated with varying concentrations of VPA, the significantly upregulated genes from 
each concentration comparison were analysed by inputting into DAVID for gene 
ontology and pathway annotation. Biological processes enriched in the up regulated 
gene set are listed (using BP_DIRECT), as well as the number of genes clustered in each 
process. 
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The PANTHER tool was then used to identify other neurologically relevant genes. 
Like in the downregulated gene set, no enrichment of pathways with multiple 
genetic associations was elucidated. However, some individual genes were found 
to have relevance to human disease (Table 4.27). Arf-1.1 (WBGene00000190) is 
involved in integrin signaling, and has been linked to Huntington’s disease. Rab-
GO	Term Molecular	Function Count
GO:0042302 structural	constituent	of	cuticle 62
GO:0016758 transferase	activity,	transferring	hexosyl	groups 28
GO:0015020 glucuronosyltransferase	activity 23
GO:0004185 serine-type	carboxypeptidase	activity 11
GO:0016491 oxidoreductase	activity 43
GO:0042329 structural	constituent	of	collagen	and	cuticulin-based	cuticle 7
GO:0004497 monooxygenase	activity 18
GO:0016705 oxidoreductase	activity,	acting	on	paired	donors,	with	incorporation	or	reduction	of	molecular	oxygen 17
GO:0016740 transferase	activity 63
GO:0005506 iron	ion	binding 17
GO:0030246 carbohydrate	binding 29
GO:0004180 carboxypeptidase	activity 7
GO:0008194 UDP-glycosyltransferase	activity 7
GO:0020037 heme	binding 18
GO:0042626 ATPase	activity,	coupled	to	transmembrane	movement	of	substances 10
GO:0022857 transmembrane	transporter	activity 14
GO:0008239 dipeptidyl-peptidase	activity 5
GO:0015562 efflux	transmembrane	transporter	activity 4
GO:0008233 peptidase	activity 21
GO:0016787 hydrolase	activity 52
GO:0004364 glutathione	transferase	activity 6
GO:0051119 sugar	transmembrane	transporter	activity 3
GO:0016887 ATPase	activity 10
GO:0016757 transferase	activity,	transferring	glycosyl	groups 12
GO:0016747 transferase	activity,	transferring	acyl	groups	other	than	amino-acyl	groups 8
GO:0003993 acid	phosphatase	activity 5
GO:0003959 NADPH	dehydrogenase	activity 3
GO:0008236 serine-type	peptidase	activity 5
GO:0004222 metalloendopeptidase	activity 10
GO:0008237 metallopeptidase	activity 11
GO:0051213 dioxygenase	activity 4
GO:0052689 carboxylic	ester	hydrolase	activity 4
GO:0005375 copper	ion	transmembrane	transporter	activity 3
GO:0008395 steroid	hydroxylase	activity 5
GO:0008559 xenobiotic-transporting	ATPase	activity 2
Table 4.26 – Molecular function enrichment of genes that were up regulated in response to N2 worms being 
treated with VPA. Following microarray analysis of N2 worms treated with varying concentrations of VPA, 
the significantly up regulated genes from each concentration were merged and analysed by inputting into 
DAVID for gene ontology and pathway annotation. Molecular functions enriched in the up regulated gene 
set are listed (using MF_DIRECT), as well as the number of genes associated with the molecular functions. 
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11.2 (WBGene00004275) is also linked to Huntington’s disease by the PDGF 
pathway. Genes linked to Alzheimer’s disease include Lrx-1 (WBGene00003075), 
zmp-2 (WBGene00019212) and asp-12 (WBGene00017678), which all form part 
of the presenilin pathway. Another gene found to be up regulated was Snb-2 
(WBGene00004898), which is the C. elegans ortholog of human VAMP3 and 
VAMP1. It is involved in SNARE interactions in vesicular transport and was up 
regulated at 12, 15, 18 and 24mM VPA. These data provide some insight into 
possible molecular processes that may mediate therapeutic affects of VPA in 
neurodegenerative or cognitive disorders. 
 
Although this method of analyzing the microarray data was different to that 
carried out previously (Munasinghe, 2015) , as the two methods of analyzing the 
same raw data were very different, common trends can be seen. For example in 
both methods, Wnt signaling and TGF-β signaling were clustered. The 
neuropeptide like genes were also found in both analyses (Munasinghe, 2015), 
although many other genes did not overlap.  
 
The down-regulated and up-regulated gene lists were inputted together into 
DAVID, to see whether other genes with neurological biological process 
associations would be found (Table 4.28). Interestingly three upregulated genes 
were found to be associated with axonogenesis (adding to the 12 down-regulated 
genes previously elucidated in Table 3.23). These were vem-1 
(WBGene00006890), which was up-regulated at 18mM VPA, vhp-1 
(WBGene00006923), up-regulated at 24mM VPA, and dpy-18 
(WBGene00001077), up-regulated at both 18 and 24mM VPA.  
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Wormbase	Gene	ID Gene	Symbol Gene	Name Valproate	Concentration	(mM) Panther	Pathway
WBGene00021487 Y40B10A.2 comt-3 12|15|18|24 P00001:Adrenaline	and	noradrenaline	biosynthesis,	P05912:Dopamine	receptor	mediated	signaling	pathway
WBGene00012518 Y32B12A.3 comt-2 12|24 P00001:Adrenaline	and	noradrenaline	biosynthesis,	P05912:Dopamine	receptor	mediated	signaling	pathway
WBGene00019212 H19M22.3 zmp-2 18|24 P00004:Alzheimer	disease	-	presenilin	pathway
WBGene00017678 F21F8.4 asp-12 3|6|9|12|15|18|24 P00004:Alzheimer	disease	-	presenilin	pathway
WBGene00003075 T04H1.6 lrx-1 6|9 P00004:Alzheimer	disease	-	presenilin	pathway
WBGene00009692 F44E5.5 24 P00006:Apoptosis	signaling	pathway,	P00049:Parkinson	disease
WBGene00006539 T04H1.9 tbb-6 18|24 P00016:Cytoskeletal	regulation	by	Rho	GTPase,P00025:Hedgehog	signaling	pathway,P00029:Huntington	disease
WBGene00004382 F59A6.6 rnh-1.0 12|18|24 P00017:DNA	replication
WBGene00000190 F45E4.1 arf-1.1 24 P00029:Huntington	Disease,	P00034:Integrin	Signaling	pathway
WBGene00004275 W04G5.2 rab-11.2 15|18|24 P00029:Huntington	disease,	P00047:PDGF	signaling	pathway
WBGene00000755 R09A8.4 col-182 24 P00031:Inflammation	mediated	by	chemokine	and	cytokine	signaling	pathway,	P00034:Integrin	signaling	pathway
WBGene00019644 K11D12.4 cpt-4 9|12|15|18|24 P00043:Muscarinic	acetylcholine	receptor	2	and	4	signaling	pathway
WBGene00006923 F08B1.1 vhp-1 24 P00046:Oxidative	stress	response
WBGene00015087 B0252.1 6|9|12|15|18|24 P00048:PI3	kinase	pathway
WBGene00001433 Y18D10A.25 fkb-8 18|24 P00052:TGF-beta	signaling	pathway
WBGene00015660 C09H5.2 catp-3 9|12|15|18|24 P00060:Ubiquitin	proteasome	pathway
WBGene00001149 K02A4.1 bcat-1 18|24 P02724:Alanine	biosynthesis,	P02748:Isoleucine	biosynthesis,	P02749:Leucine	biosynthesis,	P02785:Valine	biosynthesis
WBGene00003982 R11H6.1 pes-9 12|15|18|24 P02728:Arginine	biosynthesis
WBGene00022752 ZK484.6 18|24 P02735:Cobalamin	biosynthesis
WBGene00010759 K10H10.2 cysl-2 15|18|24 P02737:Cysteine	biosynthesis
WBGene00018174 F38B6.4 15|18|24 P02738:De	novo	purine	biosynthesis
WBGene00016957 C55F2.1 atic-1 24 P02738:De	novo	purine	biosynthesis
WBGene00003844 K11C4.4 odc-1 18|24 P02758:Ornithine	degradation
WBGene00014206 ZK1058.6 nit-1 18|24 P02771:Pyrimidine	metabolism
WBGene00016265 C30F12.6 nmur-4 18|24 P04394:Thyrotropin-releasing	hormone	receptor	signaling	pathway
WBGene00015048 B0218.2 faah-2 12|15|18|24 P05728:Anandamide_degradation,
WBGene00019515 K08B4.3 ugt-19 12|15|18|24 P05914:Nicotine	degradation
WBGene00019379 K04A8.10 24 P05914:Nicotine	degradation
WBGene00018543 F47C10.6 ugt-32 24 P05914:Nicotine	degradation
WBGene00017336 F10D2.11 ugt-41 6|9|12|15|18|24 P05914:Nicotine	degradation
WBGene00017331 F10D2.5 ugt-40 12|15|18|24 P05914:Nicotine	degradation
WBGene00017329 F10D2.2 ugt-39 6|9|12|15|18|24 P05914:Nicotine	degradation
WBGene00017315 F09G2.6 ugt-36 18 P05914:Nicotine	degradation
WBGene00015692 C10H11.3 ugt-25 18|24 P05914:Nicotine	degradation
WBGene00015449 C04F5.7 ugt-63 12|18 P05914:Nicotine	degradation
WBGene00013901 ZC443.6 ugt-16 18|24 P05914:Nicotine	degradation
WBGene00009255 F29F11.2 ugt-34 24 P05914:Nicotine	degradation
WBGene00008486 F01D4.2 ugt-44 6|9|12|15|18|24 P05914:Nicotine	degradation
WBGene00007946 C35A5.2 ugt-33 18 P05914:Nicotine	degradation
WBGene00007885 C33A12.6 ugt-21 6|9|12|15|18|24 P05914:Nicotine	degradation
WBGene00007455 C08F11.8 ugt-22 12|15|18|24 P05914:Nicotine	degradation
WBGene00007422 C08B6.1 ugt-17 9|12|15|18|24 P05914:Nicotine	degradation
WBGene00001479 F53F4.5 fmo-4 18|24 P05914:Nicotine	degradation
Table 4.27– Panther pathway enrichment of genes up regulated in response to VPA. Following microarray analysis of N2 worms treated with varying 
concentrations of VPA, the down regulated genes were analysed by inputting into DAVID for gene ontology and pathway annotation. Panther was used to 
elucidate pathways the genes were associated with. There was no clustering of genes in specific pathways, but individual genes had pathways associated with 
them, listed in this table. 
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4.3.11 Using WebGestalt to find disease pathways 
 
To enable further investigation into the possible spectrum of pathways being 
affected by VPA, both the up and downregulated C. elegans genes were converted 
GO	Term Biological	Process Count
GO:0045087 innate	immune	response 115
GO:0009813 flavonoid	biosynthetic	process 28
GO:0052696 flavonoid	glucuronidation 28
GO:0050829 defense	response	to	Gram-negative	bacterium 29
GO:0008152 metabolic	process 115
GO:0055114 oxidation-reduction	process 55
GO:0050830 defense	response	to	Gram-positive	bacterium 11
GO:0006629 lipid	metabolic	process 28
GO:1990170 stress	response	to	cadmium	ion 6
GO:0006508 proteolysis 38
GO:0030968 endoplasmic	reticulum	unfolded	protein	response 13
GO:0010332 response	to	gamma	radiation 5
GO:0006952 defense	response 17
GO:0051603 proteolysis	involved	in	cellular	protein	catabolic	process 11
GO:0055085 transmembrane	transport 38
GO:0040002 collagen	and	cuticulin-based	cuticle	development 15
GO:0031640 killing	of	cells	of	other	organism 3
GO:0006637 acyl-CoA	metabolic	process 4
GO:0006665 sphingolipid	metabolic	process 6
GO:0033564 anterior/posterior	axon	guidance 3
GO:0016042 lipid	catabolic	process 6
GO:1990169 stress	response	to	copper	ion 3
GO:0050832 defense	response	to	fungus 5
GO:0034219 carbohydrate	transmembrane	transport 3
GO:0043171 peptide	catabolic	process 5
GO:0005975 carbohydrate	metabolic	process 15
GO:0046513 ceramide	biosynthetic	process 3
GO:0016311 dephosphorylation 7
GO:0008652 cellular	amino	acid	biosynthetic	process 4
GO:0007409 axonogenesis 15
Table 4.28 – Biological process enrichment of genes that showed differential 
regulation (both downregulated and upregulated gene sets) in response to N2 worms 
being treated with VPA. Following microarray analysis of N2 worms treated with 
varying concentrations of VPA, the significantly upregulated genes from each 
concentration comparison were analysed by inputting into DAVID for gene ontology 
and pathway annotation. Biological processes directly associated to the gene lists are 
shown. 
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into their human orthologs (Supplementary Tables 4.7 and 4.8). Some C. elegans 
have multiple possible human orthologs, which must be considered when 
converting gene IDs.  To decide this, the human ortholog with the highest 
percentage identity, similarity and lowest percentage gaps were used. WebGestalt 
(B. Zhang, Kirov, & Snoddy, 2005) was then used to carry out gene set enrichment 
analysis, and assess potential disease association. Following this analysis, human 
IDs with neurological disease associations were converted back into worm 
orthologs for further analysis. 
 
Fifteen of the C. elegans genes that were down regulated following exposure to 
VPA were found to have human orthologs associated with mental disorders. These 
include HIP1, whose C. elegans ortholog is Y18D10A.22 (WBGene00014864). 
HIP1 is huntingtin-interacting protein, and has a clear link with the 
neurodegenerative Huntington’s disease.  Nine of these genes including 
Y18D10A.22 were also linked to other disorders of the nervous system. Seven of 
the genes that were up regulated in response to VPA were found to be associated 
with spinal dysraphism, which refers to spinal cord malformations (Table 4.29). A 
list of all of the disease groups associated with up or down regulated genes is 
provided in Table 4.30.  
Chapter 4: Sodium Valproate (VPA) 
 222 
 
Wormbase	Gene	ID Worm	Gene	name Worm	Gene	symbol Human	Gene	symbol Disorder Valproate	Regulation
WBGene00007691 C23H4.2 C23H4.2 CBS Spinal	dysraphism Up	Regulated
WBGene00018138 folt-2 F37B4.7 SLC19A1 Spinal	dysraphism Up	Regulated
WBGene00019322 ahcy-1 K02F2.2 AHCY Spinal	dysraphism Up	Regulated
WBGene00018174 F38B6.4 F38B6.4 GART Spinal	dysraphism Up	Regulated
WBGene00021215 Y18H1A.11 Y18H1A.11 PCYT1A Spinal	dysraphism Up	Regulated
WBGene00022856 cth-2 ZK1127.10 CTH Spinal	dysraphism Up	Regulated
WBGene00000512 ckb-2 B0285.9 CHKA Spinal	dysraphism Up	Regulated
WBGene00022076 daao-1 Y69A2AR.5 DAO Mental	disorders Down	Regulated
WBGene00017594 F19C7.4 F19C7.4 PRSS16 Mental	disorders Down	Regulated
WBGene0001759 F19C7.2 F19C7.2 PRSS16 Mental	disorders Down	Regulated
WBGene00017184 ncam-1 F02G3.1 NCAM1 Mental	disorders Down	Regulated
WBGene00016841 magu-3 C50F2.8 CASK Mental	disorders	and	Nervous	System Down	Regulated
WBGene00016523 C39B5.5 C39B5.5 CST3 Mental	disorders	and	Nervous	System Down	Regulated
WBGene00015077 B0238.13 B0238.13 ACHE Mental	disorders	and	Nervous	System Down	Regulated
WBGene00014864 Y18D10A.22 Y18D10A.22 HIP1 Mental	disorders	and	Nervous	System Down	Regulated
WBGene00004346 rgs-3 C29H12.3 RGS4|RGS2 Mental	disorders Down	Regulated
WBGene00002975 lev-8 C35C5.5 CHRNA1|CHRNA2|CHRNB1|CHRNA5|CHRNB4Mental	disorders	and	Nervous	System Down	Regulated
WBGene00002243 lad-2 Y54G2A.25 NRCAM Mental	disorders Down	Regulated
WBGene00002057 ifd-1 R04E5.10 NES Mental	disorders	and	Nervous	System Down	Regulated
WBGene00002055 ifc-1 F37B4.2 NES Mental	disorders	and	Nervous	System Down	Regulated
WBGene00001612 glr-1 C06E1.4 GRIA3 Mental	disorders	and	Nervous	System Down	Regulated
WBGene00000037 ace-3 Y48B6A.8 BCHE Mental	disorders	and	Nervous	System Down	Regulated
Table 4.29  – Table to show worm genes that had significant changes in expression in response to valproate treatment, which have human orthologues with known 
roles in mental disorders and/or nervous system disorders. WebGestalt was used for this analysis. Following microarray analysis of N2 worms treated with varying 
concentrations of VPA, the down or up regulated genes were analysed by converting the genes to their human orthologs (using DIOPT flyRNAi). These lists were then 
inputted into WebGestalt, where disease pathway analysis was carried out.  
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4.3.12 Ingenuity analysis of downregulated genes 
 
As different pathway analysis tools use different algorithms and provide variable 
coverage and definitions of biological processes, there is added value in using 
multiple tools to analysing data from differential gene expression studies. 
Ingenuity is another bioinformatics tool that can be used to analyse and interpret 
the potential functional implications of differential gene expression profiles. 
However, it is important to note that Ingenuity is not fully compatible with C. 
elegans data. Firstly, a significant number of differentially expressed C. elegans 
genes could not be mapped in the Ingenuity software. This may be because they 
are hypothetical proteins or proteins with no known human orthologs. With 
respect to those genes that are mapped, 109 were significantly up regulated, while 
39 genes were significantly down regulated (Supplementary Tables 4.9 and 4.10). 
Disease	Association Count
Drug	resistance 18
Metabolic	diseases 25
Translocation,	genetic 21
Cardiovascular	diseases 20
Hyperbilirubinemia 7
Metabolism,	inborn	errors 17
Drug	interaction	with	drug 17
Mental	Disorders 21
Cholestasis 8
Fatty	liver 11
Disease	Association Count
Metabolic	diseases 22
Protein	deficiency	disease 14
Fatty	liver 12
Tangier	disease 6
Alpha	1-antitrypsin	deficiency 6
Drug	resistance 13
Translocation,	genetic 15
Ototoxicity 7
Spinal	dysraphism 7
Diabetes	mellitus 13
A	 B	
Table 4.30 – A count of the number of downregulated (A) and upregulated (B) genes 
with disease associations. Following microarray analysis of N2 worms treated with 
varying concentrations of VPA, the down or up regulated genes were analysed by 
converting the genes to their human orthologs (using DIOPT flyRNAi). These lists were 
then inputted into WebGestalt, where disease pathway analysis was carried out. The 
count refers to how many genes from the list were found to be associated with each 
disease process. 
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Sets of differentially regulated genes were then analysed to investigate disease 
association. This means that several worm genes may be assigned to a single 
human ortholog. In some instances this can result in the some human genes being 
represented in both the up- and down-regulated subsets, as observed for MFSD8, 
which is associated with neuronal ceroid lipofuscinosis 8. Three C. elegans genes 
in the gene lists were orthologous to MFSD8 orthologs are F14D7.6 (down 
regulated) and C25E10.4 (up regulated) and F52F10.2 (up regulated). This gene 
therefore is discounted from the analysis.  
 
Neurological disease pathways and functions associated with the down-regulated 
gene set are presented in Table 4.31. From the GSEA in Webgestalt, some of these 
genes had already been associated with mental disorders. However, this analysis 
gave no further information regarding, for example the category of mental 
disorder. Five genes, AGRN (WBGene00018304), GRIA3 (WBGene00001612), 
CYP3A4 (WBGene00007963), HSPG2 (WBGene00006787) and MAPK8 
(WBGene00002178) were associated with Alzheimer’s disease. Also, Gria3 is 
known to be linked to synaptic transmission and X-linked mental retardation. 
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Wormbase	Gene	ID Human	Gene	Symbol Disease/Function
WBGene00001612 GRIA3 X-linked	mental	retardation	type	94,	alzheimer's	disease,	major	depression	coordination,	synaptic	transmission
WBGene00001475 CELSR1 Neural	tube	defect
WBGene00006787 HSPG2 Neural	tube	defect,	Alzheimer's	disease
WBGene00004830 KCNMA1 generalized	epilepsy	with	paroxysmal	dyskinesia,	ataxia	coordination,	nervous	system	differentiation,	synaptic	transmission
WBGene00018304 AGRN Alzheimer's	disease,	nervous	system	differentiation,	movement	disorder,	congenital	myasthenic	syndrome	type	8,	survival
WBGene00007963 CYP3A4 Alzheimer's	disease,	major	depression
WBGene00020016 LIPA Alzheimer's	disease,	apoptosis
WBGene00002178 MAPK8 Alzheimer's	disease,	nervous	system	proliferation,	apoptosis,	neural	tube	defect
WBGene00017184 NCAM1 prepulse	inhibition,	nervous	system	development,	proliferation,	major	depression,	movement	disorder,	ataxia,	apoptosis
WBGene00020509 HEXB coordination,	movement	disorder,	adult	and	juvenile	Sandhoff	disorder,	ataxia
WBGene00002055 LMNB2 nervous	system	development,	differentiation,	major	depression
WBGene00002243 NRCAM prepulse	inhibition,	nervous	system	development,	proliferation,synaptic	transmission,	ataxia,	neuromuscular	disease
WBGene00006498 TENM2 nervous	system	development
WBGene00000858 WNT5B nervous	system	development	and	function
WBGene00022076 DDO prepulse	inhibition,	learning
WBGene00000478 FZD8 nervous	system	proliferation
WBGene00000966 HSD17B6 major	depression
WBGene00000188 ARL3 movement	disorder
WBGene00003514 MYH7B movement	disorder,	neuromuscular	disease
WBGene00001398 SCD2 neuromuscular	disease
WBGene00001523 TMLHE epsilon-trimethyllysine	hydroxylase	deficiency
WBGene00004281 RAB28 apoptosis
WBGene00008793 MFSD8 Neuronal	ceroid	lipofuscinosis	7
Table 4.31 – Ingenuity disease analysis of genes down regulated in response to N2 worm treatment with VPA, where neuronal related diseases/disorders 
were selected. Following microarray analysis of N2 worms treated with varying concentrations of VPA, significantly down regulated genes were inputted 
into Ingenuity Pathway Analysis (IPA), and disease associations were found.  
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Wormbase	Gene	ID Human	Gene	Symbol Disease/Function
WBGene00003408 ABCC1 epilepsy,	cytotoxicity,	neuroblastoma
WBGene00003409 ABCC3 cytotoxicity,	analgesia,	neuroblastoma
WBGene00006418 SGPL1 apoptosis	of	cerebellar	macroneurons
WBGene00003996 Abcb1b analgesia
WBGene00015048 FAAH analgesia,	excitation	of	dopaminergic	neurons
WBGene00003914 NPEPPS analgesia
WBGene00003573 SLC8B1 proliferation	of	cortical	astrocytes
WBGene00019979 SLC2A3 epilepsy,	excitation	of	nodose	ganglion	neurons
WBGene00009801 PLA2G6 abnormal	morphology	of	gray	matter,	dystonia,	parkinsonism,	infantile	neuroaxonal	dystrophy,	Hallervorden-Spatz	disease
	Karak	syndrome,	Parkinson	disease,	disorder	of	basal	ganglia
WBGene00016957 ATIC primary	central	nervous	system	lymphoma
WBGene00018174 GART primary	central	nervous	system	lymphoma
WBGene00015359 IDE neuroblastoma,	olfactory	esthesioneuroblastoma
WBGene00006530 TUBA1C neuroblastoma,	disorder	of	basal	ganglia
WBGene00003995 ABCB1 epilepsy,	dystonia,	akathsia,	disorder	of	basal	ganglia,	movement	disorder
WBGene00015010 PTS dystonia
WBGene00016340|WBGene00016335 GBA epilepsy,	parkinsonism,	Gaucher	disease,	progressive	myoclonic	epilepsy	type	4	with	renal	failure,	disorder	of	basal	ganglia,	movement	disorder
WBGene00010762|WBGene00000972 WWOX epilepsy,	autosomal	recessive	spinocerebellar	ataxia	type	12,	early	infantile	epileptic	encephalopathy	type	28
WBGene00008741 CTSA galactosialidosis	type	I	&	II,	juvenile/adult	type	galactosialidosis,	movement	disorder
WBGene00018398 SPTLC2 hereditary	sensory	neuropathy	type	IC
WBGene00017312 SLC20A2 idiopathic	basal	ganglia	calcification	type	1,	disorder	of	basal	ganglia
WBGene00008793 MFSD8 neuronal	ceroid	lipofuscinosis	7
WBGene00012295 NMNAT3 Wallerian	degeneration
WBGene00001778|WBGene00001770|WBGene00001755|WBGene00001761| HPGDS demyelination	of	cerebellum,	astrocytosis
demyelination	of	cerebellum,	astrocytosis
demyelination	of	cerebellum,	astrocytosis
demyelination	of	cerebellum,	astrocytosis
WBGene00019322 AHCY disorder	of	basal	ganglia,	movement	disorder
WBGene00001577 CPNE5 disorder	of	basal	ganglia,	movement	disorder
WBGene00001077 P4HA1 disorder	of	basal	ganglia,	movemment	disorder
WBGene00006890 PGRMC1 disorder	of	basal	ganglia,	movement	disorder
Table 4.32 – Ingenuity disease analysis of genes up regulated in response to VPA, where neuronal related diseases/disorders were selected. Following 
microarray analysis of N2 worms treated with varying concentrations of VPA, significantly down regulated genes were inputted into Ingenuity Pathway 
Analysis (IPA), and disease associations were found.  
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VPA is used to treat epilepsy, and the worm ortholog of KCNMA1, slo-1 
(WBGene00004830) is significantly down regulated upon VPA treatment. 
KCNMA1 is linked to generalized epilepsy. Other potentially interesting links to 
neuronal effects were also revealed through the Ingenuity analysis – multiple 
genes were linked to neuronal development and differentiation, some of which 
were also identified using DAVID. However, some other genes were uniquely 
identified by Ingenuity analysis. These include NCAM1 (C. elegans ortholog: 
WBGene00017184), TENM2 (C. elegans ortholog: WBGene00006498), WNT5B (C. 
elegans ortholog: WBGene00000858), AGRN (C. elegans ortholog: 
WBGENE00018304). CELSR1 (C. elegans ortholog: WBGene00001475), HSPG2 
(WBGene00006787), LMNB2 (C. elegans ortholog: WBGENE00002055), MAPK8 
(C. elegans ortholog: WBGENE00002178), and KCNMA1 (C. elegans ortholog: 
WBGene00004830). These results clearly link VPA to neuronal development and 
differentiation, and may also provide clues as to processes involved in VPA action. 
 
4.3.13 Ingenuity analysis of upregulated genes 
 
Disease associations of the up regulated genes are shown in Table 4.32.  Analysis 
of the up regulated gene set in Ingenuity identified five genes associated with 
epilepsy (Table 4.31), which may relevant to VPA’s therapeutic role or mode of 
action. These are ABCC1 (C. elegans ortholog: WBGene00003408), SLC2A3 (C. 
elegans ortholog: WBGene00019979), ABCB1 (C. elegans ortholog: 
WBGene00003995), GBA (C. elegans orthologs: WBGene00016340 and 
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WBGene00016335) and WWOX (C. elegans orthologs: WBGene00010762 and 
WBGene00000972). 
 
Two up regulated genes were found to be associated with Parkinson’s disease – 
PLA2G6 (C. elegans ortholog: WBGene00009801) and GBA (C. elegans ortholog: 
WBGene00016340 and WBGene00016335), again suggesting that VPA may affect 
functions that contribute to neurodegenerative disease. However, from this 
analysis it is not possible to say whether the effect of these changes may be 
beneficial or detrimental. 
 
4.3.14 Comparison of microarray data with results from other VPA studies 
 
To identify conserved effects of VPA treatment, other microarrays studies 
exploring VPA treatment were found. Using the EBI ArrayExpress database, six 
VPA-treated microarray experiments were identified that could be readily 
analysed using R. Two neuronal-related microarrays were derived from the 
developing hippocampus and cortex of foetal mice brain samples (E14.5, 
Accession Number: E-GEOD-42904), and mouse neural differentiated embryonic 
stem cells (nESCs, Accession Number: E-GEOD-50217). Both of these samples are 
developmentally relevant.  Table 4.33 shows a list of the microarrays used in this 
chapter. 
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DAVID was used to convert Affymetrix ID’s into official gene symbols. Following 
this, all of the up and down regulated genes were converted into their respective 
C. elegans orthologs using Biomart, before comparing lists of significantly up and 
down regulated genes. For all of the analyses a cut-off value of a 2-fold change was 
used to determine significance. 
 
When comparing DAVID profiles, all three analyses (mouse foetal brain, nESC and 
C. elegans) had an enrichment of genes in neuron development and biological 
processes associated with differentiation. When focusing on the nESC data, many 
neurological processes were enriched. As well as a variety of neuronal 
development related processes, such as axonogenesis (6 genes), synaptic 
transmission was also clearly enriched, with seven associated genes being up 
regulated. TGF-β and Wnt signaling are also enriched in the nESC microarray. Ten 
genes were found to be involved in Wnt receptor signaling, and three in TGF-β 
signaling. These pathways were also found in the original analysis of data from the 
C. elegans VPA dose response microarray data.  GAD-1 and GAD-2 were both up 
regulated in response to VPA and are known to be important enzymes in GABA 
biosynthesis.  Table 4.34 shows biological pathways that were enriched in this 
Valproate	Microarray Model Analysed	or	Extracted?
C.	elegans Adult Analysed
Mouse	Brain Development Analysed
Mouse	Neural	ESC Development Analysed
Rat	Brain Adult Extracted	from	literature
Rat	Cortical	Neurons Adult Extracted	from	literature
Mouse	NT2	neurospheres Development Extracted	from	literature
Table 4.33 – Summary of the microarray data compared in this analysis. Analysed refers 
to having and processing the raw data using the limma package in R. If raw data was not 
available, the processed and published data was downloaded and used.  
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analysis, while Table 4.35 shows the results of pathway enrichment analysis 
performed on this data. 
 
Seven genes were shared between the nESC and worm datasets (Table 4.36). Ace-
3 (WBGene00000037) was present in both datasets, which infers a possible 
conserved effect of VPA on cholinergic signaling. The mouse ortholog of Ace-3 is 
BCHE. Significantly, Ace-3 and BCHE are down regulated in C. elegans and mice 
nESC, respectively. Glr-1 (WBGene00001612) is a glutamate receptor – required 
for memory formation and response to light nose touch. However, this gene was 
down regulated in worms, but the mouse ortholog was up regulated in mouse.  The 
human ortholog is GRIA3, which as mentioned previously has links to Alzheimer’s 
disease and x-linked mental retardation. Fpn-1.2 (WBGene00019977) is again 
down regulated in both C. elegans and nESCs. The mouse ortholog of Fpn-1.2 is 
SLC40A1, and the human ortholog is Ferroportin (SLC40A1), which plays an 
important role in forebrain patterning, and the closure of neural tubules (Mao et 
al., 2010).  
 
In the mouse E14.5 brain microarray data, 16 genes were linked to neuronal 
differentiation, and 11 in neuronal development (Table 4.37). Other enriched 
processes included the regulation of apoptosis, with 20 genes being significantly 
up or down regulated in response to VPA. VPA has been repeatedly reported to 
affect cellular proliferation and apoptosis, and has recently been used in cancer 
clinical trials.  
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Biological	Processes Mouse	Gene	Symbol(s)
Axonogenesis foxd1	(-),hoxa2	(-),Ngfr	(-),SEMA5A	(-),LOC672215	(-),SLIT3	(-)
Forebrain	Development FEZF2	(+),lhx1	(+),Tal2	(+),EOMES	(+),OTX1	(+),Otx2	(+),PGAP1	(+),Zic5	(+),
Midbrain	Development Tal2	(+),En2	(+),OTX1	(+),Otx2	(+),
Negative	Regulation	of	Neuron	Apoptosis Agtr2	(-),dlx1	(-),TGFB3	(-),Erbb3	(-)
Neuron	Differentiation BARHL2	(+),dscam	(+),FEZF2	(+),HELT	(+),lhx1	(+),En2	(+),EOMES	(+),OLIG1	(+),Otx2	(+),PAX7	(+),LOC100048863
Neuron	Fate	Commitment OLIG1	(+),Otx2	(+),PAX7	(+),
Neuron	Projection foxd1	(-),hoxa2	(-),Lamb1-1	(-),Ngfr	(-),SEMA5A	(-),LOC672215	(-),SLIT3	(-)
Neurotransmitter	biosynthetic	process Gad1	(+),GAD2	(+),
Regulation	of	nervous	system	development dlx1	(-),hoxa2	(-),hoxd3	(-),Igf1	(-),nefm	(-),Serpinf1	(-),LOC672215	(-),six1	(-),THY1	(-)
Regulation	of	neuron	differentiation hoxa2	(-),hoxd3	(-),nefm	(-),LOC672215	(-),six1	(-),THY1	(-)
Regulation	of	synpatic	transmission Grm5	(+),GRM8	(+),Gm3888	(+),	lgi1	(+),
Synaptic	transmission CHRM3	(+),Gabrg2	(+),Gjd2	(+),GRM8	(+),Gad1	(+),GAD2	(+),SLC17A6	(+),
Transmission	of	nerve	impulse CHRM3	(+),Gabrg2	(+),Gjd2	(+),GRM8	(+),Gad1	(+),GAD2	(+),SLC17A6	(+),
Wnt	Signaling rspo2	(+),Rspo3	(+),LOC100048863	(+),wnt8b	(+),	DKK2	(-),DKK3	(-),FZD4	(-),FRZB	(-),ROR2	(-),sfrp2	(-)
Table 4.34 – Biological process enrichment of genes following VPA treatment of mouse neural differentiated embryonic stem cells. Following 
microarray analysis of the raw data, significantly up and down regulated genes were inputted into DAVID for gene ontology and pathway analysis. 
Biological processes enriched in the data sets are listed, which are related to neurological function. (-) indicates that the gene was down regulated 
following VPA treatment. (+) indicates that the gene was up regulated following VPA treatment. 
 
Pathway Mo se	G ne	Symbol(s)
Metabotropic	glutamate	receptor	group	III	pathway LOC100044431	(+),Grm5	(+),GRM8	(+),SLC17A6	(+),
Heterotrimeric	G-protein	signaling	pathway-Gq	alpha	and	Go	alpha	mediated	pathway RASGRP1	(+),CHRM3	(+),Grm5	(+),GRM8	(+),RGS2	(+),
Gamma-aminobutyric	acid	synthesis Gad1	(+),GAD2	(+),
P00037:Ionotropic	glutamate	receptor	pathway CACNG3	(+),LOC100044431	(+),SLC17A6	(+),
TGF-Beta	Signaling	Pathway BMP5	(-),DCN	(-),Ltbp1	(-),TGFB3	(-)
Wnt	Signaling	Pathway Cdh19	(-),cdh5	(-),FZD4	(-),FRZB	(-),HOXA5	(-),HOXB4	(-),hoxb5	(-),HOXB7	(-),HOXC4	(-),HOXC5	(-),Hoxc6	(-),Myh3	(-),sfrp2	(-)
Table 4.35 – Pathway enrichment of genes following VPA treatment of mouse neural differentiated embryonic stem cells. Following microarray 
analysis of the raw data, significantly up and down regulated genes were inputted into DAVID for gene ontology and pathway analysis. Panther 
was used to analyse pathway enrichment. Pathways with more than one gene association are listed. (-) indicates that the gene was down regulated 
following VPA treatment. (+) indicates that the gene was up regulated following VPA treatment. 
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Wormbase	Gene	ID Mouse	Gene	Symbol Worm	Regulation Mouse	Regulation
WBGene00003514 Myh-3 - -
WBGene00000037 Bche - -
WBGene00001612 Gria3 - +
WBGene00002975 Chrna5 - -
WBGene00019977 SLC40A1 - -
WBGene00011803 Trhde + +
WBGene00002260 Crabp2 + -
Table 4.36 – Table showing the overlapping genes between the mouse neural differentiated embryonic stem cells and C. elegans microarray data 
sets. (+) indicates the gene was up regulated, and (-) indicates the gene was down regulated in response to VPA treatment. 
 
Biological	Processes Mouse	Gene	Symbol(s)
Neuron	Differentiation EFHD1	(+),FARP2	(+),FEZF2	(-),RASGRF1	(+),LOC1000477	(-)26,SOX5	(-),TBR1	(-),CCKAR	(-),DFNA5	(-),NEUROD4	(-),NEUROG1	(-),	NRTN	(+),
ONECUT2	(+),OTX2	(+),RET	(+),STAT3	(+)
Neuron	Development EFHD1	(+),FARP2	(+),FEZF2	(-),RASGRF1	(+),	FOXG1	(-),TBR1	(-),CCKAR	(-),NEUROD4	(-),NRTN	(+),ONECUT2	(+),RET	(+),
Neural	Crest	cell	migration NRTN	(+),RET	(+),ZEB2	(-),
Regulation	of	apoptosis MTHFS	(-),BBC3	(+),BMF	(+),BAG3	(+),BIK,BID	(+),GCH1	(+),IKBIP	(+),AGTR1A	(+),AVEN	(-),CDKN1A	(+),HSPA1B	(+),MITF	(+),MALT1	(+),NMNAT1	(-),
NAIF1	(-),PMAIP1	(+),GM7084	(+),PRKCD	(+),TCF7	(+)
Positive	Regulation	of	Cell	Death BBC3	(+),BIK,BID	(+),GCH1	(+),IKBIP	(+),CDKN1A	(+),NAIF1	(-),PMAIP1	(+),	PLEKHF1	(+),PRKCD	(+),
Regulation	of	MAPK	activity FGD4	(-),CAV1	(-),PXN	(+),TRIB3	(+),ZEB2	(-),
Table 4.37 – Neuronal Biological Process Enrichment of genes from the mouse E14.5 hippocampus following VPA treatment. Following microarray 
analysis of the raw data, significantly up and down regulated genes were inputted into DAVID for gene ontology and pathway analysis. Biological 
processes enriched in the data sets are listed, which are related to neurological function. (-) indicates that the gene was down regulated following 
VPA treatment. (+) indicates that the gene was up regulated following VPA treatment. 
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When converted to worm orthologs, 32 genes were shared between the mouse 
brain and worm datasets (Table 4.38). Many worm orthologs map to only one 
mouse gene, and this is especially the case for GSTA4.  11 mouse genes were 
conserved between the two data sets, including fzd-5, whose C. elegans ortholog 
is cfz-2 (WBGene00000478). However, these display opposite changes in gene 
expression following VPA treatment. Nevertheless this highlights a possible VPA 
role in Wnt signaling. 
 
There are eleven overlapping genes between the nESC and developing mouse 
brain (Table 4.39). Although the majority has opposite changes in expression in 
response to VPA, SALL1 and DEPDC1A were downregulated in both microarrays. 
OXT2 is also down regulated in both arrays and is linked to neuronal 
differentiation. FEZF2 is involved in neuron development and differentiation, and 
is up regulated in the nESC but downregulated in E14.5 arrays.  
 
Two genes were found in each of the mouse brain, embryonic stem cell and worm 
data sets (Table 4.40). These were Chrna5 (Worm ortholog: WBGene00002975, 
lev-8) and Crabp2 (Worm ortholog: WBGene00002260, lbp-8).  The lev-8 gene, 
which encodes an acetylcholine receptor subunit, is down regulated in C. elegans 
and nESCs, but is upregulated in the mouse embryonic brain. This could highlight 
differences in expression levels dependent on the stage of development. Lbp-8 
was up regulated in C. elegans and downregulated in both mice microarrays, and 
is a fatty acid binding protein.  
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Wormbase	Gene	ID Mouse	Gene	Symbol Worm	Regulation Mouse	E14.5	Regulation
WBGene00000478 Fzd5 - +
WBGene00001753 Gsta4 + +
WBGene00001754 Gsta4 + +
WBGene00001755 Gsta4 + +
WBGene00001756 Gsta4 + +
WBGene00001757 Gsta4 + +
WBGene00001760 Gsta4 + +
WBGene00001761 Gsta4 + +
WBGene00001762 Gsta4 + +
WBGene00001768 Gsta4 + +
WBGene00001770 Gsta4 + +
WBGene00001772 Gsta4 + +
WBGene00001778 Gsta4 + +
WBGene00001786 Gsta4 + +
WBGene00001787 Gsta4 + +
WBGene00002051 Lmna - +
WBGene00002055 Lmna - +
WBGene00002260 Crabp2 + +
WBGene00002975 Chrna5 - +
WBGene00003957 Prss16 + +
WBGene00003959 Prss16 + +
WBGene00006431 Fgd6 - +
WBGene00011076 Scarb1 + +
WBGene00016134 Prss16 + +
WBGene00017592 Prss16 - +
WBGene00017594 Prss16 - +
WBGene00019979 Slc2a3 + +
WBGene00002057 Lmna - +
WBGene00008273 Mfsd9 + +
WBGene00018984 Prss16 + +
WBGene00019211 Ppp1r3b - +
WBGene00019682 Prss16 + +
Table 4.38 – Table showing the overlap of genes between the mouse e14.5 
hippocampus, and C. elegans VPA studies. Microarrays were analysed using R and the 
limma package, using identical algorithms and fold cut off values. + indicates up 
regulation, and – indicates down regulation of the gene following VPA treatment. 
 
Mouse	Gene	Symbol nESC	Regulation E14.5	Regulation
sall1 - -
chrna5 - +
crabp2 - +
tmem26 - +
LRIG3 - +
depdc1a - -
KDELR3 - +
Tcfl5 - +
FEZF2 + -
Otx2 + +
ST6GAL2 + -
Table 4.39 – Overlap of differentially expressed genes between the mouse nESC and e14.5 
hippocampal VPA microarrays. Microarrays were analysed using R and the limma package, 
using identical algorithms and fold cut off values.  + indicates up regulation, and – indicates 
down regulation following VPA treatment. 
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Wormbase	ID Mouse	Gene	Symbol Worm	Regulation Mouse	Neural	ESC	Regulation Mouse	e14.5	brain	Regulation
WBGene00002260 Crabp2 + - +
WBGene00002975 Chrna5 - - +
Table 4.40 – Overlap of differentially expressed genes between the mouse nESC, mouse E14.5 hippocampal, and C. elegans VPA microarrays. Microarrays 
were analysed using R and the limma package, using identical algorithms and fold cut off values.  + indicates up regulation, and – indicates down regulation 
of the gene following VPA treatment. 
 
Wormbase	Gene	ID Human	Gene	Symbol Human	Regulation Worm	Regulation
WBGene00008621 Plb1 + +
WBGene00000067 ACTRT2 - +
Table 4.41 – Overlap of differentially expressed genes between the C. elegans and human NT2 neurospheres VPA microarrays. The processed microarray 
data from the human NT2 neurospheres was extracted from the literature and analysed. The C. elegans VPA microarray data was analysed using R and 
the limma package. + indicates up regulation, and – indicates down regulation, following VPA treatment. 
 
Biological	Process Human	Gene	Symbol(s)
GO:0042981~regulation	of	apoptosis B4GALT1	(+),	PTPN6	(+),	IFIH1	(+),	BCL2L14	(+),	MMP9	(+),	RAG1	(+),	CDH1	(+),	DDIT3	(+),	PLEKHF1	(+),	BNIPL	(+),	NOTCH1	(-),	ATG5	(+),	
NUPR1	(+),	AGT	(+),	HMOX1	(+),	FOXC1	(+),	PRNP	(+),	IGFBP3	(+),	SPP1	(+)
GO:0043065~positive	regulation	of	apoptosis PLEKHF1	(+),	B4GALT1	(+),	PTPN6	(+),	BNIPL	(+),	NOTCH1	(-),	NUPR1	(+),	MMP9	(+),	HMOX1	(+),	IGFBP3	(+),	DDIT3	(+)
GO:0043405~regulation	of	MAP	kinase	activity PTPN6	(+),	SPAG9	(-),	CEACAM2	(+),	AVPI1	(+),	PXN	(-),	CEACAM1	(+),	PTPN11	(+)
GO:0033209~tumor	necrosis	factor-mediated	signaling	pathway KRT18	(+),	KRT8	(+)
GO:0043066~negative	regulation	of	apoptosis NOTCH1	(-),	ATG5	(+),	AGT	(+),	RAG1	(+),	FOXC1	(+),	PRNP	(+),	SPP1	(+)
GO:0048568~embryonic	organ	development GSC	(+),	HAND1	(+),	ADM	(+),	KRT8	(+),	GM5604,	PBX1	(-),	DDIT3	(+),	PITX2	(+)
GO:0001701~in	utero	embryonic	development MAN2A1	(+),	NOTCH1	(-),	HAND1	(+),	ADM	(+),	POU5F1	(+),	KRT8	(+),	APBA2	(-),	FOXC1	(+),	CDH1	(+),	PITX2	(+)
Table 4.42 – Biological Process enrichment of differentially expressed genes from human NT2 neurospheres following VPA treatment. Lists of 
significantly up and down regulated genes were extracted from literature, and inputted into DAVID for gene ontology and pathway analysis. Biological 
processes that were enriched in this data set are listed. (+) indicates up regulation, and (–) indicates down regulation, following VPA treatment. 
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4.3.15 Comparison of C. elegans microarray with published data 
 
Mining the literature for published VPA microarray studies, one study was found 
that also was developmentally relevant utilizing human NT2 neurospheres (Hill et 
al., 2013), a model of neuron development. It is important to note that different 
methods of analysis were used to extract datasets. For the neurosphere dataset, 
the same two-fold cut off was used as in our analysis. However, a significance level 
of 0.01 was used. 
 
When comparing VPA microarrays of human NT2 neurospheres to C. elegans, only 
two common overlapping genes (Table 4.41), PLB1 (C. elegans ortholog: 
WBGene00008621) and ACTRT2 (C. elegans ortholog: WBGene00000067) were 
observed.  NT2 neurospheres provide a model of neuronal differentiation. 
Interestingly when this gene list is entered into DAVID, there is no biological 
enrichment in genes controlling neuron development and differentiation, yet 
apoptosis remains a key biological process, along with other embryonic 
development processes. No neuronal-specific KEGG pathways are highlighted 
from this analysis. Many genes are altered that affect the response to wounding 
and apoptosis. Table 4.42 shows the biological processes enriched in this data set. 
 
There are no other published VPA studies in C. elegans, and the only neural-related 
datasets were in developmental neuronal models/samples. As VPA most likely has 
multiple effects that are different between development and adulthood, we then 
looked at published microarray data, where the raw data was not available. These 
were from rat brain (Bosetti, Bell, & Manickam, 2005) and rat cortical neurons 
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(Fukuchi et al., 2009). In the rat brain study, a fold change cut-off of 1.4 was used, 
and the significance level was 0.05. In the rat cortical neuron study the same p 
value was used, but the fold change cut off was 2 as in our analyses. 
 
 The first microarray data extracted were from rat brain samples following 
chronic exposure to VPA. The analysed gene lists were imported in DAVID, and 
again neuron development and differentiation were enriched. As well as this, five 
genes were linked to synaptic transmission. When analysing disease relations, 
genes are clustered in three neurodegenerative diseases; Amyotrophic lateral 
sclerosis (ALS), Huntington’s disease, and Alzheimer’s disease.  Table 4.43 shows 
the enriched biological processes and Table 4.44 shows the KEGG pathways of 
interest for the rat brain study. 
 
 There are three overlapping genes between the adult rat brain and C. elegans 
(Table 4.45) – these are ckb-2 (WBGene00000512), fat-5 (WBGene00001397) 
and fat-6 (WBGene00001398). Fat-5 and Fat-6’s rat orthologs are both scd, and 
ckb-2 is Chka. Both of these are regulated in the same way from C. elegans to rats, 
with chka/ckb-2 being up regulated, and fat-5/fat-6/scd being down regulated in 
response to VPA. It must be noted, however, that the gene list published for this 
analysis only contained 81 genes. Scd is an acyl-CoA desaturase, which plays an 
important role in the synthesis of lipids. Chka is a choline kinase, which is required 
for the synthesis of phospholipids.  This adds evidence to there being a link 
between VPA treatment and lipid metabolism.
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Biological	Process Rat	Gene	Symbol(s)
GO:0050804~regulation	of	synaptic	transmission ARC	(+),	GRM3	(-),	LOC689121	(-),	GNAI2	(+),	MAP1B	(-),	DLG4	(-),	HTR2C	(-)
GO:0051969~regulation	of	transmission	of	nerve	impulse ARC	(+),	GRM3	(-),	LOC689121	(-),	GNAI2	(+),	MAP1B	(-),	DLG4	(-),	HTR2C	(-)
GO:0031644~regulation	of	neurological	system	process ARC	(+),	GRM3	(-),	LOC689121	(-),	GNAI2	(+),	MAP1B	(-),	DLG4	(-),	HTR2C	(-)
GO:0007611~learning	or	memory CASP3	(+),	PDE1B	(-),	LOC363956	(-),	TMOD2	(-),	APBB1	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0006915~apoptosis CASP3	(+),	LOC363956	(-),	PPP3R1	(-),	BCL2L1	(-),	PAWR	(+),	LOC684140	(-),	APBB1	(-),	LOC293190	(-),	ACVR1C	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0012501~programmed	cell	death CASP3	(+),	LOC363956	(-),	PPP3R1	(-),	BCL2L1	(-),	PAWR	(+),	LOC684140	(-),	APBB1	(-),	LOC293190	(-),	ACVR1C	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0019226~transmission	of	nerve	impulse GAD2	(-),	LOC363956	(-),	SCD	(-),	SYT2	(-),	TMOD2	(-),	DLG2	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0045161~neuronal	ion	channel	clustering DLG4	(-),	DLG2	(-)
GO:0008219~cell	death CASP3	(+),	LOC363956	(-),	PPP3R1	(-),	BCL2L1	(-),	PAWR	(+),	LOC684140	(-),	APBB1	(-),	LOC293190	(-),	ACVR1C	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0007268~synaptic	transmission GAD2	(-),	LOC363956	(-),	SYT2	(-),	TMOD2	(-),	DLG2	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0042981~regulation	of	apoptosis CASP3	(+),	CREB1	(-),	PPP3R1	(-),	NR4A1	(+),	HSPA1A	(+),	BCL2L1	(-),	HSPA1B	(+),	LOC684140	(-),	APBB1	(-),	LOC293190	(-),	ACVR1C	(-),	AKT2	(-)
GO:0030182~neuron	differentiation CASP3	(+),	NRP1	(-),	CREB1	(-),	MAP1B	(-),	DLG4	(-),	APBB1	(-),	DLG2	(-)
GO:0048666~neuron	development NRP1	(-),	CREB1	(-),	MAP1B	(-),	DLG4	(-),	APBB1	(-),	DLG2	(-)
GO:0007612~learning PDE1B	(-),	LOC363956	(-),	APBB1	(-),	RGD1566161	(-),	VDAC1	(-)
GO:0048167~regulation	of	synaptic	plasticity ARC	(+),	MAP1B	(-),	DLG4	(-)
Table 4.43  – Biological pathways enriched in differentially expressed genes from rat brain samples following VPA treatment. Lists of significantly upregulated 
and downregulated genes were extracted from literature, and inputted into DAVID for gene ontology and pathway analysis. Biological processes that were 
enriched in this data set are listed.  (+) indicates upregulation, and (-) indicates downregulation following treatment. 
 
KEGG	Pathway Rat	Gene	Symbol(s)
rno04210:Apoptosis CASP3	(+),	PPP3R1	(-),	BCL2L1	(-),	PRKACB	(-),	LOC684140	(-),	LOC293190	(-),	AKT2	(-)
rno04010:MAPK	signaling	pathway CASP3	(+),	MAPK14	(+),	PPP3R1	(-),	NR4A1	(+),	HSPA1A	(+),	PRKACB	(-),	HSPA1B	(+),	ACVR1C	(-),	AKT2	(-)
rno05014:Amyotrophic	lateral	sclerosis	(ALS) CASP3	(+),	MAPK14	(+),	PPP3R1	(-),	BCL2L1	(-),	LOC684140	(-),	LOC293190	(-)
rno05016:Huntington's	disease CASP3	(+),	LOC363956	(-),	CREB1	(-),	DLG4	(-),	ITPR1	(-),	RGD1566161	(-),	VDAC1	(-)
rno05010:Alzheimer's	disease CASP3	(+),	PPP3R1	(-),	CALM3	(-),	APBB1	(-),	CALM2	(-),	CALM-PS2	(-),	ITPR1	(-),	CALM1	(-)
rno04722:Neurotrophin	signaling	pathway MAPK14	(+),	CALM3	(-),	CAMK2B	(-),	CALM2	(-),	CALM-PS2	(-),	CALM1	(-),	AKT2	(-)
Table 4.44 – Pathways enriched in differentially expressed gene lists from rat brain samples following VPA treatment. Lists of significantly upregulated and 
downregulated genes were extracted from literature, and inputted into DAVID for gene ontology and pathway analysis. KEGG was used for pathway analysis, 
and pathways are listed if they had more than one gene associated with them.  (+) indicates upregulation and (-) indicates downregulation following treatment. 
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From the rat cortical neurons, interesting trends in biological process enrichment 
were observed (Table 4.46). Like in the other data sets, there is enrichment in 
genes associated with neuron development and differentiation, with 23 and 20 
down regulated genes, respectively.  Other examples of neuronal-specific 
processes clustered were neuropeptide signaling, axon guidance and synaptic 
vesicle transport. In the up regulated genes, there were also other neuron-specific 
biological processes enriched. Seventeen upregulated genes appear to be involved 
in neuron projection development. For example, there were six genes involved in 
the regulation of action potentials in neurons, and ten in the development of 
neuron projection. Throughout the data sets, there is conserved apoptosis 
enrichment. When looking at pathway enrichment, both Wnt and MAPK signaling 
are up regulated, and neurotrophin signaling is down regulated. Neurotrophins 
are essential for neuron development.  Table 4.47 shows a list of relevant 
pathways identified by KEGG analysis. 
 
Interestingly, 13 genes are conserved between the rat brain and rat cortical 
neuron samples. These include KCNC2, which is downregulated in both data sets, 
and is a voltage-gated potassium channel responsible for potassium transport in 
the brain. Csksr2 is an adapter protein involved in Ras signaling at synaptic 
Wormbase	Gene	ID Rat	Gene	symbol Worm	Regulation Rat	Regulation
WBGene00000512 Chka + +
WBGene00001397 Scd - -
WBGene00001398 Scd - -
Table 4.45 – Overlapping differentially expressed genes between the C. elegans and rat 
brain VPA microarrays. Data was extracted from literature for the rat brain VPA 
microarray data, as the raw form was not available. The C. elegans VPA microarray 
data was analysed using R and the limma package. + indicates upregulation and – 
indicates downregulation following treatment. 
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junctions and is also downregulated in response to VPA treatment in both data 
sets.  Notably, Gabbr1 is down regulated in both, and is a component of the G-
protein coupled receptor for GABA. This may provide a link between VPA and 
GABA neurotransmission. All shared genes are shown in Table 4.48. However, no 
genes are shared between all three of the rat brain, rat cortical neuron and C. 
elegans data sets. 
 
When converted to worm orthologs, fourteen downregulated rat genes 
(seventeen worm genes) and eleven upregulated rat (32 worm genes) are shared 
between the rat cortical neurons and C. elegans (Table 4.49).  Of interest were 
NRCAM, which is downregulated in both data sets, and is associated with nervous 
system development and synaptic transmission. HEXB is found in both data sets. 
However, this gene is upregulated in rat cortical neurons, and downregulated 
(hex-1, WBGene00020509) in the worm datasets. For many of these genes, there 
were also several worm orthologs found in our worm microarray data. Of note, 
similarly to the mouse brain, Gsta4 is conserved between species.   
 
These results suggest a conservation of the effects of VPA on neuron development 
and differentiation, in both the developing and adult brain. Other pathways, such 
as WNT, TGF-β, MAPK, and apoptosis are also affected. VPA may also be affecting 
both cholinergic and GABA signaling.
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Biological	Process Gene	Symbol(s)
GO:0006916~anti-apoptosis BDNF		(+),	CDC2		(+),	PRKCI		(+),	DAD1		(+),	ADAM17		(+),	FOXO1		(+),	HSPA1A		(+),	FAIM		(+),	GLO1		(+),	HSPA1B		(+),	HBXIP		(+),	API5		(+)
GO:0006917~induction	of	apoptosis LOC681486		(+),	APH1B		(+),	STK17B		(+),	SMAD3		(+),	STAT1		(+),	PTEN		(+),	GCH1		(+),	STAT4		(+),	CDKN1B		(+),	DDX19A		(+),	CDKN2C		(+),	
PSEN2		(+),	DIABLO		(+),	APAF1		(+),	CABC1		(+)
GO:0007218~neuropeptide	signaling	pathway LPHN2	(-),	PNOC	(-),	NPY	(-),	SSTR1	(-),	GPR56	(-),	ADCYAP1	(-)
GO:0007268~synaptic	transmission CPLX1	(-),	NTF3	(-),	SYT4	(-),	PNOC	(-),	NPY	(-),	SPTBN2	(-),	TMOD2	(-),	ADNP	(-),	GRIK5	(-),	APBA2	(-),	CD24	(-),	CACNA1C	(-),	GAD1	(-)
GO:0007409~axonogenesis NRCAM	(-),	CDK5R1	(-),	PTPRM	(-),	NRP1	(-),	NTF3	(-),	ANK3	(-),	CXCR4	(-),	RTN4R	(-),	ROBO2	(-),	VCAN	(-),	DCLK1	(-)
GO:0007411~axon	guidance NRCAM	(-),	CDK5R1	(-),	PTPRM	(-),	NRP1	(-),	NTF3	(-),	ANK3	(-),	CXCR4	(-),	ROBO2	(-)
GO:0007412~axon	target	recognition BDNF		(+),	STXBP1		(+)
GO:0008038~neuron	recognition CDK5R1	(-),	NRP1	(-),	CXCR4	(-)
GO:0008366~axon	ensheathment TPO1		(+),	CD9		(+),	PPARD		(+),	EGR2		(+),	HEXB		(+),	PLLP		(+)
	GO:0007272~ensheathment	of	neurons TPO1		(+),	CD9		(+),	PPARD		(+),	EGR2		(+),	HEXB		(+),	PLLP		(+)
GO:0019228~regulation	of	action	potential	in	neuron TPO1		(+),	CD9		(+),	PPARD		(+),	EGR2		(+),	HEXB		(+),	PLLP	(+)
GO:0030182~neuron	differentiation CDK5R1	(-),	PTPRM	(-),	NRP1	(-),	GNAO1	(-),	NTF3	(-),	RTN4R	(-),	DPYSL4	(-),	BRSK1	(-),	KCNIP2	(-),	GAS7	(-),	ITGB1	(-),	KCHIP2	(-),	
NRCAM	(-),	LINGO1	(-),	ANK3	(-),	CXCR4	(-),	VEGFA	(-),	ROBO2	(-),	VCAN	(-),	CD24	(-),	DCLK1	(-),	DSCAM	(-)
GO:0031175~neuron	projection	development ALS2		(+),	FGFR1		(+),	NRTN		(+),	EGR2		(+),	MAP2K1		(+),	FGFR1L		(+),	PAX6		(+),	STXBP1		(+),	LOC692021		(+),	CTNNA1		(+),
	PTEN		(+),	ALCAM		(+),	SEMA5A		(+),	BDNF		(+),	NUMB		(+),	LOC290415		(+),	PHGDH		(+),	CNTN4		(+)
GO:0031175~neuron	projection	development CDK5R1	(-),	PTPRM	(-),	NRP1	(-),	GNAO1	(-),	NTF3	(-),	RTN4R	(-),	GAS7	(-),	ITGB1	(-),	NRCAM	(-),	LINGO1	(-),	CXCR4	(-),	
ANK3	(-),	ROBO2	(-),	VCAN	(-),	CD24	(-),	DCLK1	(-),	DSCAM	(-)
GO:0042981~regulation	of	apoptosis IRAK1	(-),	CDK5R1	(-),	NTF3	(-),	NELL1	(-),	ARNT2	(-),	ADNP	(-),	NFKBIA	(-),	INHA	(-),	PEA15A	(-),	LOC684638	(-),	SRC	(-),	
MAGED1	(-),	AKT1	(-),	ATF5	(-),	PCGF2	(-),	AKT1S1	(-),	ANK3	(-),	BOK	(-),	LCK	(-),	VEGFA	(-),	NEUROD1	(-),	CD24	(-),	NSMAF	(-),	MYC	(-),	IP6K2	(-)
GO:0043524~negative	regulation	of	neuron	apoptosis BDNF		(+),	HDAC1		(+),	WFS1		(+),	MSH2		(+),	LOC364295		(+),	HDAC1L		(+),	LIG4		(+),	GCLM		(+),	LOC360472		(+)
GO:0045664~regulation	of	neuron	differentiation NRP1	(-),	RGS6	(-),	RTN4R	(-),	ADNP	(-),	NEUROD1	(-),	ROBO2	(-),	CDH2	(-),	CD24	(-),	MT3	(-)
GO:0048489~synaptic	vesicle	transport CPLX1	(-),	SPTBN2	(-),	APBA2	(-),	CD24	(-)
GO:0048666~neuron	development CDK5R1	(-),	PTPRM	(-),	NRP1	(-),	GNAO1	(-),	NTF3	(-),	RTN4R	(-),	DPYSL4	(-),	KCNIP2	(-),	GAS7	(-),	ITGB1	(-),	KCHIP2	(-),	NRCAM	(-),	LINGO1	(-),	
ANK3	(-),	CXCR4	(-),	VEGFA	(-),	ROBO2	(-),	VCAN	(-),	CD24	(-),	DCLK1	(-),	DSCAM	(-)
GO:0048812~neuron	projection	morphogenesis CDK5R1	(-),	NRP1	(-),	PTPRM	(-),	NTF3	(-),	RTN4R	(-),	GAS7	(-),	ITGB1	(-),	NRCAM	(-),	CXCR4	(-),	ANK3	(-),	ROBO2	(-),	VCAN	(-),	DCLK1	(-),	DSCAM	(-)
GO:0050767~regulation	of	neurogenesis ATF5	(-),	LINGO1	(-),	NRP1	(-),	NTF3	(-),	RGS6	(-),	RTN4R	(-),	ADNP	(-),	NEUROD1	(-),	ROBO2	(-),	CDH2	(-),	CD24	(-),	MT3	(-)
GO:0050768~negative	regulation	of	neurogenesis ATF5	(-),	LINGO1	(-),	NRP1	(-),	RTN4R	(-),	CD24	(-),	MT3	(-)
GO:0051960~regulation	of	nervous	system	development ATF5	(-),	LINGO1	(-),	NRP1	(-),	NTF3	(-),	RGS6	(-),	RTN4R	(-),	ADNP	(-),	NEUROD1	(-),	ROBO2	(-),	CDH2	(-),	CD24	(-),	MT3	(-)
Table 4.46 - Biological pathways enriched in differentially expressed genes from rat cortical neuron samples following VPA treatment. Lists of 
significantly upregulated and downregulated genes were extracted from literature, and inputted into DAVID for gene ontology and pathway 
analysis. Neurologically relevant biological processes with more than one gene association are listed. (+) indicates upregulation, and (-) indicates 
downregulation following VPA treatment. 
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KEGG	Pathways
rno04010:MAPK	signaling	pathway rno04310:Wnt	signaling	pathway rno04722:Neurotrophin	signaling	pathway
FGFR1	(+) SENP2	(+) AKT1(-)
MAP2K1	(+) LOC295194	(+) MAGED1(-)
LOC499736	(+) PPARD	(+) IRAK1(-)
FGFR1L	(+) PPP2R5A	(+) NTF3(-)
HSPA1A	(+) CCND2	(+) PIK3CD(-)
PPM1B	(+) JUN	(+) NFKBIA(-)
HSPA1B	(+) CAMK2D	(+) CAMK2B(-)
DDIT3	(+) SMAD3	(+) ARHGDIB(-)
STK3	(+) RGD1565588	(+)
RGD1564956	(+) FZD2	(+)
LOC681749	(+) CHP	(+)
MAPK1	(+) AXIN2	(+)
RPS6KA6	(+) RGD1564956	(+)
BDNF	(+)
ARRB2	(+)
RPS6KA1	(+)
DUSP14	(+)
JUN	(+)
RGD1565588	(+)
LOC365977	(+)
CHP	(+)
GADD45B	(+)
MAP2K6	(+)
Table 4.47 – Pathways enriched in differentially expressed gene lists from rat cortical neuron 
samples following VPA treatment. Lists of significantly upregulated and downregulated genes 
were extracted from literature, and inputted into DAVID for gene ontology and pathway analysis. 
KEGG was used for pathway analysis, and pathways are listed if they had more than one gene 
associated with them. (+) Indicates upregulation and (-) indicates down regulation following 
treatment. 
Gene	Symbol Cortical	Regulation Brain	Regulation
Kcnc2 - -
Bbx + +
Mcm6 + +
Cnksr2 - -
Camk2b - -
Dpp6 - -
Grm3 - -
Zeb1 + -
Tmod2 - -
Gabbr1 - -
Srd5a1 + +
Hspa1a + +
Lta4h + +
Table 4.48 – Overlapping differentially expressed genes between the rat cortical neuron and brain 
samples following VPA treatment. Data was extracted from literature for the rat brain and rat cortical 
neuron VPA microarray data, as the raw form was not available. + indicates upregulation, and – 
indicates downregulation following treatment. 
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Wormbase	Gene	ID Rat	Symbol Rat	regulation Worm	regulation
WBGene00000768 Coro1a - -
WBGene00002260 Fabp7 - +
WBGene00002243 Nrcam - -
WBGene00019322 Ahcy - +
WBGene00017471 Cfp - +
WBGene00011880 Cfp - -
WBGene00021487 Comtd1 - +
WBGene00012518 Comtd1 - +
WBGene00015479 Abcg4 - +
WBGene00001149 Bcat1 - +
WBGene00008479 B3gat1 - -
WBGene00008160 B3gat1 - -
WBGene00004275 Rab11b - +
WBGene00001577 Cpne5 - +
WBGene00000067 Acta1 - +
WBGene00008681 Plscr3 - +
WBGene00017312 Slc20a1 - +
WBGene00008479 B3gat2 + -
WBGene00008160 B3gat2 + -
WBGene00016507 Abhd4 + +
WBGene00016506 Abhd4 + +
WBGene00001077 P4ha1 + +
WBGene00005649 Serpini1 + +
WBGene00001824 Rest + -
WBGene00021503 Ctsa + +
WBGene00008741 Ctsa + +
WBGene00019605 Ctsa + +
WBGene00019617 Ctsa + +
WBGene00017969 Ctsa + +
WBGene00020509 Hexb + -
WBGene00016435 Nxn + +
WBGene00021796 Nxn + +
WBGene00008273 Mfsd9 + +
WBGene00012467 Txnip + +
WBGene00012464 Txnip + +
WBGene00001757 Gsta4 + +
WBGene00001772 Gsta4 + +
WBGene00001761 Gsta4 + +
WBGene00001754 Gsta4 + +
WBGene00001753 Gsta4 + +
WBGene00001762 Gsta4 + +
WBGene00001778 Gsta4 + +
WBGene00001770 Gsta4 + +
WBGene00001756 Gsta4 + +
WBGene00001787 Gsta4 + +
WBGene00001786 Gsta4 + +
WBGene00001768 Gsta4 + +
WBGene00001755 Gsta4 + +
WBGene00001760 Gsta4 + +
Table 4.49 – Overlapping differentially expressed genes between the C. elegans and rat 
cortical neuron VPA microarrays. Data was extracted from literature for the rat 
cortical neuron VPA microarray data, as the raw form was not available. The C. elegans 
VPA microarray data was analysed using R and the limma package. + indicates 
upregulation and – indicates downregulation following treatment. 
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4.4 Discussion 
 
4.4.1 Using C. elegans as a model system to screen for novel regulators of synaptic 
function 
 
In this chapter, data from a previous global microarray gene expression study 
(Munasinghe, 2015)  was reanalyzed, in which differential gene expression 
profiles were analysed following exposure of C. elegans N2 worms to increasing 
doses (3mM-24mM) of VPA. Unlike the initial analysis, where trends in gene 
expression profiles were correlated with increasing VPA dose, the full profile of all 
genes whose expression was significantly altered by exposure to VPA was 
investigated in this chapter. However, it may be significant to note that Wnt, MAPK 
and TGF-β pathways were enriched in both rounds of analysis. 
 
From these screens sixteen candidates were found to cause a significant RIC or 
HIC phenotype. One of these, itsn-1, had previously been observed to cause a HIC 
phenotype (Rose et al., 2007), although this study was not tested in the Tu3311 or 
Tu3335 strains. They also reported a HIC phenotype in itsn-1 deletion mutants. 
Itsn-1 encodes intersectin, which has been shown to interact with proteins in both 
endo- and exocytic pathways, and has been reported to have an inhibitory effect 
of neurotransmission (Rose et al., 2007). In our studies this theory may still be 
valid, as inhibition of cholinergic signaling would confer a RIC phenotype. 
However, further investigation would be required to determine why wild-type 
worm knockdown or mutation of itsn-1 leads to hypersensitivity, whereas 
knocking down of the same gene in a neurosensitive strain leads to the opposite 
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phenotype. This result could possibly be due to a greater proportion of dsRNA 
reaching the neurons, and less entering the muscle. 
 
Sel-12 is another interesting hit from the screens performed in this study. The 
human ortholog of Sel-12 is presenilin 2 (PSEN2). Both proteins are multi-pass 
trans-membrane proteins, however the role of presenilins in neurotransmission 
is not yet characterized.  There is some evidence to suggest that PSEN2 may be a 
catalytic subunit of the γ-secretase complex, which cleaves proteins such as Notch 
receptors and APP (Lee et al., 2002). Mutations in PSEN2 have been shown to 
increase the cleavage of APP into the toxic Aβ42 molecule (in comparison to Aβ40, 
(Can Zhang, Browne, Kim, & Tanzi, 2010)), which form part of Alzheimer’s disease 
related plaques. Presenilins have also been found to be essential for the regulation 
of neurotransmitter release (C Zhang et al., 2009). In our study, knockdown of sel-
12 in a neurosensitive worm strain conferred a RIC phenotype, suggesting that 
knocking down presenilin could be effecting either excitatory (cholinergic) or 
inhibitory (GABA) signaling. If conserved in human neurons this phenotype could 
clearly have pathological consequences. 
 
Dhhc-2 is a member of the palmitoyl-acyl transferase family of proteins. The 
human ortholog of dhhc-2 is zDHHC9, which encodes the DHHC9 enzyme. DHHC9 
is known to palmitoylate N-Ras and H-Ras (Swarthout et al., 2005b), and four 
mutations (one frame-shift, two missense, and one splice-site mutation) have 
been found in this gene to cause X-linked mental retardation (Mitchell et al., 2014). 
Palmitoylation of Ras is essential for its trafficking between the Golgi apparatus 
and the plasma membrane, and so clearly regulation of this process may well have 
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implications for cancer biology. However, protein palmitoylation has also been 
heavily implicated in neuronal plasticity and development (Fukata & Fukata, 
2010). Given that data from each of the microarray studies showed a conserved 
role of VPA in neuronal development and differentiation, this makes dhhc-2 and 
the regulation of protein palmitoylation a very interesting area of further study 
into novel regulators of synaptic function or modulation. 
 
4.4.2 VPA induced changes in neuronal genes 
 
From the comparison of microarray datasets, some clear effects of VPA exposure 
can be established. VPA is known to be a teratogen as the chance of a foetus having 
neural tube defects is increased upon taking VPA during pregnancy (Alsdorf & 
Wyszynski, 2005). The data analysed in this study suggest that observed changes 
in expression of HSPG2, CELSR1 and MAPK8 might contribute to neural tube 
defects. Each of these genes was down regulated in response to VPA treatment. 
HSPG2 encodes the heparin sulphate proteoglycan perlecan, which has previously 
been associated with neural tube defects in mice (Allache, De Marco, Merello, 
Capra, & Kibar, 2012). Perlecan (also known as HSPG2) is essential for both 
cartilage and cephalic development. CELSR1 is a key member of the planar cell 
polarity (PCP) pathway, and mutations in CELSR1 have been shown to cause 
neural tube defects (Boutin, Goffinet, & Tissir, 2012).  MAPK8 also known as JNK1, 
is a key component of the MAP kinase-signaling pathway, which is a conserved 
pathway, affected by VPA treatment. In mice, when JNK1 and JNK2 are both 
knocked out, neural tube defects are observed due to dysregulation of apoptosis 
in the brain (Kuan et al., 1999; Sabapathy et al., 1999). 
Chapter 4: Sodium Valproate (VPA) 
 248 
 
Neuronal development and differentiation pathways were enriched in all studies 
, with the exception of the neurosphere study. Children born to mothers taking 
VPA during pregnancy have been reported to have an increase incidence of 
developing autism spectrum disorders. (Christensen et al., 2013).  Interestingly, 
trends identified in this analysis may provide clues as to why this may occur. The 
human ortholog of the C. elegans gene lad-2 (WBGene00002243) is NRCAM, which 
plays a role in the outgrowth of neurites and the formation of nodes of Ranvier on 
myelinated neurons (Hortsch et al., 1996). NRCAM is a strong candidate for 
autism, from both association studies and studies in NRCAM-null mice (Marui et 
al., 2009; Moy, Nonneman, Young, Demyanenko, & Maness, 2009). Lad-2/NRCAM 
was down regulated in C. elegans and rat cortical neurons following exposure to 
VPA.  
 
As well as being used to treat epilepsy, VPA has also been used in Alzheimer’s 
disease trials (X. Z. Zhang, Li, & Zhang, 2010). In this study, multiple genes 
exhibiting VPA-induced changes in gene expression had human orthologs that 
have been linked to Alzheimer’s disease.  These include C. elegans orthologs of 
human HSPG2, AGRN, CYP3A4, LIPA and MAPK8 genes, all of which were down 
regulated following exposure to VPA.  HSPG2 is found on chromosome 1p36, a 
region implicated in late-onset Alzheimer’s disease. It, and other proteoglycans 
are linked to Alzheimer’s due to their contribution to the increasing build-up of 
amyloid and tau plaques (Van Horssen, Wesseling, Van Den Heuvel, De Waal, & 
Verbeek, 2003). The role of HSPG2 is however controversial, with some studies 
showing no association to Alzheimer’s disease. One study performed on a Finnish 
Chapter 4: Sodium Valproate (VPA) 
 249 
population found associations in people who carried the apolipoprotein epsilon 4 
(APOe4) allele, which is itself associated with a higher risk of Alzheimer’s disease 
(Iivonen et al., 2003). For these reasons, the mechanisms of action of HSPG2 in this 
context remain unclear. 
 
AGRN encodes Agrin, which is another heparin sulphate proteoglycan, and is an 
important constituent of the blood brain barrier. In mouse models of Alzheimer’s 
disease, AGRN deletion in endothelial cells led to increased Aβ levels in the brain, 
although deletion from neurons did not have this effect (Rauch et al., 2011). These 
results suggest that VPA may decrease heparin sulphate expression, which may 
have pathophysiological effects. LIPA is also located on human chromosome 10, 
with known associations to late onset Alzheimer’s disease. LIPA protein is also 
known to be involved in cholesterol metabolism (von Trotha et al., 2006). More 
study is needed to understand whether down regulation of these genes is found in 
humans, and whether it is beneficial or detrimental to AD patients. 
 
Four of the genes that were up regulated in response to VPA were previously 
linked to epilepsy. Of these, WWOX shows the clearest link, with a study showing 
that whole exon deletion of WWOX leads to both epilepsy and intellectual 
disability (Ben-Salem, Al-Shamsi, John, Ali, & Al-Gazali, 2015).   
 
The C. elegans ortholog of the human KCNMA1 gene (slo-1) was down regulated 
in response to VPA. KCNMA1 is a calcium activated potassium channel subunit, 
and gain of function mutations in KCNMA1 have been linked to generalized 
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epilepsy and paroxysmal dyskinesia (Du et al., 2005). Therefore, this gene may be 
a target of VPA that is beneficial to epileptic patients. 
 
PRSS16 is a schizophrenia-associated gene conserved between worms and the 
dataset from the developing mouse brain (at developmental stage e14.5). PRSS16 
is up regulated in the e14.5 brain. Five C. elegans genes were significantly up 
regulated, whose closest human ortholog was PRSS16. These were pcp-2 
(WBGene00003957), pcp-4 (WBGene00003959), C26B9.5 (WBGene00016134), 
F56F10.1 (WBGene00018984) and K12H4.7 (WBGene00019682). In a GWAS 
study in 2012, they found a ZNF804a single nucleotide polymorphism associated 
with schizophrenia and bipolar disorder, and showed that expression of this 
protein increased levels of PRSS16 (Girgenti, LoTurco, & Maher, 2012). VPA has 
been used in combination with antipsychotic medications, and studies have found 
that this combination of drugs resulted in an overall improvement in 
psychopathology, compared to using only the antipsychotic drug (Tseng et al., 
2016).  How increased PRSS16 leads to schizophrenia has not yet been explained, 
however, changes in the expression of the PRSS16 gene may explain some of the 
therapeutic benefits of VPA. 
 
4.4.3 Conservation of signaling pathways following VPA treatment 
 
Firstly, changes in the expression of genes involved in cholinergic signaling, such 
as ace-3/BCHE and lev-8/chrna5 were conserved between C. elegans and mice 
nESC, indicating that VPA causes changes to cholinergic signaling.  Lev-8/chrna5 
was shared between the mouse nESC, e14.5 brain and worm data sets, which is 
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the alpha subunit of an N-acetylcholine receptor. When the C. elegans microarray 
studies were initially carried out, the Falciani lab found that another ACh receptor 
subunit (acr-17) was also down regulated (Munasinghe, 2015). As ace-3/BCHE is 
down regulated in response to VPA, this suggests that decreased amounts of 
acetylcholine would be degraded at the synapse. However, whether this leads to 
increased excitatory neurotransmission remains to be elucidated. In the mouse 
nESC microarray data, genes involved in GABA synthesis and GABA receptor 
pathways were up regulated in response to VPA. However, this change was not 
observed in C. elegans. 
 
Another conserved pathway altered in response to VPA treatment was Wnt 
signaling. Significantly, the Wnt signaling pathway was enriched in mouse nESC, 
rat cortical neurons and C. elegans microarrays. VPA treatment in rats has been 
suggested to promote Wnt signaling. Due to demethylation of wnt1 and wnt2 
promoter regions, expression levels of wnt1 and wnt2 were reported to increase 
(Wang et al., 2010). Cwn-2 is a C. elegans Wnt ligand, and cfz-2 is a frizzled 
receptor, both of which were down regulated in response to VPA.  Also, as VPA is 
a histone deacetylase inhibitor, it would be interesting to see if this deacetylase 
activity is conserved in worms, and whether it is of pathological relevance in 
humans.  
 
VPA may also be affecting the MAP kinase signaling and TGF-β pathways as these 
pathways were found to be enriched for differentially expressed genes/proteins 
in several microarray dataset. There could even be cross talk between the MAP 
kinase, TGF-β and Wnt signaling pathways. In human hepatocytes, VPA has been 
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shown to promote the ERK signaling cascade, which again may be due to its HDAC 
activity. It would therefore be interesting to carry out a similar microarray 
analysis using a derivative of VPA, valpromide, which is identical to VPA but has 
no HDAC inhibitory activity (Fujiki, Sato, Fujitani, & Yamashita, 2013).  
 
Apoptosis was enriched in all arrays analysed in this study and in data extracted 
from literature. Multiple studies have reported pro – and anti-apoptotic effects of 
VPA. For example, in human neuroblastoma cell lines, VPA treatment has been 
shown to enhance staurosporine-induced cell death by down-regulating surviving 
(Shah et al., 2013). However, there is conflicting data as to the role of KCNMA1 in 
apoptosis, as valpromide was also found to have caused this effect (Shah et al., 
2013). However, in another paper, VPA was shown to be pro-apoptotic against 
neural progenitor cells (but not the embryonic stem cell derived glutamatergic 
neurons), which was found to be dependent on its HDAC activity (Fujiki et al., 
2013). From these results it is clear that genes in the apoptotic pathway are 
altered in response to VPA treatment, but a consensus as to how this occurs, and 
whether it is different in development and adulthood is unclear.  
 
4.4.4 Conclusion 
 
From the re-analysis of available microarray data, many interesting pathways 
appear to be affected by exposure to VPA, especially in neuronal development and 
differentiation. Also, there appears to be some degree of evolutionary 
conservation of VPA-induced changes between species. This makes VPA an 
interesting effector in neurons, although further studies are needed to understand 
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the ability of VPA to influence synaptic function. Aldicarb screening of potential 
synaptic regulators identified in this study revealed some interesting candidates, 
including the novel regulator dhhc-2, which then became the focus of further 
functional studies. 
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5.1 Abstract 
 
Results presented in Chapter 4 demonstrate that knockdown of the C. elegans 
dhhc-2 gene in Tu3311 worms caused a significant RIC phenotype. As dhhc-2 is one 
of a family of 15 palmitoyl acyltransferase (PATs) encoded in the C. elegans 
genome, the next aim was to further investigate the dhhc-2 knockdown phenotype 
and test the possibility that other members of the PAT family may also influence 
synaptic function. To address this point, aldicarb-sensitivity assays were 
performed on other PAT family members, following gene-targeted neuron-
specific RNAi knockdown. In a complementary study, corresponding genetic 
knockouts of PAT family members were also analysed to assess relative aldicarb 
sensitivity. Interestingly, data from this study indicated that knockdown of dhhc-
12 also led to reduced aldicarb sensitivity. Although genetic mutation of dhhc-2 
did not cause a significant change in aldicarb sensitivity, mutation of dhhc-14 and 
dhhc-13 conferred significant RIC and HIC phenotypes, respectively.  
 
Previous work performed in the Falciani group (Munasinghe, 2015) showed that 
VPA induced paralysis in sma-6 mutant worms. In addition, preliminary results 
suggested that combined treatment of VPA and aldicarb greatly increased the rate 
of paralysis in wild type worms. To further investigate this phenotype, these 
effects were reassessed in the N2, sma-6 and unc-38 worm strains, which were 
also used in the previous study (Munasinghe, 2015). The extent of VPA-induced 
paralysis was also examined in PAT mutant worms, and following targeted 
knockdown of PAT family members in the Tu3311 strain.  
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To elucidate conserved effectors of synaptic function, mouse and human orthologs 
of C. elegans PAT family members were cloned. Cytoplasmic N-terminal fragments 
of mouse zDHHC17, zDHHC13, and a C-terminal fragment of human zDHHC5 were 
cloned for use in the Matchmaker Y2H library screens, in order to identify novel 
interaction partners. Following stringently controlled screening of a normalized 
human foetal brain Y2H library, 35 novel interacting partners were identified, of 
which 7 had previously been shown to be palmitoylated. Unfortunately, although 
the N- and C-terminal fragments of zDHHC9 (the human ortholog of C. elegans 
dhhc-2) were also tested in Y2H library screens, no interaction partners were 
identified. However, 17 novel interaction partners were found when full-length 
zDHHC9 used analysed using the MYTH membrane Y2H system. Data from these 
interaction studies was assembled into a new PAT network, which provides a 
resource to inform future studies into the potential mechanism of action of human 
PAT family members. 
 
5.2 Introduction 
 
5.2.1 Understanding the C. elegans PAT family 
 
The results from aldicarb-sensitivity screens (Chapter 4, section 4.3.2) 
demonstrated that targeted knockdown of the C. elegans PAT family member 
dhhc-2 resulted in a significant and reproducible RIC phenotype. Palmitoylation is 
an essential reversible reaction; in which PATs facilitate the addition of palmitoyl-
acyl groups onto substrate proteins. Families of PATs are found throughout 
evolution from yeast to Drosophila, zebrafish and humans. At the level of the 
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synapse, palmitoylation is known to play a crucial role in SNAP-25 folding during 
SNARE complex formation and neurotransmitter release (Washbourne P et al,. 
2001). Defects in palmitoylation have also been linked to neurological diseases, 
including adult neuronal ceroid lipofuscinosis (ANCL), where mutations in the 
cysteine-string-domain of CSPα confer global changes in neuronal palmitoylation, 
affecting multiple synaptic proteins (Henderson et al., 2016). 
 
To date, there have been few comparative studies performed on the PAT family 
members in C. elegans, with only one study (Edmonds & Morgan, 2014) 
performing systematic functional comparisons of family members. Bioinformatics 
analysis identified 15 PAT family members in C. elegans (dhhc-1-14, and spe-10), 
each of which contains the characteristic DHHC-CRD motif (Edmonds & Morgan, 
2014). Although numerous phenotypic assays were previously performed (Tables 
5.1 and 5.2), aldicarb-sensitivity assays were not carried out on the mutant strains 
nor following RNAi mediated knockdown of PAT family members. Also neuron-
specific RNAi worm strains such as Tu3311 were not used in previous studies, 
although the rrf-3 RNAi hypersensitive strain was used. For this reason, other 
members of the C. elegans PAT family may also show aldicarb-sensitive 
phenotypes if tested in a different genetic background.  
 
 
Strain Gene Allele Mutation Phenotypes	previously	observed
RB1044 dhhc-2 ok990 deletion Reduced	width
VC2067 dhhc-9 gk985 deletion Reduced	mean	and	median	lifespan
VC2039 dhhc-12 gk1013 insertion/deletion Reduced	width,	reduced	thrashing	in	liquid,	increased	time	to	90%	mortality
VC108 dhhc-13 gk36 deletion Increased	median	lifespan	and	increased	time	to	90%	mortality
VC918 dhhc-14 ok1032 insertion/deletion Reduced	width,	increased	thrashing	in	liquid,	decreased	mean	life	span	and	decreased	time	to	90%	mortality
Table 5.1 – Summary of previously reported phenotypes in genetic PAT mutant worms (Edmonds & 
Morgan, 2014) 
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5.2.2 Using pharmacological agents to elucidate novel C. elegans phenotypes 
 
Data presented in Chapter 4 was derived from microarray studies performed on 
wild-type worms exposed to increasing concentrations of VPA. In addition, VPA-
induced paralysis had been observed in the sma-6 mutant worm strain. VPA is an 
interesting drug due to its broad medical use to treat epilepsy and bipolar 
disorder. However, much remains to be understood about the underlying 
mechanism of VPA action. As dhhc-2 was selected for further investigation based 
on network informed predictions from these previous studies, we were 
particularly interested to see whether genetic mutation or RNAi mediated neuron-
specific knockdown of PAT family members would lead to VPA-induced paralysis. 
In addition, we wished to re-test if aldicarb and VPA had additive effects on the 
rate of paralysis of wild type worms, and test if comparable phenotypes were 
observed in PAT mutant strains and corresponding RNAi mediated knockdown 
studies. If altered expression of any of the PATs induced changes in aldicarb 
sensitivity profiles, this could be indicative of a role at either cholinergic or GABA 
terminals.  
 
RNAi Phenotypes	previously	observed
dhhc-1 decreased	time	to	90%	mortality
dhhc-6 decreased	thrashing	in	liquid
dhhc-9	+	dhhc-12 decreased	time	to	90%	mortality
dhhc-10	+	dhhc-1 increased	thrashing	in	liquid,	decreased	time	to	90%	mortality
dhhc-13	+	dhhc-14 increased	median	lifespan,	decreased	time	to	90%	mortality
spe-10	+	dhhc-4 increased	mean	and	median	lifespan
Table 5.2 – Summary of previously reported phenotypes when C. elegans PAT family 
members were knocked down using RNAi (Edmonds & Morgan, 2014). 
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5.2.3 Use of multiple Y2H systems to identify novel interaction partners of human 
PATs 
 
The principle of “Guilt by association” suggests that insight into the function or 
mode of action of a protein can be obtained by defining its interaction partners, as 
proteins that form part of the same complex may function in the same biological 
process (Oliver, 2000).  Therefore, given the current paucity of data for human 
PAT family members we aimed to use two forms of Y2H assays to identify novel 
interaction partners. These may provide new insight into the mode of action or 
regulation of human PAT family members. Y2H library screens provide an 
unbiased method of screening for novel direct (or ‘binary’) interaction partners. 
Although PAT family members are found throughout evolution, few of these 
proteins have well defined partner profiles in any organism. 
 
Also, little of the existing interaction data is derived from techniques such as Y2H, 
which defines only direct partner interactions. One exception to this was a study 
carried out on DHHC17 (also known as HIP14), where the enzyme was fragmented 
into three domains that still contained trans-membrane domains. Bait clones 
encoding these three domains were then pooled and used to screen a classical 
yeast-two-hybrid library (Butland et al., 2014). Although the classical Y2H system 
normally does not function well with trans-membrane proteins, in this study they 
found many novel interaction partners that appear to be physiologically relevant, 
due to a known relation with HTT.  
 
As the aim of this work was to use C. elegans as a model system to provide new 
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insight into the diversity of synaptic regulation and the potential implications of 
genetic changes in human neurons, Y2H library screens were performed using 
human orthologs of C. elegans PAT family members. 
 
5.2.4 Aims 
 
The aims of this chapter were to: 
 Perform aldicarb-sensitivity assays to assess the relative effects of PAT 
family member knockdown on synaptic function. 
 Establish if knockdown of PAT family members influences VPA-induced 
paralysis. 
 Elucidate the combined effects of aldicarb and VPA on PAT mutants or PAT 
RNAi treated neurosensitive worms. 
 Identify conserved orthologs of PAT family members and create a multi 
species PAT family “interolog” protein-interaction network, containing all 
known and predicted PAT family member binding partners. 
 Carry out MYTH library screens on full length PATs, in addition to classical 
Y2H screens on cytoplasmic fragments of a selection of PAT family 
members, in order to identify novel interaction partners and enhance local 
interactome coverage. 
 Combine all known and novel PAT family protein interaction data to 
generate an improved one-step PAT interactome. 
 
 5.3 Results 
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5.3.1 Effect of aldicarb on PAT mutants and PAT RNAi knockdowns  
 
Following RNAi knockdown of C. elegans PAT family members, aldicarb-sensitivity 
assays were performed, as described in Chapter 2, section 2.4. A paired T-test was 
performed on the percentage paralysis values for the negative control (L440) and 
Tu3311 worms knocked down with each PAT family member. In each case, a 
significance threshold of p-value < 0.05 was imposed (Figures 5.1- 5.3 and Table 
3.3). Data from this analysis show that in addition to dhhc-2, RIC phenotypes were 
also observed following RNAi mediated knockdown of dhhc-3,  dhhc-12 and spe-
10. In addition, significant HIC phenotypes were observed following knockdown 
of dhhc-1 and dhhc-5 family members. 
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Figure 5.1 – Induced changes in aldicarb sensitivity following RNAi mediated 
knockdown of dhhc-1, -2, -3, -4, -5 and -6. In each case aldicarb sensitivity assays were 
performed in triplicate on adult worms following RNAi mediated knockdown as 
described in materials and methods. Percentage paralysis was measured after 140 
minutes. * denotes significance p< 0.05. n=3. Error bars represent standard deviation. 
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Figure 5.2 – Induced changes in aldicarb sensitivity following RNAi mediated 
knockdown of dhhc-7, -8, -9, -10, and -11. In each case aldicarb sensitivity assays were 
performed in triplicate on adult worms following RNAi mediated knockdown as described 
in materials and methods. Percentage paralysis was measured after 140 minutes. * 
denotes significance p< 0.05.  n=3. Error bars represent standard deviation. 
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Figure 5.3 – – Induced changes in aldicarb sensitivity following RNAi mediated 
knockdown of dhhc-12, -13, -14, and spe-10. In each case aldicarb sensitivity assays 
were performed in triplicate on adult worms following RNAi mediated knockdown as 
described in materials and methods. Percentage paralysis was measured after 140 
minutes. * denotes significance p< 0.05. n=3. Error bars represent standard deviation. 
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To further explore these phenotypes, relative changes in aldicarb sensitivity were 
also assessed in genetic mutant strains of PAT family members (Figures 5.4 – 5.7). 
Mutants obtained from the CGC included: RB1044 (dhhc-2), VC2067 (dhhc-9), 
VC2039 (dhhc-12), VC108 (dhhc-13) and VC918 (dhhc-14). This analysis revealed 
some variation in phenotypes observed between RNAi knockdown and related 
genetic mutants, however, it should be noted that the parental worm strains are 
different in each case. Although neither dhhc-13 nor dhhc-14 exhibited significant 
changes in aldicarb sensitivity following RNAi knockdown in Tu3311 worms, 
genetic mutants of dhhc-13 (VC108) and dhhc-14 (VC918) showed reproducible 
HIC and RIC phenotypes respectively. Detection of changes in aldicarb-sensitivity 
in RNAi assays but not in genetic mutants may indicate that the effect is occurring 
in the pre-synaptic neuron at neuromuscular junctions, as theoretically in the 
Tu3311 strain knockdown should not be occurring in post-synaptic muscle cells. 
It is also possible that there could be varying degrees of functional compensation 
when the target gene is globally deleted throughout the whole worm. However, it 
is important to note that because assays were performed in a high-throughput 
format, the relative efficacy of RNAi knockdown or mutant perturbation of gene 
expression was not assessed. As such, only reproducible positive phenotypes can 
be interpreted with confidence. Results showing no effect following RNAi 
treatment (dhhc-13 and dhhc-14) may be due to inefficient depletion of the 
corresponding proteins.   
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Due to time restrictions RNAi-mediated knockdowns of PAT family members were 
not performed in the Tu3335 strain.  
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Figure 5.4 – Full time-course aldicarb sensitivity assays performed on N2, dhhc-2 
(RB1044) and dhhc-12 (VC2039) worm strains. In each case 20 gravid mutant worms 
were picked onto 1mM aldicarb plates, and paralysis was assessed as described in 
materials and methods. n=3. Error bars represent standard deviation. 
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Figure 5.5 – Full time-course 1mM aldicarb assay of N2 and dhhc-9 (VC2067). 20 
gravid mutant worms were picked onto 1mM aldicarb plates, and paralysis was assessed 
as described in materials and methods. n=3. Error bars represent standard deviation. 
 
 
Figure 5.6– Full time-course 1mM aldicarb assay of N2 and dhhc-13 (VC108). 20 
gravid mutant worms were picked onto 1mM aldicarb plates, and paralysis was 
assessed as described in materials and methods. n=3 . Error bars represent standard 
deviation. 
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5.3.2 Investigating the involvement of PAT family members in postsynaptic 
function. 
 
Although results from the aldicarb-sensitivity assays indicate that PAT family 
members can influence the function of neuromuscular synapses, it was not 
possible to establish if the observed effects were specifically due to pre- or post -
synaptic events. To test if the observed mutant phenotypes were a consequence 
of changes at the postsynaptic terminal, mutant and N2 worms were exposed to 
0.1 mM levamisole, a well-characterized cholinergic receptor antagonist (Locke et 
al., 2008). Under these conditions a change in paralysis rate would indicate that 
the knockdown of a specific protein affected some required post-synaptic 
Figure 5.7 – Full time-course 1mM aldicarb assay of N2 and dhhc-14 (VC918). 20 gravid 
mutant worms were picked onto 1mM aldicarb plates, and paralysis was assessed as described 
in materials and methods. n=3. Error bars represent standard deviation. 
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function. Conversely, if the effect is specific to neurons, no phenotypic change 
would be observed in the presence of 0.1mM levamisole, although a change would 
be seen following aldicarb-sensitivity assays.  
 
Levamisole sensitivity assays were carried out on all of the available PAT mutants 
and the sma-6 mutant (LT186). As LT186 mutation had previously been shown to 
cause a strong HIC phenotype in response to levamisole treatment this strain was 
also used as a positive control in this study (Figure 5.8 and Table 5.4) 
(Munasinghe, 2015). From this it can be seen that dhhc-2 (RB1044), and dhhc-13 
(VC108) show a RIC phenotype in comparison to N2 worms at both of the selected 
time points. 
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As the Tu3311 worm strain was originally generated to allow preferential uptake 
of dsRNA into neurons, the effect of levamisole following dsRNA knockdown of 
PAT family members in the Tu3311 strain was not tested.  
Figure 5.8 –Levamisole sensitivity assays performed on a selection of PAT family and sma-6 
(LT186) mutant worm strains. In each case paralysis assays were performed as described in 
materials and methods and the percentage of paralysed worms compared to the N2 worms 
was determined after 60 and 120 minutes. * denotes significance (p < 0.05). n=3. Error bars 
represent standard deviation. 
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5.3.3 Comparison of aldicarb sensitivity scoring methods  
 
Primary microarray data used in this study was initially generated and analyzed 
in the Falciani lab (Munasinghe, 2015), however, in that study neuronal 
phenotypes were assessed using a different scoring system to that classically used 
to assess changes in aldicarb sensitivity. In particular, movement of worms was 
visually monitored following pipetting onto aldicarb plates, rather than the 
conventional approach of assessing changes in response to touch. Using this 
approach the Falciani lab found evidence for a cooperative phenotype resulting 
from the combinatorial effects of VPA and aldicarb exposure. 
 
Table 5.4 – Data relating to phenotypes presented in Figure 5.8.  
 
Strain %	Change	in	Paralysis	at	60	Minutes Standard	Deviation	60	Minutes P	value Significant?
N2 0.00 21.97 - -
LT186 83.27 37.41 0.008 Yes
RB1044 -57.26 11.26 0.005 Yes
VC2039 -7.76 23.08 0.641 No
VC108 -70.33 24.28 0.013 Yes
VC918 -42.94 13.43 0.016 Yes
VC2067 -29.49 18.72 0.078 No
Strain %	Change	in	Paralysis	at	120	Minutes Standard	Deviation	120	Minutes P	Value Significant?
N2 0.00 16.38 - -
LT186 88.64 23.01 <0.001 Yes
RB1044 -29.60 14.26 0.036 Yes
VC2039 21.81 27.83 0.249 No
VC108 -61.28 27.07 0.022 Yes
VC918 -30.50 26.11 0.126 No
VC2067 3.80 28.39 0.827 No
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To reassess this phenotype using conventional touch based methods of assessing 
paralysis aldicarb sensitivity assays were performed on N2, sma-6 mutant 
(LT186) and unc-38 (CB904) mutant worms. Data from assays performed in the 
Falciani lab show hypersensitivity to aldicarb (HIC phenotype) in LT186 mutant 
worms and resistance to aldicarb (RIC phenotype) in CB904 worms (Munasinghe, 
2015). Re-analysis using conventional scoring methods showed that a HIC 
phenotype was reconfirmed in LT186 worms (Figure 5.9). However, in our assays 
CB904 did not display a significant RIC phenotype 
Interestingly, whilst carrying out our initial high throughput screens (chapter 2), 
we also tested the effect of specifically knocking down sma-6 in neurons (in the 
Tu3311 worm strain). However, we did not detect any HIC phenotype, suggesting 
that the aldicarb effect may be due to post-synaptic changes, which would agree 
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Figure 5.9 - Results from conventional touch based aldicarb sensitivity assays 
performed on N2, sma-6 (LT186) and unc-38 (CB904) mutant worms. In each 
case paralysis assays were performed in triplicate as described in materials and 
methods. Error bars indicate standard deviation. n=3.  
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with preliminary data and conclusions from initial studies performed in the 
Falciani lab ((Munasinghe, 2015) (Figure 5.10).  
5.3.4 Investigating the relative effects of VPA on genetically ablated PAT mutants 
and corresponding RNAi knockdowns 
 
Prior to performing a global microarray analysis of the effects of VPA exposure, 
the Falciani group found that a sma-6 mutant strain of worms exhibited VPA-
induced paralysis (Munasinghe, 2015). They then hypothesized that this 
phenotype may be the result of changes in some postsynaptic function.  
 
0	
20	
40	
60	
80	
100	
0	 20	 40	 60	 80	 100	 120	 140	 160	 180	
%
	p
ar
al
ys
is
	
Time	(minutes)	
L440	
Sma-6	
Figure 5.10 – Change in aldicarb sensitivity following sma-6 knockdown in Tu3311 
worms. Paralysis assays were performed in triplicate as described in materials and 
methods. Error bars indicate standard deviation. n=3 
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Data from this study confirms that treating sma-6 mutant (LT186) worms with 15 
mM VPA reproducibly causes significant paralysis (Figure 5.11). It is also 
interesting to note that low levels (<10 %) of paralysis were reproducibly seen in 
N2 worms (Figures 5.12 and 5.13) following exposure to 15 mM VPA, indicating 
that VPA may affect the normal function of neuromuscular synapses.  
As the C. elegans dhhc-2 protein was initially identified as a potential regulator of 
synaptic function using a module prediction algorithm, applied to a combined RIC 
VPA response network (Chapter 4), we were interested to know if any other PAT 
family mutants would also confer increased paralysis when exposed to VPA. 
Initially, all members of available C. elegans PAT family member mutants were 
assessed using a full-time course assay (Figures 5.12 and 5.13). Although, sma-6 
(LT186) mutant worms showed the strongest paralysis phenotype some PAT 
mutants also showed signs of VPA-induced paralysis compared to N2 worms 
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Figure 5.11 – Independent and cumulative effects of 1 mM aldicarb and 15 mM VPA on 
the rate of paralysis of N2 and sma-6 mutants (LT186) worms. In each case paralysis 
was assessed in triplicate as described in materials and methods.   Error bars indicate 
standard deviation.. n=3. 
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(Table 5.5). In particular, both dhhc-2 and dhhc-14 showed a small but significant 
increase in paralysis in the presence of 15mM VPA. 
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Figure 5.12 – Comparative rates of VPA induced paralysis in PAT mutant worms. 
LT186 is included as a positive control, previously known to cause paralysis. in each 
case paralysis assays were performed in triplicate as described in materials and 
methods. Error bars represent standard deviation. n=3. 
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To investigate this phenotype further, the same assay was performed following 
RNAi mediated knockdown of each of the PAT family members in the neuro-
sensitive Tu3311 worm strain (Figure 5.14 and Table 5.6). The relative degree of 
paralysis was measured 140 minutes after exposure to 15mM VPA. Dhhc-2 (18.5 
% paralysis, p=0.015), dhhc-13 (12.4 % paralysis p = 0.0178) and dhhc-9 (23.2 % 
paralysis, p = 0.0488) all demonstrated significant paralysis.   
Table 5.5 – Data relating to phenotypic trends shown in Figures 5.12 and 5.13 
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Figure 5.13 –Analysis of VPA induced paralysis in dhhc-13 (VC108) mutant worms. 
Paralysis assays were performed in triplicate as described in materials and methods. Error 
bars represent standard deviation . n=3. 
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5.3.5 Comparative effects of combined VPA and aldicarb treatment on the 
induction of paralysis in PAT family mutants and RNAi knockdowns 
 
Table 5.6 – Data relating to phenotypes shown in Figure 5.14. 
 
Figure 5.14 – Comparison of VPA induced paralysis following RNAi mediated knockdown of 
PAT family members. Paralysis assays were performed in triplicate as described in materials 
and methods. Error bars represent standard deviation. * denotes significance between the PAT 
and L440, where the p <0.05. n=3. 
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Previous unpublished data (Munasinghe, 2015) indicated that aldicarb and VPA 
act synergistically to increase aldicarb-sensitivity in wild-type worms. In 
particular, data from these preliminary studies showed an additive effect with 
regards to the observed rate of paralysis, suggesting that aldicarb and VPA are 
acting via different mechanisms to impose a change in synaptic function. To 
further investigate this phenotype it was necessary to establish if the same 
combinatorial phenotype could be reproduced using our scoring methodology in 
worms with a different genetic background. Significantly, our data confirmed that 
the combination of 1mM aldicarb and 15mM VPA confers a significant increase in 
the rate of paralysis of N2 worms when compared to 1 mM aldicarb alone (Figure 
5.15).  
Having established that the synergistic effects of VPA and aldicarb could be 
detected by conventional methods of assessing paralysis, we then tested this 
phenotype in the neurosensitive Tu3311 strain. This secondary analysis was 
essential, as differences in aldicarb sensitivity between N2 and Tu3311 worms 
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Figure 5.15 – Additive effects of VPA and aldicarb on the rate of paralysis of N2 
worms. In each case assays were performed in triplicate as described in materials and 
methods. Error bars represent standard deviation. n=3. 
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had been observed previously (Chapter 3, Figure 3.2). In these assays, LT186 
worms were used as a positive control as they are known to be hypersensitive to 
aldicarb and VPA in comparison to N2 worms (Munasinghe, 2015). Results from 
this comparative analysis show that the Tu3311 strain reproducibly shows a 
higher rate of paralysis than N2 worms, although the Tu3311 strain was not as 
hypersensitive as LT186 worms (Figure 5.16).  
 
 
The combined effects of 1mM aldicarb and 15mM VPA were analyzed in worm 
strains in available PAT family member mutants, as well as in Tu3311 knocked 
down with dsRNA specific to each family member. In all cases responses to 
combined drug treatment were compared to those observed for wild type N2 
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Figure 5.16 –VPA induced changes in rate of paralysis for N2, Tu3311 and sma-6 
(LT186) mutant worms. In each case assays were performed in triplicate as described 
in materials and methods. Error bars represent standard deviation. n=3. 
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worms. In these assays significant deviation from the N2 responses indicates that 
Figure 5.17 – Relative changes in rate of paralysis following combined exposure to 
1mM aldicarb and 15mM VPA for N2, dhhc-2 (RB1044) and dhhc-12 (VC2039) 
worms. In each case assays were performed in triplicate as described in materials and 
methods. Error bars represent standard deviation. n=3. 
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Figure 5.18 – Relative changes in rate of paralysis following combined exposure 
to 1 mM aldicarb and 15 mM VPA for N2, dhhc-9 (VC2067) and dhhc-14 (VC918) 
worms. In each case assays were performed in triplicate as described in materials and 
methods. Error bars represent standard deviation. n=3. 
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the gene in question has the ability to influence drug-induced paralysis, which in 
turn implies an involvement in the regulation or efficacy of synaptic function. 
 
Initial analysis of genetically mutated PAT family worm strains showed that dhhc-
2 (RB1044) exhibited a slower rate of paralysis than N2 worms (Figure 5.17), 
while dhhc-9 (VC2067) increased the rate of paralysis compared to control N2 
worms (Figure 5.18). None of the other PAT family mutants caused a significant 
change in the rate of paralysis (Figures 5.17-5.19).  
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Figure 5.19 – Relative changes in rate of paralysis following combined exposure to 
1mM aldicarb and 15mM VPA for N2 and dhhc-13 (VC108) worms. In each case assays 
were performed in triplicate as described in materials and methods. Error bars represent 
standard deviation. n=3. 
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When PAT family members were knocked down in Tu3311, dhhc-2 and dhhc-9 
displayed no significant differences in paralysis as compared to the negative 
control when treated with aldicarb and VPA (Figure 5.20, Table 5.7). However, 
dhhc-4 (46.5% change, P value = 0.023), dhhc-14 (61.1% change, P value = 0.0394) 
Figure 5.20 – High-throughput analysis of the combined effect of 1mM aldicarb and 
15mM VPA on Tu3311 worms following RNAi mediated knockdown PAT family 
members. All assays were performed in triplicate as described in materials and methods. 
Error bars represent standard deviation. n=3. 
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Table 5.7– Data relating to phenotypic trends shown in Figure 5.20.  
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and spe-10 (86.7% change, P value = 0.0171) all showed hypersensitivity in 
comparison to L440 knockdowns. Also, dhhc-5 (-63.1% change, P value = 0.0195), 
dhhc-6 (-35.9% change, P value = 0.0057) dhhc-7 (-49.1% change, P value = 0.036) 
and dhhc-12 (-39.6 % change, P value = 0.0365) showed a slower rate of a paralysis 
compared to the control. Tables 5.8 and 5.9 summarize the combined effects of 
drug treatment of PAT family mutants and corresponding  
RNAi knock down studies.  
5.3.6 Data mining of the PAT family 
 
To better understand the possible conserved roles of PAT family members, the 
closest orthologs of each of the C. elegans PAT family of proteins were identified. 
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Although this phylogenetic analysis has been carried out before (Edmonds & 
Morgan, 2014), we decided to check the analyses, and found some differences. 
ITOL is a program used to create trees of life, dependent on sequence homology 
and identity (Letunic & Bork, 2016). We used this program to create a combined 
PAT family tree of life for worms, mouse, and human. This tree includes isoforms 
for each of the family members to ensure a whole representation of the family 
(Figure 5.21). 
 
The sequence similarities between C. elegans PAT family members and their 
closest human orthologs were analyzed (Table 5.10). This data indicated that 
dhhc-2, the gene found in the earlier aldicarb screen, had the highest similarity to 
human zDHHC9, having 43 % identity, 61 % similarity and 8 % gaps. Although 
previous predictions identified isoform 2 of zDHHC14 to be the closest ortholog 
(Edmonds & Morgan, 2014), this has a lower percentage identity to C. elegans 
dhhc-2 (40% identity, 59% similarity, 10% gaps) than zDHHC9.  
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Figure 5.21 – Tree of Life of the PAT family members, in humans, mice and worms. This tree 
was generated by iTOL (Letunic & Bork, 2016). 
 
C.	elegans	Gene	Symbol Closest	Human	Ortholog %	Identity %	Similarity %	Gaps
dhhc-1 ZDHHC24 31 43 16
dhhc-2 ZDHHC9 43 61 8
dhhc-3 ZDHHC3 51 62 13
dhhc-4 ZDHHC15 38 61 8
dhhc-5 ZDHHC23 31 43 23
dhhc-6 ZDHHC6 36 52 14
dhhc-7 ZDHHC21 31 43 19
dhhc-8 ZDHHC8 36 47 18
dhhc-9 ZDHHC16 30 43 19
dhhc-10 ZDHHC24 31 47 14
dhhc-11 ZDHHC11 27 46 14
dhhc-12 ZDHHC23 28 39 15
dhhc-13 ZDHHC13 26 43 17
dhhc-14 ZDHHC17 30 47 14
spe-10 ZDHHC15 34 48 17
Table 5.10 - Table to show the worm PAT family and their closest human orthologues. 
This was determined using DIOPT flyRNAi (Hu et al., 2011), and the percentage identity, 
similarity and gaps were calculated. 
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5.3.7 Construction of a PAT family PPI interactome 
 
To better understand the potential role of PAT family members in synaptic 
function, a PAT family PPI network was assembled, which encompassed all known 
and predicted interactions involving PAT family members, including interolog 
data from human, mouse, worm and fly (Chapter 2, section 2.5). PAT family 
members and their closest neighbours were extracted to generate a PAT one-step 
network of 654 nodes and 852 edges (Figure 5.22).  
 
The profile of the interaction partners for each PAT family member are shown in 
Table 5.11, which also specifies how many interactions are known to occur in 
humans. From this data it is clear that there is a large range in the number of 
known interaction partners for different PAT members. The only protein with a 
large number (>20) of human interaction partners was DHHC17 with 343 
interaction partners, 240 of which were elucidated in humans.  
 
5.3.8 Cloning the PAT family 
 
In order to extrapolate phenotypic data from C. elegans to provide new insight into 
potential regulators of human synaptic function, as many human PAT family 
members were cloned as was technically possible. Genes that were successfully 
amplified from a human HeLa cDNA library (zDHHC3, zDHHC4, zDHHC5, zDHHC7, 
zDHHC9, and zDHHC16) were transferred into the pDONR223 Gateway 
compatible vector. The primers used to clone these genes are found in Chapter 2, 
Table 2.3. 
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Although 
the remaining members of the human PAT family could not be cloned from the 
HeLa cell cDNA, the whole set of mouse PAT clones was also obtained from Masaki 
Fukata (National Institute for Physiological Sciences, Myodaiji), and Luke 
Chamberlain (Strathclyde Institute of Pharmacy and Biological Sciences). Table 
5.12 shows the closest human orthologues of each mouse clone. Of note, mouse 
zDHHC17 obtained from Fukata and Chamberlain contains a short N-terminal 
deletion of sixty nucleotides at the N-terminus. 
 
 
 
Figure 5.22 – One-step network of the PAT family. Family members are shown in red, one-
step interaction partners are shown in grey. The edge colour denotes the type of 
interaction. Dark blue edges represent direct human interactions, light blue represent indirect 
human interactions, green are direct orthologous interactions and pink are orthologous indirect 
interactions. Cytoscape v3.2.1 was used to generate this network, using the spring-embedded 
display. 
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Due to time constraints the PAT family members were prioritized based on 
structural features and known disease associations as indicated in DisGenet 
(Pinero et al., 2015) (Table 5.13). 
 
Proteins that were found to have any association to neurological disorders were 
of particular interest. ZDHHC9 is the closest ortholog of dhhc-2, and mutations of 
ZDHHC9 have been linked to XLID (Mitchell et al., 2014). ZDHHC17 is linked to 
Huntington’s disease (56. 57). Interestingly, HIP14L (encoded by zDHHC13) has 
67.1 % similarity to DHHC17 and both proteins have N-Ankyrin repeat domains 
Gene	Symbol Human	and	ortholog	Interactors Human	Interactors
zDHHC1 13 6
zDHHC2 31 2
zDHHC3 28 5
zDHHC4 1 1
zDHHC5 10 5
zDHHC6 117 13
zDHHC7 8 5
zDHHC8 7 2
zDHHC9 24 19
zDHHC11 17 10
zDHHC12 2 1
zDHHC13 68 6
zDHHC14 1 1
zDHHC15 5 0
zDHHC16 3 1
zDHHC17 373 240
zDHHC18 19 17
zDHHC19 1 1
zDHHC20 4 1
zDHHC21 6 6
zDHHC22 1 1
zDHHC23 94 5
zDHHC24 18 2
Table 5.11 – Number of interaction partners of the PAT family, according to the network 
generated in Figure 5.20. Interaction data was collected from several databases including 
Biogrid, CCSB, and Bioplex, as well as from literature curation. 
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at their N-terminus (Figure 5.21). Furthermore, this region of the two proteins is 
known to be responsible for the binding of some substrates.  
 
ZDHHC8 is implicated in schizophrenia, and DHHC5 is highly homologous to 
isoform 2 of DHHC8, having a 59.3 % similarity. Both have long C-termini (Figure 
5.23), with DHHC5 and DHHC8 having 502 (70.2 % of the whole protein) and 553 
(72.2 % of the whole protein) amino acids between their final trans-membrane 
domain and the C-terminus, respectively. Other PAT family members that have 
relevance to neurological disorders include zDHHC15, which plays a role in some 
forms of mental disability and Huntington’s disease and zDHHC12, which is also 
linked to Huntington’s disease (Bhattacharyya, Barren, & Kovacs, 2013). 
Mouse	Gene	Symbol Human	Gene	Symbol %	Identity %	Similarity %	Gaps
ZDHHC1 ZDHHC1 74 77 10
ZDHHC2 ZDHHC2 95 97 0
ZDHHC3 ZDHHC3 89 90 9
ZDHHC4 ZDHHC4 74 85 0
ZDHHC5 ZDHHC5 98 99 0
ZDHHC6 ZDHHC6 93 97 0
ZDHHC7 ZDHHC7 85 87 11
ZDHHC8 ZDHHC8 92 95 0.4
ZDHHC9 ZDHHC9 98 99 0
ZDHHC11 ZDHHC11 60 75 1
ZDHHC12 ZDHHC12 83 86 5
ZDHHC13 ZDHHC13 91 96 0
ZDHHC14 ZDHHC14 95 98 0
ZDHHC15 ZDHHC15 98 99 0
ZDHHC16 ZDHHC16 95 96 0
ZDHHC17 ZDHHC17 99 100 0
ZDHHC18 ZDHHC18 93 95 2
ZDHHC19 ZDHHC19 69 76 3
ZDHHC20 ZDHHC20 91 94 1
ZDHHC21 ZDHHC21 98 99 0
ZDHHC22 ZDHHC22 92 97 0
ZDHHC23 ZDHHC23 90 95 1
ZDHHC24 ZDHHC24 88 92 0
ZDHHC25 ZDHHC3 41 53 15
Table 5.12 – Conservation of human and mouse PAT family members. Sequences were 
compared using diopt FlyRNAI (Hu et al., 2011), and matches with the highest % 
identity, similarity and the lowest % gaps were chosen as the closest orthologs. 
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Figure 5.23 shows topological diagrams of each of the PAT family members that 
were selected for the Y2H studies. 
Figure 5.23 –Visualizations of the topologies of the PAT proteins of interest DHHC5, 
8, 9, 13 and 17. (Adapted from Protter, (Omasits, Ahrens, Müller, & Wollscheid, 2014). 
 
DHHC5	 DHHC8	
DHHC9	 DHHC13	
DHHC17	
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Table 5.13 – Disease associations of the human PAT family, according to DisGeneNet (Pinero et al., 2015). Z in figure capital or not 
 
ID Disease
ZDHHC1 Rheumatoid	Arthritis,	Crohn	Disease,	Diabetes	Mellitus	(insulin	dependent	and	independent),	Herpes	Simplex	infections,	Coronary	heart	disease
zDHHC2	 Rheumatoid	Arthritis,	Diabetic	retinopathy,	liver	neoplasms,	malignant	neoplasm	of	stomach,	Melanoma,	Neoplasm	metastasis,	stomach	neoplasms
Tobacco	Use	disorder,	Weight	gain,	Gastric	adenocarcinoma,	Secondary	malignant	neoplasm	or	lymph	node,	Stomach	carcinoma,	Liver	carcinoma
zDHHC5 Non-Small	Cell	Lung	Carcinoma
zDHHC6 Tobacco	use	Disorder
zDHHC7 Breast	carcinoma
zDHHC8 DiGeorge	Syndrome,	Mesothelioma,	Parkinon's	disease,	schizophrenia,	weight	gain,	shprintzen	syndrome,	malignant	mesothelioma,	22q11	deletion	syndrome
ZDHHC9 Adenocarcinoma,	Colonic	neoplasms,	colorectal	carcinoma,	precancerous	conditions,	Lujan	Fryns	syndrome,	Colorectal	cancer,	X-linked	mental	retaradation
zDHHC11 Bladder	neoplasm,	Tobacco	Use	Disorder,	Disease	Progression,	Carcionoma	of	bladder
zDHHC12 Huntington's	Disease
ZDHHC13 Alopecia,	Amyloidosis,	Huntington's	disease,	Osteoporosis
zDHHC14 Malignant	neoplasm	of	prostate,	Prostate	carcinoma,	Xenograft	model,	Fibrogen	adverse	event
zDHHC15 Huntington's	disease,	Neuronal	Ceroid-Lipofuscinoses,	Severe	mental	retardation,	Mental	retardation	X-linked
zDHHC17 Huntington's	disease,	Paroxysmal	artrial	tachycardia
zDHHC20 Creatinine	finding
Gene	Symbol Localization N-terminus	localization C-terminus	localization
zDHHC1 Endoplasmic	Reticulum,	Extracellular	Exosome Cytosol Cytosol
zDHHC2 Endoplasmic	Reticulum,	Golgi	Apparatus,	Plasma	Membrane Cytosol Cytosol
zDHHC3 Golgi	Apparatus Cytosol Cytosol
zDHHC4 Golgi	Apparatus Cytosol Cytosol
zDHHC5 Plasma	Membrane,	Dendrite Cytosol Cytosol
zDHHC6 Endoplasmic	Reticulum Cytosol Cytosol
zDHHC7 Golgi	Apparatus,	Nucleus Cytosol Cytosol
zDHHC8 Golgi	Apparatus,	Mitochondria Cytosol Cytosol
zDHHC9 Endoplasmic	Reticulum,	Golgi	Apparatus Cytosol Cytosol
zDHHC11 Endoplasmic	Reticulum Human:	organelle,	Mouse:	cytosol Human:	organelle,	Mouse:	cytosol
zDHHC12 Endoplasmic	Reticulum,	Golgi	Apparatus Organelle Organelle
zDHHC13 Endoplasmic	Reticulum,	Golgi	Apparatus Cytosol Cytosol
zDHHC14 Endoplasmic	Reticulum Cytosol Cytosol
zDHHC15 Golgi	Apparatus,	Extracellular	Exosome Cytosol Cytosol
zDHHC16 Endoplasmic	Reticulum,	Golgi	Apparatus Cytosol Cytosol
zDHHC17 Golgi	Apparatus,	Presynaptic	Membrane Cytosol Cytosol
zDHHC18 Golgi	Apparatus Cytosol Cytosol
zDHHC19 Endoplasmic	Reticulum Human:	organelle,	Mouse:	cytosol Human:	organelle,	Mouse:	cytosol
zDHHC20 Plasma	Membrane Human:	cytosol,	Mouse:	organelle Human:	cytosol,	Mouse:	organelle
zDHHC21 Golgi	Apparatus,	Plasma	Membrane Cytosol Cytosol
zDHHC22 Endoplasmic	Reticulum,	Golgi	Apparatus Organelle Organelle
zDHHC23 Integral	component	of	membrane Cytosol Cytosol
zDHHC24 Integral	component	of	membrane Human:	organelle,	Mouse:	cytosol Human:	cytosol,	Mouse:	organelle
Table 5.14 – Predicted subcellular localization of each 
of the human PAT proteins, determined by Protter 
(Omasits et al., 2014). N- and C- termini localizations 
were determined using Uniprot. 
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5.3.9 MYTH library screening of full-length DHHC family members 
 
Unfortunately, classical yeast two hybrid systems are not ideal for studying full-
length trans-membrane proteins. For this reason the trans-membrane yeast-two-
hybrid technique known as split-ubiquitin membrane yeast two-hybrid (MYTH) 
assay was used in this study. In principle, the MYTH system should allow bait 
proteins that contain one or more trans-membrane domains, to be screened 
against a MYTH prey library in order to identify novel binary protein interaction 
partners as described in Chapters 1 and 2 (sections 1.16.2 and 2.8.9 to 2.8.11). 
Briefly, in the MYTH system if an interaction occurs between bait and prey, two 
fragments of ubiquitin (Nub and Cub) interact, leading to recognition and cleavage 
by deubiquitinating enzymes (DUBs) in the yeast, resulting in the release of a 
transcription factor, which then translocates into the nucleus to drive expression 
of the HIS2, ADE3 and lacZ reporter genes, which facilitate growth and blue colour 
development on selective plates.   
 
As the MYTH system can only be used on transmembrane proteins that have N- or 
C- cytoplasmic domains, the predicted topology of each PAT family member was 
analyzed in order to select family members that were suitable for analysis using 
the MYTH system. Table 5.14 shows the predicted subcellular localization and 
membrane topology of each PAT family member. From this information human 
zDHHC5 and zDHHC9 and mouse zDHHC8, 13 and 17 were selected for analysis in 
MYTH protein interaction assays. Tables 2.3 and 2.20 (Chapter 2) show the gene-
specific sequences used in the primer design.  
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Once the constructs had been cloned and sequenced, they were transformed into 
the yeast strain NMY51. Transformants were then checked for auto-activation, 
using the MYTH NubG/I test (Chapter 2, section 2.8.11). All constructs passed this 
bait auto-activation test. Figure 5.24 shows an example of a typical bait auto-
activation test, using zDHHC17 in the pAMBV vector as bait. However, when 
screened against the foetal brain MYTH cDNA library, no colonies appeared on 
plates where human zDHHC5, and mouse zDHHC8, 13 and 17 were used as baits.  
 
ZDHHC9 was successfully screened with the help of lab members, Vanessa Pitz and 
Jennifer McNamee. Potential interaction partners were retested for specificity 
before being sequenced to reveal the identity of the binary interaction partner. 
This revealed twelve interaction partners (Table 5.15), as well as five interaction 
partners that have the potential to be non-specific partners (Table 5.16).  
Figure 5.24 – An example of a MYTH Bait auto-activation test. The bait of interest is 
transformed with Ost1/Fur4 NubG/NubI constructs. If successful, growth of all 
constructs should occur on –WL, while only bait co-transformed with NubI constructs 
will grow on the –WLH and –WLAH plates. This example is of mouse zDHHC17-pAMBV. 
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Table 5.15 – Brief description of interacting proteins found in the MYTH ZDHHC9 screen. Descriptions were chelated from NCBI and Uniprot. 
Localizations were determined using the COMPARTMENTS database (Binder et al., 2014). 
 
Gene	Symbol Brief	Description Localization
TECR Encodes	a	multi-pass	membrane	protein	residing	in	the	endoplasmic	reticulum,	and	belongs	to	the	steroid	5-alpha	reductase	family.	 Nucleus	and	ER
EMC4 ER	membrane	protein	complex	subunit	4.	May	mediate	anti-apoptotic	activity. ER
ATP5G3 Encodes	a	subunit	of	mitochondrial	ATP	synthase. Mitochondria
OST4 Oligosaccharyltransferase	Complex	Subunit	4,	Non-Catalytic.	May	be	involved	in	N-glycosylation	with	its	association	with	N-oligosaccharyl	transferase. ER
SELK Encodes	a	selenoprotein,	which	is	localized	to	the	endoplasmic	reticulum	and	is	highly	expressed	in	the	heart,	where	it	may	function	as	an	antioxidant. Golgi	and	ER
TMEM128 Transmembrane	protein	128.	 Membrane
SPCS1 Component	of	the	microsomal	signal	peptidase	complex,	which	removes	signal	peptides	from	nascent	proteins	as	they	are	translocated	into	the	lumen	of	the	ER. ER
TRO Encodes	a	membrane	protein	that	mediates	cell	adhesion	between	trophoblastic	cells	and	the	epithelial	cells	of	the	endometrium.	 Plasma	membrane
Participates	in	cell	signalling	during	embryo	implantation,	and	may	be	involved	in	cancer	formation.
FZD1 Member	of	the	'frizzled'	gene	family,	which	encodes	7-transmembrane	domain	proteins	that	are	receptors	for	Wnt	signaling	proteins. Plasma	membrane
Contains	a	signal	peptide,	a	cysteine-rich	domain	in	the	N-terminal	extracellular	region,	7	transmembrane	domains,	and	a	C-terminal	PDZ	domain-binding	motif.
RTN4 Belongs	to	the	family	of	reticulon	encoding	genes.	Associated	with	the	ER,	and	are	involved	in	neuroendocrine	secretion	or	membrane	trafficking	in	neuroendocrine	cells.	ER
The	gene	product	is	a	potent	neurite	outgrowth	inhibitor	which	may	also	help	block	the	regeneration	of	the	central	nervous	system	in	higher	vertebrates.	
GTF2F1 Endodes	a	general	transcription	factor,	which	binds	to	RNA	polymerase	II	and	helps	to	recruit	the	initiation	complex	with	TFIIB. Nucleus
ARV1 Encodes	a	transmembrane	protein	with	a	conserved	zinc	ribbon	motif	at	the	N-	terminus.	A	similar	protein	in	mouse	is	thought	to	function	in	fatty	acid	homeostasis.	 Golgi	and	ER
Mutations	in	this	gene	are	associated	with	early	infantile	epileptic	encephalopathy.
Gene	Symbol Brief	Description Localization
C14ORF1 Probable	ergosterol	biosynthetic	protein	28 ER
TMEM14A Protein	coding	gene.	Associated	with	ovarian	cystadenocarcinoma	and	generalized	epilepsy	type	5. Membrane	component
RNF41 E3	ubiquitin	ligase.	Controls	the	balance	between	JAK2-associated	cytokine	receptor	degradation	and	ectodomain	shedding.	 Cytosol
C4ORF3 Protein	coding	gene. Membrane	component
TMEM230 Protein	coding	gene. Recycling	endosome,	synaptic	vesicle
Table 5.16 – Brief description of the interacting proteins found in the MYTH zDHHC9 screen, which were thought to be non-specific interaction 
partners. Descriptions were chelated from NCBI and Uniprot. Localizations were determined using the COMPARTMENTS database (Binder et 
al., 2014). 
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5.3.10 Cloning PAT fragments for use in classical Y2H library screens 
 
Due to significant technical issues with our initial MYTH screens, the standard Y2H 
library system was also used to in an attempt to elucidate novel interaction 
partners of the PAT family members. In this system, proteins are truncated so that 
cytoplasmic domains can be investigated in isolation, although this approach will 
only be effective if truncated cytoplasmic domains continue to fold correctly even 
without the transmembrane domains.  
 
Truncations of the same proteins used in the MYTH screens were cloned, as these 
were of more interest due to their known disease relations. Secondly, DHHC5, 8, 
13 and 17 all have interesting cytoplasmic domains that could be studied in 
isolation. zDHHC13 and 17 both have proposed N-Ankyrin repeat substrate 
binding domains in their N-terminus, while zDHHC5 and 8 have long C-terminal 
tails containing a type II PDZ ligand (Thomas, Hayashi, Chiu, Chen, & Huganir, 
2012). 
 
In total, six cytoplasmic regions of human DHHC proteins were successfully cloned 
(Table 5.17) and transferred into the Y2H bait vector pGBKT7, including N-
terminal fragments of zDHHC17 (DHHC17N) and zDHHC13 (DHHC13N), and C-
terminal fragments of zDHHC5 (DHHC5CT) and zDHHC8 (DHHC8CT), Following 
transformation into Y2HGold yeast all of the bait clones passed auto-activation 
and toxicity tests (Figure 5.25).  
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Bait clones were then individually screened against a normalized brain pGADT7 
library (Clontech). However, it should be noted that several aspects of the 
screening protocol had to be optimized, due to the facilities available in the lab. 
These differences are described in Chapter 2, section 2.8. As well as optimizing the 
protocol itself, the original library was also amplified to allow the screening of 
multiple baits (Chapter 2, section 2.8.4). Figure 5.26 and 5.27 show an example 
Gene	Symbol Organism Fragment	region	(bp) Primer Primer	sequence
zDHHC9 Human 750-1092 Forward atggtggctctcaaccagaca
Reverse	(-	stop) ctacttctcagcttcagctgc
1-568 Forward ATGtctgtgatggtggtgaga
Reverse	(-	stop) tcaaaggatgaagaggtagaagta
zDHHC5 Human 639-2147 Forward ATGaggggacgcacaaccaat
Reverse	(-	stop) tcacaccgaaatctcata
zDHHC8 Mouse 633-2288 Forward ATGactggtcacgcggggccgcac
Reverse	(-	stop) tcacaccgagatttcata
zDHHC13 Mouse 1-876 Forward ATGgagggcccgggcctgggc
Reverse	(-	stop) ctaggctctcatcttggc
zDHHC17 Mouse 1-912 Forward ATGaccaagatggcggacggc
Reverse	(-	stop) ctaataccctttcgcttg
Table 5.17 – Truncations generated for the Matchmaker Y2H library screens. Primer 
sequences shown are the gene-specific DNA regions used to generate the constructs. 
 
Figure 5.25 – Example of bait auto-activation test for the Y2HGold system. 
DHHC13N was transformed into Y2HGold and plated out onto –W, -W + X-alpha Gal, 
and –W + X-alpha Gal + Aureobasidin. To pass the auto-activation test, no growth 
should occur on plates containing the aureobasidin A. 
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plate following the screening process, on the double selection (-WL and 
Aureobasidin A) and quadruple selection (–WLAH, X-Alpha-Gal and Aureobasidin 
A plates), respectively. 
 
The screening of DHHC8CT against the normalized brain library did give rise to a 
few colonies, but none of these had prey inserts. DHHC5CT, 13N and 17N all 
showed good transformation efficiencies (18.5 %, 11 % and 19.2 %), and many 
bands of different sizes were seen on a gel following yeast colony PCR 
amplification of prey.  
Chapter 5: Palmitoyl Acyltransferases 
 296 
The yeast colony PCR reaction is performed to amplify prey insert sequences of 
interacting proteins, which then need to be gap repaired back into the prey 
(pGADT7) vector. An example result is shown in Figure 5.28. The preys in this case 
were interaction partners of DHHC5CT. If the prey YCPCR fragment recombines 
with the cut pGADT7 prey vector, multiple colonies grow per spot (Chapter 2). 
Colonies were then picked and mated against the original bait construct in the 
reconfirmation test. Multiple spots failed the reconfirmation test, as the prey 
showed growth on selective plates when combined with both test bait and the 
Figure 5.26 – Example –WL + Aureobasidin A plate following screening of 
DHHC17N against the normalized brain library. Colonies picked were more than 
1 mm wide. Pink colonies were not picked.  
 
Figure 5.27 – Example of bait screened against the normalized human brain library, 
when picked onto –WLAH + X-alpha-Gal + Aureobasidin A plates. Colonies that 
displayed robust growth and turned blue were picked for further analysis. 
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negative control (empty-pGBKT7 vector). An example reconfirmation is shown in 
Figure 5.29. However, following the screens, 48 prey YCPCR fragments were 
elucidated from the zDHHC5CT, 27 from the zDHHC13N, and 39 from the 
zDHHC17N screens to send for sequencing. These were sent with the pGADT7.F 
sequencing vector. 
 
 
 
Figure 5.28 – An example of a library gap repair reaction for the Y2HGold 
library screening. Prey fragments are transformed with the cut pGADT7 vector 
into Y187 yeast. Image shows results from the zDHHC5CT library screen. 
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Results from this screen are shown in Tables 5.18, 5.19 and 5.20. The subcellular 
localization of these hits were also elucidated using the COMPARTMENTS web 
resource, to better understand whether the hits were logical (Binder et al., 2014). 
The localization of the interacting proteins is shown in Table 5.21. From Table 
5.14 it can be see that zDHHC5 is localized in the plasma membrane and dendrites, 
zDHHC13 and 17 are both localized in the Golgi apparatus, whereas zDHHC13 is 
also localized in the endoplasmic reticulum. 
 
Figure 5.29 – Example reconfirmation of preys against the bait of interest and the 
negative control. Colonies that grew on the –WLAH + X-alpha-Gal + Aureobasidin plates, only 
in the presence of the bait vector, were considered positive hits and were sent for sequencing.  
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Gene	Symbol Brief	Description
SNRPG Core	component	of	spliceosome	U1,	U2,	U4	and	U5	small	nuclear	ribonucleoproteins.
MFF Mitochondrial	fission	factor.	Promotes	the	recruitment	and	association	of	the	fission	mediator	dynamin-related	protein	1	(DNM1L)	to	the	mitochondrial	surface.	
May	be	involved	in	regulation	of	synaptic	vesicle	membrane	dynamics	by	recruitment	of	DNM1L	to	clathrin-containing	vesicles
PDE4DIP Myomegalin.	May	function	as	an	anchor	sequestering	components	of	cAMP-dependent	pathway	to	Golgi	and/or	centrosomes
WDR61 Component	of	PAF1	complex	-	functions	during	transcription	by	RNA	polymerase	II
RSL24D1 Involved	in	biogenesis	of	60s	ribosomal	subunit
EFCAB7 EF-hand	calcium-binding	domain	containing	protein	7
NME7 Major	role	in	the	synthesis	of	nucleotide	triphosphates	other	than	ATP
RAB40B May	be	a	substrate-recognition	component	of	a	SCF-like	ECS	E3	ubiquitin	ligase
CCNJ Cyclin	J
ELAVL4 May	play	a	role	in	neuron	specific	RNA	processing
ZNF350 Transcriptional	repressor
Table 5.18 - DHHC5CT interaction partners, elucidated from the normalized human brain library. Uniprot and NCBI were used to mine data about 
the interaction partners. 
 Gene	Symbol Brief	Description
DCAF6 Ligand	dependent	co-factor	of	nuclear	receptors
C19orf12 Small	transmembrane	protein.	Mutations	cause	of	a	form	of		hereditary	spastic	paraplegia	(SPG43),	and	neurodegeneration	with	brain	iron	accumulation-4
EFEMP1 Binds	EGFR,	inducing	EGFR	autophosphorylation	and	activation	of	downstream	signaling
EPRS Glutamate/proline	tRNA	ligase
EIF1B Translation	factor
CCDC34 Chromosoal	aberration	involving	CCDC34	found	in	patient	with	hamartoma	of	RPE	and	retina
NEMF Component	of	ribosome	quality	control	complex
MINA Oxygenase	that	can	act	as	both	a	histone	lysine	demethylase	and	ribosomal	histidine	hydroxylase
RAB7A Key	regulator	in	endolysosomal	trafficking.	Controls	endosomal	trafficking	and	neurite	outgrowth.	Charcot-marie	Tooth	disease	association
SAP18 Component	of	SIN3-repressing	complex	-	enhances	SIN3-HDAC1	mediated	transcriptional	repression
CCDC65 May	play	role	in	motile	cilia	function.
Table 5.19 - Brief descriptions of the zDHHC13N interaction partners, elucidated from the normalized human brain library.  Uniprot and NCBI were 
used to mine data about the interaction partners. 
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Gene	Symbol Brief	Description
RAB7A Key	regulator	in	endolysosomal	trafficking.	Controls	endosomal	trafficking	and	neurite	outgrowth.	Charcot-marie	Tooth	disease	association
HNRNPL Heterogeneous	nuclear	ribonucleoprotein	L
APP Amyloid	Precursor	Protein.	Cell	surface	receptor/precursor	protein	cleaved	to	form	a	number	of	peptides,	promoting	transcriptional	activation	or	amyloid	plaques.
PICALM Assembly	protein	recruiting	clathrin	and	adapter	protein	complex	2	to	the	cell	membrane.	Involved	in	AP2-dependent	clathrin	mediated	endocytosis	at	NMJ
RAB40B May	be	a	substrate-recognition	component	of	a	SCF-like	ECS	E3	ubiquitin	ligase
ARHGAP21 Functions	as	GTPase	activating	protein	for	RhoA	and	CDC42.
PPIE Accelerates	protein	folding,	May	be	involved	in	pre-mRNA	splicing
CCAR1 Cell	division	cycle	and	apoptosis	regulator	protein	1
CLIP3 Functions	as	cytoplasmic	linker	protein
NDUFA9 Accessory	subunit	of	complex	1	in	membrane	respiratory	chain.	Associated	with	Alzheimers.
B2M Component	of	MHC.
TAX1BP1 Inhibits	TNF-induced	apoptosis	by	mediating	TNFAIP3	anti-apoptotic	activity.
DHX9 Unwinds	dsDNA	and	RNA	in	3'	to	5'	direction.
Table 5.20 - DHHC17N interaction partners, elucidated from the normalized human brain library. Uniprot and NCBI were used to mine data about 
the interaction partners. 
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 Gene	Symbol DHHC	Interaction	Partner Localization	(COMPARTMENTS)
C19orf12 DHHC13N Mitochondrion,	ER
CCDC34 DHHC13N No	evidence
CCDC65 DHHC13N Cilium
DCAF6 DHHC13N Cul4-Ring	E3	ubiquitin	ligase	complex,	nucleus,	cytoplasm
EFEMP1 DHHC13N Extracellular	space
EIF1B DHHC13N No	evidence
EPRS DHHC13N Cytoplasm
MINA DHHC13N Nucleus,	Cytoplasm
NEMF DHHC13N Nucleus
SAP18 DHHC13N Nuclear	speck,	ASAP	complex,	histone	deacetylase	complex
RAB7A DHHC13N,	DHHC17N Lysosome,	extracellular	exosome,	late	endosome,	phagocytic	vesicle
APP DHHC17N membrane,	dendritic	spine,	endosome,	golgi,	vesicle
ARHGAP21 DHHC17N Cytoplasm
B2M DHHC17N Membrane,	focal	adhesion,	extracellular	exosome
CCAR1 DHHC17N Nucleoplasm,	perinuclear	region	of	cytoplasm
CLIP3 DHHC17N Recycling	endosome	membrane,	early	endosome	membrane,	trans-golgi	network	membrane
DHX9 DHHC17N Nucleus
HNRNPL DHHC17N extracellular	exosome,	nucleoplasm
NDUFA9 DHHC17N Mitochondrial	matrix,	mitochondrial	membrane
PICALM DHHC17N golgi,	clathrin-coated	vesicle
PPIE DHHC17N Nucleus
TAX1BP1 DHHC17N Extracellular	exosome
CCNJ DHHC5CT nucleus
EFCAB7 DHHC5CT primary	cilium
ELAVL4 DHHC5CT no	evidence,	could	be	ribonucleoprotein	complex
MFF DHHC5CT mitochondrion	outer	membrane,	type	iv	membrane	protein,	peroxisome,	cytoplasmic	vesicle,
secretory	vesicle,	synaptic	vesicle
NME7 DHHC5CT centrosome,	mitochondria
PDE4DIP DHHC5CT cytoskeleton,	nucleus,	golgi
RSL24D1 DHHC5CT nucleus
SNRPG DHHC5CT spliceosome
WDR61 DHHC5CT nucleus
ZNF350 DHHC5CT nucleus
RAB40B DHHC5CT,	DHHC17N plasma	membrane
Table 5.21 - Subcellular localization of novel interaction partners of zDHHC5CT, zDHHC13N and zDHHC17N. Localization was 
determined using the COMPARTMENTS database (Binder et al., 2014). 
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5.3.11 Cloning fragments of zDHHC9 
 
Fragments from zDHHC9 were also cloned. DHHC9 does not have a long 
cytoplasmic domain, or cytoplasmic regions with known interaction domains. For 
this reason, the C-terminal domain was first cloned (Table 5.17). Although this 
was successfully cloned into pGBKT7, only a few prey colonies grew on the double 
selection plates following library screening, and non of these passed the 
subsequent reconfirmation test. This may indicate that the C-terminal domain is 
not responsible for binding.  
 
The N-terminal domain of zDHHC9 is very small, and so a fragment was cloned 
that extended from the N-terminus to the DHHC domain. Although this consisted 
of three trans-membrane domains, as mentioned previously, a similar zDHHC17 
truncation product had previously been used to identify hundreds of interaction 
partners (Butland et al., 2014). It is important to note however, that in the Butland 
et. al.  study, several different DHHC17 baits were combined in one library screen.  
 
In our hands, although the construct passed the bait auto-activation and toxicity 
testing, no colonies passed the reconfirmation stage. This indicates that 
interaction with zDHHC9 may require a co-factor, such as GCP16 (Swarthout et al., 
2005a), or binding could in part require  transmembrane domains. It is also 
possible that the fragments fold differently in comparison to the full-length 
protein. 
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The human PAT network was updated with the new interaction partners from 
both, the classical and MYTH screens performed in this study (Figure 5.30), with 
the novel interaction partners highlighted as yellow nodes. From this it can be 
seen that APP was previously known to interact with DHHC3, and SNRPG and 
RSL24D1 interacted with DHHC23. 
 
5.4 Discussion 
 
5.4.1 Elucidating a theory to explain the VPA phenotype 
 
Figure 5.30 – One step PAT network with updated novel yeast two-hybrid interaction 
partners. Yellow nodes represent novel Y2H interaction partners, whereas yellow edges 
represent the novel interactions found in fragment Y2H library screens. PAT family members 
are shown as red nodes while grey nodes indicate non PAT one-step interaction partners. The 
edge colour denotes the type of interaction as indicated. Cytoscape v3.2.1 was used to 
generate this network, using the spring-embedded display. 
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Many interesting phenotypes were observed in the C. elegans experiments, both 
when testing the mutants and neurosensitive RNAi mediated knockdowns. The 
discrepancies observed between the mutant and knockdown phenotypes could 
have occurred for several reasons. Firstly, RNAi is known to be less than 100 % 
efficient, and due to time limitations, no accurate measure to calculate knockdown 
efficiency was carried out. Tu3335 has been reported to be more sensitive to 
neuronal RNAi but concerns remained with respect to the report of secondary 
lin15-b mutation in this strain (Calixto et al., 2010). Secondly, mutations are not 
targeted towards neurons, meaning that they occur throughout the worm. The 
RNAi, on the other hand, should be predominantly targeting neurons. This 
indicates that if an effect is observed in the mutant but not in the knockdown, the 
phenotype is due to defects at the muscular membrane, or even due to a secondary 
effect occurring in the worm. 
 
It was previously suggested that as N2 is hypersensitive to aldicarb and VPA, in a 
similar way to the rate of paralysis of unc-25 mutants treated with aldicarb, the 
VPA might be inhibiting GABA neurotransmission in a similar manner 
(Munasinghe, 2015). Unc-25 encodes glutamic acid decarboxylase, which is 
involved in the biosynthesis of GABA (Jorgensen, 2005). By this theory, GABA 
biosynthesis is partially inhibited by VPA. Previously, VPA has been shown to 
increase GABA concentrations in the brain, possibly by inhibiting GABA 
catabolism (Lloyd, 2013). GABA is an inhibitory neurotransmitter in both C. 
elegans and mammalian brains. These opposing theories suggest that the role of 
VPA may either not be fully conserved between organisms, or its role is highly 
complex. 
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Multiple alternative mechanisms of VPA action have been proposed, making its 
molecular role very complex. For example, VPA has been reported to inhibit 
inositol-phosphate signaling in C. elegans (Yuan et al., 2001). It is important to 
note that the experiments in this paper revealed a resistance to paralysis when 
worms were treated with aldicarb and VPA. This could be due to differences in the 
assay methodology, as in their assay worms were picked onto plates containing 
VPA, then 2 hours later, picked onto plates containing aldicarb.  
 
5.4.2 Decreased expression of PAT family members alters cholinergic and/or 
GABA signaling 
 
If the previous theory that VPA partially inhibits GABA neurotransmission is 
correct, a mechanism to understand some of the phenotypes can be described. 
Nevertheless, it is vital to consider that VPA could instead be increasing excitatory 
neurotransmission, for example by moderately increasing acetylcholine secretion. 
This would lead to the same phenotype.  
 
Under wild-type conditions the majority of worms do not paralyse following VPA 
treatment, as the change in GABA or acetylcholine levels may not be high enough 
to cause hypercontraction and paralysis. When aldicarb and VPA are combined, 
however, acetylcholine degradation is inhibited, meaning that there is a larger 
imbalance in the ratio of acetylcholine: GABA levels. This therefore leads to the 
increased rate of paralysis observed in the wild-type worms.  
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This theory can also be used to hypothesize why VPA induces paralysis in some 
mutants. When the expression of a gene involved in GABA and/or cholinergic 
neurotransmission is decreased, GABA neurotransmission may be further 
inhibited or cholinergic neurotransmission further excited, creating the large 
imbalance between the ratio of acetylcholine: GABA, which causes paralysis.  
 
Both dhhc-2 and dhhc-13 mutants and knockdowns were paralyzed following 
treatment to VPA. This would lead to the suggestion that dhhc-2 and dhhc-13 play 
roles at the GABA synapse and/or the cholinergic synapse, thus have roles in 
excitatory and/or inhibitory neurotransmission. When added to the phenotypes 
seen when treated with aldicarb and levamisole, the role seems to be very 
complex. 
 
Dhhc-2 mutants were resistant to levamisole, but showed no change in aldicarb-
sensitivity. Knocking down dhhc-2 in a neurosensitive strain however, lead to an 
increased resistance to aldicarb. This suggests that dhhc-2 may be playing roles at 
both the pre- and post-synaptic terminals. For example, dhhc-2 may be involved 
in palmitoylating proteins required for GABA release, and also cholinergic 
receptors. When the mutant is treated with aldicarb, no phenotype is observed 
because a lower level of GABA has been secreted, but there are higher levels of 
cholinergic receptor. However, when dhhc-2 is specifically knocked down in the 
neurons, the level of cholinergic receptors is not altered, thus resistance to 
aldicarb occurs. The reason for levamisole resistance could be that more nicotinic 
cholinergic receptors are produced/trafficked to the postsynaptic membrane, 
following dhhc-2 mutation in comparison to levamisole-sensitive receptors.  
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When treated with both aldicarb and VPA, the dhhc-2 mutants were less sensitive 
to paralysis than treated N2 worms. If mutating dhhc-2 causes an increase in the 
number of cholinergic receptors and decreases GABA levels, this may explain this 
phenotype as the acetylcholine: GABA ratio is less skewed. However, it is 
necessary to point out that to elucidate the mechanism behind this phenotype, an 
experiment directly comparing dhhc-2 mutants when treated with aldicarb 
and/or VPA is required. 
 
Dhhc-13’s closest human ortholog is DHHC13, which is a PAT family member 
associated to Huntington’s disease, albeit not as strongly as DHHC17. Both the 
mutant and knocked down dhhc-13 worms were paralyzed when treated with 
VPA. The dhhc-13 mutant displayed hypersensitivity to aldicarb, but resistance to 
levamisole. This suggests that there may be an overall decrease in the number of 
cholinergic receptors, but that the proportion of receptors that are sensitive to 
levamisole has greatly decreased. Hence, both dhhc-2 and dhhc-13 may play a role 
in the trafficking or folding of subunits of the levamisole-sensitive cholinergic 
receptors.  
 
When aldicarb and VPA treatments were combined, no difference was observed 
between dhhc-13 mutants (or knock downs) and wild type worms. However, it 
would be necessary to carry out an experiment to directly compare the dhhc-13 
mutant/knock down on aldicarb and/or VPA-treated plates, to elucidate the 
mechanism behind this phenotype. The phenotypes do suggest non-redundant 
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roles of at least these two PAT family members, and that both are vital for synaptic 
function. 
Dhhc-14 also displayed some interesting phenotypes, and the closest human 
orthologs are DHHC17 (30 % identity, 47 % similarity, 14 % gaps) and DHHC13 
(27 % identity, 48 % similarity, 12 % gaps). The dhhc-14 mutant was resistant to 
aldicarb, but this was not observed in the neurosensitive knockdown, suggesting 
it may have a postsynaptic role. However, resistance to levamisole was only 
observed at one of the time points measured, indicating that dhhc-14 does not play 
a significant role with regards to cholinergic signaling. Dhhc-14 may instead play 
a role in GABA receptor subunit trafficking or folding. When mutated increased 
levels of GABA receptors may be functional at the postsynaptic membrane, leading 
to aldicarb resistance. However, when dhhc-14 was knocked down, 
hypersensitivity was observed when treated with both aldicarb and VPA. In the 
knock down, the level of GABA receptors would not be altered, and therefore 
suggests that subtle changes in presynaptic cholinergic or GABA signaling may 
occur when the expression of dhhc-14 is decreased in neurons. This suggests that 
dhhc-14 is another interesting candidate for further study, and that it may be 
playing roles at both the pre- and post-synaptic terminals. 
 
5.4.3 Novel interaction partners elucidated in the DHHC9 MYTH library screen 
 
Many interesting proteins were elucidated in the DHHC9 screen. A paper 
published in 2014 chelated all known mammalian palmitoylated proteins from 
numerous high-throughput screens to create a palmitoylome (Sanders et al., 
2015). If interacting proteins are found in this palmitoylome, the protein may be 
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a substrate of DHHC9. TECR and EMC4 were both shown to be palmitoylated in 
one and two studies, respectively. In addition, five studies found RTN4 to be 
palmitoylated, increasing the confidence of RTN4 being a novel substrate of 
DHHC9.  
 
When analyzing the PAT network (Figure 5.20 and 5.30), TECR was found to 
interact with another PAT family member, DHHC6. SELK encodes selenoprotein 
K, and reports indicate that this protein acts as a cofactor of DHHC6 to 
palmitoylate inositol-1, 4, 5-triphosphate receptor (IP3R) in the endoplasmic 
reticulum (Hoffmann, 2016). The binding of SELK to DHHC6 is reported to be 
through its Src homology (SRC)-3 domain, which DHHC9 does not have. Therefore, 
it would be necessary to validate this interaction to understand where the 
interaction is occurring, and whether the interaction has a similar role to that of 
DHHC9’s known cofactor, GCP16 (Swarthout et al., 2005b). 
 
The COMPARTMENTS subcellular localization database was used to extract the 
predicted localization of the interaction partners (Binder et al., 2014). DHHC9 is 
localized in the ER and Golgi apparatus, and seven of the interaction partners and 
one non-specific partner co-localized in these organelles (Table 5.15 and 5.16). 
Nevertheless, proteins not localised in the ER, such as FZD1, may still require 
zDHHC9 interaction during their processing and thus should not be discounted at 
this stage. 
 
The MYTH screening of zDHHC5, 8, 13 and 17 in the MYTH system was 
unsuccessful in our hands. All PAT family members have between four and six 
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trans-membrane domains, which may be the cause of the difficulty using these 
proteins in the MYTH system. It is plausible that the ER of the yeast has become 
oversaturated due to overexpression of these multiple trans-membrane proteins. 
This could prevent the proteins from being able to bind to their interaction 
partners. Matings of full-length PAT proteins have been carried out in a different 
membrane-based yeast-two-hybrid system (known as MBSUS, (Lemonidis et al., 
2015)). This suggests a different system may be required to use the other PAT 
family members in a library.  
 
5.4.4 Y2H screening of members of the mammalian PAT family 
 
At the time of writing, no other Matchmaker Y2H screens had been carried out in 
the lab. This suggests that following future screens, some of the interaction 
partners may be found to be non-specific binding partners. To increase confidence 
in the interaction partners, the palmitoylome was used to elucidate interaction 
partners of the truncated PAT family members, which had been shown to be 
palmitoylated previously. None of the novel interaction partners of DHHC5CT 
were known to be palmitoylated. Five of the DHHC17N and three of DHHC13N 
Gene	Symbol ID DHHC	interactor Source(s)
EFEMP1 2202 DHHC13N wei	2014,	
EPRS 2058 DHHC13N kang	2008,	martin	2009,
RAB7A 7879 DHHC13N,	DHHC17N kang	2008,	martin	2012,	wan	2014,	wilson	2011
HNRNPL 3191 DHHC17N wan	2014,	wilson	2011
ARHGAP21 57584 DHHC17N kang	2008,	wan	2014,	
NDUFA9 4704 DHHC17N wan	2014
DHX9 1660 DHHC17N wan	2014,	wilson	2011
Table 5.22 - The palmitoylome database was used to determine which of the interaction 
partners from the yeast two-hybrid screen had been predicted to be palmitoylated. 
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partners had previously shown to be palmitoylated, including Rab7a, which was 
shared between these screens (Table 5.22).  
Using the COMPARTMENTS website, we analysed the subcellular localizations of 
the interaction partners of the PAT family members and the interaction partners 
(Binder et al., 2014). Many were not annotated to have the same localization as 
the PAT proteins. For example, CSL and RSL24D1 are localized in the nucleus, yet 
zDHHC5 is localized at the plasma membrane and dendrites. This does not 
necessarily rule out an interaction, but does require further testing. One possible 
experiment would be to analyse the subcellular localization of the full length 
zDHHC5 in cells, and carry out co-localization studies with interaction partners.  
 
Some proteins were found to co-localize with their interacting PAT family 
member. Rab40B is localized on the plasma membrane, which is the predominant 
localization of DHHC5. DHHC13 and DHHC17 localize in the ER and Golgi. 
C19orf12 was found to interact with DHHC13N and is localized in the ER. APP, 
PICALM and CLIP3 all have Golgi localizations and interacted with DHHC17. Due 
to the localization of DHHC13 and DHHC17, these enzymes may play a role in 
protein folding and assembly, rather than their final folded form.  
 
Of note, CLIP3 has previously been shown to be both S-acylated as well as be an 
interaction partner of both DHHC13 and DHHC17. This protein therefore is acting 
as a positive control, demonstrating that the optimized Y2H screen is valid in 
determining physiologically relevant interaction partners. A paper published in 
2015, described a novel sequence motif of substrate proteins binding to DHHC17 
and DHHC13 – ΨβXXQP – where Ψ is an aliphatic amino acid (Valine, Isoleucine, 
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Alanine or Proline), β is a C-beta branched amino acid (Valine, Isoleucine or 
Threonine) and X is any amino acid (Lemonidis et al., 2015). The results of this 
paper indicate that CLIP3 had this consensus motif (VTMTQP). Of the novel 
zDHHC17 interaction partners, as well as CLIP3, PICALM (PVMTQP), ARHGAP21 
(PVLTQP), B2M (VTLSQP), TAX1BP1 (VVCSQP) and DHX9 (IVVTQP) all had this 
consensus sequence. With respect to the zDHHC13 interaction partners, CCDC34 
(PVISQP) and NEMF (PVKKQP) had this sequence. This suggests these proteins 
may be substrates of zDHHC13/17, although it is vital to check this via 
mutagenesis of these regions and carrying out Y2H matings with the full-length 
proteins. 
 
One interesting cluster of proteins was found to interact with DHHC17N. Three 
genes; APP, NDUFA9 and PICALM are all associated with Alzheimer’s disease. APP 
encodes amyloid-precursor protein and is vital in the development of Alzheimer’s 
disease, as it cleaved to form the Aβ peptides, which are found in amyloid plaques 
in the brains of patients. Interestingly, although APP has not been found in the 
palmitoylome database (Sanders et al., 2015), there are studies to demonstrate 
palmitoylation of APP by DHHC15, which has been suggested to target APP to lipid 
rafts and increase the processing of APP to the pathogenic Aβ peptide via BACE1 
cleavage (Bhattacharyya et al., 2013).  
 
NDUFA9 is expressed in the hippocampus and also plays a role in Alzheimer’s 
disease (L. Zhang et al., 2015). NDUFA9 plays a role in oxidative phosphorylation 
by acting as an accessory subunit to complex 1. Following KEGG analysis, NDUFA9 
is also linked to Parkinson’s and Huntington’s disease. Furthermore it has been 
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shown to be palmitoylated (Sanders et al., 2015), suggesting it may be a substrate 
of zDHHC17.  
PICALM has been elucidated as part of a susceptibility locus of late onset 
Alzheimer’s disease through GWAS studies. Other data suggests that it plays a role 
in Alzheimer’s disease by regulating the Aβ peptide; through its production, 
trafficking and clearance (W. Xu, Tan, & Yu, 2015). 
 
C19orf12 was found as a novel interaction partner of DHHC13N in our study, and 
would co-localize with full-length zDHHC13. C19orf12 is mutated in one form of 
hereditary spastic paraplegia (HSP) type 43 (SPG43). This is an autosomal 
recessive form of HSP (Landouré et al., 2013). C19orf12 is also mutated in a 
condition known as neurodegeneration with associated brain iron accumulation 
(NIBA). Although it has not previously been found to be palmitoylated, and it does 
not contain the ΨβXXQP consensus sequence, its pathological role makes it an 
interesting candidate for further study. As there is an overlap between zDHHC13 
and zDHHC17 interaction partners, it would also be of interest to test the 
interaction between c19orf12 and zDHHC17. 
 
Rab7a was found in the palmitoylome in four independent studies (Sanders et al., 
2015). This protein is implicated in Charcot-Marie-Tooth disease, type 2B 
(CMT2B) (BasuRay, Mukherjee, Romero, Seaman, & Wandinger-Ness, 2013).  
Charcot-Marie-Tooth disease affects the peripheral nervous system, and type 2 is 
classified as having primary peripheral axonal neuropathy without obvious sign 
of myelin degeneration. It has been suggested that mutated forms of Rab7 may 
lead to the peripheral neuropathy by reducing its rate of membrane cycling. As 
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palmitoylation is known to play key roles in the cycling of other proteins (such as 
Ras proteins) between the cytosol and plasma membrane, it is plausible that 
palmitoylation of Rab7a is affected in the mutations. L129F, K157N, N161T and 
V162M are mutations that have been associated to CMT2B (BasuRay et al., 2013). 
Our study suggests that Rab7a interacts with both DHHC13 and 17, possibly via 
the N-Ankyrin repeat domain. This domain contains several ankyrin repeats, 
which may not only play a role in binding substrates, but also have other functions 
such as the activation of JNK signaling and suppression of heterotrimeric G-
protein signaling. This association between the two N-ankyrin repeat-containing 
PATs and Charcot-Marie-Tooth disease is an interesting one, and the role of 
palmitoylation in this disease requires further study. 
 
The C-terminal fragment of mouse zDHHC8 did not work in this Y2H system. As 
can be seen in Table 5.13, the mouse and human orthologues share 92 % identity 
for the full-length proteins. When comparing the C-terminal fragments specifically 
they share 89.2% identity, 93.1% similarity and 0.5% gaps. Any differences 
between these sequences may be causing the lack of interaction partners. To test 
this, it would be necessary to generate C-terminal fragments of human zDHHC8, 
and screen this against the normalized foetal brain library. Alternatively, a mouse 
brain library could be tested with the mouse zDHHC8 ortholog. 
 
5.4.5 Conclusions 
 
In this chapter C. elegans were tested for their sensitivity to aldicarb, VPA, 
levamisole and the combination of aldicarb and VPA. Where possible, PAT family 
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mutants were also tested as well as Tu3311 that had been knocked down with 
dsRNA targeting each of the PATs individually. This revealed many interesting 
phenotypes that require further study to establish the molecular basis of this 
phenotype.  This study demonstrates that many PATs play a role at NMJs in C. 
elegans, and that the molecular basis of VPA action is still not clear. 
 
In the Y2H studies, many novel interaction partners of DHHC5, 13 and 17 were 
elucidated, increasing our understanding of the PAT family. Clusters of these 
proteins have links to neurological disease; again highlighting the potential role 
that PAT proteins may play in neuropathology. A total of 17 novel interaction 
partners of DHHC9 were discovered using the MYTH system, although eight of 
these are possibly non-specific interaction partners. In future it will be necessary 
to find other techniques to elucidate interaction partners of the whole PAT family, 
and to determine their relevance in synaptic function. 
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6.1 Screening genes with high connectivity and betweenness values in a one-step 
aldicarb network 
 
This work aimed to elucidate novel effectors of synaptic function in C. elegans. For 
this the aldicarb-sensitivity assay was optimized and used, as it is a well-
characterized technique for studying the effect of altered gene expression at NMJs.  
In order to elucidate novel effectors, genes were extracted, which were known to 
cause a change in aldicarb-sensitivity when their expression was altered. At the 
time of the study, 240 genes were known to cause delayed paralysis in the 
presence of aldicarb, and 12 genes were shown to cause an increased rate of 
paralysis.   
 
Using merged Wormnet (Cho et al., 2014) and CCSB (Simonis et al., 2009) 
networks, interaction partners of these genes were extracted and mapped. 
Connectivity to genes known to cause a significant change in aldicarb sensitivity 
were measured and ranked. The top hundred candidates were then tested where 
appropriate, through genetic knockdown in the neurosensitive Tu3311 strain. 
After independent validation, 19 novel genes were found to cause a RIC 
phenotype. It is important to note that many other genes did not re-confirm when 
independent testing was carried out. This could be due to differences in the 
efficiency of RNAi, or in the choice of a time point. In the future, the candidates 
who showed a phenotype in one high-throughput screen but not another, should 
be tested using full time course assays to check for this phenotype. 
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For the betweenness analysis core genes were added, which was associated with 
synaptic transmission GO terms. Another future experiment would be to re-
calculate the connectivity rankings in the aldicarb and GO term one-step synaptic 
network, in order to elucidate other genes for analysis. This testing revealed there 
was a large degree of overlap between the connectivity and betweenness data 
sets. 10 novel genes were found to cause a change in aldicarb sensitivity, which 
were solely in the betweenness data set. The overlap may indicate that proteins of 
importance have both high connectivity and betweenness centrality. An exception 
of this is unc-37, whose knockdown caused a significant RIC phenotype, but has 
low connectivity to known aldicarb-sensitivity genes. This highlights that when 
elucidating lists of candidates to test, multiple factors including GO terms should 
be taken into account, and different forms of centrality used. 
 
Both lists of novel positive effectors of aldicarb sensitivity were converted into 
human orthologs, and the synaptome database (Pirooznia et al., 2012) was used 
to predict whether the proteins were localized at the pre- or post-synaptic 
terminal. Interestingly, of the genes whose human orthologs were found in the 
database, the majority was post-synaptically localized. This is of interest, as in 
principle, the Tu3311 strain should only be knocking down genes in neurons, and 
hence pre-synaptically at neuromuscular junctions. This may indicate that the 
gene is localized in a different neuronal type, such as sensory or interneurons. If 
synaptic transmission is affected in these neurons, this could also cause a defect 
in the response to being pressed by a wire and paralysis. 
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Future work is required to elucidate why the genetic knockdown of these genes 
leads to delayed paralysis of worms on aldicarb plates. This could be carried out 
through the microinjection of fluorescent constructs of interest into the wild-type 
worms (under the control of a pan-neuronal promoter), and examining the 
localization of the protein under a fluorescent microscope. For a higher spatial and 
temporal resolution on free moving worms, optogenics could also be carried out, 
which has been used successfully to analyze mechanosensory and motor neural 
circuits in C. elegans. Specific mutants of the genes of interest could also be 
generated and tested (for example, through the use of CRISPR (Katic & Grosshans, 
2013)). If an effect was observed in the mutants, levamisole could be used to 
determine if the effect is pre- or post-synaptic (and whether the effect is occurring 
at cholinergic NMJ) (Locke et al., 2008). Due to the neuronal sensitivity of Tu3311, 
this strain is not suitable to be tested with levamisole (Calixto et al., 2010). 
 
In future experiments it would be wise to check the RNAi efficiency prior to high 
throughput assays, in order to have confidence that the RNAi knockdown has been 
successful. This could be carried out through the use of real time polymerase chain 
reactions (RT-PCR) and western blots (with specific antibodies) following worm 
genetic knockdown and lysis, in order to determine whether the gene expression 
and protein levels decreased following knockdown (Ahringer, 2006). However, 
the number of potential candidate to be studied may restrict this level of detailed 
analysis in large-scale screens. 
 
In the high throughput experiments, standard T-tests were used to filter for high 
confidence changes in aldicarb sensitivity. This meant that many genes were 
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found to be insignificant due to variability between plates. For this reason, in the 
future a different statistical test such as the chi2 test (for categorical data) could 
be used, which may elucidate borderline candidates that could be tested further. 
 
6.2 Using the VPA microarray to elucidate novel effectors of synaptic function 
 
Other methods of elucidating novel effectors of synaptic function were also 
investigated. VPA is a drug used to treat epilepsy, but its mechanism of action is 
unclear (Lloyd, 2013). A microarray was carried out on wild-type C. elegans, which 
had been treated with varying concentrations of VPA. Analysis was carried out, 
and genes showing expression level changes were clustered. If the expression of 
two genes changes to a similar extent, they are likely to be working together, for 
example in a signaling or metabolic pathway. This analysis was combined with a 
basic RIC one-step Wormnet (version 1) network, generating modules of genes 
known to cause a RIC phenotype, and genes that had not been tested for an 
aldicarb-sensitivity phenotype previously. The original microarray analysis and 
network generation were created prior to the work carried out here, and all 
networks used bar this one used the latest versions of Wormnet (Cho et al., 2014) 
and CCSB (Simonis et al., 2009). One piece of work that could be carried out in the 
future would be to re-generate the modules using the updated Wormnet, and the 
most up-date one-step RIC and HIC network. This may generate more leads to be 
tested by the aldicarb-sensitivity assay. 
 
The hits found in this analysis should also be analyzed further. This is discussed 
in detail in Chapter 4.4. Sel-12 is a specifically interesting gene for further study 
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due to it being an ortholog of PSEN2. PSEN2, PSEN1 and APP are the three main 
genes linked to early onset Alzheimer’s disease. PSEN2 mutations are the least 
common, with only 19 potentially pathogenic mutations having been discovered 
(Jayadev et al., 2010). As PSEN2 was not found in the SynaptomeDB to be localized 
in the pre- and post-synaptic terminals, it would be interesting to analyze the 
localization of PSEN2 in human or mouse neuronal cell lines. This would improve 
our understanding of whether it serves a conserved function between mammals 
and worms. Furthermore, in C. elegans further study could be carried out through 
the use of mutant strains and carrying out full time course pharmacological assays 
(such as aldicarb- and levamisole-sensitivity assays). 
 
In the work leading up to the microarray analysis, VPA was shown to cause 
paralysis in specific C. elegans mutants, such as sma-6 (Munasinghe, 2015). 
Another interesting experiment could be to test these knockdowns with VPA, to 
elucidate whether the worms underwent VPA-induced paralysis. This may give a 
better insight into the role that VPA plays in both C. elegans and humans.  
 
6.3 VPA as an effector of synaptic function 
 
The focus of the research was then switched onto VPA itself, as it appears to be a 
drug that alters synaptic function from the worm microarray analysis as well as 
other literature. In order to understand the role VPA plays at the synapse, the VPA 
microarray data in C. elegans was re-analyzed, and information was extracted 
from other microarrays. When re-analyzing the microarray data, genes were listed 
if they significantly increased or decreased in expression following VPA treatment. 
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Other microarrays were then downloaded and analyzed using identical 
algorithms in R. After finding the C. elegans orthologs of the differentially 
expressed genes, the data was compared and many processes were shared, 
especially in neurodevelopment.  
 
From this microarray data, many other interesting genes were found to be 
significantly up or down regulated in C. elegans. To further this work, genes of 
interest could be knocked down in a neurosensitive strain and tested for a change 
in aldicarb sensitivity. This would provide a link between the microarray analysis 
and phenotypic effects in C. elegans, and further link VPA to synaptic function. 
Examples of interesting genes would be lrx-1, asp-12 and zmp-2, which all are 
reported to be part of the presenilin pathway, and were down regulated in 
response to VPA. The closest ortholog of asp-12 is Beta-site amyloid precursor 
protein-cleaving enzyme (BACE2). Increased BACE2 protein and mRNA levels 
have been found in the frontal lobe of patients with Down’s syndrome and 
Alzheimer’s disease (Barbiero et al., 2003). 
 
In research carried out in this study as well as from previous work (Munasinghe, 
2015), VPA-induced paralysis was observed in some worm mutants and RNAi 
strains. Given that VPA has been shown to extend C. elegans lifespan, other 
phenotypes could also be studied, such as morphology and behavioural assays. An 
example of a behavioural assay is thrashing, as decreased thrashing can be a sign 
of neurodegeneration (Edmonds & Morgan, 2014).   
 
Chapter 6: Summary and Future Work 
 324 
Conserved genes and pathways could also be tested using different experimental 
techniques. One example of an interesting gene to investigate further is C. elegans 
fpn-1.2, whose mouse ortholog is SLC40A1 and whose human ortholog is 
ferroportin. As this protein has been described to be involved in neural tube 
closure (Mao et al., 2010), it could be an important gene modified by VPA. To test 
whether such genes are of importance, they could be knocked down in 
neurologically relevant cell lines and phenotypic characteristics elucidated. These 
cells could also be treated with a physiologically relevant concentration of VPA, 
and QPCRs carried out to validate whether these genes are up and down regulated 
as expected. Microarrays could also be carried out on these cells, as to date, there 
are no published microarrays following the treatment of human neuronal cell 
lines with VPA. It would be necessary to use a therapeutically relevant dosage for 
these experiments. 
 
Two distinct groups of microarrays were analyzed or extracted in this work – 
those that were related to development, for example mouse embryo brain 
cultures, and those that were found in the adult, for example rat brain. This 
revealed distinct patterns of gene expression changes. The key process shared 
between the majority of the data sets were changes in genes related to neuronal 
differentiation and development. Given the teratogenicity of VPA, these changes 
may help to explain the molecular basis of the defects. In the adult rat brain, 
changes in genes related to synaptic transmission, learning and memory were also 
elucidated, confirming VPA’s possible role at the synapse outside of development. 
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The analysis of microarray data carried out in Chapter 4 links VPA treatment to 
several neurodegenerative diseases, namely Alzheimer’s and Huntington’s 
disease. VPA has been shown to have beneficial motor, behavioural and lifespan 
effects in both cellular and mouse models of Huntington’s disease. Treatment in 
humans however has been controversial (Scheuing, Chiu, Liao, Linares, & Chuang, 
2014). In addition, few theories have been proposed to explain this beneficial 
effect. The human or mouse orthologs of these genes would be ideal choices for 
the QPCR analysis mentioned previously. Y18D10.22 was down regulated in 
response to VPA, whose closest human ortholog is HIP1. HIP1 is one of the most 
widely studied interactors of huntingtin, and from this, could provide a link 
between the proposed beneficial roles of VPA. Huntingtin levels itself could also 
be checked following cell treatment with VPA to elucidate which pathways are 
being affected by VPA. From the KEGG analysis of the adult rat brain data a further 
seven genes were linked to Huntington’s disease, and eight to Alzheimer’s disease. 
These therefore add to the theory that VPA affects processes linked to these two 
diseases. 
 
6.4 Understanding the role of PAT family members at the NMJ 
 
When dhhc-2 was knocked down in Tu3311, a significant resistance to paralysis 
was seen when the knocked down worms were picked onto aldicarb plates. For 
this reason the rest of the PAT family were tested, as these experiments had not 
been previously carried out and published, and the family were an interesting 
family to study, given their links to intellectual disability and neurodegenerative 
diseases.  
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The results from chapter 5 require much further study. Firstly, from the worm 
work, full time course assays should be carried out on Tu3311 knocked down with 
each PAT. Previously, few phenotypes were elucidated from the PAT worm family. 
These phenotypes could be re-analyzed following the knockdown of the PAT 
family in the neurosensitive Tu3311 or Tu3335 strain, and then analyzing the 
morphological and behavioural phenotypes carried out previously (Edmonds & 
Morgan, 2014). Wild type and rrf-3 worms could also be knocked down with each 
PAT family member. Aldicarb-sensitivity assays would then reveal the strains that 
an effect was seen in, and allow hypotheses to be generated to explain the 
reasoning behind this. Double knockdowns of the PAT family could also be carried 
out. 
  
In the Y2H work, many interesting interaction partners of certain fragments of 
human and mouse PAT family members were identified.  The N-terminal fragment 
of DHHC17 provided the greatest number of interesting hits, as three proteins 
were linked to Alzheimer’s disease, one of which was APP. The N-terminal 
fragment of DHHC13 was shown to bind to c19orf12, whose mutations are known 
to cause hereditary spastic paraplegia type 43.   
 
The first experiment to be carried out following this work would be the validation 
of interactions through the use of Y2H matings. As c19orf12 is mutated in SPG43, 
one experiment would be to clone c19orf12, and then specifically mutate the gene 
to the form found in SPG43. The interaction of DHHC13 against the mutated 
c19orf12 could then be tested. Co-localization of the full length PATs and 
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proposed interaction partners could also be determined in neuronal cell lines. Co-
immunoprecipitation experiments could also be carried out as a validation 
technique. Another interesting area to explore would be to discover whether the 
interaction partners are palmitoylated by the PAT of interest, for example 
DHHC17. For example, acyl resin assisted capture (acyl-RAC) coupled to mass 
spectrometry could be used to determine endogenous palmitoylation sites of 
specific proteins (Forrester et al., 2011).    
 
In the time frame available, the only construct that functioned in the MYTH library 
system was DHHC9.  There is a variation of MYTH that has been used to carry out 
matings with PAT family members previously, known as MbSUS (Grefen, Obrdlik, 
& Harter, 2009). This could be used in the future, as well as re-testing the MYTH 
constructs in the four other recommended vectors (two of which are N-terminal, 
three are C-terminal) (Lemonidis, Gorleku, Sanchez-Perez, Grefen, & Chamberlain, 
2014; Stagljar & Fields, 2002). Constructs could also be sent to companies that 
specialize in high throughput Y2H assays, such as Dualsystems.  
 
Nevertheless the Y2H work elucidated interaction partners that provide new links 
between PATs and neurological processes, which in the future may help in the 
better understanding of diseases such as Alzheimer’s disease, and may provide 
clues as to novel therapeutics. 
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